» 2018 International Congress

Date: Thursday, January 1, 1970

Time: 12:00am-12:00am

Meeting:

1:45pm-3:15pm: ‘PDSAFE’ – A multi-dimensional fall rehabilitation intervention for people with Parkinson’s with specialist physiotherapy training: qualitative exploration of physio’s experiences

K. Seymour, S. Hulbert, V. Goodwin, L. Rochester, A. Nieuwboer, A. Ashburn (Southampton, United Kingdom)

1:45pm-3:15pm: “Wine glass” appearance in a primary lateral sclerosis and frontotemporal dementia case

M. Velez, L. Torres (Lima, Peru)

1:45pm-3:15pm: [11 C] DASB PET imaging in dopa-responsive dystonia patients: The role of serotonin in motor and non-motor symptoms

E. Timmers, D. Vállez García, A. Bartels, A. Kuiper, R. Dierckx, M. Smit, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: 5 Years’ Experience of Ixcellence Network®, an International Innovative Educational Program to improve Cervical Dystonia and Spastic paresis Management Practices

C. Colosimo, T.M. Chung, L.J. Jacinto, K. Bahtia, T. Landreau, R. Bhidayasiri (Roma, Italy)

1:45pm-3:15pm: 7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?

E. Dellapina, F. Ory-Magne, A. Sommet, V. Rousseau, D. Devos, S. Thobois, L. Defebvre, C. Brefel-Courbon, JC. Corvol, O. Rascol, F. NS-PARK/FCRIN Network (Toulouse, France)

1:45pm-3:15pm: 8-Contact Multiple Independent Current Control vs. 4-Contact Standard Deep Brain Stimulation of Subthalamus in Parkinson’s disease: a Double-blind Cross-over Trial

D. Soh, M. Algarni, R. Munhoz, A. Lozano, S. Kalia, M. Hodaie, A. Fasano (Toronto, ON, Canada)

1:45pm-3:15pm: A case of early onset parkinsonism caused by PLA2G6 gene mutation

L. Chen, S. Xu (Guangdong, China)

1:45pm-3:15pm: A Case of Paraneoplastic Myoclonus Attributed to Non-Small Cell Lung Cancer

J. Nichols (Portland, OR, USA)

1:45pm-3:15pm: A Case of Secondary Myoclonic Hyperkinesia

K. Harutyunyan, H. Amirjanyan, I. Gabrielyan, C. Asatryan, L. Galstyan, S. Khachaturyan, G. Avagyan, H. Manvelyan (Yerevan, Armenia)

1:45pm-3:15pm: A case of tardive dyskinesia and parkinsonism following use of phentermine for weight loss

R. Barmore, C. Hess, N. McFarland, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: A case report of an Egyptian family with a rare condition of choreoacanthocytosis and amyotrophy

A. Dahshan, S. Ahmed, A. Hasan, A.S. Othman, D. Mekkawy, O. Yakoub, D. Abdulatif, Y. Gamil (Cairo, Egypt)

1:45pm-3:15pm: A clinical tool to ensure delivery of modern personalised medicine for Parkinson’s disease: first description of a personalised medicine checklist

N. Titova, K. Ray Chaudhuri (Moscow, Russian Federation)

1:45pm-3:15pm: A Computer-Aided Prescription Model for Parkinson’s Disease could predict the suitable drugs for Parkinson’s disease (PD) patients

Y. Pan, L. Zhang (Nanjing, China)

1:45pm-3:15pm: A controlled trial of ParkinSong singing groups to improve communication and wellbeing in Parkinson’s disease

J. Tamplin, A. Vogel, C. Marigliani, F. Baker, M. Morris (Southbank, Australia)

1:45pm-3:15pm: A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Phase IIa Trial to Evaluate the Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson’s Disease

JC. Corvol, F. Durif, W. Meissner, JP. Azulay, R. Haddad, D. Bricout, X. Wang-Zhang, L. Benel, O. Rascol, Fr. NS-Park/F-CRIN Network (Paris, France)

1:45pm-3:15pm: A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease

H. Huttunen, S. Booms, J. Koskinen, M. Saarma (Espoo, Finland)

1:45pm-3:15pm: A framework to facilitate competence in practice for Parkinson’s Disease Nurse Specialists in the United Kingdom

H. Martin, J. Price, L. Ebenezer (Coventry, United Kingdom)

1:45pm-3:15pm: A German-Austrian multicenter, non-interventional, prospective study for the treatment with abobotulinumtoxinA injections in naïve and previously treated patients suffering from cervical dystonia

W. Jost, A. Schramm, M. Müngersdorf, A. Stenner, P. Schwingenschuh, P. Maisonobe, M. Koch, B. Haslinger (Wolfach, Germany)

1:45pm-3:15pm: A multimodal motor skill balance training with rhythmical cues to improve and maintain balance control in Parkinson’s disease

T. Capato, J. Nonnekes, J. Tornai, I. Kayo, J. IntHout, E. Barbosa, N. de Vries, M. Piemonte, B. Bloem (Sāo Paulo, Brazil)

1:45pm-3:15pm: A new distinct spastic ataxia with hypomyelination: Clinical, neuroimaging and molecular expression of NKX6-2 mutations

V. Chelban, N. Kaya, M. Alsagob, S. Efthymiou, J. Vandrovcova, D. Lynch, K. Kloth, A. Chirita-Emandi, F. Alkuraya, N. Wood, H. Houlden (London, United Kingdom)

1:45pm-3:15pm: A new SPG4/SPAST mutation in an Italian family with hereditary spastic paraplegia and Alzheimer’s disease

A. Orlacchio, C. Montecchiani, R. Rumore, F. Gaudiello, M. Miele, C. Caltagirone, T. Kawarai (Rome, Italy)

1:45pm-3:15pm: A novel homozygous splice site mutation in the KIF1C gene (SPAX2, SPG58) found in a consanguineous turkish family

E. Grauer, N. Pluta, P. Müller, D. Zeller, C. Ip, J. Volkmann, E. Kunstmann, T. Musacchio (Würzburg, Germany)

1:45pm-3:15pm: A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID

D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Conquet (Plan-les-Ouates, Switzerland)

1:45pm-3:15pm: A novel mutation in VRK1 associated with distal spinal muscular atrophy

L. Li, L. Wang, Z. Lu, X. Sun, X. Suo, J. Li, J. Peng, R. Peng (Chengdu, China)

1:45pm-3:15pm: A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone

S. Janhunen, J. Venäläinen, J. Kaskinoro, L. Saloranta, J. Tuunainen (Turku, Finland)

1:45pm-3:15pm: A Patient-Centered Decision-Making Algorithm for Deep Brain Stimulation Surgery in Parkinson’s Disease

S. Joza, K. Yen, F. Ba, J. Miyasaki (Edmonton, AB, Canada)

1:45pm-3:15pm: A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale

S. Papapetropoulos, M. Lee, S. Boyer, M. Versavel (Cambridge, MA, USA)

1:45pm-3:15pm: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design

T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Chicago, IL, USA)

1:45pm-3:15pm: A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update

R. Holloway, D. Oakes, T. Simuni, K. Hodgeman, B. Greco, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, K. Biglan (Rochester, NY, USA)

1:45pm-3:15pm: A phase Ib trial studying the safety and tolerability of IRL790 in patients with Parkinson’s disease and levodopa-induced dyskinesia

P. Svenningsson, A. Johansson, D. Nyholm, P. Tsitsi, C. Sonesson, J. Tedroff (Stockholm, Sweden)

1:45pm-3:15pm: A Physiotherapy Exercise Program for Parkinson’s Disease Patients with Impaired Gait and Postural Control

J. Yeung, A. Lau, E. Chan, J. Chung, L. Chan (Hong Kong)

1:45pm-3:15pm: A Preliminary Study of Cinnamomum verum on Anxiety, Locomotor Activity and Emotionality Behaviour in Wistar Albino Rats

N. Ahmed (Aligarh, India)

1:45pm-3:15pm: A prospective MRI study of edema surrounding deep brain stimulation leads

L. Borellini, F. Cogiamanian, S. Sbaraini, E. Scola, G. Carrabba, M. Locatelli, S. Avignone, F. Mameli, F. Ruggiero, R. Ferrucci, G. Ardolino, S. Barbieri, P. Rampini (Milano, Italy)

1:45pm-3:15pm: A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson’s disease

K.K. Chong, S.Y. Lim, M.A.A. A Manap, J.L. Lim, S.C. Low, S. K Mahadeva, A.H. Tan (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: A Randomized Trial of Deferiprone for Pantothenate Kinase-Associated Neurodegeneration

T. Klopstock, F. Tricta, L. Neumayr, I. Karin, G. Zorzi, C. Fradette, T. Kmieć, B. Buechner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, P. Dušek, F. Zhao, F. Zibordi, N. Nardocci, C. Aguilar, S. Hayflick, M. Spino, A. Blamire, P. Hogarth, E. Vichinsky (Munich, Germany)

1:45pm-3:15pm: A Real-world Assessment of Hospitalizations Due to Falls among Patients with and without OFF episodes in Parkinson’s Disease

K. Rajagopalan, A. Lee, J. Barton, J. Pike (Marlborough, MA, USA)

1:45pm-3:15pm: A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients

M. Winterholler, H. Erxleben (Schwarzenbruck, Germany)

1:45pm-3:15pm: A study of correlation between screening tools for cognitive decline and gait status using three-dimensional gait analysis

PJ. Park (Busan, Republic of Korea)

1:45pm-3:15pm: A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design

B. Mollenhauer, F. Boess, K. Marek, W. Poewe, R. Postuma, K. Taylor, J. Dukart, M. Lindemann, L. Verselis, M. Niggli, T. Barata, A. Post, M. Koller, D. Ness, D. Selkoe, J. Sevigny (Göttingen, Germany)

1:45pm-3:15pm: A Virtual Reality Exercise Program Improves the Balance Function and Quality of Life of Patients with Parkinson’s Disease

G. Lee (Cheonan, Republic of Korea)

1:45pm-3:15pm: A wireless brain-spine interface alleviating gait deficits of non-human primates model of Parkinson’s disease

F. Raschella, T. Milekovic, M. Perich, S. Sun, G. Schiavone, C. Hitz, Y. Jianzhong, W. Ko, Q. Li, C. Qin, S. Lacour, J. Bloch, S. Micera, E. Bezard, G. Courtine (Geneva, Switzerland)

1:45pm-3:15pm: Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model

P. Blanchet, G. Hernandez, S. Mahmoudi, M. Cyr, J. Diaz, D. Levesque (Montreal, QC, Canada)

1:45pm-3:15pm: Abrogation of Rotenone Induced Behavior, Biochemical and Mitochondrial Deficits in Mice by Curcumin and Ginkgo Biloba: New Combinational Therapy Approach for Parkinson’s Disease

D. Khatri, M. Panchwadkar, P. Rane, V. Undale (Pune, India)

1:45pm-3:15pm: Absence of wearing-off in Parkinson’s disease patients with treatment beyond 10 years

Q. Wei, R. Ou, Y. Wu, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

1:45pm-3:15pm: Activities of Daily Living and Quality of Life in Patients with Advanced Parkinson’s Disease Who Are Treated with or Planning to Use Device-Aided Treatments

A. Fasano, K. Seppi, V. Fung, Z. Pirtosek, J.C. Parra, L. Bergmann, O. Sanchez-Soliño, B. Elibol, K. Onuk (Toronto, ON, Canada)

1:45pm-3:15pm: Acute efficacy and tolerability of the COMT inhibitor opicapone

F. Gandor, D. Sykora, D. Gruber, G. Ebersbach (Beelitz-Heilstätten, Germany)

1:45pm-3:15pm: Advanced Parkinson’s disease Diagnosis and Treatment Trends in Israel – Sub-Analysis of the OBSERVE-PD Multi-Country, Cross-Sectional Study

R. Djaldetti, S. Hassin-Baer, M. Anca-Herschkovitsch, R. Gross, R. Cohen, H. Banayan, K. Onuk, T. Gurevich (Petah Tikva, Israel)

1:45pm-3:15pm: After Deep Brain Stimulation Surgery for Parkinson’s Disease risk Factors for Postoperative Delirium

F. Rakhimov, G. Rakhimbaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Age related changes of cortical effective connectivity during bimanual motor control

P. Loehrer, F. Nettersheim, I. Weber, F. Jung, L. Timmermann (Marburg, Germany)

1:45pm-3:15pm: Alleviation of freezing of gait in patients with Parkinson’s disease by high-frequency rTMS over SMA is associated with normalization of brain connectivity patterns

T.M. Mi, S. Garg, F. Ba, T. Wu, P.P. Liang, L.L. Gao, K.C. Li, P. Chan, M. McKeown (Beijing, China)

1:45pm-3:15pm: Alterations of the intestinal microbiota were correlated with the severity of Tourette syndrome in children

WT. Lee, LC. Wong (Taipei, Taiwan)

1:45pm-3:15pm: Ambulosono – A Music Walking Program Improves Gait Disorders in Parkinson’s Disease

W. Xian, B. Hu, T. Wu, L. Jiang, L. Chen, Z. Pei (Guangzhou, China)

1:45pm-3:15pm: An early-onset parkinsonism revealing a Gaucher disease with a heterozygous mutation in GBA gene: A case report

R. Zouari, S. Ben Romdhan, N. Farhat, S. Sakka, H. Haj Kacem, O. Hdiji, M. Dammak, C. Mhiri (Sfax, Tunisia)

1:45pm-3:15pm: An evaluation of the availability and format of information provided to patients who have a new diagnosis of Parkinson’s disease (PD)

L. Ebenezer, J. Price, H. Martin (Bridgend, United Kingdom)

1:45pm-3:15pm: An international survey of stiff person spectrum disorders: Exploring the clinical spectrum and unmet needs

B. Balint, E. Gatto, J. Etcheverry, M. Cesarini, V. Virginia Parisi, M. Rodriguez Violante, P. Garcia Ruiz, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: An investigation of the potential neuroprotective role of curcumin in Parkinson’s disease patient-derived fibroblasts

S. Abrahams, C. vander Merwe, A. Neethling, J. Carr, S. Bardien (Cape Town, South Africa)

1:45pm-3:15pm: An Objective Tool to Guide Target Selection for DBS in PD (GPi vs STN) – integration into Thomas Jefferson’s multidisciplinary Movement Disorders Center

L. Meytin, TW. Liang, J. Ratliff (Philadelphia, PA, USA)

1:45pm-3:15pm: An oculogyric crisis after administation of alizapride: A tardive phenomenon?

A. Boogers (Edegem, Belgium)

1:45pm-3:15pm: An open labeled, observational study for the Satisfaction and Preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia (SAFE-ADPD) in Koreans

M. Park, D. Shin (Daegu, Republic of Korea)

1:45pm-3:15pm: An Unusual Case of Peripheral Myoclonus

M. de Lima (Phoenix, AZ, USA)

1:45pm-3:15pm: Analysis of secondary causes in Fahr’s syndrome and whole exome sequencing in Fahr disease from Northeast China and South Korean

G. Shen, B. Jeon, G. Nan, S. Park (Changchun, China)

1:45pm-3:15pm: Angiotensin-converting enzyme inhibitors are neuroprotective regarding APOE-mediated motor and non-motor experiences for Alzheimer’s dementia but not for dementia with Lewy bodies

F. Oliveira, M. Miraldo, E. Castro-Neto, F. Machado, S. Almeida, S. Matas, P. Bertolucci, M. Naffah-Mazzacoratti (São Paulo, Brazil)

1:45pm-3:15pm: Ankle proprioception and postural instability in Parkinson’s disease

H. Teasdale, E. Preston, W. Spratford, G. Waddington (Bruce, Australia)

1:45pm-3:15pm: Artisanal formulations of Cannabis in Movement Disorders. The real-life perspective in a population from Buenos Aires, Argentina. Preliminary report

M. Cesarini, JL. Etcheverry, N. Gonzalez Rojas, G. Da Prat, V. Parisi, G. Rojas, G. Persi, E. Gatto (Buenos Aires, Argentina)

1:45pm-3:15pm: Assessing the Effectiveness of Valbenazine in the Treatment of Tardive Dyskinesia as Determined by the AIMS and PGIC: Results from the KINECT 4 Trial

C. Singer, C. Comella, K. Farahmand, J. Burke, R. Jimenez, S. Siegert (Miami, FL, USA)

1:45pm-3:15pm: Association analysis of the nutritional status and serum nutritional index in patients with Parkinson’s disease

L. Chen, W. Chen, Q. Guo, L. Jiang, Y. Hu, Y. Liu, W. Xian (Guangzhou, China)

1:45pm-3:15pm: Asymmetry of pallidal neuronal activity correlates with head rotation in patients with cervical dystonia

A. Sedov, U. Semenova, V. Myrov, S. Usova, A. Gamaleya, A. Tomskiy, H. Jinnah, A. Shaikh (Moscow, Russian Federation)

1:45pm-3:15pm: Asynchronous Consultation in Movement Disorders: The East Africa Hub

M. Dekker, S. Urasa, S. Guttman, W. Howlett, M. Guttman (Moshi, United Republic of Tanzania)

1:45pm-3:15pm: Attitudes to Palliative Care in Movement Disorder Physicians in the UK

L. Wiblin, T. Wong, C. Kui, M. Lee, D. Burn (Newcastle-upon-Tyne, United Kingdom)

1:45pm-3:15pm: Attitudes toward earlier use of deep brain stimulation among patients with Parkinson’s disease

L. Cabrera, C. Sidiropoulos (East Lansing, MI, USA)

1:45pm-3:15pm: Atypical glutaric aciduria type 1 with hemidystonia and asymmetric radiological findings misdiagnosed as an ischemic stroke

D. Demailly, C. Vianey-Saban, C. Acquaviva, V. Gonzalez, I. De Antonio, F. Cyprien, T. Roujeau, A. Masoliver, N. Leboucq, P. Coubes, L. Cif (Montpellier, France)

1:45pm-3:15pm: Atypical presentation of PANK2 mutation: A case report

M. Sousa, R. Varela, A. Morgadinho, C. Januário (Coimbra, Portugal)

1:45pm-3:15pm: Augmented Reality-Based Dance Application on Balance and Mobility of Individuals with Parkinson’s Disease: A Pilot Study

T. Tunur, K. Rickford, A. DeBlois, E. Horton-Yates, L. Columna (San Marcos, CA, USA)

1:45pm-3:15pm: Autosomal dominant PANK2 mutation resulting in cervical dystonia with iron accumulation in the basal ganglia

M. van_der_Weijden, R. Lambrechts, E. Nibbeling, J. Groen, T. de Koning, O.. Sibon, M. Tijssen, D. Verbeek (Groningen, Netherlands)

1:45pm-3:15pm: Background: Transcranial magnetic stimulation (rTMS) may influence the progression of PD

J. Málly (Sopron, Hungary)

1:45pm-3:15pm: Ballism as major manifestation in Neuroleptic Malignant Syndrome in a patient toxoplasmosis cerebri

A. Wirathmawati, N. Raisa, B. Munir (Malang, Indonesia)

1:45pm-3:15pm: Basal Ganglionic Lesions in Egyptian Children: Radiological Findings in Correlation with Etiology and Clinical Manifestations

H. Zehry, S. Darwish, S. El zayat, H. Gad, H. Emam, M. (Mansoura, Egypt)

1:45pm-3:15pm: Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease

C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, M. Hacker, P. Charles, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

1:45pm-3:15pm: Beneficial nonmotor effects of subthalamic and pallidal DBS in Parkinson’s disease

H. Dafsari, M. dosSantos Ghilardi, V. Visser-Vandewalle, A. Rizos, K. Ashkan, M. Silverdale, J. Evans, R. Martinez, R. Cury, M. Barbe, G. Fink, A. Antonini, K. Ray-Chaudhuri, P. Martinez-Martin, E. Fonoff, L. Timmermann (Cologne, Germany)

1:45pm-3:15pm: Bereitschaftspotential in a Patient with Functional Propriospinal Myoclonus

C.H. Tsai, M.K. Lu, Y.F. Chen, Y.Y. Chang, J.C. Chen (Taichung, Taiwan)

1:45pm-3:15pm: Bilateral stereotypy after unilateral cerebellar infarction

S. Choi, C. Shin, T. Ahn (Seoul, Republic of Korea)

1:45pm-3:15pm: Bilateral subthalamic deep brain stimulation combined with thalamotomy for PRRT2-associated generalized dystonia: A case report

DD. Zhang, JL. Liu, J. Yan, XJ. She, XD. Cai (Shenzhen, China)

1:45pm-3:15pm: Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson’s Disease

T. Tsao, C. Fontana, A. Waite (Boston, MA, USA)

1:45pm-3:15pm: Biofabricated tissue constructs to recapitulate the anatomy and functionality of the nigrostriatal pathway in Parkinson’s disease

J. Duda, L. Struzyna, K. Browne, H. Chen, D. Cullen (Philadelphia, PA, USA)

1:45pm-3:15pm: Biological course and natural history of hereditary spastic paraplegia type 11 (SPG11)

T. Musacchio, K. Nohl, K. Boelmans, V. Maltese, D. Zeller, I. Isaias, J. Volkmann, S. Klebe (Würzburg, Germany)

1:45pm-3:15pm: Bipolar directional DBS in VIM-stimulated patients

J. Steffen, P. Reker, F. Mennicken, T. Dembek, H. Dafsari, G. Fink, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: Blinded acute assessment of electrode contact efficacy compared with contact location for Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease

G. Lim, B. Jonker, S. Bolitho, S. Tisch (Sydney, Australia)

1:45pm-3:15pm: Botulinum toxin in Essential Hand Tremor – A Randomized Double-Blind Placebo-Controlled study with Customized Injection Approach

S. Mittal, D. Machado, D. Richardson, D. Dubey, B. Jabbari (Bangalore, India)

1:45pm-3:15pm: Botulinum toxin injection for Pisa syndrome in Parkinson’s disease

CA. Artusi, M. Zibetti, P. Barbero, M. Busso, S. Bortolani, S. De Mercanti, P. Arnoffi, M. Fabbri, A. Merola, L. Lopiano (Torino, Italy)

1:45pm-3:15pm: Brief Cognitive Screening for Parkinson’s disease by the Korean Version of the Montreal Cognitive Assessment

M. Park, D. Kwon (Ansan-city, Korea)

1:45pm-3:15pm: Broad White Matter Impairment in Multiple System Atrophy: A case for Oligodendrocyte Dysfunction

N. del Campo, O. Phillips, F. Ory-Magne, M. Galitzky, C. Brefel-Coubron, C. Thalamas, K. Narr, S. Joshi, M. Singh, P. Péran, A. Pavy-LeTraon, O. Rascol (Toulouse, France)

1:45pm-3:15pm: Can blood biomarkers differentiate Idiopathic Parkinson’s disease from Parkinson plus syndromes? A study from North Indian population

R. Shree, M. Mulagala, M. Modi, S. Mehta, M. Goyal, B. Medhi, V. Lal, B. Mittal (Chandigarh, India)

1:45pm-3:15pm: Can brittle dyskinesia be one of the causes of Twiddler syndrome in Deep Brain Stimulation?

A. Acarer, H. Biçeroğlu, T. Yurtsever, Z. Çolakoğlu (Izmir, Turkey)

1:45pm-3:15pm: Can choice of games influence the therapeutic results obtained by training in virtual reality for gait improvement in people with Parkinson’s disease?

P. Barbosa, A. da Costa, A. Falconi, M. d'Alencar, M E. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: Carbon Monoxide Poisoning-Induced Parkinsonism: A Prospective Study of Clinical and Neuroimage Correlation

J-Y. Li, M-C. Chou, P-H. Lai (Kaohsiung, Taiwan)

1:45pm-3:15pm: Caudate nucleus atrophy as an early finding of Neuroferritinopathy

G. Alvarez Bravo, J. Fernández Carril, E. Orts Castro (Guadalajara, Spain)

1:45pm-3:15pm: Cerebrotendinous Xanthomatosis: A heterogeneous condition

D. Cerdán, B. Fernández, J. Eguizábal, P. Gil, A. Mendoza, A. Castrillo, F. Rodríguez, C. Tabernero, J. Duarte (Segovia, Spain)

1:45pm-3:15pm: Cervical dystonia in Modigliani’s paintings: The clue was the sensory trick

J.C. Martinez Castrillo, A. Alonso Canovas, P.J. Garcia (Madrid, Spain)

1:45pm-3:15pm: Challenging mitochondria in idiopathic Parkinson‘s disease fibroblasts

P. Antony, O. Boyd, K. Mommaerts, K. Sokolowska, M. Ostaszewski, A. Baumuratov, L. Longhino, F. Poulain, R. Krueger, R. Balling, N. Diederich (Belvaux, Luxembourg)

1:45pm-3:15pm: Change of tremor dominant body side after deep brain stimulation in patients with Parkinson’s disease

P. Wouters, M. Janssen, P. Kubben, L. Ackermans, Y. Temel, M. Kuijf (Maastricht, Netherlands)

1:45pm-3:15pm: Changes in chest wall intermuscular coherence and speech breathing kinematics during speech and non-speech tasks following LSVT LOUD® in children with dysarthria secondary to cerebral palsy

M. Ho, A. Reed, B. Mager, H. Gynane, R. Bakhtiari, C. Fox, C. Boliek (Edmonton, AB, Canada)

1:45pm-3:15pm: Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients

J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari (Tirgu Mures, Romania)

1:45pm-3:15pm: Characterization of color vision impairment in Lewy Body Diseases

T. Tousi, F. Flanigan, K. Khosravi (Cleveland, OH, USA)

1:45pm-3:15pm: Chinese patients with Wilson disease and the treatments: exampled with Unithiol (DMPS) intravenous infusion

X.P. Wang (Shanghai, China)

1:45pm-3:15pm: Chitotriosidase is a biomarker for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

S. Hayer, J. Böhringer, L. Schöls (Tübingen, Germany)

1:45pm-3:15pm: Chlorogenic acid exerts anti-neuroinflammatory effect by suppressing NF-κB pathway in Parkinsonian mice model

S. Singh, S. Rai, H. Birla, W. Zahra, S. Singh (Varanasi, India)

1:45pm-3:15pm: Choice for deep brain stimulation in Parkinson’s disease: Italian survey study

R. Ferrucci, C. Di Nuzzo, F. Ruggiero, F. Mancini, A. Priori (Milan, Italy)

1:45pm-3:15pm: Classifying Parkinsonian Gait and Turning in Daily Life with Wearable Technology

F. Horak, J. McNames, M. El Gohary, J. Nutt, C. Curtze (Portland, OR, USA)

1:45pm-3:15pm: Clinical and genetic heterogeneity in portuguese patients with Hereditary Spastic Paraplegia

I. Cunha, A. Brás, J. Ribeiro, C. Januário (Coimbra, Portugal)

1:45pm-3:15pm: Clinical and genetics characterization of patients with Myoclonus Dystonia Syndrome

B. Perez-Dueñas, M. Vanegas, L. Marti, A. Darling, D. Ortigoza-Escobar, S. Candela, H. Baide, J. Campistol, S. Aguilera, M. Marti, A. Macaya (Barcelona, Spain)

1:45pm-3:15pm: Clinical and morphometric features of the tics

S. Munasipova, Z. Zalyalova (Kazan, Russian Federation)

1:45pm-3:15pm: Clinical characteristics of turkish patients with Parkinson’s disease: A retrospective analysis of 428 patients

B. Gonenli Kocer, E. Ozturk, S. Comoglu (Ankara, Turkey)

1:45pm-3:15pm: Clinical characterization of Pramipexole induced edema and skin reaction in Parkinson’s Disease (PD) after one year of follow up

E. Urrea-Mendoza, N. Rincon, F. Revilla (Greenville, SC, USA)

1:45pm-3:15pm: Clinical characterization of tremor in patients with Phenylketonuria (PKU)

F. Nardecchia, F. Manti, S. De Leo, C. Carducci, V. Leuzzi (Rome, Italy)

1:45pm-3:15pm: Clinical effectiveness of a highly challenging balance training (HiBalance program) for Parkinson’s disease: A multi-center clinical effectiveness trial

B. Leavy, C. Joseph, N. Löfgren, H. Johansson, M. Hagströmer, E. Franzén (Stockholm, Sweden)

1:45pm-3:15pm: Clinical practice of levodopa in parkinsonism

AC. Chen (Taichung, Taiwan)

1:45pm-3:15pm: Clinical profile and predictors of outcome in Neuroleptic malignant syndrome and Parkinsonism hyperpyrexia syndrome

R. Kandadai, P. Dutta, S. Meka, T. Syed, S. Tandra, S. Turaga, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Clinical study on the correlation between Parkinson’s somatosensory evoked potentials and STN-DBS parameters

Z. Jing, Y. Xiaoxue, G. Shuzhao, S. Chunli, L. Zhanhua, (Dalian, China)

1:45pm-3:15pm: Clinical trial protocol: Restitution of oral transport, penetration and aspiration with nigral stimulation in Parkinson’s disease?

A. Schoellmann, L. Stoll, B. Hobl, C. Meisner, A. Gharabaghi, D. (Tuebingen, Germany)

1:45pm-3:15pm: Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation (CLOVER-DBS)

F. Sasaki, G. Oyama, S. Sekimoto, R. Nakamura, T. Jo, H. Iwamuro, A. Umemura, Y. Shimo, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: CLOVER-DBS: A Prospective, Multi-center Clinical Study with Blinding to Evaluate a Closed Loop Programming Algorithm for Directional Leads Based on External Feedback

A. Kuehn, G. Wenzel, C. Bruecke, L. Juarez Paz, K. Wynants, H. Scholtes, D. Blum (Berlin, Germany)

1:45pm-3:15pm: Cognition and emotion regulation in early onset ataxia

M. Coenen, D. Sival, R. Brandsma, M. Tijssen, J. Spikman (Groningen, Netherlands)

1:45pm-3:15pm: Cognition related to striatal dopaminergic function in healthy subjects, in consideration to aging

H. Li, S. Hirano, S. Furakawa, K. Kojima, K. Shimizu, Y. Nakano, H. Tai, H. Mukai, T. Uno, T. Iimori, H. Matsuda, S. Kuwabara (Chiba, Japan)

1:45pm-3:15pm: Cognitive effects of SIRT6 overexpression: Emerging role of astrocytes

N. Lev, Y. Barhum (Kfar Saba, Israel)

1:45pm-3:15pm: Combination Therapy of Ellagic Acid and Mucuna Pruriens Seeds Extract Improves Rotenone Induced Behavioural, Oxidative and Mitochondrial Deficits in Mice Model of Parkinson’s Disease

D. Khatri (Pune, India)

1:45pm-3:15pm: Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease

A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato (CA), Italy)

1:45pm-3:15pm: Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience

R.N. Taddei, V. Leta, A. Sauerbier, M. Parry, A. Podlewska, L. Hall, S. Tentis, P. Odin, W. Poewe, P. Dubois, D. van Warmelen, E.W. Lim, K.R. Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Comparative results between preoperative acute levodopa challenge test and deep brain stimulation

D. Fitas, M.J. Rosas, J. Parada Lima, C. Reis, P. Linhares, R. Vaz (Viana do Castelo, Portugal)

1:45pm-3:15pm: Comparison of clinical characteristics and treatment outcomes of botulinum neurotoxin in routine clinical practice between hemifacial spasm with and without the Babinski-2 sign in Thai patients: An exploratory study

A. Suengtaworn, Y. Pitakpatapee, P. Soontrapa, C. Hurst, P. Srivanitchapoom (Bangkok, Thailand)

1:45pm-3:15pm: Comparison of low versus high frequency stimulation on stuttering in Parkinson’s disease patients with bilateral subthalamic nucleus deep brain stimulation

O. Jitkritsadakul, K. Boonpang, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Comparison of low-frequency stimulation versus high-frequency stimulation of the subthalamic nucleus on cerebral hemodynamics in Parkinson’s disease: A transcranial Doppler Study

A. Yilmaz, E. Okuyucu, T. Yildizgoren, S. Oral, M. Aras, Y. Serarslan (Hatay, Turkey)

1:45pm-3:15pm: Comparison of Mattis and MOCA testing for neuropsychological assessment in the preoperative evaluation of subthalamic nucleus stimulation in Parkinson´s disease

L. Prilop, M. Alsalem, A. Gulberti, C. Gerloff, C. Buhmann, W. Hamel, C. Moll, J. Köppen, M. Pötter-Nerger (Hamburg, Germany)

1:45pm-3:15pm: Comparison of virtual-reality-gaming and activity-based gait and balance training on gait, balance and quality of life in patients with Parkinson’s disease

A. Ogundele, M. Olaogun, M. Komolafe (Ile-Ife, Nigeria)

1:45pm-3:15pm: Comparison of Volumetric MRI measurements between Dementia with Lewy bodies and prodromal Lewy body disease

B. Tousi, F. Flanigan, k. Khosravi (Cleveland, OH, USA)

1:45pm-3:15pm: Compensation strategies for gait impairments in Parkinson’s disease

J. Nonnekes, E. Růžička, A. Nieuwboer, M. Hallett, A. Fasano, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Compound-heterozygous mutations in VPS13D are a novel cause of spastic ataxia and lead to mitochondrial dysfunction

M. Dulovic, N. Brüggemann, J. Trinh, A. Münchau, C. Klein, K. Lohmann (Luebeck, Germany)

1:45pm-3:15pm: Connectivity profile of delayed-onset DBS side effects

M. Reich, J. Hsu, J. Joutsa, J. Roothans, N. Pozzi, J. Volkmann, I. Isaias, M. Fox (Boston, MA, USA)

1:45pm-3:15pm: Contribution of ATP-sensitive potassium channels in the subthalamic nucleus neurons towards Parkinson’s disease

C. Mahapatra, R. Manchanda (Mumbai, India)

1:45pm-3:15pm: Contribution of the French registry in the understanding of Wilson disease

A. Poujois, N. Girardot, A.S. Brunet, A. Lachaux, F. Woimant (Paris, France)

1:45pm-3:15pm: Controlled neural organoids grafting promotes functional recovery in experimental parkinsonism

E. Faggiani, M. Feyeux, K. Alessandri, P. Cohen, E. Pioli, F. Naudet, A. Benazzzouz, P. Nassoy, E. Bezard (Bordeaux, France)

1:45pm-3:15pm: Correlation between cerebral perfusion and striatal dopamine transporter activity by dual SPECT study in Parkinsonian syndromes

Y. Nakano, S. Hirano, K. Kojima, H. Li, A. Ishikawa, T. Sakurai, H. Tai, H. Mukai, T. Horikoshi, T. Uno, S. Kuwabara (Chiba, Japan)

1:45pm-3:15pm: Correlation between severity of disease, spatio-temporal variables, and kinematic variables during forward and backward walking

M. Son, C. Youm, M. Lee, H. Park (Busan, Republic of Korea)

1:45pm-3:15pm: Cortical myoclonus explained by cerebellar dysfunction: Evidence from a unique case

L. Rocchi, L. Latorre, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Cortical thinning as a neuroimaging marker of cognitive decline in X-linked dystonia-parkinsonism

J. Prasuhn, H. Hanßen, A. Domingo, C. Diesta, R. Rosales, R. Jamora, C. Klein, N. Brüggemann (Luebeck, Germany)

1:45pm-3:15pm: Corticomuscular and Intermuscular Coherence as a Biomarker of Pallidal Deep Brain Stimulation Efficacy in Dystonia

E. Doldersum, J. van Zijl, M. Beudel, H. Eggink, R. Brandsma, D. Pina Fuentes, M. van Egmond, D. Oterdoom, J. van Dijk, J. Elting, M. de Koning-Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: Could curcumin be the preventive key of parkinson’s disease?

W. Laabbar, A. Elgot, H. Gamrani (Marrakech, Morocco)

1:45pm-3:15pm: Could the rate of dopaminergic medications reduction affect outcome after STN-DBS?

S. Alusi (Liverpool, United Kingdom)

1:45pm-3:15pm: Crack Dancing: An Uncommon Drug-Induced Chorea

G. Gibb, D. Nacopoulos (Erie, PA, USA)

1:45pm-3:15pm: Deep brain stimulation (DBS) for dyskinetic cerebral palsy: A pilot study

S. Duma, N. Mahant, A. Ha, S. Kim, A. Phu, K. Stewart, M-C. Waugh, N. Wolfe, D. Russell, B. Owler, M. Krause, V. Fung (Westmead, Australia)

1:45pm-3:15pm: Deep brain stimulation and its efficacy using microelectrode recording

V. Rama Raju, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Deep brain stimulation for choreoathetosis in cerebral palsy: Pallidal versus thalamic stimulation

M. Wolf, C. Blahak, A. Saryyeva, C. Schrader, J. Krauss (Mannheim, Germany)

1:45pm-3:15pm: Deep brain stimulation for monogenic Parkinson’s disease: A systematic review

T. Kuusimäki, J. Korpela, E. Pekkonen, M. Martikainen, A. Antonini, V. Kaasinen (Turku, Finland)

1:45pm-3:15pm: Deep brain stimulation in Parkinson’s disease: From the stimulation of a nucleus to the stimulation of neuronal networks

A. Arévalo, L. López Manzanares, R. Manzanares, M.A. García-Pallero, M. Navas, P. Pastor, L. Vega Zelaya, CV. Torres Diaz. (Madrid, Spain)

1:45pm-3:15pm: Deep Brain Stimulation in Tourette Syndrome: Two illustrative cases

X. Garcia, J. Espinoza, G. Arango (Bogota, Colombia)

1:45pm-3:15pm: Deep brain stimulation matters in pediatric neurology – single-center experience

M. Freilinger, A. Zeitlberger, S. Siegert, R. Seidl, F. Alesch, G. Kranz, K. Novak (Vienna, Austria)

1:45pm-3:15pm: Deep Brain Stimulation of Globus Pallidus Internus Combined with Bilateral Anterior Capsulotomy for the Treatment of Tardive Dystonia in Patients with Refractory Schizophrenia

Y. Pan, C. Zhang, Y. Zhang, L. Wang, Z. Deng, S. Zhan, J. Zhang, Y. Li, B. Sun, D. Li (Shanghai, China)

1:45pm-3:15pm: Deep brain stimulation outcomes for primary and secondary dystonia

M. Carmona-Abellán, O. Parras, R. Valentí, J. Guridi, M. Alegre, R. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Deep brain stimulation: A Treatment Modality for Generalized Dystonia Secondary to Anoxic Brain Injury in Adults

P. Vittal, J. Rosenow, M. Nolt, J. Pallone, M. McGraw, A. Monette, L. Guzman, A. Shrivastava, M. Mercury, M. Rezak (Winfield, IL, USA)

1:45pm-3:15pm: Delayed-onset Edema Surrounding Deep Brain Stimulation Leads: Insights From A Case Series and Literature Review

Y. Hu (Guangzhou, China)

1:45pm-3:15pm: Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2

R. Hodgson, T. Parkkari, T. Martinez, M. Fell, D. Bryce, T. Heikkinen, A. Nurmi, T. Bragge, M. Taavitsainen, T. Lanz, M. Baptista (Wilmington, MA, USA)

1:45pm-3:15pm: Demographic and Clinical Characteristics of Flunarizine Induced Parkinsonism: Nationwide Data Between 2000 and 2006 in Taiwan

W. Lin, CY. Wei, HJ. Chen (ChangHua, Taiwan)

1:45pm-3:15pm: Design and Status of the BIIB054 SPARK Trial

Parkinson Study Group, A. Siderowf (NY, USA)

1:45pm-3:15pm: Design of a Pharmacokinetics Study with Multiple Doses of Accordion Pill™ Carbidopa/Levodopa in Patients with Parkinson’s disease

C. Olanow, K. Kieburtz, J. Dubow, F. Stocchi, J. Meckler, N. Navon, R. Gendreau (Sarasota, FL, USA)

1:45pm-3:15pm: Design of a Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa for Parkinson’s Disease (PD) Patients Experiencing Motor Fluctuations

P. LeWitt, R. Gendreau, J. Meckler, N. Navon (West Bloomfield, MI, USA)

1:45pm-3:15pm: Determinants of absence of dyskinesia in Parkinson’s disease patients with treatment beyond 10 years

R. Ou, Y. Wu, Q. Wei, X. Yuan, Y. Hou, H. Liu, L. Zhang, Y. Chen, B. Cao, X. Chen, H. Shang (Chengdu, China)

1:45pm-3:15pm: Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation

K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, H. Hayakawa, T. Omichi, K. Baba, K. Konaka, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system

K. Ikenaka, K. Araki, S. Sonoda, T. Takeuchi, Y. Nagai, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: Development of evidence-based clinical practice guideline (CPG) of complementary and alternative medicine (CAM) for Parkinson’s disease (PD)

K.H. Cho, S.W. Kwon, S.H. Lee, T.H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Diagnostic potential of automated middle cerebellar peduncle volumetry in variants of multiple system atrophy

F. Krismer, K. Seppi, T. Potrusil, R. Steiger, I. Zucal, G. Göbel, G. Wenning, E. Gizewski, W. Poewe, C. Scherfler (Innsbruck, Austria)

1:45pm-3:15pm: Diagnostic tips from a case series of patients with Late Onset Tay Sachs disease

G.M. Riboldi, K. Anstett, H. Lau (New York, NY, USA)

1:45pm-3:15pm: Dielectric Properties of Blood Plasma Predict Cognitive Impairment in an Amyloid-Beta-Induced Rat Model of Alzheimer’s Dementia

E. Dalle, A. Lonappan, M. Mabandla, W. Daniels (Durban, South Africa)

1:45pm-3:15pm: Diencephalic mesencephalic junction abnormalities in adult-onset movement disorders

A.M. Crespo Cuevas, V. Puente, S. Medrano, L. Planellas, D. Vilas (Barcelona, Spain)

1:45pm-3:15pm: Differential glial and neuronal response in Lipopolysaccharide induced Parkinson’s disease model: Modulation with Apocyanin and Curcumin

N. Sharma, B. Nehru (Chandigarh, India)

1:45pm-3:15pm: DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Intra-visit Impedance Changes

F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, PR. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

1:45pm-3:15pm: DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Visualization of Optimal Directionally Stimulated Anatomy

F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, PR. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

1:45pm-3:15pm: DIRECT DBS: A Prospective, Multicenter Clinical Study with Double-Blinding for a Directional Deep Brain Stimulation Lead – Therapeutic Windows with Directional Stimulation

F. Steigerwald, J. Volkmann, C. Matthies, A. Dalal Kirsch, S. Chabardes, R. de Bie, P. Schuurman, E. Moro, V. Fraix, S. Meoni, D. Blum, L. Juarez Paz, K. Wynants, N. Van Dyck (Würzburg, Germany)

1:45pm-3:15pm: Directional DBS; clinical experience at Unit of Functional Neurosurgery. Ramón y Cajal University Hospital,Madrid, Spain

M. del Alamo, I. Martinez-Camacho, L. Cabañes, I. Regidor, M. Villadoniga, J. Garcia-de-la-Cruz, I. Avilés-Olmos (Madrid, Spain)

1:45pm-3:15pm: Directional DBS: A new algorithm to determine lead rotation

T. Dembek, M. Barbe, A. Hellerbach, M. Hoevels, J. Wirths, A. Horn, V. Visser-Vandewalle, H. Treuer (Cologne, Germany)

1:45pm-3:15pm: Directional deep brain stimulation in Parkinson’s disease guided by local field potentials

F. Alonso-Frech, C. Fernandez-Garcia, M. Monge, M.J. Catalan Alonso, G. Foffani (Madrid, Spain)

1:45pm-3:15pm: Directional Deep Brain Stimulation: First experiences in centers across the globe

T. ten Brinke, V. Odekerken, J. Dijk, P. vd Munckhof, P. Schuurman, R. de Bie (Amsterdam-Zuidoost, Netherlands)

1:45pm-3:15pm: Directional Lead Impedances and Their Possible Effects on Deep Brain Stimulation

L. Juarez Paz, A. Dalal Kirsch, F. Steigerwald, C. Matthies, S. Meoni, V. Fraix, T. Ten Brinke, R. de Bie, K. Wynants, D. Blum, N. Van Dyck, PR. Schuurman, E. Moro, S. Chabardes, J. Volkmann (Valencia, CA, USA)

1:45pm-3:15pm: Dissecting molecular signatures of X-linked dystonia-parkinsonism (XDP) through integrative genomics studies

A. Domingo, S. Sharma, A. Aneichyk, W. Hendriks, Y. Yadav, D. Shin, D. Gao, C. Vaine, B. Currall, N. Kulkarni, T. Multhaupt-Buell, E. Penney, M. Dy, C. Go, RD. Jamora, R. Rosales, M. Ang, U. Müller, C. Klein, P. Acuña, X. Breakefield, L. Ozelius, DC. Bragg, M. Talkowski (Boston, MA, USA)

1:45pm-3:15pm: Distance to white matter tracts predicts STN deep brain stimulation outcome of tremor and dysarthria in Parkinson’s disease

L. Boon, N. Prent, W. Potters, M. Caan, H. Berendse, R. de Bie, P. vd Munckhof, P. Schuurman, A. van Rootselaar (Amsterdam, Netherlands)

1:45pm-3:15pm: Distinct abnormality of movement-related cortical potential between patients with Holmes tremor and cerebellar degeneration

M.K. Lu, J.C. Chen, S.M. Liu, C.H. Tsai (Taichung, Taiwan)

1:45pm-3:15pm: Does altering medication to avoid dyskinesia positively alters the breadth of the motor repertoire of patients with Parkinson’s disease? A pilot study

S. Bogard, E. Goubault, K. Lebel, C. Duval (Montreal, QC, Canada)

1:45pm-3:15pm: Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?

S. Chung, H. Yoo, J. Oh, J. Kim, P. Lee, Y. Sohn (Seoul, Republic of Korea)

1:45pm-3:15pm: Does Niemann Pick Type C heterozygosity predispose to late-onset neurodegeneration?

T. Bremova, C. Sztatecsny, M. Moser, A. Rominger, T. Stephan, J. Havla, K. Hartmann, D. Clevert, M. Strupp, S. Schneider (Munich, Germany)

1:45pm-3:15pm: Does the effect of continuous levodopa infusion treatment for Parkinson’s disease regress as the day progresses?

I. Thomas, M. Memedi, D. Nyholm, J. Westin (Borlange, Sweden)

1:45pm-3:15pm: Dopaminergic impairments following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin through inflammatory cytokines in rats

R. Shukla, R. Gupta, S. Goel, A. Pant, V. Khanna (Bhopal, India)

1:45pm-3:15pm: Dopaminergic medication changes affect cognitive, mood, and quality of life outcomes after STN DBS

D. Floden, O. Hogue, M. Saupe, R. Busch, K. Wilson, A. Ahmed (Cleveland, OH, USA)

1:45pm-3:15pm: Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period

A. Azimov, R. Sadykov, G. Rakhimbaeva, F. Azimov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic therapy

A. Videnovic, S. Rutten, W. Croft, H. Erickson, J. Groves, C. Havemann, T. Herrington, S. Hendrix, K. Kieburtz, Y. vander Werf, O. vanden Heuvel (Boston, MA, USA)

1:45pm-3:15pm: Dual Competition between the Basal Ganglia and the Cortex: 1 from Action-Outcome to Stimulus-Response

T. Boraud (Bordeaux, France)

1:45pm-3:15pm: Dual device aided therapy for patients with advanced Parkinson’s Disease: A case series

A. Faust- Socher, G. Yahalom, M. Kestenbaum, A. Hilel, S. Israeli-Korn, A. Thaler, H. Strauss, H. Shabtai, S. Hassin-Baer, N. Giladi, T. Gurevich, O. Cohen (Tel Aviv, Israel)

1:45pm-3:15pm: Dual task in the daily life of patients with Parkinson’s disease

K. Mejia (Lima, Peru)

1:45pm-3:15pm: Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

J. Pagonabarraga, E. Tolosa, J. Ferreira, A. Lees, E. Arbe, J. Rocha, P. Soares-da-Silva (Barcelona, Spain)

1:45pm-3:15pm: Dyskinesia-hyperpyrexia syndrome (DHS) after sudden interruption of deep brain stimulation and increase of oral dopaminergic therapy: A case report

F. Dematteis, A. Cormio, C. Fronda, M. Lanotte, M. Zibetti, S. Amarù, L. Lopiano, M. Rizzone (Rivoli, Italy)

1:45pm-3:15pm: Dysphagia predicts poor outcome in late-stage Parkinson’s disease

M. Fabbri, D. Abreu, L. Guedes, M. Rosa, A. Antonini, M. Zibetti, L. Lopiano, J. Fereira, M. Coelho (Lisbon, Portugal)

1:45pm-3:15pm: Dystonia ataxia (DYTCA) syndrome with prominent handwriting deterioration associated with ADCK3 mutation: two new cases and an overview of the literature

S. Galosi, T. Schirinzi, E. Bertini, R. Haas, F.M. Santorelli, V. Leuzzi, J.R. Friedman (Rome, Italy)

1:45pm-3:15pm: Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy

F. Adib Saberi, D. Dressler (Hamburg, Germany)

1:45pm-3:15pm: Educating Movement Disorders through a web based counselling service in Mauritius

M. Busgopaul (Port Louis, Mauritius)

1:45pm-3:15pm: Education in hyperkinetic movement disorders in Cameroonian health providers

M.H.G. Monje, M.M. Kurtis, M. Molina, C. Delgado-Suárez, P. Gómez-Iglesias, I. García-Morales, D. García-Azorín (Móstoles, Madrid, Spain)

1:45pm-3:15pm: Effect of Ba Duan Jin Exercise on Non-Motor Symptoms, Motor Symptoms, Gait and Balance in Patients with Mild to Moderate Parkinson’s Disease

Z. Cai, S. Dong (Lianyungang City, China)

1:45pm-3:15pm: Effect of Cold Compression Before Botulinum Neurotoxin Injection in Hemifacial Spasm

P. Dhanachanvisith, T. Tantirittisak (Bangkok, Thailand)

1:45pm-3:15pm: Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease

I.U. Song, K.S. Lee, Y.A. chung (Incheon, Republic of Korea)

1:45pm-3:15pm: Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease

J. Chen, J. Hong, L. Chunfeng (Suzhou, China)

1:45pm-3:15pm: Effect of dual task as rehabilitation therapy in Parkinson’s disease in the UPDRS III

C. Mejia (Lima, Peru)

1:45pm-3:15pm: Effect of exercise on neurodegenerative parkinsonism unmasked by dopamine blocking drugs (DRBD)

J. Morley, S. Wood, G. Cheng, K. Browne, K. Robinson, D. Weintraub, J. Duda (Philadelphia, PA, USA)

1:45pm-3:15pm: Effect of finger rhythmic movement training on freezing of gait in Parkinson’s disease patients: A study protocol

H. Nakano, S. Murata, T. Kodama, H. Nakae, M. Soma (Kyoto-city, Japan)

1:45pm-3:15pm: Effect of lidocaine injection into the external oblique muscle on camptocormia and the lateral slant posture in patient with Parkinson’s disease

Y. Higashi, M. Tabata, T. Tabuchi, Y. Hattori (Himeji, Japan)

1:45pm-3:15pm: Effect of mindfulness yoga on psychological distress in people with Parkinson’s disease (PD): A randomized controlled trial

J.Y.Y. Kwok, J.C.Y. Kwan, M. Auyeung, C.T. Mok, C.K.Y. Lau, H.Y.L. Chan (New Territories, Hong Kong)

1:45pm-3:15pm: Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS and DaT SBR in PPMI study

J. Cedarbaum, K. Evans, M. Yang, J. Xiao (Cambridge, MA, USA)

1:45pm-3:15pm: Effect of Post-Operative Symptomatic Lead Edema Associated with Subthalamic Deep Brain Stimulation On Clinical Outcomes

V. Sharma, K. Lyons, J. Nazzaro, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Effect of Thalamic Deep Brain Stimulation in Isolated Dystonia Associated with Prominent Tremor

J. Choi, S. Heath, D. Wang, P. Starr, P. Larson, D. Lim, M. San Luciano, M. Volz, J. Ostrem (San Francisco, CA, USA)

1:45pm-3:15pm: Effect of Viewpoint and Visual Texture on Object Recognition in Dementia with Lewy Bodies and in Alzheimer’s Disease

Y. Oishi, K. Suzuki, T. Imamura, T. Shimomura (Niigata, Japan)

1:45pm-3:15pm: Effective physiotherapy program for Parkinson’s disease

I. Toyoshima, K. Hasegawa, M. Doi (Yurihonjo, Japan)

1:45pm-3:15pm: Effectiveness and safety of acupuncture in the treatment of Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials

CN. Ko, SU. Park, SY. Cho, JM. Park (Seoul, Korea)

1:45pm-3:15pm: Effectiveness of a Multi-disciplinary Parkinson’s Disease (PD) Clinic: A 2-year Prospective Observational Study

G. Chan, N. Cheung, S. Or, I. Chan, A. Leung, C. Li, D. Chau, C.W. Woo, B. Chee, W.C. Fong (Hong Kong)

1:45pm-3:15pm: Effectiveness of Rotigotine plus Intensive and Goal-based Rehabilitation versus Rotigotine alone in “de-novo” Parkinsonian subjects: A Randomized Controlled Trial with 18-month Follow-up

D. Ferrazzoli, P. Ortelli, G. Riboldazzi, R. Maestri, G. Frazzitta (Gravedona ed Uniti, Italy)

1:45pm-3:15pm: Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy

J. Francês Brito, M. Akkari, A. Pinheiro Alves, A. Barbosa de Sousa Junior, B. De Oliveira, O. Vieira Kishi, Jose Roberto Bentes Capeloni (Belem, Brazil)

1:45pm-3:15pm: Effects of droxidopa when measuring gait speed, kyphosis, and functional reach in Parkinson’s disease

C. Kutz, L. Adams, E. Moncheski (Colorado Springs, CO, USA)

1:45pm-3:15pm: Effects of Expiratory Muscle Strength Training and Voice Therapy on Parkinsonian Speech

T.S. Tong, M.W. Ng (Pokfulam, Hong Kong)

1:45pm-3:15pm: Effects of High-frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS) Combined with Task Specific Training in Individuals with Parkinson’s Disease

J. Thanakamchokchai, J. Tretriluxana, B. Fisher, N. Pakaprot, A. PisarnPong (Nakhon Pathom, Thailand)

1:45pm-3:15pm: Effects of Intensive Voice and Articulation Treatments on Voice Quality in Parkinson’s disease

J. Spielman, L. Ramig, K. Freeman, A. Halpern, Y. Maryn (Denver, CO, USA)

1:45pm-3:15pm: Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease

B. Lee, C. Noelker, W. Chiu, D. Feuerbach, L. Timmerman, W. Oertel (Marburg, Germany)

1:45pm-3:15pm: Effects of Korean Medicine on Postural Instability and Gait Difficulty in Patient with Parkinsonism

HM. Lee, SB. Yang, SY. Cho, JM. Park, CN. Ko, SU. Park (Seoul, Republic of Korea)

1:45pm-3:15pm: Effects of Long-Term Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 4 Study Results

C. Comella, C. Singer, S. Marder, J. Burke, K. Farahmand, R. Jimenez, S. Siegert (Chicago, IL, USA)

1:45pm-3:15pm: Effects of MRI-guided Focused Ultrasound unilateral subthalamotomy on characteristics of EMG activity underlying reaction time and tapping test in Parkinson’s disease

D. Urso, B. Fernández-Rodríguez, R. Rodríguez-Rojas, M. del Álamo, F. Hernández-Fernández, J. Pineda-Pardo, M. Dileone, G. Foffani, I. Obeso, C. Gasca-Salas, L. Vela, R. Martínez-Fernández, F. Alonso-Frech, J. Obeso (Móstoles, Spain)

1:45pm-3:15pm: Effects of non-invasive brain stimulation on motor-speech disorders in Parkinson’s disease

I. Rektorova, P. Klobusiakova, L. Brabenec, J. Mekyska, Z. Galaz, M. Kostalova (Brno, Czech Republic)

1:45pm-3:15pm: Effects of PGE inhibition on Striatal Neuroinflammation in 6-OHDA lesion

T. Adu, M. Mabandla (Durban, South Africa)

1:45pm-3:15pm: Effects of progressive resistance and flexibility exercise program of trunk on static and dynamic stability for Parkinson’s disease

M. Lee, C. Youm, M. Son, H. Park, Y. Kim (Busan, Republic of Korea)

1:45pm-3:15pm: Effects of Rock Steady Boxing on Activities of Daily Living and Motor Symptoms of Parkinson’s Disease

D. Larson, D. Bega, E. Johnson, L. Slowey (Chicago, IL, USA)

1:45pm-3:15pm: Effects of rTMS on three cortical areas in Parkinson’s Disease

V. Goyal, P. Bhat, C. Goyal, A. Srivastava, S. Kumaran, M. Behari, S. Dwivedi (Delhi, India)

1:45pm-3:15pm: Effects of the Lee Silverman Voice Treatment (LSVT LOUD ®) on Facial Expressivity in Individuals with Parkinson’s Disease (PD) as a function of Emotional Valence

A. Bono, K. Scorpio, R. Stafford, M. Halfacre, E. Murray, J. Twaite, K. Alterescu, J. Spielman, A. Halpern, L. Ramig, J. Borod (Flushing, NY, USA)

1:45pm-3:15pm: Efficacy and safety of combined unilateral subthalamic nucleus and contralateral globus pallidus deep brain stimulation in Parkinson’s disease

N.R. Choi, K.W. Park, H.S. Ryu, M.S. Kim, S.J. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies

A. Chimagomedova, O. Levin, M. Anikina, I. Ayzenberg (Moscow, Russian Federation)

1:45pm-3:15pm: Efficacy and safety of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: A systematic review of randomized controlled trials

S. Hussain, A. Najmi (New Delhi, India)

1:45pm-3:15pm: Efficacy and security starting safinamide treatment with 100 mg/day in PD

N. Foncea (Galdakao, Spain)

1:45pm-3:15pm: Efficacy of combined treatment with acupunture and bee venom acupuncture for Parkinson’s disease: Double blind randomized controlled trial

S.U. Park, H.M. Lee, S.Y. Cho, J.M. Park, C.N. Ko (Seoul, Republic of Korea)

1:45pm-3:15pm: Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease

R. Pahwa, I. Abeynayake, M. Klingler, A. Sedkov, C. Kenney, C. Oh (Overland Park, KS, USA)

1:45pm-3:15pm: Efficacy of ND0612 for nocturnal problems and early morning OFF

F. Stocchi, W. Poewe, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience

A. Antonini, J. Ferreira, W. Poewe, O. Rascol, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Padova, Italy)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Responder analyses from the BIPARK-I double-blind experience

J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience

J. Kulisevsky, E. Tolosa, J. Ferreira, A. Lees, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience

G. Ebersbach, J. Ferreira, F. Stocchi, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da- (Beelitz, Germany)

1:45pm-3:15pm: Efficacy of prolonged release melatonin for REM sleep behaviour disorder in Parkinson’s disease: A double blind, randomised, placebo-controlled trial

M. Gilat, R. Grunstein, N. Marshall, D. Hammond, A. Coeytaux Jackson, A. Mullins, J. Hall, S. (Sydney, Australia)

1:45pm-3:15pm: Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial

S. Factor, S. Isaacson, K. Sciarappa, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Atlanta, GA, USA)

1:45pm-3:15pm: Efficacy of zonisamide on motor symptoms in dementia with Lewy bodies: A post-hoc analysis of a phase 3 study

H. Maruyama, M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, K. Kosaka (Tokyo, Japan)

1:45pm-3:15pm: Electrophysiological characteristics of task-specific and position-specific tremor: A variant of dystonic tremor?

P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Emotional Lability Following Deep Brain Stimulation Targeting Subthalamic Nucleus, Globus Pallidus Internus and Ventrointermedial Nucleus of Thalamus

S. Joza, T. Sankar, F. Ba (Edmonton, AB, Canada)

1:45pm-3:15pm: Emulating the natural timing of dopamine receptor activation in Parkinson’s Disease

J. Reynolds, B. Hyland, J. Wickens, E. Tan (Dunedin, New Zealand)

1:45pm-3:15pm: Epidemiological and clinical profile of Parkinson’s disease in Douala

J. Doumbe, H. Bohongwe, Y. Mapoure, C. Kuate (Douala, Cameroon)

1:45pm-3:15pm: Epigenetic silencing in the humanized mouse model of Friedreich ataxia

L. Rodden, K. Gilliam, S. Bidichandani (Oklahoma City, OK, USA)

1:45pm-3:15pm: Estimates of cost and saving effects of increasing rechargeable devices on the sustainability of a deep brain stimulation program

Y. Compta, A. Cámara, P. Roldán, E. Muñoz, J. Rumià, MJ. Marti, F. Valldeoriola (Barcelona, Catalonia)

1:45pm-3:15pm: Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics

R. Pahwa, R. Dorsey, P. Kandukuri, Y. Bao, J. Zamudio, I. Pan, Y. Jalundhwala (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluating the Knowledge, Practice and Experience about Management of Parkinson’s Disease among Physiotherapists in Ghana: A Cross sectional Survey

M. Agoriwo (Accra, Ghana)

1:45pm-3:15pm: Evaluation clinical-biochemical features of Parkinson’s disease

D. Daminov, G. Rakhmatullaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Evaluation of apathy before and after subthalamic nucleus deep brain stimulation therapy in advanced Parkinson’s disease patients

S. Caferova, O. Gönül, D. Gunal (Istanbul, Turkey)

1:45pm-3:15pm: Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

1:45pm-3:15pm: Exercise to improve upper limb function in people with Parkinson’s disease: A systematic review

E. Proud, J. Blennerhassett, J. Tan, K. Miller, M. Morris, J. McGinley (Parkville, Australia)

1:45pm-3:15pm: Exosomal alpha synuclein secretion is beneficial for cellular models of Kufor-Rakeb syndrome

T. Tsunemi, Y. Ishiguro, A. Yoroisaka, W. Akamatsu, D. Krainc, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Expanding the clinical phenotype of autosomal recessive spinocerebellar ataxia with Adult onset; a collection of case series

A. Persaud, O. Oguh (Jacksonville, FL, USA)

1:45pm-3:15pm: Expanding the clinical phenotype of BPAN: A case report

M. Boca, A. Herwadkar, C. Breen, M. Silverdale, C. Kobylecki (Salford, United Kingdom)

1:45pm-3:15pm: Exploring the neural correlates of gait asymmetry in idiopathic REM Sleep Behaviour Disorder

K. Ehgoetz Martens, E. Matar, J. Hall, M. Georgiades, M. Gilat, J. Shine, S. Lewis (Camperdown, Australia)

1:45pm-3:15pm: Exploring the utility of the ChulaPD intelligent Parkinson’s disease car to determine naturalistic driving ability in Parkinson’s disease patients: A pilot study of 10 patients

O. Jitkritsadakul, S. Krootjohn, P. Yanthitirat, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Explosive flurry of seizures and new-onset cortical-subcortical lesions in a patient with Wilson disease

A. Aggarwal, M. Munshi, P. Gadgil, D. Sanghvi, M. Bhatt (Mumbai, India)

1:45pm-3:15pm: Eye Movement Abnormalities Correspond to Pontine Atrophy in Wilson Disease

J. Hanuška, P. Dušek, J. Rusz, O. Ulmanová, A. Burgetová, E. Růžička (Prague, Czech Republic)

1:45pm-3:15pm: Familial SCA2-parkinsonism presented as intractable oromandibular dystonia

K. Woo, B. Jeon, J. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Fasciculations from a cholinesterase inhibitor

W. Deeb (Gainesville, FL, USA)

1:45pm-3:15pm: Feasibility and Efficacy of Brainstem Modulation Therapy for the Management of Parkinson’s Disease

K. Ade, A. Podlewska, T. Pellet-Higgins, S. Banducci, M. Bodani, M. Sakel, D. Wilkinson (Raleigh, NC, USA)

1:45pm-3:15pm: Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

R. Hauser, R. Pahwa, C. Tanner, W. Oertel, R. Johnson, L. Felt, MJ. Stempien, R. Patni (Tampa, FL, USA)

1:45pm-3:15pm: Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

S. Isaacson, R. Pahwa, C. Tanner, R. Hauser, W. Oertel, R. Johnson, L. Felt, M.J. Stempien, R. Patni (Boca Raton, FL, USA)

1:45pm-3:15pm: First Results from the Ixcellence Network® Survey: Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis

R. Bhidayasiri, K. Bahtia, L.J. Jacinto, TM. Chung, T. Landreau, C. Colosimo (Bangkok, Thailand)

1:45pm-3:15pm: Five Year Outcomes of a Prospective, Multicenter Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s Disease

L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Siejo, E. Suarez-San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Köln, Germany)

1:45pm-3:15pm: Frequency-dependent effects of subthalamic deep brain stimulation on motor symptoms in Parkinson’s disease

D. Su, W. Hu, H. Chen, J. Zhou, T. Feng (Beijing, China)

1:45pm-3:15pm: From Non-rechargeable to Rechargeable Technology: Insights and Management of Pallidal Deep Brain Stimulation in Dystonia after Switching to a Rechargeable Implantable Pulse Generator

M. Wolf, A. Saryyeva, D. Schulte, J. Krauss, C. Blahak (Mannheim, Germany)

1:45pm-3:15pm: Functional Conundrum in Wilson’s Disease

S. Raju (Bengaluru, India)

1:45pm-3:15pm: Future doctors as health educators: Undergraduate medical students raise awareness and unite for Parkinson’s disease

S. El-Jaafary, H. Amer, A. Fouad, B. Tawfiq, L. El Sabbahy, A. Bayoumy, B. Abulkarim, B. Gamal, H. Nafea, H. Shehata, M. El-Tamawy (Cairo, Egypt)

1:45pm-3:15pm: Gait disorders in Parkinson’s disease: 19 observations at the University Hospital Center of Conakry

F. Sakadi, C. Abass, T. Rahamatou, B. Talibé, N. Woga, B. Kenda, C. Amara (Conakry, Guinea)

1:45pm-3:15pm: Gait speed after applying anodal-transcranial Direct Current Stimulation in people with Parkinson’s disease? Preliminary results

V. Alizad, M. Meinzer, L. Frossard, R. Polman, S. Smith, G. Kerr (Brisbane, Australia)

1:45pm-3:15pm: Gastric Retention of the Accordion Pill™: Results From MRI Studies With Parkinson’s Disease Patients and Healthy Volunteers

N. Navon, R. Gendreau, J. Meckler (Jerusalem, Israel)

1:45pm-3:15pm: GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease

J. Martinez Castrillo, A. Alonso Canovas, G. Fernandez Pajarin, L. Vela Desojo, J. Garcia Caldentey, P. Sanchez Alonso, M. Fernandez Moreno, M. Mata, J. Herreros Rodriguez, J. Infante, J. Ruiz Martinez, C. Ruiz Huete, S. Fanjul Arbos, P. Garcia Ruiz (Madrid, Spain)

1:45pm-3:15pm: Genetic analysis of Wilson’s disease in Taiwan

T.H. Yeh, C.S. Lu, C.C. Huang, S.C. Lai (Taipei, Taiwan)

1:45pm-3:15pm: Genetic defects causing complex movement disorders and basal ganglia degeneration in childhood

H. Baide-Mairena, L. Martí-Sánchez, J. Muchart, M. Rebollo, E. Turón, JC. Cabrera López, Y. Tong-Hong, M. Madruga-Garrido, O. Alonso-Luengo, P. Quijada-Fraile, M.T. García-Silva, A. Cerisola, R. Velazquez-Fragua, E. Schuler, E. López-Laso, L. Gutiérrez-Solana, C. Cáceres-Marzal, I. Marti, O. García-Campos, M. Tomas-Vila, A. Macaya, H. Ben-Pazi, G.I. Rice, Y. Crow, R. Pons, J.D. Ortigoza-Escobar, B. Pérez Dueñas (Barcelona, Spain)

1:45pm-3:15pm: Ginsenoside Rb1 protects dopaminergic neurons through Foxm1-Nurr1 pathway in mice model of Parkinson’s disease

T. Zhou, X. Huang, L. Li, J. Yang, Z. Liang (Dalian, China)

1:45pm-3:15pm: Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia

S. Lessig, S. Marder, C. Verghese, J. Burke, R. Jimenez, S. Siegert, G. Liang (San Diego, CA, USA)

1:45pm-3:15pm: Globus pallidus deep brain stimulation (GPi-DBS) in one patient with complex early-onset dystonia and KMT2B mutation: A case report

O. Morsi, G. Valero, J. Jimenez, J. Lopez, AE. Baidez, B. Cuartero, M. Felipe, R. Sanchez, J. Zamarro (Murcia, Spain)

1:45pm-3:15pm: Gradient-like representation of emotional valence and arousal within the subthalamic nucleus in Parkinson’s disease

T. Serranová, T. Sieger, F. Růžička, E. Bakštein, P. Dušek, P. Vostatek, D. Novák, E. Růžička, D. Urgošík, R. Jech (Prague, Czech Republic)

1:45pm-3:15pm: Hardware-related infections seen after implantable pulse generator replacement in Parkinson‘s patients who underwent Deep Brain Stimulation: A Single Center Experience

A. Acarer, H. Biçeroğlu, E. Özgiray, Z. Çolakoğlu (Izmir, Turkey)

1:45pm-3:15pm: Hemidystonia due to midbrain hemorrhage: An unusal complication of Deep Brain Stimulation

G. Sciacca, S. Bonvegna, F. Dematteis, M. Lanotte, A. Romagnolo, L. Lopiano, U. Dimanico, M. Rizzone (Catania, Italy)

1:45pm-3:15pm: Hereditary spastic paraplegia presenting as limb dystonia with a novel SPG7 mutation

S. Schaefer, J. Moeller, S. Tinaz (New Haven, CT, USA)

1:45pm-3:15pm: High amplitude jerky tremor in developmental dopamine deficiency

S. Galosi, M.R. Pons, B. Zouvelou, V. Leuzzi, J. Friedman (Rome, Italy)

1:45pm-3:15pm: High dose of levodopa and Segawa disease

M. Taghiyeva (Baku, Azerbaijan)

1:45pm-3:15pm: Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease

A. Hamadjida, D. Bedard, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: Home based exercises to reduce falls in people with Parkinson’s disease: A randomized trial

M. Morris, N. Taylor, J. McGinley, M. Danoudis, H. Menz (Bundoora, Australia)

1:45pm-3:15pm: Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders

B. Carroll, F. Mu, R. Ayyagari, S. Ghandi (Frazer, PA, USA)

1:45pm-3:15pm: Identifying therapeutic targets from spontaneous beneficial brain lesions

J. Joutsa, L. Shih, A. Horn, M. Reich, J. Hsu, O. Wu, N. Rost, M. Fox (Charlestown, MA, USA)

1:45pm-3:15pm: Imaging Analysis of the International Tourette Syndrome Deep Brain Stimulation Registry and Database

K. Johnson, D. Servello, M. Porta, A. Bona, J. Ostrem, E. Bardinet, ML. Welter, A. Lozano, J.C. Baldermann, J. Kuhn, D. Huys, T. Foltynie, M. Hariz, E. Joyce, L. Zrinzo, Z. Kefalopoulou, JG. Zhang, FG. Meng, C. Zhang, Z. Ling, A. Smeets, L. Ackermans, V. Visser-Vandewalle, A. Mogilner, M. Pourfar, W. Hu, A. Gunduz, K. Foote, M. Okun, C. Butson (Salt Lake City, UT, USA)

1:45pm-3:15pm: Immediate Effect of Elastic Taping on Balance and Postural Control in Early Parkinson’s Disease: A Pilot Study

E. Göz, B. Balci, B. Dönmez, Çolakoğlu, R. Çakmur (Izmir, Turkey)

1:45pm-3:15pm: Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease

L. Scourfield, S. Sultana, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

1:45pm-3:15pm: Impact of changes in resistance on current delivered in constant voltage DBS stimulator in Parkinson’s Disease

S. Meka, T. Syed, S. Kumar, S. Tandra, R. Kandadai, S. Turaga, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Impact of Disease Duration and Anatomical Target on Health Related QoL in Patients Receiving DBS: Results from the Product Surveillance Registry

M. Schiess, S. Falowski, S. Palfi, J. Azulay, A. Lopez-Rios, L. Defebvre, J. Espinoza, K. Sandberg, B. Van Dorn, T. Weaver, P. Konrad, J. Krauss (Houston, TX, USA)

1:45pm-3:15pm: Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials

R. Pahwa, S. Isaacson, J. Jimenez-Shahed, I. Malaty, A. Deik, R. Gandhy, R. Johnson, R. Patni (Kansas City, KS, USA)

1:45pm-3:15pm: Impact of electrode impedance changes in clinical outcomes of patients with Parkinson’s disease and subthalamic nucleus deep brain stimulation

ME. Contreras Pinto, J. Martins, C. Cerquera, S. Dias, D. Giraldo Salazar, JS. Saavedra Moreno, F. Vallderiola Serra (La Serena, Chile)

1:45pm-3:15pm: Impact of STN-DBS on Medication Reduction

M. Carmona-Abellán, G. de Ulibarri, J. Guridi, P. Clavero, M. Alegre, R. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Impact of Subthalamic Nucleus Stimulation on Striatal Dopamine Transporter in Parkinsonian Rat Models

W. Xian, Q. Guo, L. Jiang, Z. Pei, L. Chen (Guangzhou, China)

1:45pm-3:15pm: Impact of SYN120 (a Dual 5-HT6/5-HT2A antagonist) on psychiatric symptoms in patients with Parkinson’s disease dementia: Results from a Phase 2a Study

D. Weintraub (Philadelphia, PA, USA)

1:45pm-3:15pm: Impact on the Quality of Life (CV) of people with Parkinson’s disease participating in community workshops of the public health system of Coquimbo, Chile

S. Stange, D. Mansilla, Y. Diaz, Y. Córdoba (Coquimbo, Chile)

1:45pm-3:15pm: Improved sleep structure after cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus

N. Nishida, T. Murakami, Y. Watanabe, H. Toda, S. Matsumoto, K. Iwasaki (Osaka, Japan)

1:45pm-3:15pm: Improvement in chorea and function in a patient with dystonia-choreoathetosis cerebral palsy after treatment with bilateral pallidal deep brain stimulation

Y. Fernandez, B. Kopell, W. Tse (New York, NY, USA)

1:45pm-3:15pm: Improvement in Patient Perceived Quality of Life with DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia

C. Comella, A. Brashear, J. Jankovic, D. Truong, A. Patel, M. Evatt, N. Kapa, Y. Liu, T. Nguyen-Cleary (Chicago, IL, USA)

1:45pm-3:15pm: Improvements of tremor control and life quality of refractory essential tremor patients after MR-guided focused ultrasound thalamotomy – A Taiwan experience

H.C. Lai, K. Tsai, W.C. Chang, T. Taira, C.Y. Wei (Changhua County, Taiwan)

1:45pm-3:15pm: Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion

K. Kashihara, M. Kitayama (Okayama, Japan)

1:45pm-3:15pm: Incremental hourly burden of “OFF” episodes on patient quality of life and health resource use among patients with Parkinson’s disease: A Neurologist/Patient Real World Assessment in the US

K. Rajagopalan, J. Barton, J. Pike (Marlborough, MA, USA)

1:45pm-3:15pm: Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

1:45pm-3:15pm: Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

P. Korlipara, J. Ferreira, H. Gama, A. Santos, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Inherited neuromyotonia associated with a dominant-negative KCNQ2 mutation

Y.T. Hsu, W.D. Lin, Y.W. Yang, D.C. Wu, C.H. Tsai (Taichung, Taiwan)

1:45pm-3:15pm: Inhibition of HDAC4 attenuates rotenone-induced abnormal increase of α-synuclein levels and affects autophagic flux in human dopaminergic SH-SY5Y cells

L. Wang, L. Liu, T. Wang (Wuhan, China)

1:45pm-3:15pm: Insular atrophy as a marker of depression in Multiple System Atrophy: A voxel-based morphometry study

N. del Campo, N. Wolpe, O. Phillips, C. Arbus, F. Ory-Magne, M. Galitzky, C. Thalamas, C. Brefel-Courbon, A. Pavy-LeTraon, P. Péran, O. Rascol (Toulouse, France)

1:45pm-3:15pm: Integrated Complimentary Yoga and Ayurveda Treatment Confers Significant Benefits in PD Patients

H. Babu, U. Kumbhare, T. Raju, N. R, N. R (Bengaluru, India)

1:45pm-3:15pm: Interaction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesiaInteraction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesia

J.Y. Lin, Z.G. Liu, C.L. Xie, A.J. Yan (Shanghai, China)

1:45pm-3:15pm: Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease

S. V G, P. Vavia (Mumbai, India)

1:45pm-3:15pm: Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease

S. Bhargava, V. Bhargava, A. Jain (Kanpur, India)

1:45pm-3:15pm: Intraoperative Electromyography can optimize pallidotomy for Parkinson’s disease and dystonias

P. Brainer, A. Campos, A. Brainer, J. Brainer, P. Brainer, P. Coutinho, C. Lima, S. Laurentino, R. Bandin, M. Andrade (Recife, Brazil)

1:45pm-3:15pm: Intraoperative local field potential recordings from deep brain stimulation electrodes help predict efficacy of subthalamic nucleus stimulation in patients with Parkinson’s disease

C. Chen, M. Liu, H. Chan, P. Tu, C. Lu, P. Brown (Taoyuan City, Taiwan)

1:45pm-3:15pm: Intraparenchymal Cyst Formation: A Rare Complication of Deep Brain Stimulation

K. Tan, C. Zadikoff (Chicago, IL, USA)

1:45pm-3:15pm: Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease

M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. Gershanik, J. Ferrario (CABA, Argentina)

1:45pm-3:15pm: INTREPID: A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s disease

J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

1:45pm-3:15pm: Intronic pentanucleotide TTTCA repeat insertion in SAMD12 gene causes familial cortical myoclonic tremor with epilepsy type 1

Y. Chen, ZD. Cen, XS. Zheng, F. Xie, XD. Yang, XJ. Lu, ZY. Ouyang, HW. Wu, S. Chen, HM. Yin, X. Qiu, S. Wang, MP. Ding, YL. Tang, C. Jiao, CY. Liu, JF. Xiao, W. Luo (Hangzhou, China)

1:45pm-3:15pm: Investigation on the neural effects by differing the parameters of electrical stimulation for the relief of parkinsonian symptoms

G.T. Kim, K.S. Kim, S.M. Lee (InCheon, Republic of Korea)

1:45pm-3:15pm: Is early onset ataxia phenotypically discernible from developmental disorders with impaired coordination?

T. Lawerman, R. Brandsma, N. Maurits, O. Martinez-Manzanera, R. Lunsing, R. Brouwer, H. Kremer, D. Sival (Groningen, Netherlands)

1:45pm-3:15pm: Is lowering stimulation frequency a feasible option to improve speech in Parkinson’s disease patients undergoing subthalamic deep brain stimulation?

M. Fabbri, M. Zibetti, G. Ferrero, A. Accornero, I. Guimaraes, M. Rizzone, A. Romagnolo, J. Ferreira, L. Lopiano (Lisbon, Portugal)

1:45pm-3:15pm: Is there a relationship between depression/anxiety and physical inactivity in Parkinson Disease?

B. Aktar, B. Balci, B. Donmez Colakoglu (Izmir, Turkey)

1:45pm-3:15pm: It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

1:45pm-3:15pm: Juvenile parkinsonism associated with a novel HSD17B10 mutation in a patient with HSD10 disease

M. Rosário, O. Moldovan, S. Reimão, I. Chendo, J. Crawford, M. Rosa, L. Guedes (Lisbon, Portugal)

1:45pm-3:15pm: Knowledge of Parkinson’s Disease in Urban Population of Kyrgyz Republic

C. Shambetova, A. Arykova, I. Nisheglotova, B. Abdildaev, SY. Lim, AH. Tan (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: Kratom withdrawal induced orobuccal dyskinesia

K. Methawasin (Nakhon Nayok, Thailand)

1:45pm-3:15pm: L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study

N. Malek, S. Kanavou, M. Lawton, K. Grosset, V. Pitz, N. Bajaj, R. Barker, D. Burn, T. Foltynie, J. Hardy, N. Wood, N. Williams, H. Morris, Y. Ben-Shlomo, D. Grosset (Ipswich, United Kingdom)

1:45pm-3:15pm: Level of serum Mortalin in Parkinson’s disease correlating with -Synuclein: Assessment of protein marker for early detection

S. Dey, A. Singh, T. Bajaj, A.B. Dey (New Delhi, India)

1:45pm-3:15pm: Levodopa Effect on Dual-Tasking in Freezing of Gait in Parkinson’s Disease

E. Bayram, J. Longhurst, S. Banks, Z. Mari, B. Bluett (Las Vegas, NV, USA)

1:45pm-3:15pm: Levodopa effect on non-motor symptoms in late stage Parkinson’s disease

K. Rosqvist, P. Odin, P. Hagell, S. Iwarsson, M. Nilsson, A. Storch (Lund, Sweden)

1:45pm-3:15pm: Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)

M. Lin, R. Laureno (Washington, DC, USA)

1:45pm-3:15pm: Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study

K. Thiankhaw, S. Tanprawate, A. Soontornpun, A. Nudsasarn, S. Chankrachang (Chiang Mai, Thailand)

1:45pm-3:15pm: Levosulpiride Induced Movement Disorder: 7 cases

D. Radhakrishnan, V. Goyal (New Delhi, India)

1:45pm-3:15pm: Lewy body disease with visual hallucination: Optic radiation abnormalities on phase difference-enhanced imaging (PADRE)

M. Miyata, S. Kakeda, T. Yoneda, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

1:45pm-3:15pm: Linking neuroplastic effects to behavioral changes after balance training in Parkinson’s disease: a study protocol of a randomized controlled trial

E. Franzén, H. Johansson, M. Freidle, U. Ekman, E. Schalling, A. Lebedev, M. Lövdén, S. Holmin, P. Svenningsson, M. Hagströmer (Huddinge, Sweden)

1:45pm-3:15pm: Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease

C. Sung, M. Danoudis, R. Iansek (Melbourne, Australia)

1:45pm-3:15pm: Long term clinical outcome after deep brain stimulation of the thalamic VIM in Holmes Tremor: A case series

J. Becktepe, S. Paschen, F. Goevert, A. Helmers, G. Deuschl (Kiel, Germany)

1:45pm-3:15pm: Long Term Outcome of the Subthalamic Nucleus DBS for Advanced Parkinson’s Disease: An Eight Years Follow-Up Study in China

Q. Guo, J. Liu, C. Yang, W. Xian, L. Jiang, S. Xu, W. Chen, Y. Hu, L. Chen (Guangzhou, China)

1:45pm-3:15pm: Long Term Response to L-dopa in Parkinson Disease

H. Gupta, N. Wachter, K. Lyons, R. Pahwa (Kansas, KS, USA)

1:45pm-3:15pm: Long-Duration Response to Levodopa in advanced Parkinson’s Disease: Relevance for RCT on Disease-Modifying therapies

R. Cilia, E. Cereda, A. Akpalu, S. Sarfo, M. Cham, G. Pezzoli (Milan, Italy)

1:45pm-3:15pm: Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD

T. Xie, L. Bloom, M. Padmanaban, B. Bertacchi, W. Kang, A. Dachman, E. MacCracken, C. Zadikoff, K. Markopoulou, P. Warnke, U. Kang (Chicago, IL, USA)

1:45pm-3:15pm: Long-term effect of subthalamic nucleus deep brain stimulation on freezing of gait in patients with advanced Parkinson’s disease

R. Kim, C.W. Shin, H. Park, A. Kim, H.J. Kim, S.H. Paek, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Long-term habituation of deep brain stimulation for essential tremor: An observer-blinded study

S. Paschen, J. Forstenpointner, J. Becktepe, H. Hellriegel, K. Witt, AK. Helmers, G. Deuschl (Kiel, Germany)

1:45pm-3:15pm: Longitudinal follow-up of dual-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor

B. Patel, R. Barmore, A. Elkouzi, P. Zeilman, X. Bai, L. Almeida, K. Foote, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Longitudinal observational study on late onset Parkinson’s disease over a decade

S. Raha, L. Ebenezer (Bridgend, United Kingdom)

1:45pm-3:15pm: Low-Fat Versus Ketogenic Diet In Parkinson’s Disease: A Pilot Randomized Controlled Trial

M. Phillips, D. Murtagh, L. Gilbertson, F. Asztely, C. Lynch (Hamilton, New Zealand)

1:45pm-3:15pm: Lycopene ameliorates haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation

S. Jamwal, P. Kumar (Baddi, India)

1:45pm-3:15pm: Magnetic resonance imaging-guided focused ultrasound unilateral pallidotomy for Parkinson’s disease: A report of 2 patients

H. Ito, T. Taira, S. Fukutake, K. Yamamoto, T. Yamaguchi, T. Kamei (Fujisawa, Japan)

1:45pm-3:15pm: Malignant neuroleptic syndrome following a sudden deep brain stimulation battery drain: Report of two cases

O. Yilmaz Kusbeci, A. Acarer, Y. Unsal, Z. Colakoglu, R. Bilgin (Izmir, Turkey)

1:45pm-3:15pm: Management of chronic polyneuropathy associated with levodopa-carbidopa intestinal gel infusion in Parkinson’s disease: Review of the strategies and perspectives

C. Cransac, J. Dupouy, P. Loubiere, B. Ackett, P. Cintas, C. Brefel Courbon, O. Rascol, F. ory Magne (Toulouse, France)

1:45pm-3:15pm: Microelectrode recording for optimization of the long-term outcome in subthalamic deep brain stimulation for Parkinson’s disease

A. Gamaleya, A. Tomskiy, A. Poddubskaya, S. Omarova, A. Dekopov, E. Salova, E. Bril, N. Fedorova (Moscow, Russian Federation)

1:45pm-3:15pm: Mild Cognitive Impairment in Parkinson’s Disease Before and After Deep Brain Stimulation

A. Troster, A. Abbott, F. Ponce, H. Shill, S. Oravivattanakul, G. Moguel-Cobos, N. Salins, A. Lieberman, K. Hanson (Phoenix, AZ, USA)

1:45pm-3:15pm: Mild to moderate dyskinesia is not significantly related to the level of activity engagement or quality of life of patients with Parkinson’s disease

E. Goubault, S. Bogard, K. Lebel, C. Duval (Montréal, QC, Canada)

1:45pm-3:15pm: Mirthful laughter avoided by directional stimulation in a Parkinson’s disease patient treated with deep brain stimulation

F. Alonso-Frech, M. Monge, C. Fernandez-Garcia, C. Villanueva (MADRID, Spain)

1:45pm-3:15pm: Mitochondrial morphometrics in idiopathic Parkinson‘s disease fibroblasts

P. Antony, O. Boyd, K. Mommaerts, K. Sokolowska, M. Ostaszewski, A. Baumuratov, L. Longhino, F. Poulain, R. Krueger, R. Balling, N. Diederich (Belvaux, Luxembourg)

1:45pm-3:15pm: Modified Frameless Stereotaxy for Gene Therapy in Pediatric Movement Disorder Patients

CH. Tai, SH. Tseng, RM. Wu, WL. Hwu (Taipei, Taiwan)

1:45pm-3:15pm: Molecular immunological action and epigenetic modification of the human papillomavirus vaccination and associated neuropsychiatric side effects

N. Kanzato, K. Nakachi, Y. Takahashi (Okinawa, Japan)

1:45pm-3:15pm: Motor and cognitive progression in GBA-related PD patients submitted to Deep Brain Stimulation

L. Correia Guedes, C. Silva, R. Machado Bouça, N. Gonçalves, M. Fabbri, A. Castro Caldas, P. Pita Lobo, M.M. Rosa, B. Cattoni, H. Carvalho, A. Gonçalves Ferreira, J.J. Ferreira, M. Coelho (Lisbon, Portugal)

1:45pm-3:15pm: Motor and non-motor correlates of APOE-ε4 mediated cerebrospinal fluid concentrations of amino acids and monoamine metabolites in dementia with Lewy bodies compared with Alzheimer’s dementia and healthy controls

F. Oliveira, M. Miraldo, E. Castro-Neto, F. Machado, S. Almeida, S. Matas, P. Bertolucci, M. Naffah-Mazzacoratti (São Paulo, Brazil)

1:45pm-3:15pm: Motor and non-motor correlates of APOE-ε4 mediated cerebrospinal fluid concentrations of biomarkers of amyloidogenesis and neurodegeneration in dementia with Lewy bodies compared with Alzheimer’s dementia and healthy controls

F. Oliveira, M. Miraldo, E. Castro-Neto, F. Machado, S. Almeida, S. Matas, P. Bertolucci, M. Naffah-Mazzacoratti (São Paulo, Brazil)

1:45pm-3:15pm: Motor cortical excitability during voluntary inhibition of involuntary tic movements

C. Ganos, L. Rocchi, A. Latorre, L. Hockney, C. Palmer, E. Joyce, K. Bhatia, P. Haggard, J. Rothwell (Berlin, Germany)

1:45pm-3:15pm: Motor limitations are the most distressing alterations for people living with Parkinson’s disease?

C. Dias, M. d'Alencar, C. Ribas, M. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: Movement disorder associated with 3-Idroxyisobutyryl-Coa hydrolase (HIBCH) deficiency

F. Nardecchia, L. Pollini, C. Carducci, M. Tolve, S. De Leo, C. Carducci, V. Leuzzi (Rome, Italy)

1:45pm-3:15pm: Movement disorder masquerading as seizure disorder

K. Ganesh (Madurai, India)

1:45pm-3:15pm: Movement Disorders as Postinfectious Neurologic Syndromes

H. Mori (Kurashiki, Okayama, Japan)

1:45pm-3:15pm: Movement Disorders in Children with Autoimmune Diseases

D. Munoz, M. Troncoso, P. Santander, M. Hidalgo, R. Ruiz, V. Naranjo, P. Gonzalez, C. Elgueta, P. Parra, A. Hernandez, S. Lara, M. Franco, J. Zamora (Santiago, Chile)

1:45pm-3:15pm: Movement disorders in mitochondrial disease: Radio clinical correlation in pediatric patients

R. Zouari, M. Naifar, F. Kamoun, S. Ben Nsir, R. Ben Jemaa, W. Bouchaala, F. Ayadi, C. Triki (Sfax, Tunisia)

1:45pm-3:15pm: Movement Disorders Phenomenology in Focal Motor Seizures

A. Fasano, C. Di Bonaventura, F. Bove, A. Espay, F. Morgante, G. Fabbrini, R. Munhoz, D. Andrade, F. Borlot, F. Bui, G. Di Gennaro, R. Iorio, H. Katzberg, M. Luigetti, P. Striano, G. Defazio, A. Berardelli (Toronto, ON, Canada)

1:45pm-3:15pm: MRI-guided Focused Ultrasound thalamotomy for Multiple Sclerosis-associated tremor: A case report

B. Fernández-Rodríguez, D. Urso, M. Monje, JA. Pineda-Pardo, M. del Álamo, R. Blazquez-Navarro, F. Hernández-Fernández, L. Vela, F. Alonso-Frech, R. Martínez-Fernández, J. Obeso (Móstoles, Spain)

1:45pm-3:15pm: Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

B. Greco, R. Holloway, K. Hodgeman, S. Henderson, C. Tarolli, K. Biglan, T. Simuni (Rochester, NY, USA)

1:45pm-3:15pm: Multimodal evoked potential analysis in Woodhouse-Sakati Syndrome

A.H. Abusrair, I. AlHamoud, S. Bohlega (Riyadh, Saudi Arabia)

1:45pm-3:15pm: Multimodal MRI markers modifications in multiple system atrophy: A longitudinal study

P. Péran, WG. Meissner, O. Rascol, A. Pavy-Le Traon (Toulouse, France)

1:45pm-3:15pm: Myoclonus in the pediatric age group: A retrospective analysis of clinical and electrophysiological characteristics of patients referred to an electrophysiology laboratory

A. Gunduz, H. Yılmaz, V. Demirbilek, C. Yalçınkaya, N. Yeni, S. Saltık, M. E. Kızıltan (Istanbul, Turkey)

1:45pm-3:15pm: Neurologic Wilson’s Disease: Case Series on a Diagnostic and Therapeutic Emergency

R. Porlas, L. De Castillo, C. Dioquino (Manila, Philippines)

1:45pm-3:15pm: Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease

D. Bega, J. Bronstein, D. Nicholl, F. Askari, A. Ala, P. Ferenci, C. Bjartmar, KH. Weiss, M. Schilsky, A. Czlonkowska (Chicago, IL, USA)

1:45pm-3:15pm: Neuromelanin Imaging and Midbrain Volumetry in Progressive Supranuclear Palsy and Parkinson’s Disease

D. Taniguchi, T. Hatano, K. Kamagata, A. Okuzumi, M. Hori, S. Aoki, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Neuromelanin-MRI in REM sleep behaviour disorder predicts dopaminergic dysfunction and clinical risk of Parkinson’s disease

T. Barber, L. Griffanti, K. Bradley, D. McGowan, M. Crabbe, C. Lo, C. Mackay, J. Klein, M. Hu (Oxford, United Kingdom)

1:45pm-3:15pm: Neuromodulatory propensity of Ginko biloba to offset rotenone induced behaviour and biochemical alteration

K. Rode, D. Khatri, M. Panchawadkar, P. Rane (Pune, India)

1:45pm-3:15pm: Neuromodulatory properties of flavonoids from Persea americana Peel: Role in CNS redox homeostasis and neurobehavioral markers

S. Grace SR, PR, J. Chauhan, G. Chandran (Mys, India)

1:45pm-3:15pm: Neuromodulatory role of subthalamic nucleus deep brain stimulation in Parkinson’s disease patients

S. Szlufik, A. Przybyszewski, K. Duszynska-Was, I. Laskowska-Levy, J. Dutkiewicz, A. Drzewinska, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

1:45pm-3:15pm: Neuropathology of a South Korean with Perry syndrome with DCTN1 T78C mutation

S. Kim, E. Chung, J. Baik (Busan, Republic of Korea)

1:45pm-3:15pm: Neuroprotective Effects of A Combination of Curcumin and Mucuna Prurience in Rotenone Induced Mice Model of Parkinson’s Disease

M. Panchwadkar, P. Rane, D. Khatri, V. Undale (Pune, India)

1:45pm-3:15pm: Neuroprotective effects of coffee ingredients against rotenone-induced neurodegeneration in parkinsonian model

I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, Y. Kitamura, M. Asanuma (Okayama, Japan)

1:45pm-3:15pm: Neuroprotective role of Tinospora cordifolia in MPTP induced Parkinsonian mouse model

S. Singh, H. Birla, S. Rai, W. Zahra, S. Singh (Varanasi, India)

1:45pm-3:15pm: Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

1:45pm-3:15pm: New Nomenclature Of Genetic Myoclonus Syndromes

S. Veen, R. Zutt, C. Klein, C. Marras, S. Berkovic, J. Caviness, H. Shibasaki, T. De Koning, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: Nigral stimulation for the treatment of refractory gait disturbances in Parkinson’s disease

M. Carmona-Abellán, D. Moreno, M. Alegre, J. Guridi, R. Luquin (Pamplona, Spain)

1:45pm-3:15pm: No deleterious effect of unilateral Gamma Knife thalamotomy on gait and posture in patients with essential tremor

T. Witjas, E. Boutin, A. Eusebio, R. Carron, J. Régis, JP. Azulay, M. Vaugoyeau (Marseille, France)

1:45pm-3:15pm: Non-motor symptoms and alteration of brain networks in patients with blepharospasm and hemifacial spasm

YJ. Guo, CM. Chen, MH. Chang (Taichung, Taiwan)

1:45pm-3:15pm: Novel biomarkers of autonomic regulation and sleep in Parkinson’s Disease derived from Network Physiology

O. Vaou, P. Ivanof, A. DePold-Hohler, F. Lombardi, R. Endalatpour, A. Quaicoe (Boston, MA, USA)

1:45pm-3:15pm: Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys

T. Kitajima, M. Bonifácio, P. Moser, P. Soares-da-Silva, M. Tanaka (Osaka, Japan)

1:45pm-3:15pm: Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches

S. Iqbal (Chennai, India)

1:45pm-3:15pm: Novel missense variants in KMT2B in segmental dystonia

J. Ma, X.H. Wan (Beijing, China)

1:45pm-3:15pm: Objective analysis of walking tremor in Parkinson’s disease: A spectrum of classical rest tremor?

N. Dadphan, O. Jitkritsadakul, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Objective Predictors of ‘Early Tolerance’ to Ventral Intermediate nucleus of thalamus DBS In Essential Tremor Patients

S. Merchant, S. Kuo, S. Pullman, B. Ford (Bethesda, MD, USA)

1:45pm-3:15pm: Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

K. Chaudhuri, A. Sauerbier, J. Ferreira, F. Stocchi, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience

A. Ceballos-Baumann, K. Eggert, J. Ferreira, W. Poewe, O. Rascol, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Munich, Germany)

1:45pm-3:15pm: Ocular motor function in stiff person syndrome – Role of GABA and beyond

F. Wang, L. Neilson, H. Wang, G. Wilmot, A. Shaikh (Cleveland, OH, USA)

1:45pm-3:15pm: ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects

J. Tuunainen, J. Ellmén, M. Vahteristo, A. Holopainen, D. Strugala (Espoo, Finland)

1:45pm-3:15pm: Olfactory dysfunction predicting cognition

X. Yu (Cleveland, OH, USA)

1:45pm-3:15pm: Oligosymptomatic Fahr’s syndrome (2 clinical cases)

Y. Solodovnikova (Odessa, Ukraine)

1:45pm-3:15pm: On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

1:45pm-3:15pm: Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, D. Bédard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis

T. Dam, L. Zhang, I. Qureshi, M. Grundman, G. Tirucherai, C. Bechtold, M. Ahlijanian, L. Golbe, L. Honig, S. Isaacson, M. Grossman, N. McFarland, I. Litvan, D. Geldmacher, T. Xie, Y. Bordelon, P. Tuite, P. O’Suilleabhain, T. Zesiewicz, B. Han, A. Boxer (Cambridge, MA, USA)

1:45pm-3:15pm: Optimized Imaging at 3.0 T of the Rostral Zona Incerta (rZI) for Deep Brain Stimulation (DBS) in Parkinson’s Disease (PD)

A. Thaker, K. Reddy, J. Thompson, P. David-Gerecht, A. Abosch, D. Kern (Aurora, CO, USA)

1:45pm-3:15pm: Optimizing the Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) outcome in Parkinson’s disease patient with interleaving stimulation

C. Lau, C. Zhu, D. Chan, K. Ma, A. Chan, J. Yeung, V. Mok, W. Poon (Hong Kong)

1:45pm-3:15pm: Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

1:45pm-3:15pm: Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

1:45pm-3:15pm: Outcomes of a Prospective, Multi-center International Registry of Deep Brain Stimulation for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, S. Paschen, A. Andrea Kühn, M. Pötter-Nerger, J. Volkmann, J. Vesper (Kiel, Germany)

1:45pm-3:15pm: Pallidal and thalamic oscillations are associated with tic severity in patients with Tourette syndrome

WJ. Neumann, J. Huebl, C. Brücke, R. Lofredi, A. Saryyeva, K. Müller-Vahl, J. Krauss, A. Kühn (Berlin, Germany)

1:45pm-3:15pm: Pallidotomy in dystonia –Experience from a tertiary care centre in a developing country

K. Garg, M. Singh, V. Goyal, R. Sharma (New Delhi, India)

1:45pm-3:15pm: Papez circuit atrophy in Dementia with Lewy Bodies

E. Matar, S. Wong, R. Tan, O. Piguet, M. Hornberger, J. Krill, J. Hodges, G. Halliday (Sydney, Australia)

1:45pm-3:15pm: Parkinsonism & Cognitive Dysfunction Severity Correlation in NPH with a Suggested Novel Phenotypic Subclassifcation of NPH

A. Acharya, A. Biswas, S. Das (Kolkata, India)

1:45pm-3:15pm: Parkinsonism in Christianson Syndrome: A Unique Presentation of a Unique Syndrome

S. Chandra, K. Rao, A. Ghosh, J. Ray, H. Northrup, E. Stimming (Houston, TX, USA)

1:45pm-3:15pm: PASSPORT, An Ongoing Phase 2 Study in Patients with PSP– Baseline Characteristics

T. Dam, A. Boxer, L. Golbe, G. Höglinger, H. Morris, I. Litvan, J.C. Corvol, A. Lang, C. Bechtold, I. Qureshi, M. Grundman, B. Han, J. O'Gorman, T. Olsson, S. Budd Haeberlein (Cambridge, MA, USA)

1:45pm-3:15pm: Patient and Caregiver Experience With Pantothenate Kinase-Associated Neurodegeneration

H. Jinnah, W. Lenderking, A. Collins, M. Escolar, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, R. Marshall (Atlanta, GA, USA)

1:45pm-3:15pm: Patient and Provider Experiences and Attitudes toward Rytary

S. Horn, D. Coughlin, J. Chou, F. Wang, M. Stacy, R. Dolhun, C. Kopil, N. Amondikar, A. Deik, H. Sarva (Philadelphia, PA, USA)

1:45pm-3:15pm: Patient with secondary dystonia treated with internal globus pallidus deep brain stimulation (GPi-DBS), 2 years results: A case report

O. Morsi, AE. Baidez, J. Jimenez, J. Lopez, G. Valero, B. Cuartero, M. Felipe, R. Carrasco, J. Zamarro (Murcia, Spain)

1:45pm-3:15pm: Patient’s Choice of Device-Based Treatments in Parkinson’s Disease

M. Kuzu Kumcu, S. Tezcan Aydemir, Ç. Ulukan, B. Bakırarar, C. Akbostancı (Ankara, Turkey)

1:45pm-3:15pm: Patients experiencing peak-dose dyskinesia use re-distribution of involuntary movement amplitude throughout their body to minimize the functional impact of dyskinesia

K. Lebel, E. Goubault, S. Bogard, C. Duval (Montréal, QC, Canada)

1:45pm-3:15pm: Patterns of dopamine transporter imaging in subtypes of Multiple System Atrophy

F.T. Liu, L.L. Bu, Y.J. Yang, P. Wu, C.T. Zuo, J. Wang (Shanghai, China)

1:45pm-3:15pm: Peculiarities of Opsoclonus-Myoclonus Syndrome in India: A Systematic Review of reported cases

J. Sahu, S. Negi (Chandigarh, India)

1:45pm-3:15pm: Pediatric Tics and DCD: Motor Network Disorders?

M. Kuiper, R. Brandsma, W. Eggink, M. Egmond, J. de Vries, P. Hoekstra, A. Dietrich, D. Sival (Groningen, Netherlands)

1:45pm-3:15pm: Perceived Psychosocial Impacts of a Therapeutic Yoga Intervention for Individuals with Parkinson’s Disease (PD)

B. Hawkins, M. Van Puymbroeck, A. Walter, K. Woschkolup, E. Urrea-Mendoza, F. Revilla, A. Schmid (Clemson, SC, USA)

1:45pm-3:15pm: Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study of gait parameters

Z. Guduru, G. Gera, G. Quintero, C. Van Horne, G. Gerhardt (Lexington, KY, USA)

1:45pm-3:15pm: Perry syndrome: Proposal of international diagnostic criteria and a new disease concept

T. Mishima, S. Fujioka, H. Tomiyama, I. Yabe, R. Kurisaki, N. Fujii, R. Neshige, O. Ross, M. Farrer, D. Dickson, Z. Wszolek, N. Hattori, Y. Tsuboi (Fukuoka, Japan)

1:45pm-3:15pm: Persistent downbeat nystagmus due to Arnold-Chiari type I malformation

W. Chen, L. Zhao, Q. He, L. Wu, R. Dong (Shanghai, China)

1:45pm-3:15pm: PLG restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models

J. Liu, H. Yang (Beijing, China)

1:45pm-3:15pm: Polysomnographic data in Dementia with Lewy Bodies: Correlation with clinical features and comparison with other alfa-synucleinopathies

P. Bugalho, M. Salavisa, J. Marto, C. Borbinha, L. Alves (Lisbon, Portugal)

1:45pm-3:15pm: Poor responders to STN DBS in Parkinson’s disease: 1 year follow-up study

M. Zibetti, L. Ricciardi, E. Montanaro, M. Sarchioto, M. Edwards, L. Lopiano, F. Morgante (Toriino, Italy)

1:45pm-3:15pm: Post-Deep Brain Stimulation Psychosis in Parkinson’s Disease: A Meta-analysis

YC. Tai, N. Mahant, B. Stubbs, A. Carvalho, YW. Chen, TY. Chen, SP. Hsu, PT. Tseng (Kaohsiung, Taiwan)

1:45pm-3:15pm: PPMI driven sample size estimation for clinical trials in Parkinson’s disease

K. Marek, J. Seibyl, C. Caspell-Garcia, C. Coffey, B. Mollenhauer, K. Kieburtz, C. Tanner, L. Chahine, A. Siderowf, T. Simuni (New Haven, CT, USA)

1:45pm-3:15pm: Practice patterns, motor outcomes and health disparities in patients undergoing Deep Brain Stimulation for Parkinson’s disease

C. Luca, D. Garbin diLuca, H. Moore, C. Singer, I. Cajigas, J. Jagid (Miami, FL, USA)

1:45pm-3:15pm: Preclinical evaluation of a novel autologous substrate for cell-based therapy

S. Benoit, H. Xu, J. Ronald, P. Foster, S. Schmid, M. Hebb (London, ON, Canada)

1:45pm-3:15pm: Predicting patient risk and discharge disposition subsequent to deep brain stimulation surgery

F. Farrokhi (Seattle, WA, USA)

1:45pm-3:15pm: Predictor for speech deterioration following STN-DBS in PD patients

Y. Tanaka, T. Tsuboi, H. Watanabe, D. Nakatsubo, S. Maesawa, S. Kato, Y. Kajita, M. Sato, R. Odake, M. Hattori, M. Yamamoto, T. Wakabayashi, M. Katsuno, G. Sobue (Nagoya, Japan)

1:45pm-3:15pm: Preliminary evidence for an altered relationship between uric acid levels and resting state functional connectivity in REM sleep behavior disorder

M. Schiess, J. Suescun, L. Giancardo, R. Castriotta, T. Ellmore (Houston, TX, USA)

1:45pm-3:15pm: Prevalence, Distribution and Management of Parkinson among Pakistani Population

S. Naureen (Rawalpindi, Pakistan)

1:45pm-3:15pm: Primary familial brain calcification – The impact of calcifications on the development of motor symptoms

D. Alvarez-Fischer, C. Schiemenz, G. Mahlke, A. Keller, A. Westenberger, J. Erdmann, Z. Aherrahrou, C. Klein (Lübeck, Germany)

1:45pm-3:15pm: Programming for Freezing of gait after Bilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease

H. Zheng, F. Sun, L. Zhang (Nanjing, China)

1:45pm-3:15pm: Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor

S. Papapetropoulos, M. Lee, S. Boyer (Cambridge, MA, USA)

1:45pm-3:15pm: Propionibacterium acnes Infection with Intracerebral Abscess in Deep Brain Stimulation

R. Lewis, F. Farrokhi, M. Marsans (Seattle, WA, USA)

1:45pm-3:15pm: Propofol-induced acute dystonic reaction after orthopedic surgery in a young healthy woman

R. Barbosa, M. Salavisa, M. Mendonça (Lisbon, Portugal)

1:45pm-3:15pm: PROtein, LEucine And vitamin D Enhancing Rehabilitation (PRO-LEADER) in patients with Parkinson’s disease or parkinsonism: A RCT

M. Barichella, E. Cereda, G. Pinelli, L. Iorio, D. Caroli, I. Masiero, V. Ferri, E. Cassani, C. Bolliri, S. Caronni, P. Ortelli, D. Ferrazzoli, A. Maras, G. Riboldazzi, G. Frazzitta, G. Pezzoli (Milano, Italy)

1:45pm-3:15pm: Public Awareness on Parkinson’s disease in Urban Central Asia

O. Turgunkhujaev, F. Aliyeva, A. Khashimova, A. Mukanova, O. Okhunov, S.H. Ikramova, A.H. Tan, S.Y. Lim (Moscow, Russian Federation)

1:45pm-3:15pm: Pulvinar low intensity on susceptibility-weighted imaging may predict cognitive worsening after deep brain stimulation therapy in Parkinson’s disease patients

K. Matsuura, M. Maeda, M. Satoh, K. Tabei, T. Araki, M. Umino, H. Kajikawa, N. Nakamura, H. Tomimoto (Tsu, Mie, Japan)

1:45pm-3:15pm: Putative treatment of Parkinson’s Disease using extract of Bacopa monnieri

S. Sinha, P. Kumar (Allahabad, India)

1:45pm-3:15pm: Quality of Life in Tic Disorders: An Observational, Mainstream School-Based Population Study over Time

E. Casas-Peña, B. Ouyang, Y. Liu, E. Cubo, K. Kompoliti (Burgos, Spain)

1:45pm-3:15pm: Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia

E. Pioli, P. Stanley, W. Ko, Q. Li, R. Kozak, P. Popiolek, E. Bezard (Manchester, United Kingdom)

1:45pm-3:15pm: Quantitative assessment of the effectiveness of adaptive Deep Brain Stimulation in Parkinson’s disease

D. Piña-Fuentes, M. Tijssen, M. Oterdoom, S. Little, J. van Zijl, T. van Laar, P. Brown, M. van Dijk, M. Beudel (Groningen, Netherlands)

1:45pm-3:15pm: Quantitative EEG and medial temporal lobe atrophy in early Parkinson’s disease with behavioral and psychological symptoms

J.Y. Ahn, H.T. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Quantitative oculomotor assessment and non-motor biomarkers in late-onset GM2 gangliosidosis

C. Stephen, D. Balkwill, P. James, K. Sassower, J. Schmahmann, R. Lewis, F. Eichler (Boston, MA, USA)

1:45pm-3:15pm: Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

K. Chaudhuri, D. Weintraub, A. Antonini, W. Robieson, M. Li, K. Chatamra, J. Benesh, M. Facheris (London, United Kingdom)

1:45pm-3:15pm: Real-World Outcomes Using a Novel Directional Lead from a Deep Brain Stimulation (DBS) Registry for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, A. Kühn, M. Pötter-Nerger, J. Volkmann, S. Paschen, J. Vesper (Kiel, Germany)

1:45pm-3:15pm: Reduction of neuroinflammation by selective inhibition of the N-type calcium channel is beneficial in various animal models of neurodegeneration, here in the SOD1G93A transgenic mouse model of ALS

J. Post-Schulz, A. Willuweit, V. Kogel, K. Langen, J. Kutzsche, D. Willbold (Jülich, Germany)

1:45pm-3:15pm: Relationship between Age-related Frailty and Intra-individual Variability of Reaction Time in Healthy Seniors: Implications for Parkinson’s disease

L. Lu (Guangzhou, People’s Republic of China)

1:45pm-3:15pm: Relationship between CTG repeats, Muscle Weakness and Respiratory Dysfunction in Myotonic Dystrophy Type 1

A. Hawkins, K. Abdul Razak, T. Khoo, K. Tran, R. Jackson (Meadowbrook, Australia)

1:45pm-3:15pm: Relationship between non-motor symptom symptoms and clinical symptoms in Parkinson’s disease using “Non-Motor Symptom assessment scale for Parkinson’s disease”

T. Matsubara, K. Suzuki, H. Fujita, M. Matsubara, A. Numao, H. Sakuramoto, Y. Watanabe, T. Kadowaki, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm: Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II

J. Ferreira, W. Poewe, O. Rascol, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:45pm-3:15pm: Remotely supervised home-based aerobic exercise for Parkinson patients

N. vd Kolk, N. de Vries, B. Post, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Resting-state fMRI study on drug-naive essential tremor patients with head tremor

L. Wang, N. Li, X. Suo, Z. Lu, J. Li, J. Peng, Q. Gong, R. Peng (Chengdu, Sichuan Province, China)

1:45pm-3:15pm: Reversible asymmetric parkinsonism and vertical gaze limitation as an initial manifestation of dural arteriovenous fistula

W. Yoon (Seoul, Republic of Korea)

1:45pm-3:15pm: Review of mealtime difficulties following frontotemporal lobar degeneration

C. Lewis, A. Vogel, M. Walterfang, D. Velakoulis (Melbourne, Australia)

1:45pm-3:15pm: Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative diseases

P. Kumar, N. Baquer (New Delhi, India)

1:45pm-3:15pm: Rose Anthocyanins protect against Parkinson’s pathophysiology: Behavioral and biochemical changes in young Drosophila

G. Chandran, P. Chandrashekar, M. Jayaraju, J. Chauhan (Mysuru, India)

1:45pm-3:15pm: Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes

M. Asanuma, I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, E. Nakayama, K. Shin, D. Yamamoto, Y. Kitamura (Okayama, Japan)

1:45pm-3:15pm: Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)

1:45pm-3:15pm: Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial

R. Pahwa, R. Hauser, M. Worden, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Kansas City, KS, USA)

1:45pm-3:15pm: Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

1:45pm-3:15pm: Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)

1:45pm-3:15pm: Safinamide in Parkinson’s disease

G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

1:45pm-3:15pm: Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson’s Disease

G. Padoani, S. Novello, C. Pisanò, C. Caccia, E. Melloni, S. Vailati, C. Keywood, M. Morari (Bresso (Milan), Italy)

1:45pm-3:15pm: Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial

M. Schwarzschild, E. Macklin, R. Bakshi, S. Bhattacharyya,, R. Logan, A. Ascherio; on behalf of the Parkinson Study Group SURE-PD Investigators (Boston, MA, USA)

1:45pm-3:15pm: Simple Programming Method in STN-DBS using directional lead

K. Kimura, H. Kishida, T. Kawasaki, K. Hamada, N. Ueda, F. Tanaka (Yokohama, Japan)

1:45pm-3:15pm: Single centre experiences of directional leads in Parkinson patients

U. Scheller, G. Wenzel, R. Lofredi, D. Kroneberg, K. Faust, G.H. Schneider, A.A. Kühn (Berlin, Germany)

1:45pm-3:15pm: Single limb stance test performance – Difference between tremor dominant and akinetic rigid dominant parkinson’s disease – A pilot study

S. Durairaj, A. Christina, V. Mathew, M. Gowri (Vellore, India)

1:45pm-3:15pm: Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial

W. Meissner, A. Pavy-Le Traon, A. Foubert-Samier, M. Galitzky, B. Laurens, U. Sabatini, S. Schmidhuber, D. Winter, G. Galabova, G. Staffler, A. Schneeberger, A. Kutzelnigg, O. Rascol (Bordeaux Cedex, France)

1:45pm-3:15pm: Speech Intelligibility in Parkinson’s disease following Intensive Voice and Articulation Treatments

G. Schulz, A. Halpern, J. Spielman, L. Ramig, I. Panzer, A. Sharpley, H. Hodges (Silver Spring, MD, USA)

1:45pm-3:15pm: Spontaneous peri-electrode edema, 7 years after subthalamic nucleus deep brain stimulation (STN-DBS) in a patient with Parkinson´s disease (PD): A case report

O. Morsi, J. Lopez, J. Jimenez, L. Fuentes, G. Valero, A.E. Baidez, E. Andreu (Murcia, Spain)

1:45pm-3:15pm: STEEred vs RING-mode Deep Brain Stimulation for Parkinson’s disease: STEERING trial

T. ten Brinke, V. Odekerken, J. Dijk, P. vd Munckhof, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

1:45pm-3:15pm: STN deep brain stimulation can directly suppress levodopa-induced dyskinesia in Parkinson’s disease

J. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm: STN-DBS causing persistent dyskinetic movements in OFF-State

J. Muellner, J. Michelis, L. Lachenmayer, K. Petermann, I. Debove (Bern, Switzerland)

1:45pm-3:15pm: Striatal dopamine function in multiple system atrophy and progressive supranuclear palsy: A meta-analysis of imaging studies

V. Kaasinen, T. Kankare, J. Joutsa, T. Vahlberg (Turku, Finland)

1:45pm-3:15pm: Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa-Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson’s Disease. ADEQUA Study

F. Valldeoriola, M.J. Catalán, F. Escamilla-Sevilla, E. Freire, J. Olivares, E. Cubo, D. Santos, J.C. Parra, G. Arroyo, J.M. Arbelo (Barcelona, Spain)

1:45pm-3:15pm: Studying genes involved in abnormalities of the basal ganglia and iron homeostasis using gene co-expression network analysis

M. van der Weijden, M. Tijssen, D. Verbeek (Groningen, Netherlands)

1:45pm-3:15pm: Subthalamic deep brain stimulation is safe and effective treatment for elderly patients with Parkinson’s disease

J. Youn, M. Kim, JH. Park, K.R. Cho, J.H. Ahn, JI. Lee, J.W. Cho (Seoul, Republic of Korea)

1:45pm-3:15pm: Subthalamic neuromodulation restores motor learning in Parkinson’s disease

A.L. Marcelino, A. Horn, A. Kühn, W.J. Neumann (Berlin, Germany)

1:45pm-3:15pm: Subthalamic nucleus deep brain stimulation evoked neural activity predicts clinical response to DBS

S. Xu, N. Sinclair, K. Bulluss, T. Perera, W. Lee, H. McDermott, W. Thevathasan (East Melbourne, Australia)

1:45pm-3:15pm: Superior cerebellar peduncles atrophy of PSP on PADRE imaging; comparison with idiopathic PD

S. Kakeda, M. Miyata, T. Yoneda, S. Ide, K. Okada, H. Adachi, Y. Korogi (Kitakyushu, Japan)

1:45pm-3:15pm: SURE-PD3 Trial Participant Features prior to Randomization

E. Macklin, A. Videnovic, C. Lungu, C. Kamp, C. Casaceli, D. Oakes, A. Ascherio, M. Schwarzschild; on behalf of the Parkinson Study Group SURE-PD3_Investigators (Boston, MA, USA)

1:45pm-3:15pm: Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

V. Kumar (Allahabad, India)

1:45pm-3:15pm: Surgery-, hardware – and chronic stimulation-related adverse events following subthalamic nucleus deep brain stimulation for Parkinson’s disease

B. Gonenli Kocer, E. Ozturk, S. Comoglu, M. Sorar, H. Kertmen (Ankara, Turkey)

1:45pm-3:15pm: Swimming in PD patients with STN-DBS: A pilot exploratory study

D. Flisar, S. Ibrulj, M. Trošt, M. Benedičič, P. Mušič, S. Korelc, K. Groleger Sršen (Ljubljana, Slovenia)

1:45pm-3:15pm: Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study

O. Fabregues, E. Tolosa, J. Ferreira, A. Lees, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

1:45pm-3:15pm: Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)

1:45pm-3:15pm: Symptom specified target and procedure selection for Parkinson’s disease: A case report

W. Linbin, L. Dianyou, P. Yixin, Z. chencheng, S. Bomin (Shanghai, China)

1:45pm-3:15pm: SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results

H. Fernandez (Cleveland, OH, USA)

1:45pm-3:15pm: Tardive Myoclonus: A Case Report

S. Gazioglu, F. Civil Arslan, V. Altunayoglu Cakmak, M. Korucuk, M. Ozmenoglu (Trabzon, Turkey)

1:45pm-3:15pm: Targeted Next Generation Sequencing in Diagnosis of Dystonia Patients

J. Ma, X.H. Wan (Beijing, China)

1:45pm-3:15pm: Targeting GPi: DBS Treating Dystonia in a Patient with Wilson’s Disease

L. Sperry, X. Duan, F. Girgis, K. Denny, S. Farias, D. Kahn, V. Medici, L. Zhang, K. Shahlaie (Sacramento, CA, USA)

1:45pm-3:15pm: Teed and primary cell longevity: Results from product surveillance registry

P. Konrad, G. Plotkin, S. Palfi, E. Cuny, J-P. Azulay, T. Witt, T. Theys, Y. Temel, G. Johnson, K. Bhatia, T. Weaver, M. Schiess, J. Krauss, S. Falowski (Nashville, TN, USA)

1:45pm-3:15pm: Thalamic deep brain stimulation of the ventral intermediate nucleus in patients with dystonic head tremor

M. Wolf, C. Blahak, A. Saryyeva, J. Runge, J. Krauss (Mannheim, Germany)

1:45pm-3:15pm: The Adaptation of Card Games for Education in Movement Disorders

S. Schaefer, A. Vives Rodriguez (New Haven, CT, USA)

1:45pm-3:15pm: The Akt/mTOR/P70S6K/4EB-P1 signaling pathway is activated by metformin in a toxin-induced cellular model of Parkinson’s disease

P. Dharmasaroja, P. Chanthammachat (Bangkok, Thailand)

1:45pm-3:15pm: The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, D. Bedard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease

W. Poewe, F. Stocchi, A. Espay, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Innsbruck, Austria)

1:45pm-3:15pm: The change of heart rate variability after subthalamic nucleus deep brain stimulation in patients with Parkinson’s disease: A Meta⁃analysis

X.Y. Luo, R. Ou, H.F. Shang (Chengdu, People’s Republic of China)

1:45pm-3:15pm: The combined effect of repetitive transcranial magnetic stimulation and treadmill training in people with Parkinson’s disease – A randomized controlled trial

C. Chung, M. Mak, M. AuYeung, Y. Chan, N. Cheung, V. Mok, M. Hallett (Hong Kong, Hong Kong)

1:45pm-3:15pm: The comparison of the clinical characteristics and treatment outcomes between non-troublesome and troublesome hemifacial spasm in Thai patients

Y. Pitakpatapee, A. Suengtaworn, P. Soontrapa, P. Srivanitchapoom (Bangkok, Thailand)

1:45pm-3:15pm: The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease

T. Kadowaki, M. Hamaguchi, H. Sakuramoto, T. Shiina, H. Fujita, K. Suzuki, K. Hirata (Mibu, Japan)

1:45pm-3:15pm: The correlation studies between cholinergic cognitive impairment of Parkinson’s disease and the cortex thickness of brain

Y. Zhang, B. Li (Guang Zhou, China)

1:45pm-3:15pm: The course of Parkinson’s disease in patients with impaired carbohydrate metabolism

F. Akhmedova, B. Shagazatova, D. Artikova, F. Mirxaydarova (Tashkent, Uzbekistan)

1:45pm-3:15pm: The Development of Interactive, Video-Based Modules for Movement Disorders Education

S. Schaefer, L. Vadlamani, P. Juthani (New Haven, CT, USA)

1:45pm-3:15pm: The Effect of Conduction Exercise and Self-acupressure in Treatment of Parkinson’s Disease: A Pilot Study

M. Li, K.K. Chua, C.S. Yuen, Z.Y. Zhuang, W.H. Lau, H.Y. Chow (Hong Kong)

1:45pm-3:15pm: The Effect of Short Pulse Width Settings on Speech in Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s disease

V. Dayal, T. Grover, E. Tripoliti, P. Limousin, T. Foltynie (London, United Kingdom)

1:45pm-3:15pm: The effectiveness of boxing exercise in elderly patients including Parkinson’s disease patients

N. Kawashima, M. Isogai, M. Matsuhashi, M. Komachi, H. Ikebe, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

1:45pm-3:15pm: The effectiveness of deep brain stimulation in dystonia: A patient-centered approach

H. Eggink, R. Toonen, J. van Zijl, M. van Egmond, A. Bartels, R. Brandsma, MF. Contarino, K. Peall, J M. van Dijk, DLM. Oterdoom, M. Beudel, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: The effects of bright light therapy on depression, sleep and circadian rhythm in patients with Parkinson’s disease and a depressive disorder: Results of a double-blind randomized controlled trial

S. Rutten, C. Vriend, J. Smit, H. Berendse, E. van Someren, A. Hoogendoorn, J. Twisk, Y. vd Werf, O. vd Heuvel (Amsterdam, Netherlands)

1:45pm-3:15pm: The effects of deep brain stimulation of the pedunculopontine nucleus on cognition in Parkinson’s disease and Progressive Supranuclear Palsy

F. Leimbach, J. Gratwicke, T. Foltynie, M. Hariz, P. Limousin, L. Zrinzo, M. Jahanshahi (London, United Kingdom)

1:45pm-3:15pm: The effects of Nordic walking on gait functions in people with Parkinson’s disease: A long-term pilot study

M. Mak, I. Wong-Yu (Hong Kong, Hong Kong)

1:45pm-3:15pm: The effects of STN-DBS on the Parkinson’s disease patients with different progressive rates

R. Qi, H. Yu, J. Li, X. Geng (Kunming, China)

1:45pm-3:15pm: The effects of treadmill training augmented by virtual reality on postural control and freezing of gait in Parkinson’s disease

E. Bekkers, A. Mirelman, S. Del Din, L. Avanzino, F. Nieuwhof, J. Hausdorff, A. Nieuwboer (Leuven, Belgium)

1:45pm-3:15pm: The efficacy and safety of STN-DBS under general anesthesia for PD patients

W. Chen, L. Chen (Guangzhou, China)

1:45pm-3:15pm: The efficacy of intensive inpatient rehabilitation treatment in Parkinson’s disease patients

J. Shiraishi, T. Okazaki, S. Saeki (Fukuoka, Japan)

1:45pm-3:15pm: The establishment of Deep Brain Stimulation Nurse Association (DBSNA) in United Kingdom (UK)

J. Candelario-Mckeown, L. Partington-Smith, U. Brechany, L. Mooney-Messer, J. Kausar, B. Forrow, S. Perides, L. Nelson (London, United Kingdom)

1:45pm-3:15pm: The first case of Perry syndrome in Estonia

K. Vender, T. Toomsoo, I. Kalju, I. Rubanovits, K. Joost, P. Taba (Tallinn, Estonia)

1:45pm-3:15pm: The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial: Utilization of a Novel Primary Efficacy Outcome in Patients with Pantothenate Kinase-Associated Neurodegeneration

F. Greblikas, M. Escolar, T. Klopstock, R. Marshall, B. Perez, S. Tuller, A. Videnovic (San Diego, CA, USA)

1:45pm-3:15pm: The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

I. Frouni, D. Bedard, S. Belliveau, E. Bourgeois-Cayer, A. Hamadjida, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: The History of Huntington Disease Description in Russia

D. Labunskiy (Santa Rosa, CA, USA)

1:45pm-3:15pm: The impact of thalamic lesions on visuomotor behavior: A behavioral and fMRI study

M. Wilke, C. Schmidt-Samoa, P. Dechent, K. Miloserdov, J. Liman, M. Holzgraefe, I. Kagan, M. Bähr (Goettingen, Germany)

1:45pm-3:15pm: The Impact of Vocal Fold Augmentation with Injection Laryngoplasty on Voice Quality in Patients with Parkinson Disease

O. Klepitskaya, J. Barr, Y. Liu, S. Sillau, J. Litts, D. Fink, M. Shaffer, J. Newcombe, A. Klepitskaya, M. Clary (Aurora, CO, USA)

1:45pm-3:15pm: The Interface of advanced therapies as Parkinson’s disease progresses – case reports

C. Liang, S. Williams, L. Jones, C. Sue, P. Silberstein (St Leonards, Australia)

1:45pm-3:15pm: The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America

W. Oertel, H. Müller, C. Schade-Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, M. Unger, K. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

1:45pm-3:15pm: The nigral hyperintensity on 3 Tesla susceptibility-weighted MRI in patients with vascular parkinsonism

K.J. Kim, Y.J. Bae, J.M. Kim, S.E. Kim, B.S. Jeon (Goyang, Republic of Korea)

1:45pm-3:15pm: The outcome of directional subthalamic deep brain stimulation in advanced Parkinson’s disease

M. Koivu, F. Scheperjans, J. Eerola-Rautio, J. Resendiz-Nieves, J. Marjamaa, R. Kivisaari, E. Pekkonen (Helsinki, Finland)

1:45pm-3:15pm: The PDSAFE falls prevention programe for people with Parkinson’s: A multicentre randomised controlled trial

A. Ashburn, R. Pickering, L. Rochester, H. Roberts, C. Ballinger, S. Hulbert, I. Marian, C. Fitton, E. McIntosh, V. Goodwin, A. Nieuwboer, S. Lamb, K. Chivers Seymour (Southampton, United Kingdom)

1:45pm-3:15pm: The possibility of medicamentous correction of the lower urinary tract dysfunction in patients with Parkinson’s disease

M. Tukhtamishev, T. Khodjimetov, F. Akhmedova (Tashkent, Uzbekistan)

1:45pm-3:15pm: The possible neuroprotective potential of galantamine along with soya-lecithin and hydroxychloroquine against ICV-STZ induced cognitive dysfunction in rats

A. Singh, A. Kumar (Patiala, India)

1:45pm-3:15pm: The relationship between family care giver number and progression speed of dementia

Y. Liu, S.L. Yang, Y.C. Wu (Shanghai, China)

1:45pm-3:15pm: The Research of the Structural Changes of Cerebellar Tissue in Tremor-type Parkinson’s Disease Based on DKI

T. Siyu, T. Dan, X. xiaoyan, Q. Jin, H. Xiushuang (Dalian, China)

1:45pm-3:15pm: The role of Genes and Gene x Environment Determinants of Stress in the pathogenesis of Functional Neurological Disorders

P. Spagnolo, C. Maurer, C. Hodgkinson, D. Goldman (Bethesda, MD, USA)

1:45pm-3:15pm: The shared risk of apolipoprotein E ɛ4-allele on hippocampal volume across the spectrum of Alzheimer’s disease and dementia with Lewy bodies: Evidence from the Sunnybrook Dementia Study

U. Saeed, S. Mirza, B. MacIntosh, N. Herrmann, J. Keith, J. Ramirez, S. Nestor, J. Knight, W. Swardfager, E. Rogaeva, E. Black, M. Masellis (Toronto, ON, Canada)

1:45pm-3:15pm: The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease

D. Price, M. Koike, W. Wrasidlo, A. Khan, E. Rockenstein, E. Masliah, D. Bonhaus (San Diego, CA, USA)

1:45pm-3:15pm: The Ultrastructural study of the effects of different types of chronic motor deficit on the morphology of limbic, extrapyramidal and neocortical regions of rat brain

M. Zhvania, N. Lomidze, N. Gogokhia (Tbilisi, Georgia)

1:45pm-3:15pm: The use of gliatilin in the complex treatment of vascular parkinsonism

S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist in development for Essential Tremor and Parkinson’s disease Tremor in Cav3 driven neurological models

M. Lee, E. Newbold, S. Papapetropoulos (Cambridge, MA, USA)

1:45pm-3:15pm: Tics in Wilson’s Disease and Review of the Literature

AY. Yılmaz, M. Kuzu Kumcu, MC. Akbostancı (Ankara, Turkey)

1:45pm-3:15pm: Toe dystonia in Parkinson’s disease: Impact of subthalamic nucleus deep brain stimulation

C. Laurencin, S. Montaut, T. Danaila, C. Vial, S. Thobois (Lyon, France)

1:45pm-3:15pm: Toward optimized nonlinear deformation algorithms for subcortical DBS target regions in MRI

S. Ewert, A. Horn, F. Finkel, N. Li, A. Kühn, T. Herrington (Berlin, Germany)

1:45pm-3:15pm: Training in parkinsonism among health providers in Cameroon

M. Kurtis, M. Monje, C. Delgado-Suarez, I. Garcia-Morales, P. Gomez-Iglesias, M. Molina, D. Garcia-Azorin (Madrid, Spain)

1:45pm-3:15pm: Transient dystonia of infancy: 25 cases

V. Naranjo, M. Troncoso, A. Barrios, L. Troncoso, S. Witting, S. Lara, D. Muñoz, M. Hidalgo, I. Ruiz (Santiago, Chile)

1:45pm-3:15pm: Transplantation therapy of human iPS cell-derived dopamine neural progenitor cells for Parkinson’s disease

R. Nakamura, G. Oyama, T. Jo, K. Ishikawa, R. Nonaka, Y. Shimo, W. Akamatsu, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection

S. Isaacson (Boca Raton, FL, USA)

1:45pm-3:15pm: Treatment with levodopa/carbidopa intestinal gel of advanced Parkinson’s disease patients: Bulgarian experience

E. Chorbadzhieva (Sofia, Bulgaria)

1:45pm-3:15pm: TreCap: Quantify and assess tremor in real-time with a new wearable device

R. Bremm, J. Goncalves, K. Koch, F. Hertel (Belvaux, Luxembourg)

1:45pm-3:15pm: Unusual eye movement found in antineuronal nuclear autoantibody type 2 (ANNA-2); both seesaw nystagmus and opsoclonus may provide a novel mechanism

M. Rizvi, L. Cameron, A. Shaikh, C. Kilbane (Cleveland, OH, USA)

1:45pm-3:15pm: Update on The Personalized Parkinson Project: Partnering with Patients to Understand Disease Progression Through a Multi-Dimensional Approach

B. Bloem, R. Kapur, T. v/d Zande, M. Faber, W. Marks, Jr (Nijmegen, Netherlands)

1:45pm-3:15pm: Use of safinamide: A clinical practice review of 2 year experience

C. Borrue-Fernandez (San Sebastian Reyes, Spain)

1:45pm-3:15pm: Using tablet devices to educate patients about dystonia and botulinum toxin for movement disorders

S. Bobker, A. Hanineva, P. Popa, H. Ellsworth, X. Wu, I. Diaz, N. Hellmers, C. Henchcliffe, H. Sarva (New York, NY, USA)

1:45pm-3:15pm: Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

V. Pitz, N. Malek, K. Grosset, D. Grosset (Glasgow, United Kingdom)

1:45pm-3:15pm: VIT-D and Tics Movement Disorder

N. Gemawat (Mumbai, India)

1:45pm-3:15pm: Vitamin B3 and Neurodevelopment in Parkinson’s Disease

A. Williams, S. Griffin, R. Fricker (Birmingham, United Kingdom)

1:45pm-3:15pm: VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial

P. Larson, K. Bankiewicz, A. Van Laar, R. Richardson, B. Ravina, A. Kells, B. Boot, A. Martin, M. Thompson, C. Christine (San Francisco, CA, USA)

1:45pm-3:15pm: Weight loss and nutritional status in Parkinson’s disease patients under levodopa/carbidopa intestinal gel infusion treatment

M. Fabbri, M. Zibetti, L. Beccaria, A. Romagnolo, E. Montanaro, J. Ferreira, L. Lopiano (Lisbon, Portugal)

1:45pm-3:15pm: Weight loss in STN DBS in Parkinson’s Disease? Long-term outcome of a prospective cohort at 5 years

D. Chan, C. Chan, A. Chan, C. Lau, C. Zhu, W. Poon, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion

B. Fernández-Rodríguez, J. Dupouy, E. Harroch, MH. Fabre-Delcros, C. Barthélémy, P. Loubière, K. Barange, C. Brefel-Courbon, O. Rascol, F. Ory-Magne (Toulouse, France)

1:45pm-3:15pm: What is the relationship between dyskinesia and performance of activities of daily living in patients with Parkinson’s disease?

E. Goubault, S. Bogard, K. Lebel, C. Duval (Montreal, QC, Canada)

1:45pm-3:15pm: What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years

T. Dominey, S. Buff, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture

J. Ferrario, A. Bernardi, P. Ballestero, M. Ferrario, M. Schenk, E. Avale, S. Guerrero, O. Gershanik (Buenos Aires, Argentina)

1:45pm-3:15pm: Zonisamide improves parkinsonism in DLB patients: A randomized phase 3 trial

M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, M. Tagawa, K. Kosaka (Kodaira, Japan)

1:45pm-3:15pm: “Appropriate Doses Treatment” of IncobotulinumtoxinA in spasticity

G. Ianieri, R. Marvulli (Bari, Italy)

1:45pm-3:15pm: “Stiff Young Woman”: Case report

M. Sousa, R. Varela, D. Carneiro, C. Januário, A. Morgadinho (Coimbra, Portugal)

1:45pm-3:15pm: [18F]FP-CIT and [18F]FDG PET findings in MSA patients with cognitive impairment

KB. Lee, YJ. Park, C. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: 18F-FDG PET brain in Parkinsonism

F. Amod (Durban, South Africa)

1:45pm-3:15pm: 2 cases of Parkinonism secondary to neurosyphilis

M. Li, F. Lou, Y. Ren, X. Luo (Shenyang, China)

1:45pm-3:15pm: 91 years old woman with Sjogren’s syndrome and Parkinsonism

M. Augusto, PV. Perin (Atibaia, Brazil)

1:45pm-3:15pm: A 15-year review of a movement disorder database in Singapore

A. Wong, S. Neo, H.L. Ng, W. Li, K.Y. Tay, W.L. Au, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: A case of levodopa responsive rapid onset dystonia-parkinsonism

Y. Fernandez, S. Frucht (New York, NY, USA)

1:45pm-3:15pm: A Case of Parkinsonism due to the Hypoxic-Ischemic Lesions of the Striatum

H. Kaleagasi, N. Oksuz, O. Dogu (Mersin, Turkey)

1:45pm-3:15pm: A clinical and pathological study of small fibers in Friedreich´s Ataxia

E. Indelicato, W. Nachbauer, A. Eigentler, A. Fanciulli, J.P. Ndayisaba, W. Poewe, G. Wenning, J. Wanschitz, S. Boesch (Innsbruck, Austria)

1:45pm-3:15pm: A comparative study on the alterations in the cortical excitability and central motor conduction time in spinocerebellar ataxias 1, 2, 3 and 12

A. Stezin, K. Jhujhunwala, N. Kamble, P. Pal (Bangalore, India)

1:45pm-3:15pm: A comparison of relative displacement by double integration with root mean square in the quantitative evaluation of gait ataxia by triaxial accelerometers

S. Shirai, I. Yabe, M. Matsushima, H. Sasaki (Sapporo, Japan)

1:45pm-3:15pm: A Diagnostic Algorithm for Pediatric Early Onset Ataxia

R. Brandsma, C. Verschuuren, H. Kremer, T. de Koning, M. de Koning-Tijssen, D. Sival (Groningen, Netherlands)

1:45pm-3:15pm: A functional micro-electrode mapping of ventral thalamus in Essential Tremor

D. Pedrosa, P. Brown, H. Cagnan, V. Visser-Vandewalle, J. Wirths, L. Timmermann, J. Stuart-Brittain (Marburg, Germany)

1:45pm-3:15pm: A longitudinal study of brain quantitative MRI analysis before and after diagnosis of progressive supranuclear palsy

K. Seo, T. Yamamoto, H. Kawasaki, A. Miyake, T. Hukuoka, Y. Nakazato, T. Takahasi, I. Matunari, H. Matuda, N. Tamura, N. Araki (Saitama, Japan)

1:45pm-3:15pm: A machine learning approach to determine the important patient characteristics for tremor prevalence and tremor irregularity in dystonia

S. Balta Beylergil, L. Scorr, A. Cotton, H. Jinnah, A. Shaikh (Cleveland, OH, USA)

1:45pm-3:15pm: A Mcleod syndrome family and novel XK gene mutation in China mainland

L. Xu, P. Hua, W. Liu (Nanjing, China)

1:45pm-3:15pm: A nationwide epidemiological study of Parkinson’s disease in Korea using national health insurance database

WW. Lee, B. Jeon, BK. Kim, HJ. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: A new clinical and research smartphone application to assess tremor and bradykinesia in patients with movement disorders

C. Duval, J.F. Daneault, B. Carignan, C.É. Coderre, S. Bogard (Montreal, QC, Canada)

1:45pm-3:15pm: A New Scale to Measure Impairment in Patients with Writer’s Cramp

E. Shamim, O. Ahmad, T. Wu, P. Srivanitchapoom, P. Diomi, B. Karp, K. Alter, C. Toro, B. Hodsdon, S. Pandey, J. Park, S. Meunier, M. Hallett (Largo, MD, USA)

1:45pm-3:15pm: A Novel Telerehabilitation Strategy to Prevent Falls in Parkinson’s Disease (PD)

C. Park, M. Afshari, J. Guenther, M. Patel, H. Bhide, C. Tanner, N. Galifianakis (San Francisco, CA, USA)

1:45pm-3:15pm: A panel of CSF and plasma biomarkers reveals novel biological insights into atypical parkinsonian syndromes

E. Jabbari, J. Woodside, N. Magdalinou, A. Lees, H. Zetterberg, H. (London, United Kingdom)

1:45pm-3:15pm: A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)

M. Delnomdedieu, Y. Tan, A. Ogde, Z. Berger, R. Reilmann (Cambridge, MA, USA)

1:45pm-3:15pm: A Registry of Real-World Outcomes Using Deep Brain Stimulation for the Treatment of Dystonia

J. Krauss, C. Nicholson, M. Barbe, V. Visser-Vanderwalle, A. Kuehn, M. Poetter-Nerger, R. Jain, H. Scholtes, N. Van Dyck, A. Albanese (Hannover, Germany)

1:45pm-3:15pm: A strategic approach to understand microsatellite repeat loci among Indian spinocerebellar ataxia patients

V. Suroliya, M. Faruq, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: A Study on Combined Brain Positron Emission Tomography (PET) – Magnetic Resonance Imaging (MRI) Using Fluorodeoxyglucose (18FDG) (FDG-PET/MRI) in Premanifest Huntington’s Disease Gene-expansion Carriers

M. Hellem, T. Vinther-Jensen, C. Hansen, E. Budtz-Jørgensen, L. Hjermind, I. Law, J. Nielsen (Copenhagen, Denmark)

1:45pm-3:15pm: A study on pre-adoption of a self-management application by Parkinson’s disease patients

M. Memedi, J. Lindqvist, T. Tunedal, A. Duvåker (Örebro, Sweden)

1:45pm-3:15pm: A voxel-wise meta-analysis of gray matter abnormalities in essential tremor

Q. Han, Y. Hou, H. Shang (Chengdu, China)

1:45pm-3:15pm: A Young Man with Multiple System Atrophy: A Case Report

DR. Carneiro, M. Sousa, C. Januário, A. Morgadinho (Coimbra, Portugal)

1:45pm-3:15pm: A53T mutant human α-synuclein BAC transgenic mice as a model for Parkinson’s disease

T. Taguchi, I. Masashi, M. Uemura, Y. Hatanaka, N. Uemura, H. Yamakado, R. Takahashi (Kyoto, Japan)

1:45pm-3:15pm: Abnormal cerebellar learning in cervical dystonia

T. Bäumer, E. Tzvi, J. Junker, J. Verrel, S. Loens (Luebeck, Germany)

1:45pm-3:15pm: Accelerometer-based measures and analyses of nonmotor symptoms of patients with Parkinson’s Disease

C. Virbel-Fleischman, Y. Retory, S. Hardy, J.C. Corvol, D. Grabli (Paris, France)

1:45pm-3:15pm: Accessing Speech and Language Therapy (SLT) in a Multi-Disciplinary Movement Disorders Clinic (MDC)

J. Martin, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Accuracy of the International Parkinson Disease and Movement Disorder Society Progressive Supranuclear Palsy Diagnostic Criteria (IPD-MDS-PSP)

A. Shoeibi, I. Litvan, J. Juncos, Y. Bordelon, D. Riley, S. Reich, D. Shprecher, D. Hall, C. Marras, B. Kluger, N. Olfati, J. Jankovic (Mashhad, Islamic Republic of Iran)

1:45pm-3:15pm: Acoustic, respiratory, cognitive and wellbeing comparisons of two groups of people with Parkinson’s disease participating in voice and choral singing group therapy (VCST) versus a music appreciation activity

R. Matthews, S. Purdy, L. Tippett (Auckland, New Zealand)

1:45pm-3:15pm: Acoustical characteristics of speech impairment in Primary Generalized Dystonia

M.C. Cuartero, R. Bertrand, D. Grabli, M. Vidailhet, S. Pinto (Aix-en-Provence, France)

1:45pm-3:15pm: Acute concomitant presentation of chorea and subacute combined degeneration secondary to vitamin B12 deficiency

E. Natera, F. Acebrón, A. Sánchez, V. Ros, A. Gómez, F. Ruiz, B. Zarza, C. Estévez, A. Alonso, JC. Martínez-Castrillo, I. Corral (Madrid, Spain)

1:45pm-3:15pm: Acute Stroke in Middle Cerebellar Peduncle in a Patient with FXTAS

A. Fraint, D. Hall, R. Dafer (Chicago, IL, USA)

1:45pm-3:15pm: ADCY5-related disorder associated with status dystonicus

A. Castro Caldas, P. Pita Lobo, L. Correia Guedes, M. Coelho (Lisboa, Portugal)

1:45pm-3:15pm: Adolescent onset RBD converting to PD after 48 years

Z. Xu, J. Oliver, K. Anderson (Singapore, Singapore)

1:45pm-3:15pm: Affective impairment and emotional tone of early Richardson’s syndrome and Progressive Supranuclear Palsy with predominant parkinsonism: The role of Alexithymia and Anhedonia

C. Pellicano, F. Assogna, L. Cravello, C. Savini, M. Pierantozzi, A. Stefani, B. Mercuri, C. Caltagirone, F. Pontieri, G. Spalletta (Rome, Italy)

1:45pm-3:15pm: Alterations of cerebello-cortical networks related to the cognitive performance in multiple system atrophy

K. Hara, H. Watanabe, K. Kawabata, E. Bagarinao, R. Ohdake, M. Masuda, T. Yokoi, A. Ogura, T. Tsuboi, M. Ito, M. Katsuno, G. Sobue (Nagoya, Japan)

1:45pm-3:15pm: Alternating thalamic deep brain stimulation for Essential Tremor: A trial to reduce habituation

M. Seier, A. Hiller, J. Quinn, C. Murchison, M. Brodsky, S. Anderson (Omaha, NE, USA)

1:45pm-3:15pm: Amantadine extended release (Gocovri) reduces dyskinesia and bradykinesia: Evaluation of clinical response with the wearable PKG (Personal Kinetigraph) watch

N. Chhabria, S. Isaacson, K. Lyons, R. Pahwa (Boca Raton, FL, USA)

1:45pm-3:15pm: Amyotrophic Lateral Sclerosis-Progressive Supranuclear Palsy Phenotype with Negative C9ORF72 Mutation

S.C. Low, A.H. Tan, M. Ellis, K.J. Goh, S.Y. Lim, A. Ahmad-Annuar, N. Shahrizaila, M. Kennerson (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: An atutopsy case of argyrophilic grain disease, clinically presenting with Parkinson dementia

R. Sengoku, D. Kaneda, M. Kameyama, A. Tokumaru, K. Ishii, K. Kanemaru, Y. Saito, S. Murayama (Tokyo, Japan)

1:45pm-3:15pm: An automated algorithm for detection and quantification of tremor from pen-on-paper Archimedes spirals

R. Rajan, A. R, A. Pandit, V. Venugopalan, D. Vibha, S. Krishnan, A. Srivastava, K. Prasad, A. Kishore (New Delhi, India)

1:45pm-3:15pm: An efficient algorithm for predicting pathological high-voltage spindles related to Parkinsonian resting tremor from local field potential recordings

R. Perumal, V. Vigneron, C. Chuang, Y. Chang, S. Yeh, H. Chen (Hsinchu, Taiwan)

1:45pm-3:15pm: An EMG-Motion capture analysis of Golfers with the Yips

G. Revankar, I. Ogasawara, Y. Kajiyama, N. Hattori, Y. Uno, K. Konaka, Y. Gon, M. Mihara, S. Kawamura, K. Nakata, H. Mochizuki (Osaka, Japan)

1:45pm-3:15pm: An extraordinary cause of psychosis: Anti-NMDA receptor encephalitis

H. Batur Caglayan, F. Sahin, T. Altıparmak, E. Turksoy, S. Candansayar, A. Bora Tokcaer (Ankara, Turkey)

1:45pm-3:15pm: An Observational Study Using Multimodal Wearable Sensors and Environmental Monitors in Healthy Volunteers to Characterize Activities Pertaining to Health, Wellbeing, and Daily Living

T. Kangarloo, F. Hameed, C. Demanuele, D. Psaltos, H. Zhang, R. Lopez, S. Amato, K. Hallock, X. Cai (Cambridge, MA, USA)

1:45pm-3:15pm: Analysis of sensory tricks in 45 patients with pantothenate kinase-associated neurodegeneration

J. Martins, A. Darling, C. Garrido, C. Espinós, B. Dueñas, T. Temudo (Porto, Portugal)

1:45pm-3:15pm: Analysis of Tau Burden and Distribution on the Spectrum of PSP Subtypes

J. Sanchez-Ruiz Gordoa, P. Clavero, M. Zelaya, C. López-Molina, A. Galbete, V. Coca, M. Mendioroz, E. Erro (Pamplona, Spain)

1:45pm-3:15pm: Analysis of the electromyographic profile of a subject with spasticity during the lateral reactive postural control test

M. Maldonado (Santiago, Chile)

1:45pm-3:15pm: Anemia in men and increased Parkinson’s disease risk: A population-based cohort study using big data

V. Rozani, N. Giladi, B. El-Ad, T. Gurevich, J. Tsamir, B. Hemo, C. Peretz (Tel Aviv, Israel)

1:45pm-3:15pm: Annual Clinical Evaluation in Out Patient Clinic May Improve Quality of Life in Patients with Parkinson’s Disease

M. Tomiyama, T. Ueno (Aomori, Japan)

1:45pm-3:15pm: Antiglycine Receptor Antibodies and Rapidly Progressive Corticobasal Syndrome

A. Muñoz González, A. Contreras Chicote, M. Vales Montero, J.M. Velázquez Pérez, B. Dela Casa, E. Luque Buzo, F. Graus, F. Grandas (Madrid, Spain)

1:45pm-3:15pm: Antihypertensive medications have protective associations with PD outcomes in PD-hypertension

V. Kotagal (Ann Arbor, MI, USA)

1:45pm-3:15pm: Antisense FMR1 splice variant: A predictor of fragile X-associated tremor/ataxia syndrome

P. Vittal, S. Pandya, K. Sharp, E. Berry-Kravis, L. Zhou, B. Ouyang, J. Jackson, D. Hall (Winfield, IL, USA)

1:45pm-3:15pm: Apolipoprotein E and multiple system atrophy

K. Ogaki, Y. Martens, M. Heckman, S. Koga, L. Labbé, O. Lorenzo-Betancor, A. Wernick, R. Walton, A. Soto, E. Vargas, H. Nielsen, S. Fujioka, T. Kanekiyo, R. Uitti, J. van Gerpen, W. Cheshire, Z. Wszolek, P. Low, W. Singer, N. Hattori, D. Dickson, G. Bu, O. Ross (Tokyo, Japan)

1:45pm-3:15pm: Application of Chinese version of SWAL-QOL in Parkinson’s Disease

H.F. Chan, H. Kim, M. Ng, DY. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Approach to Health Care Shaped by Generational Expectations (The AGE Study): Patients’ preferences for healthcare providers

D. Hengartner, T. Rasameesoraj, J. Lin, O. Hogue, Y. Li, O. Wenzel, E. LaPlante, J. Liang, H. Fernandez, X. Yu (Cleveland, OH, USA)

1:45pm-3:15pm: Approaching Health Care Shaped by Generational Expectations (The AGE Study): A perspective on technology and research

T. Rasameesoraj, D. Hengartner, J. Lin, O. Hogue, E. LaPlante, Y. Li, O. Wenzel, J. Liang, H. Fernandez, X. Yu (Cleveland, OH, USA)

1:45pm-3:15pm: Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time

J. Lin, D. Hengartner, T. Rasameesoraj, O. Hogue, Y. Li, O. Wenzel, E. LaPlante, J. Liang, H. Fernandez, X. Yu (Cleveland, OH, USA)

1:45pm-3:15pm: Are Lewy bodies associated with sympathetic pathology in dementia subjects?

D. Shprecher, M. Callan, B. Cutler, G. Serrano, C. Adler, H. Shill, J. Caviness, M. Sabbagh, C. Belden, E. Driver-Dunckley, S. Mehta, L. Sue, K. Davis, E. Zamrini, T. Beach (Sun City, AZ, USA)

1:45pm-3:15pm: ARISE study: Study Design and Baseline Characteristics for a Phase 2 Trial of the Anti-Tau Antibody ABBV-8E12 in Progressive Supranuclear Palsy

N. Mendonca, R. Bateman, A. Boxer, J. Braunstein, D. Claassen, D. Holtzman, D. Kerwin, B. Rendenbach-Mueller, H. Soares, D. Wang, G. Höglinger (Ludwigshafen, , Germany)

1:45pm-3:15pm: Arm swing asymmetry in Parkinson Disease patients using a portable RGBD camera

J. Orozco, B. Munoz, J. Valderrama, A. Navarro, Y. Castaño, J. Arango (Cali, Colombia)

1:45pm-3:15pm: Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients

R. Pahwa, L. Garrison, M. Zimmerman, R. Johnson, J. Nguyen, M. Li, R. Patni (Kansas City, KS, USA)

1:45pm-3:15pm: Assessing the potential of EEG as a biomarker in Huntington’s disease using machine learning automatic classification

O. Odish, K. Johnsen, P. van Someren, R. Roos, G. van Dijk (Leiden, Netherlands)

1:45pm-3:15pm: Assessment of cognitive functions, depression-anxiety scales and quality of life in patients and their relatives with Cervical Dystonia and Botulinum Toxin Treatment

D. Ceylan, S. Erer, M. Zarifoglu, N. Turkes, A. Demiralay (Bursa, Turkey)

1:45pm-3:15pm: Assessment of CSF biomarkers clinical value in Progressive Supranuclear Palsy

T. Schirinzi, G. Sancesario, G. Di Lazzaro, N. Mercuri, S. Bernardini, A. Lang, A. Pisani (Rome, Italy)

1:45pm-3:15pm: Assessment of Motor Symptoms in Parkinson’s disease using Flexible Wearable Sensors and Deep Neural Networks: A CIS-PD substudy

L. Lonini, A. Dai, C. Poon, N. Shawen, L. Shimanovich, T. Simuni, D. Daeschler, J. Rogers, A. Jayaraman (Chicago, IL, USA)

1:45pm-3:15pm: Association of impaired melatonin secretion with sleep disturbance in multiple system atrophy

T. Nakamura, M. Ueda, M. Suzuki, E. Imai, G. Tohnai, M. Katsuno (Nagoya, Japan)

1:45pm-3:15pm: Asynchronous Telehealth Consultations for Movement Disorders in Africa

J. Guenther, M. Katz, E. Cubo, N. Galifianakis, S. Guttman, N. Okubadejo, M. Spindler, J. Aldred, M. Guttman (San Francisco, CA, USA)

1:45pm-3:15pm: Ataxia and cerebellar atrophy in Charcot-Marie-Tooth neuropathy type 4C

M. Paucar, H. Skott, K. Samuelsson, H. Malmgren, G. Solders, P. Svenningsson (Stockholm, Sweden)

1:45pm-3:15pm: Atypical Dopamine Responsive Parkinsonism in HIV Seroconversion

N. Siddi Ganie, I. Siddi Ganie, N. Soni (Durban, South Africa)

1:45pm-3:15pm: Atypical presentation in 4 patients of Subacute Sclerosing Pan Encephalitis (SSPE), –widening phenotypic horizon

P. Basu, A. Ghosal, S. Shubham, J. Ganguly, Y. Kumar, K. Kumar (Kolkata, India)

1:45pm-3:15pm: Atypical Response to Apomorphine in a Patient with Multiple System Atrophy

S. Ozben, F. Genc, F. Tuter Yilmaz, A. Erdal, N. Atis (Antalya, Turkey)

1:45pm-3:15pm: Auditory rhythmic cueing changes motor control during walking in Parkinson’s disease

A. Islam, C. Chen, l. Alcock, K. Nazarpour, L. Rochester, A. Pantall (Newcastle-upon-Tyne, United Kingdom)

1:45pm-3:15pm: Auto-antibodies and clinical-imaging associations in patients with Movements Disorders from a Neurological Institute in Mexico

H. Martinez-Hernandez, N. Gandarilla-Martinez, J. Flores-Rivera, O. Cardenas-Saenz, R. Garcia-Santos, V. Rivas, N. Kerik-Rotenberg, S. Vargas-Cañas, M. Espinola-Nadurille (Mexico City, Mexico)

1:45pm-3:15pm: Background pathology of ‘corticobasal degeneration (CBD) mimics’ -Japanese validation study of CBD (J-VAC study)

T. Shimohata, I. Aiba, M. Yoshida, Y. Toyoshima, S. Murayama, T. Uchihara, T. Arai, Y. Saito, H. Takigawa, K. Hasegawa, T. Ikeuchi, M. Hasegawa, T. Komori, K. Wakabarashi, A. Tokumaru, K. Sakurai, K. J-VAC study (Gifu, Japan)

1:45pm-3:15pm: Baseline predictors of clinical and imaging progression in Parkinson’s disease: Results from the PPMI study

L. Chahine, A. Siderowf, C. Caspell-Garcia, J. Barnes, N. Seedorff, C. Coffey, D. Galasko, B. Mollenhauer, V. Arnedo, N. Daegele, M. Frasier, C. Tanner, K. Kieburtz, K. Marek (Pittsburgh, PA, USA)

1:45pm-3:15pm: Benign hereditary chorea with nocturnal dyskinesias

A. Mook, C. Kilbane (Cleveland, OH, USA)

1:45pm-3:15pm: Bilateral Deep Brain Stimulation of the Ventral Intermediate Thalamic Nucleus for Orthostatic Tremor: A Case Report

N. Warneke, E. Wilbers, T. Warnecke, W. Stummer (Münster, Germany)

1:45pm-3:15pm: Body concept and quality of life in patients with idiopathic dystonia

L. Paracka, F. Wegner, C. Escher, M. Klietz, M. Abdallat, J. Krauss (Hannover, Germany)

1:45pm-3:15pm: Botulinum toxin A (BoNT A) treatment of postsurgical/posttraumatic focal movements not responding to oral therapy

A. Lozza, A. Castagna, G. Castelnovo, E. Alfonsi, A. Montini, L. Marchetta, M. Fresia, A. Arrigo, R. Manni (Pavia, Italy)

1:45pm-3:15pm: Botulinum toxin A injection for treatment of adductor spasmodic dysphonia under guidance of fiber laryngoscope combined with needle electromyography: 2 case reports

X. Zhang, Z. Zhang, Y. Pan, L. Jin (Shanghai, China)

1:45pm-3:15pm: Botulinum toxin in Restless Leg Syndrome – A Randomized Double-Blind Placebo-Controlled Study

S. Mittal, D. Machado, D. RIchardson, D. Dubey, B. Jabbari (Bangalore, India)

1:45pm-3:15pm: Botulinum toxin injections improve daily life activities in patients with upper limb tremor

A. Kreisler, B. Bouchain, L. Defebvre (Lille, France)

1:45pm-3:15pm: Botulinum Toxin Injections in Upper Limb Tremor

W. Fung, M. Ligtermoet, K. Bertram, D. Williams, J. Kamel (Melbourne, Australia)

1:45pm-3:15pm: Bradykinesia assessment using evolutionary algorithms in Parkinson’s disease: Clinical validation

C. Gao, S. Smith, M. Lones, S. Jamieson, J. Alty, J. Cosgrove, P. Zhang, J. Liu, Y. Chen, J. Du, S. Cui, H. Zhou, S. Chen (Shanghai, China)

1:45pm-3:15pm: Burden among Patients with Progressive Supranuclear Palsy

T. Xie, X. Ye, L. Kandukuri, Y. Bao (Chicago, IL, USA)

1:45pm-3:15pm: Burden of progressive supranuclear palsy: A systematic literature review

S. Chen, I. Jakab, T. Zelei, L. Szilberhorn, R. Bendes, B. Elezbawy, Z. Kaló, M. Mann, M. Potashman, J. Pitter (Cambridge, MA, USA)

1:45pm-3:15pm: C-spine injury with progressive gait difficulty, drop foot, bizarre gait and serum positive stiff person syndrome: A case report

K.W. Chen, K.L. Ho, A.C. Chen, J.J. Lin (Taichung, Taiwan)

1:45pm-3:15pm: Can a novel digital pen system assist clinicians in the differential diagnosis of Parkinson’s disease?

M. Agarwal, K. Vallely, R. Zietsma, W. Gray, R. Walker (Newcastle upon Tyne, United Kingdom)

1:45pm-3:15pm: Can cerebellar dysfunction help differentiate idiopathic from functional cervical dystonia?

A. Stephan, D. Benninger (Lausanne, Switzerland)

1:45pm-3:15pm: Caregiver Burden in a Multidisciplinary MSA Clinic

M. Salinas, E. Kent, S. Vernino, P. Khemani (Dallas, TX, USA)

1:45pm-3:15pm: Case of Friedreich’s ataxia with extremely large repeat expansion without systemic disease

K. Niotis, H. Ellsworth, J. Weaver, H. Sarva (New York, NY, USA)

1:45pm-3:15pm: Case report of hyperglycemic nonketotic chorea with rapid radiological resolution

T. Herath (Colombo, Sri Lanka)

1:45pm-3:15pm: Case series of Holmes tremor at the Clinical Hospital of State University of Campinas

F. de Moraes, F. de Paula, S. Filho, P. de Azevedo, L. Piovesana (Campinas, Brazil)

1:45pm-3:15pm: CASPR2 antibody mediated autoimmune encephalitis presenting with profound chorea

S. Scotton, F. Manfredonia, P. Newman (Coventry, United Kingdom)

1:45pm-3:15pm: Cerebellar Ataxia as a Manifestation of Hashimoto Encephalopathy

S. Thakolwiboon, D. Ruthirago, V. Senanarong (Lubbock, TX, USA)

1:45pm-3:15pm: Cerebellar Ataxia case series study from southern Spain: Clinical and molecular description

A. Adarmes Gomez, S. Jesus Maestre, C. Mendez delBarrio, D. Macias Garcia, F. Carrillo Garcia, M. Carballo, P. Gomez Garre, P. Mir Rivera (Seville, Spain)

1:45pm-3:15pm: Cerebellar signs in progressive supranuclear palsy

D. Crosiers, A. Sieben, J. Baets, J.J. Martin, P. Cras (Edegem, Belgium)

1:45pm-3:15pm: Cerebello-spinal stimulation in neurodegenerative ataxia: A randomized, double-blind, sham-controlled, crossover trial

A. Benussi, V. Dell'Era, V. Cantoni, E. Bonetta, R. Grasso, R. Manenti, M. Cotelli, A. Padovani, B. Borroni (Brescia, Italy)

1:45pm-3:15pm: Cerebral and pulmonary thromboembolism in a patient with hyperhomocystinemia treated with high dose levodopa/carbidopa intestinal gel

E. Saka Topcuoglu, L. Mehdikhanova, E. Arsava, M. Topcuoglu, B. Elibol (Ankara, Turkey)

1:45pm-3:15pm: Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI

F. Rodrigues, L. Byrne, E. De Vita, E. Johnson, N. Hobbs, J. Thornton, R. Scahill, E. Wild (London, United Kingdom)

1:45pm-3:15pm: Cerebrospinal fluid levels of cytokines in multiple system atrophy: A cross-sectional study of the atalan msa registry (CMSAR)

Y. Compta, S. Dias, M. Pulido-Salgado, D. Giraldo, A. Pérez-Soriano, M. Fernández, A. Cámara, P. Bravo, E. Muñoz, J. Saura, MJ. Marti (Barcelona, Spain)

1:45pm-3:15pm: Cerebrospinal fluid proteomics reveals alterations of the renin-angiotensin system in Huntington’s disease

V. Niemelä, J. Sundblom, A.M. Landtblom, D. Nyholm (Uppsala, Sweden)

1:45pm-3:15pm: Cerebrotendinous Xanthomatosis: A Rare Lipid Storage Disease

H. Hanagasi, G. Yunisova, B. Bilgic, O. Dogu, H. Kaleagasi, Z. Tufekcioglu, E. Lohmann, H. Gurvit, M. Emre (Istanbul, Turkey)

1:45pm-3:15pm: Cervical dystonia – changes in resting state cerebellar connectivity induced by botulinum toxin

M. Nevrlý, P. Hok, P. Otruba, M. Kaiserová, L. Hvizdošová, Z. Tüdös, P. Hluštík, P. Kaňovský (Olomouc, Czech Republic)

1:45pm-3:15pm: Cervical dystonia presentation and associated injection practices for patients undergoing routine treatment with abobotulinumtoxinA over 1 year of follow-up

R. Trosch, V. Misra, S. Om, P. Maisonobe (Farmington Hills, MI, USA)

1:45pm-3:15pm: Cervical dystonia priori to ataxia in spinocerebellar ataxia type 3 patients

X.Q. Yuan, R. Dutta, H.F. Shang (Chengdu, China)

1:45pm-3:15pm: Changes detected in swallowing function in Friedreich ataxia over 12 months

M. Keage, M. Delatycki, J. Dyer, L. Corben, A. Vogel (Carlton, Australia)

1:45pm-3:15pm: Changes in balance and gait after a single session of combined cerebellum and primary motor cortex transcranial direct current stimulation (tDCS) in a person with SCA1

M. León, P. Chaná (Santiago, Chile)

1:45pm-3:15pm: Changes in brain network activation (BNA) in patients with fragile x-associated tremor/ataxia syndrome (FXTAS)

T. Fay Karmon, S. Israeli-Korn, G. Yahalom, G. Issachar, Y. Yahav, A. Geva, Z. Peremen, S. Hassin-Baer (Ramat Gan, Israel)

1:45pm-3:15pm: Characteristics of leg tremors on standing in primary orthostatic tremor and Parkinson’s disease

J. Tashiro, H. Ohtsuka, M. Hirotani, S. Hamada, H. Soma, M. Nonaka, S. Honma, K. Hamada, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)

1:45pm-3:15pm: Characterizing Bulbar Dysfunction in X-Linked Dystonia-Parkinsonism (XDP): A Pilot Study

J. de Guzman, B. Perry, C. Go, J. Green, N. Sharma (Boston, MA, USA)

1:45pm-3:15pm: Characterizing the spectrum of Non-motor Symptoms in Progressive Supranuclear Palsy

C. S P, V. Holla, S. Prasad, A. Stezin, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

1:45pm-3:15pm: Chorea and Ataxia as Manifestations of Xeroderma Pigmentosum: A Case Report

A. Jocson, K. Ngo, D. Togasaki, B. Fogel (Los Angeles, CA, USA)

1:45pm-3:15pm: Choreaathetosis as clinical manifestation of Fahr Syndrome inTurner Syndrome Patient

S. Marisdina, M. Mukhlisa, K. Merryn (Palembang, Indonesia)

1:45pm-3:15pm: Chronological view of peak and diphasic dyskinesia, wearing off and freezing in Parkinson’s disease: 1212 Korean population

Y.E. Kim, B. Jeon. (Anyang, Republic of Korea)

1:45pm-3:15pm: Clinical and genetic data of Huntington disease in Uzbekistan patient

M. Rakhimova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Clinical and Molecular Characterization of a Family with Ataxia with Oculomotor Apraxia Type 2

T. Tropea, N. Jain, T. Unger, A. Chen-Plotkin. (Philadelphia, PA, USA)

1:45pm-3:15pm: Clinical and mutation spectrum of Ataxia with oculomotor apraxia-2: An Indian perspective

S. Shakya, M. Faruq, A. Srivastava, I. Singh, A. Garg, R. Rajan, V. Goyal (New Delhi, India)

1:45pm-3:15pm: Clinical characteristics of a family harbouring a novel CCDC88C mutation (SCA40)

W. Nachbauer, E. Indelicato, A. Eigentler, S. Boesch (Innsbruck, Austria)

1:45pm-3:15pm: Clinical Characteristics of Functional Movement Disorders: A Clinic-Based Study

J. Park (Goyang, Republic of Korea)

1:45pm-3:15pm: Clinical effectiveness of cerebellar repetitive transcranial magnetic stimulation (rTMS) on essential tremor

N. Olfati, A. Shoeibi, E. Abdollahian, V. Vakili, H. Ahmadi, H. Masoudian, A. Hoseini, M. Foroughipour, F. Rezaeitalab, M. Farzadfard, P. Layegh, S.H. Naseri (Mashhad, Islamic Republic of Iran)

1:45pm-3:15pm: Clinical experiences in Whole systems Ayurveda Management of Parkinson’s Disease

P. Shankar, P. R, P. Devkumar, A. Godbole, U. Muthane (Bangalore, India)

1:45pm-3:15pm: Clinical features and natural history of pathologically-confirmed corticobasal degeneration: A Japanese validation study of CBD (J-VAC study)

I. Aiba, T. Shimohata, S. Murayama, K. Hasegawa, Y. Iwasaki, O. Yokota, H. Fujimura, M. Sakai, T. Yokota, I. Yabe, H. Takigawa, K. Sugaya, K. Mori, M. Ito, C. Ishida, M. Kobayashi, Y. Hashizume, T. Ikeuchi, M. Hasegawa, M. Yoshida, T. Komori, K. Wakabayashi, Y. Saito, A. Tokumaru, K. Sakurai, K. Nakashima (Nagoya, Japan)

1:45pm-3:15pm: Clinical indicators of advanced Parkinson’s disease: Evaluating diagnostic properties from retrospective analysis of multi-country, cross-sectional observational study

P. Odin, Z. Pirtosek, R. Rodriguez, P. Martinez-Martin, D. Shah, P. Kandukuri, O. Koray, J. Zamudio, Y. Bao, Y. Jalundhwala, A. Antonini (Lund, Sweden)

1:45pm-3:15pm: Clinical profiles of late-onset psychiatric patients with incidental REM sleep without atonia

H. Fujishiro, M. Okuda, K. Iwamoto, S. Miyata, Y. Torii, S. Iritani, N. Ozaki (Nagoya, Japan)

1:45pm-3:15pm: Clinical spectrum of vascular Parkinsonism: A hospital-based study in south India

J. Kuragala, J. Murthy, N. Chaudhary, s. Sharma, S. Jaiswal, Y. Reddy (Anantapur, India)

1:45pm-3:15pm: Clinico-genetic correlation in Indian Spinocerebellar ataxia Type 1 (SCA1) patients

A. Takkar, I. Ahmed, S. Shakya, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: Clonazepam for REM sleep behavior disorder in Parkinsonism: A randomized, placebo-controlled trial

C. Shin, H. Park, W. Lee, B. Jeon, H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Coexisting CACNA1A pathogenic variant and MJD expansion in the same family

L. Leitão, C. Figueiredo, M. Santos, A.F. Brandão, A. Lopes, J. Sequeiros, I. Alonso, C. Costa (Amadora, Portugal)

1:45pm-3:15pm: Cognitive function impacts gait, functional mobility and falls in Fragile X-Associated Tremor/Ataxia Syndrome

J. O'Keefe, E. Robertson, B. Ouyang, D. Carns, Y. Liu, M. Swanson, B. Bernard, E. Berry-Kravis, D. Hall (Chicago, IL, USA)

1:45pm-3:15pm: Cognitive functions are associated with tremor severity in essential tremor

C.Y. Wei, W.K. Tsai, H.C. Lai, W.C. Chang, T. Taira (Changhua Country, Taiwan)

1:45pm-3:15pm: Cognitive impairment and neuropsychological disorders in essential tremor

J.X. Peng, N.N. LI, L. Wang, Z.J. Lu, J.Y. LI, R. Peng (Chengdu, China)

1:45pm-3:15pm: Cognitive impairment in multiple system atrophy: A Nepalese tertiary center study

R. Ojha, K. Oli (Kathmandu, Nepal)

1:45pm-3:15pm: Cognitive Reserve and Physical Activity Modulate Functional Brain Re-organisation in Premanifest Huntington’s Disease: Preliminary Evidence

M. Soloveva, S. Jamadar, G. Poudel, N. Georgiou-Karistianis (Melbourne, Australia)

1:45pm-3:15pm: Cohort profile of the Japan Dystonia Consortium: Genetic diagnosis and characteristics of movement disorders in Japan

T. Kawarai, R. Miyamoto, A. Orlacchio, R. Kaji (Tokushima, Japan)

1:45pm-3:15pm: Combined EMG and endoscopy guided botulinum toxin injection of the longus capitis muscle in cervical dystonia with anterocaput

J. Michelis, F. Schuler, I. Debove, J. Müllner, L. Lachenmayer, E. Seifert (Bern, Switzerland)

1:45pm-3:15pm: Comorbid Pediatric Early Onset Ataxia and Dystonia – Is the Cerebellum Involved?

D. Sival, M. Tijssen, D. Verbeek (Groningen, Netherlands)

1:45pm-3:15pm: Comorbidity and retirement in primary focal cervical dystonia

R. Ortiz, F. Scheperjans, T. Mertsalmi, E. Pekkonen (Helsinki, Finland)

1:45pm-3:15pm: Comparative study of non-motor symptoms in patients with progressive supranuclear palsy and age, gender, duration of illness matched patients with Parkinson’s disease

V. Holla, C. SP, A. Lenka, A. Stezin, S. Prasad, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

1:45pm-3:15pm: Comparative study of the cognitive and behavioral disturbances between progressive supranuclear palsy phenotypes

A. Horta-Barba, J. Pagonabarraga, S. Martinez-Horta, I. Illán, I. Aracil, J. Pérez-Pérez, B. Pascual, H. Bejr-Kasem, J. Marin, F. Sampedro, M. Botí, C. Izquierdo, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Comparing risperidone and olanzapine to tetrabenazine for the management of Huntington’s chorea

J. Schultz, J. Kamholz, P. Nopoulos, A. Killoran (Iowa City, IA, USA)

1:45pm-3:15pm: Comparison of botulinum toxin injections in forearm flexor and extensor muscles versus pure flexor muscles for the treatment of essential hand tremor (FLEX-D ET)

S. Patel, X. Yu, J. Lin, O. Hogue, T. Rasameesoraj, D. Hengartner, H. Fernandez (Cleveland, OH, USA)

1:45pm-3:15pm: Comparison of quantitative analysis of finger and forearm movements between early stage Parkinson’s disease and scans without evidence of dopaminergic deficit (SWEDD)

D.Y. Kwon, M.H. Park, J.W. Kim (Ansan-city, Republic of Korea)

1:45pm-3:15pm: Consensus for the measurement of the camptocormia angle

N. Margraf, R. Wolke, O. Granert, A. Berardelli, D. Berg, B. Bloem, R. Djaldetti, A. Espay, A. Fasano, Y. Furusawa, N. Giladi, M. Hallett, J. Jankovic, M. Murata, M. Tinazzi, J. Volkmann, G. Deuschl (Kiel, Germany)

1:45pm-3:15pm: Contingent negative variation in patients with cervical dystonia related to sensory tricks

HW. Shin, HJ. Cho, SW. Lee, M. Hallett (Seoul, Republic of Korea)

1:45pm-3:15pm: Cortical and brainstem neurodegeneration associate with the clinical severity in spinocerebellar ataxia patients

D. Tamuli, M. Kaur, S. Kumaran, A. Jaryal, A. Srivastava, K. Deepak (New Delhi, India)

1:45pm-3:15pm: Corticobasal Syndrome: A Single Center Case Series

M. Siddiqui, C. Goas (Winston Salem, NC, USA)

1:45pm-3:15pm: Costs and outcomes for Parkinson’s disease patients who have their management adjusted by Personal KinetiGraph (PKG)

P. Lynch, D. Jackson, D. Tilden, M. Horne (Minnetonka, MN, USA)

1:45pm-3:15pm: Creating a safe home for Parkinson’s disease patients: Designed principles for modifications

T. Jantanapornchai, J. Sringean, S. Pensook, P. Sankham, N. Kantachadvanich, S. Phumphid, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: CRISPR/Cas9-based fluorescent tyrosine hydroxylase-reporter lines

A. Rakovic, F. Vulinovic, C. Klein (Lübeck, Germany)

1:45pm-3:15pm: DBS neuromodulation reduces severe dystonic pain in children and young people

S. Perides, J.P. Lin, G. Lee, H. Gimeno, R. Selway, K. Ashkan, M. Kaminska (London, United Kingdom)

1:45pm-3:15pm: Decision making in Huntington’s disease

B. Heim, M. Peball, P. Ellmerer, C. Saft, S.M. von Hein, W. Poewe, K. Seppi, A. Djamshidian (Innsbruck, Austria)

1:45pm-3:15pm: Decreased blood beta-Glucosidase activity and GBA mutations in Dystonia

S. Schreglmann, D. Burke, A. Batla, N. Kresojevic, N. Wood, S. Heales, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Deep brain stimulation (DBS) of the caudal zona incerta improving gait stability and truncal tremor in a patient with essential tremor

W. Tse, J. Iseringhausen, B. Kopell (New York, NY, USA)

1:45pm-3:15pm: Deep brain stimulation in a patient with Spinocerebellar ataxia type 2 presenting as Parkinson’s disease: A case report

J. Im, Y. Lee, S. Paek, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Determinants of Bed Mobility Proficiency in Patients with Parkinson’s Disease: A Pilot Study

S. Taniguchi, N. D’Cruz, T. Osaki, M. Nakagoshi, A. Nieuwboer, T. Shimokawa (Kobe, Japan)

1:45pm-3:15pm: Determinates and predictors of quality of life improvements after subthalamic deep brain stimulation in Parkinson’s disease

F.T. Liu, L.Q. Lang, Y.J. Yang, J. Zhao, J. Wang, J.J. Wu (Shanghai, China)

1:45pm-3:15pm: Developing a Self-Administered Instrumented Motor Exam for Home-based Parkinson’s Disease Assessment Using Wearable Sensors

S. Patel, C. Demanuele, B. Ho, P. Wacnik, H. Zhang, T. Kangarloo, V. Ramos, S. Amato, D. Volfson, P. Bergethon, M. Erb (Cambridge, MA, USA)

1:45pm-3:15pm: Development of a system to measure the kinetic responses of parkinsonian animal model

G.T. Kim (InCheon, Republic of Korea)

1:45pm-3:15pm: Diagnostic Impact of Movement Disorders Subspecialty Consultations at a VA Hospital

B. Barton (Chicago, IL, USA)

1:45pm-3:15pm: Diagnostic value and capability of DaT (dopamine-transporter) SEPCT scan to assess clinically uncertain Parkinsonism Diseases as a single institutional experience in Kuwait Population

S. Al Tailji, M. Elgadafi1, W. Kamel, J. Al-Hashel (Kuwait, Kuwait)

1:45pm-3:15pm: Difference in sleep disorders among Parkinson’s disease, cervical dystonia and patients with depression

S. Tomic, D. Degmecic, S. Milanovic, F. Gjoni, I. Dumencic, Z. Popovic, T. Gilman Kuric (Osijek, Croatia)

1:45pm-3:15pm: Different Characteristics of Action Tremor in Essential Tremor and Tremor Associated with Dystonia

P. Panyakaew, S. Lee, M. Hallett (Bangkok, Thailand)

1:45pm-3:15pm: Diffusion magnetic resonance imaging for predicting the severity of Progressive supranuclear palsy

X.A. Zhao, S.H. Lin, C.C. Tsai, Y.M. Wu, W.Y. Lin, Y.H. Weng, L.S. Lu, Y.L. Chen, J.J. Wang (Taoyuan City, Taiwan)

1:45pm-3:15pm: Discrepancies in assessments of freezing of gait: Self-report, clinical, and physical therapy assessments

B. Bluett, E. Bayram, J. Longhurst, S. Banks, Z. Mari, I. Litvan (Las Vegas, NV, USA)

1:45pm-3:15pm: Disease Modeling of DYT1 Using Patient Induced Pluripotent Stem Cells

A. Dinasarapu, D. Sutcliffe, M. Zwick, H. Jinnah (Atlanta, GA, USA)

1:45pm-3:15pm: Disease Modeling of Lesch-Nyhan Disease Using Induced Pluripotent Stem Cells

D. Sutcliffe, A. Dinasarapu, M. Zwick, H. Jinnah (Atlanta, GA, USA)

1:45pm-3:15pm: Disease progression and survival of multiple system atrophy: A prospective French cohort study

A. Foubert-Samier, A. Pavy-Letraon, F. Guillet, C. Helmer, M. LeGoff, F. Tison, F. Rascol, C. Proust-Lima, W. Meissner (Bordeaux, France)

1:45pm-3:15pm: Dissociative effects of thyrotropin releasing hormone on classical cerebellar ataxic signs and cerebellar adaptation in patients with spinocerebellar degeneration

T. Shimizu, R. Hanajima, R. Tsutsumi, N. Tominaga, Y. Ugawa, K. Nishiyama (Sagamihara, Japan)

1:45pm-3:15pm: Distinguishing isolated asymmetric limb tremor from essential tremor: An electrophysiological study

F. Gövert, J. Becktepe, F. Brugger, L. Rocchi, A. Garrido, B. Balint, R. Hannah, T. Walter, J. Rothwell, R. Elble, K. Bhatia, G. Deuschl (Kiel, Germany)

1:45pm-3:15pm: Distribution Characteristics of Limbs Discomfort in Restless Legs Syndrome

X. Li, L.Y. Ni, X.Y. Zhu, T.T. Wu, Y.C. Wu (Shanghai, China)

1:45pm-3:15pm: Does ‘DYT23’ exist? Report of a second family with adult- onset focal dystonia and a CACNA1AB mutation – causative or coincidental?

P. Agarwal, M. Desai, S. Ravat (Mumbai, India)

1:45pm-3:15pm: Does having more children really delay Parkinson’s age of onset in women?

M. MacAskill, D. Myall, T. Pitcher, T. Melzer, J. Dalrymple-Alford, T. Anderson (Christchurch, New Zealand)

1:45pm-3:15pm: Does the degree of improvement after deep brain stimulation surgery for Parkinson’s disease (PD) meet the patient’s expectations?

J. Candelario-Mckeown, M. Torkamani, H. Sheridan, A. Coutts, M. Hartigan, M. Salazar, P. Limousin, M. Hariz, L. Zrinzo, J. Hyam, F. Foltynie, M. Jahanshahi (London, United Kingdom)

1:45pm-3:15pm: Does the Parkinson’s Kinetigraph change clinical practice?

S. Jones, C. Grose, S. Mahon, T. Williams, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

1:45pm-3:15pm: Dopaminergic neurons in Substantia Nigra pars compacta code the vigor of movement sequences

M. Mendonça, J. da Silva, L. Hernandez, I. Castela, J. Obeso, R. Costa (Lisboa, Portugal)

1:45pm-3:15pm: Dopaminergic stem cells reside in the rostral migratory stream

K. Schweyer, C. Steiner, G. Höglinger, T. Rösler (Munich, Germany)

1:45pm-3:15pm: Driving performance of Huntington’s disease gene carriers

M. Jacobs, E. Hart, Y. Mejia Miranda, G.J. Groeneveld, J. van Gerven, R. Roos (Leiden, Netherlands)

1:45pm-3:15pm: Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension

S. Kymes, K. Jackson, M. Widolff, C. Sullivan, L. Hewitt, S. Raj (Deerfield, IL, USA)

1:45pm-3:15pm: Duration of response with abobotulinumtoxinA in cervical dystonia: Patient distribution results from two open label extension studies

R. Hauser, D. Truong, M. Jog, D. Grimes, P. Picaut, A. Mann (Tampa, FL, USA)

1:45pm-3:15pm: Dystonia, Tremor, and Dystonic Tremor

A. Shaikh, A. Rosen, L. Scorr, A. Cotton, R. Barbano, C. Testa (Cleveland, OH, USA)

1:45pm-3:15pm: Early Experiences with Entrainment by Transcranial Alternating Current Stimulation in Patients with Essential Tremor

F. Maguire, T. Munteanu, A. Khatoun, M. Mc Laughlin, T. Lynch, R. Reilly (Dublin, Ireland)

1:45pm-3:15pm: Economic burden of advanced Parkinson’s disease in a national sample of elderly US Medicare beneficiaries: A prevalence-based estimate

N. Dahodwala, P. Li, J. Jahnke, V. Ladage, P. Kandukuri, J. Zamudio, Y. Bao, Y. Jalundhwala, J. Doshi (Philadelphia, PA, USA)

1:45pm-3:15pm: Effect of multiple sessions of transcranial direct current stimulation in Writer’s cramp: Does it hold promise?

S. Jaiswal, S. Choudhury, S. Halder, M. Baker, S. Baker, H. Kumar (Kolkata, India)

1:45pm-3:15pm: Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: A retrospective analysis of medical claims data

J. Ypinga, N. de Vries, L. Boonen, X. Koolman, M. Munneke, A. Zwinderman, B. Bloem (Tilburg, Netherlands)

1:45pm-3:15pm: Effectiveness of an Activity-based Integrative Group Therapy (ParkEASE) on Health-Related-Quality of Life of People with Parkinson’s Disease and of their Caregivers: A Retrospective Pilot Study

D. Tsang, R. Wong, C. Lau, A. Chan, D. Chan, X.L. Zhu, W.S. Poon, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: Effectiveness of Occupational Therapy (OT) Multi-modal group program for Parkinson’s patients at intermediate & advanced stage in improving quality of life (QoL) & relieving carer’s stress

R. Wong, D. Tsang, T. Tang, C. Lau, A. Chan, D. Chan, X.L. Zhu, W.S. Poon, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: Effectiveness of peloid therapy in management of Parkinson’s disease (PD): A single center experience

C.S. Khoo, E. Tokareva, O. Rybalko, I. Sukhareva (Cheras, Malaysia)

1:45pm-3:15pm: Effects of a combined approach with botulinum toxin (BONT) and motor-learning techniques (MLT) on sensori-motor functional connectivity in patients with cervical dystonia (CD)

A. Castagna, M. Cabinio, M. Ramella, L. Magistrelli, M. Laganà, F. Baglio (Milano, Italy)

1:45pm-3:15pm: Effects of Aquatic Physical Therapy on Parkinson’s disease under a vision of the International Classification of Functioning, Disability and Health (ICF)

V. Israel, B. Yamaguchi, M. Ferreira (Curitiba, Brazil)

1:45pm-3:15pm: Effects of balance training in patients with cervical dystonia

J. Richter, C. Weise, A. Villringer, P. Ragert, D. Weise (Leipzig, Germany)

1:45pm-3:15pm: Effects of L-DOPA on Quantitative Gait Parameters Measured with Wearable Sensors

M. Brys, J. Paskavitz, A. Dowling, V. Auclair, A. Wood, D. McLaren, R. Postuma, B. Bedell, J. Cedarbaum (Cambridge, MA, USA)

1:45pm-3:15pm: Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)

N. Lev, Y. Barhum (Kfar Saba, Israel)

1:45pm-3:15pm: Effects of multi-session repetitive transcranial magnetic stimulation on performance of motor control and dynamics of spontaneous brain activity in multiple system atrophy

Z. Liu, H.Z. Ma, X.M. Wang, Z. Wang, Y.Q. Wang, J.H. Zhou, T. Feng (Beijing, China)

1:45pm-3:15pm: Efficacy of multidisciplinary care in people with Parkinson’s disease: A systematic review and meta-analysis

S. Balakrishnan, D. Tan (Singapore)

1:45pm-3:15pm: Electroglottographic(EGG) and Acoustic characteristics of voice in patients with Essential tremor(ET)

P A. Shetty, B K. Yamini, R. Yadav, N. Shivashankar, PK. Pal (Bangalore, India)

1:45pm-3:15pm: Electrophysiological characteristics of tremor in spinocerebellar ataxia type12 (SCA-12) and essential tremor (ET)

A. Srivastava, M. Narang, R. Rajan, G. Shukla, F. Mohammad, A. Pandit, D. Vibha, M. Singh, M. Srivastava, K. Prasad (New Delhi, India)

1:45pm-3:15pm: Elevated serum α-synuclein levels in Huntington’s disease patients

M. Breza, E. Emmanouilidou, G. Karadima, C.H. Kartanou, M. Panas, K. Vekrellis, G. Koutsis (Athens, Greece)

1:45pm-3:15pm: Emergency and in-patient healthcare utilization in Parkinson’s disease

M. Mackenzie, G. Al Momen, A. Yu, K. Sundvick, J. Wright, A. Shiu, S. Appel-Cresswell (Vancouver, BC, Canada)

1:45pm-3:15pm: Encephalopathy in a Japanese patient with Rapid-Onset Dystonia-Parkinsonism carrying a Novel ATP1A3 mutation

K. Hoshino, T. Kawarai, M. Hayashi, K. Kimura, Y. Nagao, M. Fukumizu, R. Miyamoto, R. Kaji (Tokyo, Japan)

1:45pm-3:15pm: Evaluating the clinical utility of the Parkinson’s KinetiGraph (PKG™) in the remote management of Parkinson’s disease

T. Dominey, L. Hutchinson, E. Pearson, F. Murphy, L. Bell, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Evaluating the impact of the educational course for nurses on Parkinson’s disease: A model for continuing nursing education

S. Phumphid, O. Jitkritsadakul, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Evaluation of a driving questionnaire to facilitate awareness of issues that could compromise driving ability in a person with Parkinson’s disease

J. Price, H. Martin, L. Ebenezer (Powys, United Kingdom)

1:45pm-3:15pm: Evaluation of Balance in Hereditary Ataxias

H. Teive, B. Zeigelboim, R. Santos, S. Dias, N. Mello, V. Fonseca (Cuitiba, Brazil)

1:45pm-3:15pm: Evaluation of Effectiveness and Safety of Botulinum Toxin Type-A (BTX-A) for Chronic Focal Post-Stroke Upper Limb Spasticity in Indian Stroke Patients

L. Basumatary (Guwahati, India)

1:45pm-3:15pm: Evaluation of motor impulsivity in Huntington Disease with a choice reaction time task and brain metabolic (PET 18FDG) imaging

S. Grimaldi, E. Guedj, F. Fluchere, T. Hasbroucq, F. Vidal, JP. Azulay (Marseille, France)

1:45pm-3:15pm: Evaluation of postural changes and painful manifestations in caregivers of children with cerebral palsy

J. Francês Brito, M. Akkari, A. Barbosa de Sousa Junior, B. De Oliveira, A. Pinheiro Alves, O. Vieira Kishi, Jose Roberto Bentes Capeloni (Belem, Brazil)

1:45pm-3:15pm: Evaluation of the Clinical Efficacy of Motivational System Training in Parkinson’s disease

T. Chomiak, A. Watts, S. Tan, M. McKeown, B. Hu (Calgary, AB, Canada)

1:45pm-3:15pm: Evaluation of visual perceptive computing for Tremor Analysis

K. Otte, F. Heinrich, T. Ellermeyer, B. Kayser, S. Mansow-Model, F. Paul, A.U. Brandt, C. Skowronek, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: Evidence based management of Normal Pressure Hydrocephalus: Lessons and future directions

A. Mahajan, M. Macki, M. Kaur, M. Novikova, R. Shatz, J. Schwalb (Detroit, MI, USA)

1:45pm-3:15pm: Evolution of diagnostic certainty and PSP-predominance types in 187 pathologically confirmed PSP patients

M. Grimm, G. Respondek, I. Piot, T. Arzberger, Y. Compta, E. Englund, L. Ferguson, E. Gelpi, A. Giese, S. Roeber, D. Irwin, W. Meissner, C. Nilsson, A. Pantelyat, A. Rajput, C. Troakes, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: Evolution of Motor and Non-Motor Manifestations in Prodromal Parkinsonism

SM. Fereshtehnejad, C. Yao, A. Pelletier, J. Montplaisir, JF. Gagnon, R. Postuma (Montreal, QC, Canada)

1:45pm-3:15pm: Expanding the NINDS Parkinson’s Disease Biomarkers Program – Utilizing a Major Biomarker Resource to Address Atypical Parkinsonisms and Related Conditions

C. Lungu, K. Arce, D. Babcock, K. David, BA. Sieber, C. Swanson-Fischer, M. Sutherland (Rockville, MD, USA)

1:45pm-3:15pm: Exploration of insight competence in Huntington’s disease supplemental to a cognitive debriefing study for the FuRST2.0 rating scale

R. Fuller, P. Feigenbaum, C. Fitzer-Attas, N. La Pelle, S. Luo, C. Sampaio, G. Stebbins (Princeton, NJ, USA)

1:45pm-3:15pm: Exploring The Role of a Prescribing Pharmacist in the Management of Parkinson’s Disease

E. Wong (London, United Kingdom)

1:45pm-3:15pm: Eye movement disorders after cerebellar infaction

M. Munteanu (Bucharest, Romania)

1:45pm-3:15pm: Eye tracking in patients with restless legs syndrome with and without augmentation – interim results of an ongoing study

P. Ellmerer, B. Heim, M. Ritter, A. Stefani, E. Brandauer, E. Holzknecht, K. Seppi, B. Högl, W. Poewe, A. Djamshidian (Innsbruck, Austria)

1:45pm-3:15pm: Facial Movement Analysis in Parkinson’s disease: A decade of advances

W. Rattanachaisit, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Factors affecting quality of life in patients with Parkinson´s disease: Motor vs non-motor symptoms. Results from the COPPADIS Study Cohort

D. Santos, T. de Deus, C. Borrué, M. Mata, B. Solano Vila, A. Cots Foraster, M. Álvarez Sauco, A.B. Rodríguez Pérez, L. Vela, Y. Macías, S. Escalante, P. Estebe, S. Reverté, E. Cubo, E. Casas, S. Arnaiz, F. Carrillo Padilla, M. Pueyo, P. Mir, P. Martínez Martín, G. Coppadis Study (Ferrol, Spain)

1:45pm-3:15pm: Factors associated with Exercise Behaviour in Australians with Parkinson’s disease

D. Lee, N. Löfgren, J. Bampton, C. Canning, S. Paul (Lidcombe, Australia)

1:45pm-3:15pm: Factors associated with freezing of gait in patients with Parkinson’s disease

S.M. Choi, J.M. Kim, J.K. Lee, S.H. Kim, M.H. Park, K.W. Kang, K.H. Choi, J.T. Kim, S.H. Lee, M.S. Park, B. Kim, M.K. Kim (Gwangju, Republic of Korea)

1:45pm-3:15pm: Factors predicting patient satisfaction with botulinum toxin treatment in cervical dystonia patients who have been treated for a year

V. Misra, C. Colosimo, T. Chung, D. Charles, S. Om, P. Maisonobe (London, United Kingdom)

1:45pm-3:15pm: Falls in people with Parkinson’s disease: Results from a Multidisciplinary Movement Disorders Clinic in Singapore

D. Tan, S. Balakrishnan, A. Scully, P. Kumar (Singapore, Singapore)

1:45pm-3:15pm: Fast paced gait may be more discriminating than dual tasking for detecting severity of gait and turn deficits in FXTAS

J. O'Keefe, D. Carnes, E. Robertson, T. Young, N. Purcell, E. Berry-Kravis, D. Hall (Chicago, IL, USA)

1:45pm-3:15pm: Feasibility of a multi-sensor data fusion method for assessment of Parkinson’s disease motor symptoms

M. Memedi, S. Aghanavesi, D. Nyholm, F. Bergquist, M. Senek (Örebro, Sweden)

1:45pm-3:15pm: Finger Tapping Profile in “On State” PD Patients

JP. Romero, I. Serrano, D. Del Castillo, A. Arroyo, V. Cortés, J. Andreo, J. Periañez, M. Rios (Madrid, Spain)

1:45pm-3:15pm: Four eyelid and eye movement disorder cases misdiagnosed as seronegative ocular myasthenia gravis

M. Kamada, K. Kume (Kita-gun, Japan)

1:45pm-3:15pm: Fragile X-associated tremor/ataxia syndrome, Parkinson’s disease, and essential tremor subjects demonstrate distinct tremor characteristics using quantitative tremorography

E. Robertson, D. Hall, G. Pal, B. Ouyang, Y. Liu, A. McAsey, A. Bery, C. Huml, B. Bernard, E. Berry-Kravis, J. O'Keefe (Chicago, IL, USA)

1:45pm-3:15pm: Frailty in Patients with Parkinson’s Disease: Associations with Disability and Timed Up and Go Test

F. Fırat Ozer, S. Akın, M. Gultekin, G. Erturk, A. Ekinci (Kayseri, Turkey)

1:45pm-3:15pm: Free-living gait in REM sleep behaviour disorder: Measures of prodromal Parkinson’s disease?

S. Del Din, T. Barber, C. Lo, M. Rolinski, F. Baig, M. Hu, L. Rochester (Newcastle upon Tyne, United Kingdom)

1:45pm-3:15pm: Frequency and Phenoptypic Spectrum of KMT2B Mutations in Childhood-Onset Dystonia: Results from a Single-Centre Cohort Study

M. Carecchio, G. Zorzi, F. Invernizzi, C. Panteghini, L. Romito, F. Zibordi, V. Leuzzi, S. Galosi, P. Morana, B. Morana, C. Piano, A. Bentivoglio, C. Reale, F. Girotti, M. Topf, A. Joseph, M. Kurian, S. Lubbe, B. Garavaglia, N. Mencacci, N. Nardocci (Milan, Italy)

1:45pm-3:15pm: Functional motor disorders phenotypes. Lumping or splitting?

J. Gelauff, J. Rosmalen, J. Stone, J. Gardien, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: FXN and ATXN2 methylation profile in Friedreich’s ataxia and spinocerebellar ataxia type 2

E. Nuzhnyi, N. Abramycheva, T. Pogoda, S. Klyushnikov, M. Ershova, S. Illarioshkin, E. Fedotova (Moscow, Russian Federation)

1:45pm-3:15pm: FXTAS-like Phenotype with p.P626L Missense Mutation: A case report

X. Duan, L. Zhang, C. Liu, W. Liao, F. Tassone, Y. Yi, R. Hagerman (Shang Sha, China)

1:45pm-3:15pm: Gait 3D kinematics for assessment of High-Frequency Subthalamic Stimulation induced axial symptoms in Parkinson’s Disease: A comparison of 2 subjects

M. Mendonça, R. Matias, P. Bugalho, R. Costa (Lisboa, Portugal)

1:45pm-3:15pm: Gait and balance assessment in Hoehn and Yahr stages of Parkinson’s disease using Smartphone-based instrumental Timed Up and Go

G. Yahalom, S. Israeli-Korn, Z. Yekutieli, T. Fay-Karmon, V. Livneh, Y. Ruvel, S. Hassin-Baer (Ramat Gan, Israel)

1:45pm-3:15pm: Gait and stance events measured with smartwatches in patients with PD and ET

M. Velasco, R. Lopez-Blanco, I. Serrano, M. del Castillo, J. Romero, J. Benito-Leon, E. Rocon (Madrid, Spain)

1:45pm-3:15pm: Gamma Knife Radiosurgery for essential and parkinsonian tremor: Long-term experience in a Spanish center

JR. Perez-Sanchez, R. Martinez-Alvarez, NE. Martinez-Moreno, I. Cuervo-Arango, G. Rey Portoles, I. Parees, A. Del Barrio, J. Alvarez-Linera, MM. Kurtis (Madrid, Spain)

1:45pm-3:15pm: Gamma Knife Radiosurgery for Generalised Dystonia: Is It The Last Part in The Ship of Theseus

M. Tripathi (Chandigarh, India)

1:45pm-3:15pm: Generalized chorea in a patient with isolated leukocytosis and JAK2V617F mutation: A case report

S. Bette, H. Moore, C. Singer (Miami, FL, USA)

1:45pm-3:15pm: Generalized choreoathetoid-like movements in primary Sjögren syndrome

N. Alvarado-Franco, L. Olguín-Ramírez, A. Garza-Alpirez, G. Femat-Roldan, D. Martinez-Ramirez (Monterrey, Mexico)

1:45pm-3:15pm: Generalized dystonia and chorea with family history: Clinical case

R. Varela, R. Araújo, M. Sousa, I. Alonso, A. Morgadinho, I. Fineza (Coimbra, Portugal)

1:45pm-3:15pm: Generation and in-depth characterization of induced pluripotent stem cell (iPSC) lines from 10 affected and unaffected carriers of THAP1 mutations

H. Baumann, M. Trilck, M. Jahn, A. Münchau, V. Kostic, C. Klein, P. Seibler, K. Lohmann (Luebeck, Germany)

1:45pm-3:15pm: Genetic Markers of Essential Tremor in Restless Legs Syndrome/Willis-Ekbom Disease in Southern Chinese Population

G. Li, HD. Tang, P. Huang, YC. He, C. Wang, XM. Qi, J. Chen, JF. Ma, SD. Chen (Shanghai, China)

1:45pm-3:15pm: Genome-wide association study identifies common genetic variants associated with cervical dystonia

Y. Sun, C. L, Q. Hui, J. Perlmutter, S. Ruehl, C. Klein, J. Jankovic, R. Barbano, S. Reich, J. Bremner, V. Vaccarino, A. Quyyumi, H. Jinnah (Atlanta, GA, USA)

1:45pm-3:15pm: Genotype-phenotype correlations in 104 Uzbekish families with Spinocerebellar ataxias

F. Rakhimov, Y. Majidova, G. Rakhimbaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Gluten sensitivity in progressive cerebellar ataxia patients from India

I. Singh, A. Verma, I. Singh, A. Singh, V. Suroliya, U. Hooda, M. Faruq, V. Ahuja, G. Makharia, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: Good response to bilateral GPI-DBS after 2 years in generalized dystonia due to a mutation in the KMT2B gene (DYT28)

A. Garrido, C. Simonet, MJ. Martí, B. Pérez-Dueñas, J. Rumià, F. Valldeoriola (Barcelona, Spain)

1:45pm-3:15pm: Handwriting analysis in Writer’s cramp using a digitizing tablet

S. Halder, S. Jaiswal, S. Choudhury, M. Baker, S. Baker, H. KumaR (Kolkata, India)

1:45pm-3:15pm: Has patients affected by REM sleep Behavior Disorder a specific brain glucose metabolism pattern?

C. Liguori, R. Ruffini, E. Olivola, A. Chiaravalloti, F. Izzi, O. Schillaci, N. Mercuri, F. Placidi (Rome, Italy)

1:45pm-3:15pm: Hearing Evaluation (Peripheral and Central) in Patients with Sporadic Ataxia

H. Teive, B. Zeigelboim, A. Vom Scheidt, K. Kronbauer, N. Mello, R. Santos (Curitiba, Brazil)

1:45pm-3:15pm: Hemiballism secondary to a frontal cortical lesion

A. Nieto, J. Gamo, JJ. Rodriguez (Ciudad Real, Spain)

1:45pm-3:15pm: Hemiballismus as single manifestation of nonketotic hyperglycemia in elderly

N. Raisa, K. Jusbandi (Malang, Indonesia)

1:45pm-3:15pm: Higher self-rated obsessive-compulsion in functional compared with organic dystonia

R. Newby, J. Alty, S. Jamieson, S. Smith, P. Kempster (Leeds, United Kingdom)

1:45pm-3:15pm: HIV encephalopathy mimicking Huntington’s Disease

O. Gavriliuc, A. Andrusca (Chisinau, Republic of Moldova)

1:45pm-3:15pm: Home Care Programme for Patients with Parkinsonism

WL. Chan, ST. Chua, W. Li, HL. Ng, KY. Tay, WL. Au, CS. Tan (Singapore, Singapore)

1:45pm-3:15pm: How accurate are exercise logbooks? A comparison of participant and device recorded exercise records in people with Parkinson’s disease

M. Schmidt, S. Paul, J. Song, J. O'Duffy, S. Smith, R. Love, C. Canning, N. Allen (Hobart, Australia)

1:45pm-3:15pm: How much does botulinum toxin injection interval impact upon patient satisfaction in the routine treatment of cervical dystonia?

T. Chung, D. Charles, C. Colosimo, V. Misra, P. Maisonobe, S. Om (São Paulo, Brazil)

1:45pm-3:15pm: How well can nurses recognize motor fluctuations in Parkinson’s disease: A survey of 238 registered nurses

K. Boonpang, O. Jitkritsadakul, P. Plengsri, S. Chaiwong, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Huntington disease like 2 in South Africa

M. Khider, K. Naidu, J. Carr (Cape Town, South Africa)

1:45pm-3:15pm: Huntington’s Disease in Turkey: A Bird’s Eye Review of the Literature

Y. Karadag, MA. Akbostanci, H. Hanagasi, N. Subutay Oztekin, M. Demirkiran, AN. Basak (Ankara, Turkey)

1:45pm-3:15pm: Identification of Comprehensive PD Subtypes Using PPMI Study Data with Recurrent Neural Networks

X. Zhang, Y. Zhao, H. Sarva, C. Henchcliffe, F. Wang (New York, NY, USA)

1:45pm-3:15pm: Identification of L-DOPA “on/off” states using speech-based analysis in Parkinson’s disease subjects

R. Norel, C. Agurto, S. Heisig, R. Ostrand, B. Ho, V. Ramos, H. Zhang, K. Erb, J. Rice, G. Cecchi (Yorktown Heights, NY, USA)

1:45pm-3:15pm: Identification of modifiers of the age of onset variance and disease progression in a Dutch cohort of Machado-Joseph disease patients

M. Huang, V. Leotti, J. Vries, G. Meerman, E. Brunt, C. Bemelmans, H. Kampinga, L. Jardim, D. Verbeek (Groningen, Netherlands)

1:45pm-3:15pm: Imaging neurodegeneration biomarkers in Essential Tremor

S. Pietracupa, M. Bologna, G. Pasqua, S. Tommasin, N. Petsas, F. Elifani, A. Berardelli, P. Pantano (Pozzilli, Italy)

1:45pm-3:15pm: Immediate effects of walking training with Honda Walking Assist Device on gait parameters of Parkinson’s disease

R. Matsugaki, K. Nawata, H. Kako, J. Shiraishi, S. Saeki (Kitakyushu-shi, Japan)

1:45pm-3:15pm: Immunological causes of atypical parkinsonism

M. Cesarini, J. Etcheverry, G. Da Prat, G. Rojas, N. Gonzalez Rojas, E. Gatto (La Plata, Argentina)

1:45pm-3:15pm: Impact of a Parkinson’s Disease-Specific Order Set on Inpatient Medication Administration

D. Larson, C. Zadikoff, M. Afshari, Y. Kianirad (Chicago, IL, USA)

1:45pm-3:15pm: Impaired reaching movements in idiopathic cervical dystonia patients

A. Castagna, L. Sciumè, A. Caronni, D. Anastasi, A. Montesano, A. Marzegan (Milano, Italy)

1:45pm-3:15pm: Improving clinical data collection at patients’ home in Parkinson’s disease: The Sleep Fit app

A. Mascheroni, C. Ferlito, S. Hackethal, S. Caverzasio, E-K. Choe, Y. Luo, F. Faraci, A. Kaelin-Lang, A. Puiatti, P-L. Ratti, M. Marazza (Manno, Switzerland)

1:45pm-3:15pm: Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)

M. Alsahab, S. Pradhan, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Incidence of Parkinson’s disease: Pooled analysis of six high-quality incidence studies with long-term follow-up

A. Macleod, M. Camacho, J. Evans, C. Williams-Gray, R. Lawson, L. Forsgren, G. Alves, O.B. Tysnes, C. Counsell (Aberdeen, United Kingdom)

1:45pm-3:15pm: Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study

C. Borrue-Fernandez, J. Fernandez- Cuesta, MJ. Abenza Abildua (San Sebastian Reyes, Spain)

1:45pm-3:15pm: Incobotulinum toxin type A for the treatment of biceps/triceps co-contraction due to obstetrical brachial plexus lesion

G. Ianieri, R. Marvulli, G. Gallo (Bari, Italy)

1:45pm-3:15pm: Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series

C. Wang, E. Wang, H. Lei (Tucson, AZ, USA)

1:45pm-3:15pm: Influence of disease progression on the quality of life of individuals with spinocerebellar ataxia type 10

L. Santos, M. Zonta, H. Teive, N. Mello, F. Neto, A. Macedo (Curitiba, Brazil)

1:45pm-3:15pm: Influence of Wearing Empty Backpack on Gait and Balance in Patients with Degenerative Parkinsonian syndrome

S. Lee, D. Heo, J. Park (Bucheon, Republic of Korea)

1:45pm-3:15pm: Inpatient care for Parkinson’s disease in Germany: Analysis of more than one million cases from the years 2010 to 2015

L. Tönges, D. Bartig, S. Muhlack, W. Jost, R. Gold, C. Krogias (Bochum, Germany)

1:45pm-3:15pm: Instrumental assessment of upper extremity bradykinesia in UPDRS testing based on depth video data

K. Otte, L. Rasche, H. Röhling, B. Kayser, S. Mansow-Model, F. Paul, A. Brandt, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: Instrumented gait analysis identifies potential predictors for Parkinson’s disease converters

S. Del Din, M. Elshehabi, B. Galna, C. Hansen, M. Hobert, U. Suenkel, D. Berg, L. Rochester, W. Maetzler (Newcastle upon Tyne, United Kingdom)

1:45pm-3:15pm: Intellectual disability with spastic ataxia: Atypical Infantile neuroaxonal dystrophy with absent spheroids

A. Elavarasi, V. Goyal, P. Samal (Puducherry, India)

1:45pm-3:15pm: Intensive speech rehabilitation in degenerative ataxias improves intelligility

A. Vogel, N. Rommel, M. Synofzik (Melbourne, Australia)

1:45pm-3:15pm: Internet of Things for Empowerment and Improved Treatment of Patients with Parkinson’s Disease

L. Kani, M. Memedi, E. Kolkowska, G. Klein (Orebro, Sweden)

1:45pm-3:15pm: Interrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score certification

J. Winder, R. Roos, J.M. Burgunder, J. Marinus, R. Reilmann (Leiden, Netherlands)

1:45pm-3:15pm: Intrathecal baclofen (ITB) therapy in the treatment of severe spasticity: Safety and Product Performance from a Large Multinational Multi-Center Registry

M. Schiess, S. Eldabe, R. Spencer, K. Stromberg, T. Weaver, R. Plunkett (Houston, TX, USA)

1:45pm-3:15pm: Investigating the clinical predictors of depression in Huntington’s disease: An Enroll-HD Database Study

E. Furr Stimming, G. Colpo, N. Rocha, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm: Is chronic ocular motor dysfunction in syndrome of antiGAD antibody reversible with immune therapy?

A. Mook, S. Gunzler, G. Wilmot, A. Shaikh (Cleveland, OH, USA)

1:45pm-3:15pm: Is primary writing tremor a form fruste of dystonia?

A. Latorre, L. Rocchi, A. Berardelli, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Is safinamide useful for atypical Parkinsonian syndromes?

M. Machío Castelló, M. Oses Lara, C. Feliz Feliz, J. del Val, P. García Ruiz (Madrid, Spain)

1:45pm-3:15pm: Is there a role for miRNA in the diagnosis of PD?

A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

1:45pm-3:15pm: Jumping stump: Movement disorder with structural CNS pathology – Look before you label

A. Elavarasi, V. Goyal (Puducherry, India)

1:45pm-3:15pm: Late onset Huntington’s disease in an Argentinian cohort

M. Cesarini, J. Etcheverry, E. Gatto, J. Ziliani, G. Da Prat, N. Gonzalez Rojas, V. Parisi, G. Persi (Buenos Aires, Argentina)

1:45pm-3:15pm: Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)

P. Turcano, M. Mielke, C. Stang, J. Bower, J. Parisi, J. Cutsforth Gregory, E. Ahlskog, R. Savica (Rochester, MN, USA)

1:45pm-3:15pm: Life Expectancy for Parkinson Patients at Hoehn and Yahr Stage 5

W. Li, H.L. Ng, S. Acharyya, K.Y. Tay, W.L. Au, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: Likelihood ratios of prodromal diagnostic markers for Chinese Parkinson’s disease: A systematic review and meta-analysis

S.Y. Liu, Z. Zheng, Z.Q. Gu, C.D. Wang, P. Chan (Beijing, China)

1:45pm-3:15pm: Local field potential changes during sleep in the PSA of patients with essential tremor

L. Mueller, A. Auchter, M. Reich, F. Steigerwald, J. Volkmann (Wuerzburg, Germany)

1:45pm-3:15pm: Long-term effects of music as an auditory cue on motor and non-motor symptoms of Parkinson’s disease: A case report

F. Lindop, R. Skelly (Derby, United Kingdom)

1:45pm-3:15pm: Long-term Outcomes with Rescue Target Deep Brain Stimulation in Patients with Dystonia

A. Hatcher, A W. Shukla, P. Zeilman, E. Ofori, D. Vaillancourt, K. Foote, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Longitudinal alpha-synuclein in cerebrospinal fluid in early Parkinson’s disease, prodromal PD and healthy controls

B. Mollenhauer, C. Caspell-Garcia, C. Coffey, P. Taylor, A. Singleton, L. Shaw, J. Trojanowski, M. Frasier, T. Simuni, A. Siderowf, K. Marek, D. Galasko (Kassel, Germany)

1:45pm-3:15pm: Loss of paraplegin drives spasticity rather than ataxia in SPG7: A European cohort analysis of 238 patients

G. Coarelli, R. Schule, B. vande Warrenburg, P. de Jonghe, C. Ewenczyk, A. Martinuzzi, M. Synofzik, E. Hamer, J. Baets, M. Anheim, L. Schöls, T. Deconinck, B. Fontaine, T. Klockgether, MG. D'Angelo, ML. Monin, P. Charles, MT. Bassi, T. Klopstock, E. Ollagnon-Roman, C. Kamm, M. Papin, CS. Davoine, G. Banneau, S. Tezenasdu Montcel, D. Seilhean, A. Brice, C. Duyckaerts, G. Stevanin, A. Durr (Paris, France)

1:45pm-3:15pm: Magnetic resonance-guided focused ultrasound unilateral thalamotomy for the treatment of essential tremor: Outcomes and complications after 1 year of follow-up in 21 patients

J. Máñez-Miró, L. Vela, F. Alonso-Frech, M. Di Leone, F. Hernández-Fernández, M. Del Álamo, J. Pineda-Pardo, R. Rodríguez-Rojas, E. de Luis-Pastor, R. Martínez-Fernández (Madrid, Spain)

1:45pm-3:15pm: Maintenance of safinamide 100 mg daily long-term

N. Foncea (Galdakao, Spain)

1:45pm-3:15pm: Malignant gliomas in patients with Huntington’s disease

S. Chandra, G. Suarez-Cedeno, E. Stimming (Houston, TX, USA)

1:45pm-3:15pm: Metabolomic Profiling of Activated Microglial Cells

V. Vedam-Mai, T. Domenick, E. Gill, T. Garrett, R. Yost, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Methylphenidate in Progressive Supranuclear Palsy [PSP] – Old drug, New Indications?

N. Sawal, P. Bansal, R. Gupta (Chandigarh, India)

1:45pm-3:15pm: mGluR1 antibodies encephalitis: A rare cause of reversible ataxia and myoclonus syndrome

F. Ory Magne, C. Goillion, J. Dupouy, M. Simonetta, C. Brefel Courbon, O. Rascol, J. (Toulouse, France)

1:45pm-3:15pm: MicroRNAs Unveil Metabolic Imbalance in Spinocerebellar Ataxia Type-2

V. Swarup, R. Singh, H. Singh, I. Singh, M. Faruq, S. Vivekanandhan, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: Midbrain Diameter Measurements on High-Resolution Computer Tomography Scans to aid diagnosis of Progressive Supranuclear Palsy

S. Potluri, C. Gan, C. Thomas, B. Mohamed, S. Schwarz (Cardiff, United Kingdom)

1:45pm-3:15pm: Midbrain/pons area ratio and clinical features predict the prognosis of PSP

S. Cui, S. Chen (Shanghai, People’s Republic of China)

1:45pm-3:15pm: Mingo Supplement Trial: An Open-Labeled Randomized-Controlled Trial in X-linked Dystonia-Parkinsonism patients in the Province of Capiz, Philippines

P. Acuna, G. Solinap, M. Ang, J. de Guzman, C. Go (Charlestown, MA, USA)

1:45pm-3:15pm: Models of Parkinson’s disease in vitro

A. Dilzoda (Tashkent, Uzbekistan)

1:45pm-3:15pm: Mortality from Parkinson’s disease in China: Findings from a Ten-year follow up study in Shanghai

G. Wang, G. Xu, YQ. Zhang, SD. Chen (Shanghai, China)

1:45pm-3:15pm: Motivators, Barriers and Clinical Correlates of Physical Activity in Parkinson Disease

S. Mantri, S. Wood, J. Duda, J. Morley (Philadelphia, PA, USA)

1:45pm-3:15pm: Motor and cognitive deficits in a mouse model of tauopathy with tau isoforms imbalance: Potential therapeutic strategies

ME. Avale, SL. Espindola, A. Damianich, M. Sartor, J. Ferrario (Buenos Aires, Argentina)

1:45pm-3:15pm: Motor and Non-motor Features Predict Freezing of Gait in Parkinson’s Disease

N. D'Cruz, G. Vervoort, S. Fieuws, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

1:45pm-3:15pm: Motor and Non-motor symptoms in Parkinson’s disease (PD): Which are more important?

G. Chan, N. Cheung, A. Leung, D. Chau, C.W. Woo, B. Chee, W.C. Fong (Hong Kong)

1:45pm-3:15pm: Motor Performance and Quality of Life in a Community Exercise Program for Parkinson’s Disease

E. Stiles, K. Jaffe, B. Rossi, D. Riley (University Heights, OH, USA)

1:45pm-3:15pm: Motor speech and swallowing phenotype of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)

A. Vogel, N. Rommel, A. Oettinger, L. Stoll, E-M. Kraus, C. Gagnon, P. Krumm, M. Horger, D. Timmann, E. Storey, L. Schöls, M. Synofzik (Melbourne, Australia)

1:45pm-3:15pm: Movement and postural control in focal dystonia subjects measured using surface electromyography

F. Chang, S. Babu, S. Kim, N. Mahant, O. Vucic, V. Fung (Wentworthville, Australia)

1:45pm-3:15pm: Movement disorders after stroke in the third Moroccan level hospital, Marrakech

A. Chahidi, M. Chraa, N. Kissani (Marrakech, Morocco)

1:45pm-3:15pm: MRI and behavioural account of the aging cerebellum

M. Bares, P. Filip, C. Gallea, S. Lehericy, O. Lungu (Brno, Czech Republic)

1:45pm-3:15pm: MRI volumetrics in parkinsonian syndromes

K. Ma, A. Chan, L. Shi, J. Abrigo, T. Cheung, C. Lau, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: MSA Preliminary Panamerican Report

M. Cesarini, E. Gatto, J. Etcheverry, G. Da Prat, N. Gonzalez Rojas, H. Teive, M. Rodriguez, J. Ziliani, M. Miranda, P. Chana, F. Cardoso, A. Cardozo, C. Uribe Roca, I. Amorin, L. Abaroa, c. Cosentino, Y. Nuñez, A. Lescano, E. Dieguez, A. Alleva, I. Litvan, G. Wenning (La Plata, Argentina)

1:45pm-3:15pm: Multi-tiered Diagnostic Approaches Reveal a High Degree of Genetic Heterogeneity for Hereditary Cerebellar Ataxias: A Retrospective Review of an Australian Cohort

C. Kang, C. Liang, K. Ahmad, Y. Gu, SF. Siow, J. Colebatch, S. Whyte, K. Ng, P. Cremer, R. Davis, T. Roscioli, M. Cowley, J.S. Park, C. Sue, K. Kumar (Sydney, Australia)

1:45pm-3:15pm: Multiple single unit activity in ventral intermediate thalamus of essential tremor patients during intention tremor

F. Windels, A. Giorni, T. Coyne, P. Silburn, P. Sah (Saint Lucia, Australia)

1:45pm-3:15pm: Muscle Ultrasound Comparison Between Early And Intermediate Onset Friedreich’s Ataxia

R. Verbeek, A. Waalkens, M. Kuiper, C. Verschuuren-Bemelmans, J. vd Hoeven, J. de Vries, J. van Gaalen, M. Willemsen, H. Kremer, D. Sival (Groningen, Netherlands)

1:45pm-3:15pm: Musical sonification for the rehabilitation of Parkinsonian dysgraphia: behavioural validation

L. Véron-Delor, S. Pinto, A. Eusebio, J.L. Velay, J. Danna (Aix-en-Provence, France)

1:45pm-3:15pm: Network analysis of symptoms in a Parkinson patient using experience sampling data: An n=1 study

A. Mulders, R. Velden, M. Drukker, M. Kuijf, A. Leentjens (Maastricht, Netherlands)

1:45pm-3:15pm: Neurofilament light protein: An emerging clinical and translational biofluid biomarker for Huntington’s disease

L. Byrne, F. Rodrigues, E. Johnson, S. Gregory, R. Soylu Kucharz, M. Björkqvist, A. Heslegrave, K. Blennow, A. Durr, B. Leavitt, R. Roos, S. Tabrizi, H. Zetterberg, D. Langbehn, R. Scahill, E. Wild (London, United Kingdom)

1:45pm-3:15pm: Neurohormetic properties of mild physical stress against Parkinson’s disease phenotype

S. Kumari K.N (Zunheboto, India)

1:45pm-3:15pm: Neuromelanin sensitive MRI of substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson’s disease

L. Jin, J. Wang, Y. Li, Z. Huang, F. Ye (Shanghai, China)

1:45pm-3:15pm: Neuronal correlates of oculomotor alterations in Huntington’s disease. A 18-FDG PET study

J. Perez, S. Martinez Horta, F. Sampedro, J. Pagonabarraga, A. Horta, D. Lopez Mora, A. Lozano, V. Camacho, B. Gomez-Anson, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Neuronal responses of pallidal and cerebellar receiving thalamic nuclei to neck exertion in cervical dystonia patients

U. Semenova, R. Medvednik, A. Sedov (Moscow, Russian Federation)

1:45pm-3:15pm: Neuropathology of dopa-responsive dystonia due to Tyrosine hydroxylase deficiency

S. Schreglmann, Z. Jaunmuktane, H. Jung, C. Strand, J. Holton, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

P. Kashyap, S. Gupta (Bihar, India)

1:45pm-3:15pm: Neuropsychiatric and prognostic differences between functional and primary dystonia subtypes in a US specialized dystonia clinic: a case control study

C. Stephen, D. Perez, N. Sharma (Boston, MA, USA)

1:45pm-3:15pm: Neuropsychological characteristics of children with tremor

S. O'Shea, W. Garcia, E. Louis, R. Alcalay, V. Rauh (New York, NY, USA)

1:45pm-3:15pm: Neurostructural alterations associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s disease

C. Beal, V. Planche, C. Chassain, A. Marques, J.M. Bonny, B. Pereira, N. Vitello, M.L. Fantini, F. Durif (Clermont-Ferrand, France)

1:45pm-3:15pm: Nilotinib for treating MSA: A preclinical proof of concept study

P. Guerin, M. Lopez-Cuina, E. Bezard, W. Meissner, P-O. (Bordeaux, France)

1:45pm-3:15pm: NMSQ Application: A New Way to Access Non-Motor Symptoms in Patients with Parkinson’s Disease

P. Lolekha, K. Kulkantrakorn (Pathumthani, Thailand)

1:45pm-3:15pm: Non-motor symptoms in patients from the Catalonian Multiple System Atrophy Registry (CMSAR)

D.M. Giraldo, A. Pérez Soriano, J. Rios Guillermo, E. Muñoz, Y. Compta, J. Pagonabarraga, F. Valldeoriola, J. Hernández-Vara, S. Jauma Classen, V. Puente, C. Pont, N. Caballol, E. Tolosa, A. Bayes, J. Campdelacreu, O. Fabregues, A. Avila, M. Calopa, C. Gaig, N. Fabregat, P. Pastor, M. Aguilar, M. Pujol, L. Planellas, A. Camara, M.J. Marti (Barcelona, Spain)

1:45pm-3:15pm: Non-motor symptoms in Spinocerebellar ataxia, multiple system atrophy and Idiopathic late-onset cerebellar ataxia

YM. Park, MJ. Kim, SB. Koh (Seoul, Republic of Korea)

1:45pm-3:15pm: Not just runners: Adult onset lower limb dystonia

B. Karp, D. Ehrlich, K. Alter (Bethesda, MD, USA)

1:45pm-3:15pm: Novel CACNA1A gene mutation in a Taiwan family with episodic ataxia type 2

KF. Chen, CH. Tsai, DC. Wu (Taichung, Taiwan)

1:45pm-3:15pm: Objective assessment of Parkinson’s disease motor symptoms during leg agility test using motion sensors

S. Aghanavesi, M. Memedi, M. Senek, D. Nyholm, F. Bergquist (Borlange, Sweden)

1:45pm-3:15pm: Objective Data in Parkinson’s Disease: A description of over 20,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG)

P. Lynch, R. Pahwa, F. Bergquist, M. Horne (Minnetonka, MN, USA)

1:45pm-3:15pm: Objective Measurement in Routine Care of People with Parkinson’s Disease Improves Outcomes

M. Horne, P. Farzanehfar, H. Woodrow, M. Braybrook, S. McGregor, A. Evans, F. Nicklason (Parkville, Australia)

1:45pm-3:15pm: Objective Measures of Ataxic Gait Using Wearable Inertial Sensors

M. El-Gohary, L. Horak, C. Gomez (Portland, OR, USA)

1:45pm-3:15pm: Objective monitoring of drug response in early PD patients using remote, at-home typing data through machine learning analysis

M. Matarazzo, T. Arroyo-Gallego, P. Montero Escribano, V. Puertas-Martín, I. Butterworth, C. S. Mendoza, MJ. Ledesma-Carbayo, MJ. Catalán, JA. Molina-Arjona, F. Bermejo-Pareja, JC. Martínez Castrillo, L. López-Manzanares, A. Alonso-Cánovas, J. Herreros-Rodríguez, I. Obeso, P. Martínez Martín, JC. Martínez-Ávila, A. Gómez de-la-Cámara, M. Gray, JA. Obeso, L. Giancardo, Á. Sánchez-Ferro (Vancouver, BC, Canada)

1:45pm-3:15pm: Ocular flutter, generalized myoclonus and ataxia syndrome associated with Human Immunodeficiency Virus: A case report

K. Tan, GB. Eow, A.A. Augustine (George Town, Malaysia)

1:45pm-3:15pm: Oculomotor Behavior in Healthy Caribbean: Does it reflect an increased vulnerability to degenerative Parkinsonism?

A. Lannuzel, A. Lackmy, B. Tressières, R. Edragas, V. Pélonde-Erimée, C. Bonnet, S. Rivaud-Péchoux, E. Roze, B. Gaymard (Pointe-à-Pitre, Guadeloupe)

1:45pm-3:15pm: Olfactory testing in Parkinson plus syndromes

O. Abdukarimov, F. Akhmedova (Tashkent, Uzbekistan)

1:45pm-3:15pm: On the hunt for a link between genetically confirmed Huntington’s disease and Amyotrophic Lateral Sclerosis

L. Williams, K. O'Connell, D. Burke, J. Cryan, D. McCabe (Dublin, Ireland)

1:45pm-3:15pm: Open-label pilot trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS)

D. Hall, E. Robertson, M. Leehey, A. McAsey, B. Ouyang, E. Berry-Kravis, J. O'Keefe (Chicago, IL, USA)

1:45pm-3:15pm: Optimization of Region of Interest Analysis of the Superior Colliculus for Improved Activation Detection in Cervical Dystonia

S. Narasimham, E. McGovern, O. Killian, R. Beck, M. Farrell, S. O’Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

1:45pm-3:15pm: Orthostatic tremor does not stop during walking: Is this a stop sign for research?

W. Hu, E. Opri, Z. Jabarkheel, A. Schmitt, C. Hass, C. Hess, M. Okun, A. Wagle Shukla (Gainesville, FL, USA)

1:45pm-3:15pm: Outcomes of elective orthopedic surgery in Parkinson’s disease – a Nationwide study

M. Fullard, D. Thibault, A. Willis (Philadelphia, PA, USA)

1:45pm-3:15pm: Palliative Virtual Home Visits for Atypical Parkinsonian Disorders (PVH-Park Study)

M. Afshari, A. Butala, J. Guenther, A. Pantelyat, N. Galifianakis (San Francisco, CA, USA)

1:45pm-3:15pm: Pallidotomy for Intractable Hemichorea in Sudden Hyperglicemic Pituitary Adenoma Patient

Y. Tatang, M. Inggas (Jakarta, Indonesia)

1:45pm-3:15pm: Parallel evaluation of mutant huntingtin and neurofilament light in Huntington’s disease

L. Byrne, F. Rodrigues, E. Johnson, E. De Vita, C. Czech, S. Schobel, R. Scahill, A. Heslegrave, H. Zetterberg, W. Wild (London, United Kingdom)

1:45pm-3:15pm: Parkinson’s disease against the background of an essential tremor in people of Uzbek nationality

R. Matmurodov, K. Khalimova, F. Odinayev (Tashkent, Uzbekistan)

1:45pm-3:15pm: Parkinson’s Disease Risk in Breast Cancer

R. Mills-Joseph (Columbus, OH, USA)

1:45pm-3:15pm: Parkinson’s disease and palliative care

A. Manna, L. Khanra (East Medinipur, India)

1:45pm-3:15pm: Parkinson’s Disease Psychosis Associated Comorbidities, and Mortality in the Medicare Population

D. Weintraub, A. Willis, P. Torres, A. Shim, J. Norton, K. Liu, G. Demos (Philadelphia, PA, USA)

1:45pm-3:15pm: Parkinson’s disease-related non-motor features as risk factors for post-operative delirium in spinal surgery

SY. Kang, KH. Kim, DA. Shim, SW. Choi, MJ. Son, YH. Sohn, PH. Lee (Hwaseong, Republic of Korea)

1:45pm-3:15pm: Parkinson’s disease, peripheral neuropathy, impaired gait, and the role of physiotherapy

M. Alvarez (San Antonio, TX, USA)

1:45pm-3:15pm: Parkinsonism with rare sequence variants in VPS35 and FBXO7 genes associated with Lewy body pathology

K. Mensikova, L. Tuckova, R. Vodicka, K. Kolarikova, T. Bartonikova, J. Ehrmann, R. Vrtel, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: Paroxysmal kinesigenic dyskinesia successfully treated with lamotrigine –description of 2 cases

E. Papuć, K. Rejdak (Lublin, Poland)

1:45pm-3:15pm: Paroxysmal multifocal dystonia with hemiplegic migraine possibly related to novel CACNA1A mutation

A. Hannoun, K. Smith (Worcester, MA, USA)

1:45pm-3:15pm: Pathophysiologic insights into ataxia and spasticity through structural imaging of a spinocerebellar ataxia type 7 (SCA7) cohort

J. Parker, S. Merchant, S. Horovitz, M. Hallett (Bethesda, MD, USA)

1:45pm-3:15pm: Patient Perceptions of Dopaminergic Therapy Withdrawal in Parkinson’s disease

N. Kukreti, P. Trujillo-Diaz, N. Van Wouwe, D. Claassen (Nashville, TN, USA)

1:45pm-3:15pm: Patient Perspective in Multiple System Atrophy

A. Mahajan, Z. Mari (Detroit, MI, USA)

1:45pm-3:15pm: PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy

D. Finkelstein, P. Adlard, N. Stefanova, D. Stamler (Parkville, Vic, Australia)

1:45pm-3:15pm: People with PD have significantly impaired lower limb force production in all muscle groups: A cross sectional study

E. Preston, R. Salmon, N. Mahendran, A. Flynn (Canberra, Australia)

1:45pm-3:15pm: Peripheral immune activation was associated with multiple system atrophy

B. Cao, XP. Chen, WH. Feng, QQ. Wei, LY. Zhang, HF. Shang (Chengdu, China)

1:45pm-3:15pm: Peripheral trauma elicits a dystonic phenotype in a DYT1 transgenic mouse model

A. Stengl, L. Rauschenberger, S. Knorr, K. Grundmann, J. Volkmann, C. Ip (Wuerzburg, Germany)

1:45pm-3:15pm: Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic

F. Nahab, H. Abuhussain, L. Moreno (La Jolla, CA, USA)

1:45pm-3:15pm: Pharmacological investigation of biochemical and behavioral effects resembling Huntington’s disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor

R. Mishra (Baddi, India)

1:45pm-3:15pm: Phase-locked transcranial alternating current stimulation of the cerebellum for essential tremor

S. Schreglmann, D. Wang, E. Boyden, K. Bhatia, J. Rothwell, N. Grossman (London, United Kingdom)

1:45pm-3:15pm: Phenomenology and management of subthalamic stimulation-induced dyskinesia in a video case series of patients with isolated dystonia

K. Dodenhoff, I. Bledsoe, M. San Luciano, M. Volz, L. Markun, P. Starr, J. Ostrem (San Francisco, CA, USA)

1:45pm-3:15pm: Phenotypic Heterogeneity and Variability of Nigrostriatal Dopaminergic Function in a Dopa-Responsive Dystonia

J.J. Lin (Nantou, Taiwan)

1:45pm-3:15pm: Phenotypic variability of essential tremor based on the age at onset

S. Prasad, A. Lenka, K. Jhunjhunwala, K. Bhalsing, P. Pal (Bengaluru, India)

1:45pm-3:15pm: Physical activity in people with Parkinson’s disease: A qualitative study

J. McGinley, M. Danoudis, B. BIlney, M. Morris, R. Higgins (Parkville, Australia)

1:45pm-3:15pm: Physiological effects of Botulinum Toxin therapy in Primary Cervical Dystonia

W. Deeb, W. Hu, A. Wagle Shukla (Gainesville, FL, USA)

1:45pm-3:15pm: Pilot economic evaluation of Personal KinetiGraph (PKG) for management of Parkinson’s disease in Australia

P. Lynch, D. Jackson, D. Tilden, M. Horne (Minnetonka, MN, USA)

1:45pm-3:15pm: Pilot trial of botulinum toxin and occupational therapy for Writer’s Cramp

J. Park, E. Shamim, O. Panyakaew, P. Mathew, C. Toro, J. Sackett, B. Karp, C. Lungu, K. Alter, B. Hodsdon, M. Villegas, T. Wu, O. Ahmad, P. Srivanitchapoom, S. Auh, M. (Goyang, Republic of Korea)

1:45pm-3:15pm: Plasma transferrin level correlates with the tremor-dominant phenotype of Parkinson’s disease

S. Qian, Y. Sheng, Z. Zhong (Nanjing, China)

1:45pm-3:15pm: Possible neurotoxic hazards of common adulterants in Tea among Drosophila; ascertainment of toxicity of Tea preparations from local shops of an Indian city

C. Ratnakaran, G. Chandran (Bengaluru, India)

1:45pm-3:15pm: Postural deformities in Chinese patients with multiple system atrophy

L. Zhang, B. Cao, Y. Zou, Q. Wei, R. Ou, B. Zhao, J. Yang, Y. Wu, H. Shanng (Chengdu, China)

1:45pm-3:15pm: Postural Stability in Blepharospasm and the Effects of Botulinum Toxin Therapy

M. Balal, T. Demir, M. Erdem, M. Demirkiran (Adana, Turkey)

1:45pm-3:15pm: Postural Sway Complexity as a Measure of Motor Functionality in Fragile X Premutation Carriers

C. O'Keeffe, L. Taboada, N. Feerick, L. Gallagher, T. Lynch, R. Reilly (Dublin, Ireland)

1:45pm-3:15pm: Prayer Dancing Dystonia: A Novel Form of Non-Occupational Task Specific Focal Dystonia

L. Jaffe (Honolulu, HI, USA)

1:45pm-3:15pm: Pre-supplementary Motor Area Contributes to Motor Aspects of Sequential Risk-Taking

A. Lohse, D. Meder, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

1:45pm-3:15pm: Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis

D. Shprecher, C. Adler, N. Zhang, J. Hentz, G. Serrano, B. Dugger, H. Shill, R. Savica, J. Caviness, M. Sabbagh, C. Belden, E. Driver-Dunckley, S. Mehta, L. Sue, K. Davis, E. Zamrini, T. Beach (Sun City, AZ, USA)

1:45pm-3:15pm: Prediction of suicidality in Huntington disease: Analysis of Enroll-HD data using machine learning approach

Y. Seliverstov, A. Borzov, E. van Duijn, B. Landwehrmeyer, M. Belyaev (Moscow, Russian Federation)

1:45pm-3:15pm: Predictive factors of quality of life evolution in Parkinson’s disease patients participating in a therapeutic patient education program

C. Derollez, N. Carriere, D. Haidon, M. Kyheng, S. Peres, L. Defebvre (Lille, France)

1:45pm-3:15pm: Predictors of alcohol responsiveness in dystonia

J. Junker, V. Brandt, B. Berman, M. Vidailhet, E. Roze, A. Weissbach, C. Comella, I. Malaty, J. Jankovic, M. LeDoux, A. Berardelli, R. Barbano, S. Reich, J. Perlmutter, H. Jinnah, N. Brueggemann (Luebeck, Germany)

1:45pm-3:15pm: Predictors of health-related quality of life in Parkinson’s disease

G. Kuhlman, M. Barrett, J. Flanigan (Charlottesville, VA, USA)

1:45pm-3:15pm: Preliminary evaluation of the Integrated Parkinson’s Care Network (IPCN): An integrated care model for complex needs

T. Mestre, D. Kessler, D. Coté, K. Thavorn, C. Liddy, M. Taljaard, D. Grimes (Ottawa, ON, Canada)

1:45pm-3:15pm: Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data

E. Viscidi, T. Dam, M. Juneja, L. Li, H. Krzywy, S. Eaton, S. Chen, S. Hall, A. Dilley (Cambridge, MA, USA)

1:45pm-3:15pm: Prevalence and Correlates of Anxiety & Depression in Cervical Dystonia

M. Al Hussona, I. Ndukwe, S. O'Riordan, R. Beck, R. Reilly, M. Hutchinson (Dublin, Ireland)

1:45pm-3:15pm: Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review

D. Breen, E. Ravid, A. Lang, J. Miyasaki, R. Camicioli (Toronto, ON, Canada)

1:45pm-3:15pm: Prevalence and predictors of mood and health-related quality of life impairment among patients with parkinson’s in sub-saharan neurology clinic

U. Williams, S. Oparah, H. Okpa (Calabar, Nigeria)

1:45pm-3:15pm: Prevalence of focal task specific lower extremity dystonia symptoms in runners

R. Thompson, A. Hellman, D. Torres-Russotto (Lebanon, NH, USA)

1:45pm-3:15pm: Prevalence of REM sleep behavior disorder and sleep-disordered breathing in multiple system atrophy: A meta-analysis

SL. Wu, CS. Chuang (Changhua, Taiwan)

1:45pm-3:15pm: Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona

D. Shprecher, A. Intorcia, M. Glass, J. Curry, J. Walker, B. Cutler, M. Callan, G. Serrano, N. Zhang, L. Sue, K. Davis, T. Beach (Sun City, AZ, USA)

1:45pm-3:15pm: Prevalence of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease

S. Hung, D. Claassen, M. Edmondson, R. Reilmann, N. Svrzikapa, K. Longo, J. Goyal, M. Panzara (Cambridge, MA, USA)

1:45pm-3:15pm: Prevelance in the World

Tur. Djakhangir (Tashkent, Uzbekistan)

1:45pm-3:15pm: Probable MSA presenting initially with urinary retention

S. Simeoni, R. Sakakibara, J. Panicker (London, United Kingdom)

1:45pm-3:15pm: Prodromal features of Parkinson’s disease in women

K. Hughes, X. Gao, J. Baker, C. Stephen, I. Kim, L. Valeri, M. Schwarzschild, A. Ascherio (Boston, MA, USA)

1:45pm-3:15pm: Progressive encephalomyelitis with rigidity and myoclonus (PERM): Phenomenology, investigations and management of two recent cases

T. Munteanu, Y. LLamas-Osorio, P. Cullinane, T. Lynch (Dublin, Ireland)

1:45pm-3:15pm: Progressive Supranuclear Palsy and Eye of the Tiger Sign

O. Dogu, H. Genç, N. Öksüz (Mersin, Turkey)

1:45pm-3:15pm: PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach

J. Levin, S. Maass, M. Schuberth, A. Giese, W. Oertel, W. Poewe, C. Trenkwalder, G. Wenning, U. Mansmann, M. Suedmeyer, K. Eggert, B. Mollenhauer, A. Lipp, M. Loehle, J. Classen, A. Muenchau, J. Kassubeck, G. Ebersbach, D. Berg, S. Egert, C. Eberhardt, F. Paul, K. Boetzel, B. Ertl-Wagner, H. Huppertz, I. Ricard, G. Hoeglinger (Munich, Germany)

1:45pm-3:15pm: Pronounced synucleinopathy and nigrostriatal degeneration result in forelimb use deficits in the rat preformed alpha-synuclein fibril model

J. Patterson, M. Duffy, T. Collier, K. Luk, C. Kemp, J. Howe, P. Patel, A. Stoll, K. Miller, N. Kanaan, K. Paumier, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm: Prospective, home-based assessment of motor symptoms in Parkinson’s disease by mean of the Sleep Fit app: A potential new clinical approach

P-L. Ratti, F. Faraci, A. Mascheroni, S. Hackethal, C. Ferlito, S. Caverzasio, E-K. Choe, Y. Luo, P-E. Nunes Ferreira, A. Puiatti, A. Kaelin-Lang (Lugano, Switzerland)

1:45pm-3:15pm: Psychogenic Palatal Tremor: A Case Report

A. Tüfekçi, Ç. Hocaoğlu, D. Yanoğlu, K.S. Karataş (Rize, Turkey)

1:45pm-3:15pm: Psychosocial Impact of dysarthria: Is speech intelligibility an effective measure outcome?

C. Atkinson-Clement, A. Letanneux, M. Berthelot, D. Robert, C. Robieux, C. Moreau, G. Baille, A. Eusebio, F. Fluchère, E. Robin, T. Witjas, J.P. Azulay (Aix-en-Provence, France)

1:45pm-3:15pm: Pupillary autonomic dysfunction and oculomotor characteristics of multiple system atrophy

K.W. Park, EJ. Lee, N.R. Choi, M.S. Kim, S.J. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: Quailty of life and Parkinson’s disease: Philippine translation and validation of the Parkinson’s disease questionnaire

C. Suratos, G. Saranza, D. Sumalapao, R. Jamora (Manila, Philippines)

1:45pm-3:15pm: Quality of Life and Psychiatric Comorbidities Comparisons in Patients with Functional (Psychogenic) and Organic Movement Disorders

T. Gendre, G. Carle, F. Mesrati, M. Houot, B. Degos, B. Garcin (Créteil, France)

1:45pm-3:15pm: Quality of life in Chinese Parkinson’s disease patients with Subthalamic Deep Brain Stimulation in Hong Kong: A single center prospective study

C. Lau, C. Zhu, D. Chan, K. Ma, A. Chan, J. Yeung, W. Poon, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: Quantitative Assessment of Appendicular Bradykinesia in Parkinson’s Disease using Wearable Sensors

A. Dowling, M. Brys, J. Paskavitz, V. Auclair, D. McLaren, R. Postuma, B. Bedell, M. Cedarbaum (Cambridge, MA, USA)

1:45pm-3:15pm: Quantitative assessment of the hand motor symptoms in Parkinson’s disease based on a custom wearable device: A Proof-of-Principle Study

Q. Ye, Z. Lin, H. Dai, Y. Xiong, G. Cai (Jinjiang, China)

1:45pm-3:15pm: Quantitative characterisation of tremor in functional and organic tremor patients

Z. Dominguez-Vega, G. Kramer, J. Elting, M. de Koning-Tijssen, N. Maurits (Groningen, Netherlands)

1:45pm-3:15pm: Quantitative Midbrain Measurement in Diagnosing Variants of Progressive Supranuclear Palsy

H. Wang, YW. Zhang, J. Yuan, D. Xu, H. You, ML. Li, F. Feng (Beijing, China)

1:45pm-3:15pm: Quantitative mobility metrics from a body-fixed sensor predict incident parkinsonism in older adults

R. von Coelln, R. Dawe, J. Shulman, L. Yu, S. Leurgans, J. Hausdorff, L. Shulman, D. Bennett, A. Buchman (Baltimore, MD, USA)

1:45pm-3:15pm: Radiofrequency pallidotomy for Embouchure dystonia

S. Horisawa, T. Kawamata, T. Taira (Shinjyuku, Japan)

1:45pm-3:15pm: Radiologic Biomarkers of Acute Non-Ketotic Hyperglycemic Chorea: A Systematic Review

D. Reis Carneiro, M. Sousa, F. Rodrigues, F. Moreira, A. Morgadinho, C. Januário (Coimbra, Portugal)

1:45pm-3:15pm: Rapamycin for treating MSA: A preclinical proof of concept study

M. Lopez-Cuina, P. Guerin, E. Bezard, W. Meissner, P-O. Fernagut (Bordeaux, France)

1:45pm-3:15pm: Rapid onset hemidystonia-hemichorea in DYT 12: Is “SWAN NECK” limb deformity a clinical sign?

A. Elavarasi, V. Goyal, V. Vishnu, M. Singh, P. Srivastava MV (Puducherry, India)

1:45pm-3:15pm: Rapidly progressive ataxia caused by an undetermined paraneoplastic disorder: A case report

J. Conway, A. Feigin (New York, NY, USA)

1:45pm-3:15pm: Rare ADCY6 variants in two families with cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS)

N. Brüggemann, L. Olschewski, V. Tadic, A. Münchau, C. Helmchen, K. Lohmann (Lübeck, Germany)

1:45pm-3:15pm: Re-emergent Tremor in Parkinson’s Disease

O. Dogu, M. Bozdag, N. Oksuz (Mersin, Turkey)

1:45pm-3:15pm: Receptivity to deep brain stimulation surgery among patients with essential tremor

A. Patel, C. Chow, V. Kakade, K. Nalamada, K. Para, S. Schaefer, D. Shah, E. Louis (New Haven, CT, USA)

1:45pm-3:15pm: Recognise and treat functional myoclonus: Case report

L. Tesolin, M. Liechti, S. Aybek (Trieste, Italy)

1:45pm-3:15pm: Recruitment of Minority populations with Parkinson’s disease at an Urban Hospital

C. Branson, S. Bissonette, T. Johnson, J. Weinberg, M. Saint-Hilaire (Boston, MA, USA)

1:45pm-3:15pm: Recurrent Ataxia in a Young Lady with Hashimoto’s Thyroiditis

I. Sarker, M. Habib, H. Rahman, A. Rizvi (Dhaka, Bangladesh)

1:45pm-3:15pm: Referral and diagnostic time intervals from symptom onset to death in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Parkinson’s disease (PD)

D. Swallow, C. Counsell (Aberdeen, United Kingdom)

1:45pm-3:15pm: Regional homogeneity changes detected between Essential tremor with resting tremor and tremor-dominant Parkinson’s disease

J. Li, Z. Lu, X. Suo, N. Li, L. Wang, J. Peng, J. Zhang, Q. Gong, R. Peng (Chengdu, China)

1:45pm-3:15pm: Relationship of 10-Meter Walk Test to balance performance in Parkinson’s disease patients as a predictor of falls

A.P.C. Loureiro, B. Yamaguchi, V. Israel (Curitiba, Brazil)

1:45pm-3:15pm: Reliability and Feasibility of Telemedicine Evaluation of Cervical Dystonia

A. Fraint, G. Pal, G. Stebbins, C. Comella (Chicago, IL, USA)

1:45pm-3:15pm: REM Sleep Behavior Disorder Associations with Parkinson’s Disease Study (RAPiDS): Initial Baseline Data

D. Barone, H. Sarva, L. Ravdin, M. Vo, A. Hanineva, M. DeGrazia, A. Krieger, N. Hellmers, C. Henchcliffe (New York, NY, USA)

1:45pm-3:15pm: REM sleep-related episodes in children with Narcolepsy type 1 after treatment with Sodium Oxybate

E. Antelmi, F. Pizza, G. Plazzi (Bologna, Italy)

1:45pm-3:15pm: Repetitive Transcranial Magnetic Stimulation Therapy is a Potential Therapeutic option for Primary Orthostatic Tremor

W. Hu, J. Legacy, A. Ferng, A. Wagle Shukla (Gainesville, FL, USA)

1:45pm-3:15pm: Respiratory Complaints in Individuals with Spinocerebelar Ataxia Type 2

N. Mello, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Response to botulinum toxin in adult onset lower limb dystonia

D. Ehrlich, K. Alter, B. Karp (Bethesda, MD, USA)

1:45pm-3:15pm: Restless legs syndrome as a first manifestation of cerebral stroke: Clinical analysis of 7 cases

X.J. Zhang, X.Y. Zhu, Y. Liu, E.K. Tan, Y.C. Wu (Shanghai, China)

1:45pm-3:15pm: Restless Legs Syndrome in Pregnant Thai Women: Prevalence, Natural History, and Risk Factors

S. Panvatvanich, P. Lolekha (Pathumthani, Thailand)

1:45pm-3:15pm: Retrospective study on a cohort of 285 PD patients: Does the side of onset influence the global clinical phenotype?

G. Lazzeri, G. Franco, E. Monfrini, E. Frattini, I. Trezzi, L. Borellini, G. Ardolino, F. Cogiamanian, A. Di Fonzo (Milano, Italy)

1:45pm-3:15pm: Reversible Extrapyramidal features as unusual presentation of central pontine myelinolysis: A case report

S. El-Jaafary, A. Sabbah, S. Ahmed (Cairo, Egypt)

1:45pm-3:15pm: Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging: A Case Series from the PPMI Study

J. Massa, L. Chahine (Pittsburgh, PA, USA)

1:45pm-3:15pm: Revision of Parkinson’s disease diagnosis during a long-term follow-up

G. Coarelli, B. Garcin, E. Roze, M. Vidailhet, B. Degos (Bobigny, France)

1:45pm-3:15pm: Role of uric acid as a prognostic biomarker in Idiopathic Parkinson’s disease and Parkinson Plus Syndrome

T. Modi, M. Goyal, J. Kaur, B. Medhi (Chandigarh, India)

1:45pm-3:15pm: Rotenone model of Parkinson’s disease: The dosing options in mice revisited

M. Raza, N. Zehra, S. Malhi (Karachi, Pakistan)

1:45pm-3:15pm: Safety and efficacy of high definition tDCS for proprioception and balance in Parkinson’s disease: A pilot randomised trial

H. Teasdale, E. Preston, A. Flood, G. Waddington (Canberra, Australia)

1:45pm-3:15pm: Screening study of COL6A3 in sporadic isolated dystonia

L.Y. Ma, T. Feng (Beijing, China)

1:45pm-3:15pm: Seasonal Fluctuation in a Chinese cohort of patients with idiopathic Restless Legs Syndrome

XY. Zhu, LY. Ni, Y. Liu, XJ. Zhang, WH. Yang, YC. Wu (Shanghai, China)

1:45pm-3:15pm: Secondary dystonic tremor after medial medullary infarction

Q. Wang, S. Wu, J.H. Dong, L.R. Jin, G. Deuschl (Shanghai, China)

1:45pm-3:15pm: Segmentation of neck muscles using ultrasound in cervical dystonia

A. Siddique, R. Cunningham, M. Silverdale, P. Harding, I. Loram, C. Kobylecki (Salford, United Kingdom)

1:45pm-3:15pm: Serum cholesterol level is associated with risk of MSA

YC. Lu, MC. Kuo, RM. Wu (Taipei, Taiwan)

1:45pm-3:15pm: Serum fractalkine levels in Parkinson’s disease: Evidence for neuroinflammation

G. Nagesh Babu, M. Gupta, V. Paliwal (Lucknow, India)

1:45pm-3:15pm: Serum insulin-like growth factor-1 levels in parkinsonism or dementia disorders

K. Suzuki, S. Suzuki, Y. Ishii, T. Matsubara, H. Fujita, Y. Watanabe, M. Okamura, T. Kadowaki, H. Sakuramoto, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm: Severe Gliosis following PPN-DBS

V. Vedam-Mai, A. Elkouzi, B. Malhotra, S. Raman, A. Yachnis, K. Foote, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Shaky legs: The clinical spectrum and treatment of orthostatic tremor; a systematic review

A. Buijink, M. Meulepas, A. van Rootselaar (Amsterdam, Netherlands)

1:45pm-3:15pm: Siblings with a PRKRA (DYT16) Mutation and Startle Myoclonus

L. Wiblin, M. Baker, M. Lai, R. Horvath, N. Warren (Newcastle upon Tyne, United Kingdom)

1:45pm-3:15pm: Sing to Beat Parkinson’s®: A Group Singing Intervention for People with Parkinson’s and their Carers

J. Irons, G. Hancox, D. Stewart (Derby, United Kingdom)

1:45pm-3:15pm: Sleep Abnormalities in patients with Parkinson’s disease having REM sleep behaviour disorder with and without Psychosis

R. Yadav, V. Reddy, G. Kumar, L. George, A. Shashidharan, B. Kutty, P. Pal (Bangalore, India)

1:45pm-3:15pm: Sleep and other Non Motor Symptoms in Craniofacial Dystonia

S. Ray, R. Yadav, P. Pal, B. Kutty (Bangalore, India)

1:45pm-3:15pm: Slowly progressive anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia over 27 years without immunosuppressive treatment

E. Schegk, I. Beiser, A. Wicki, L. Achtnichts, M. Bertschi (Aarau, Switzerland)

1:45pm-3:15pm: Smartphone App-Based Assessment of Gait in patients with Parkinson’s disease

D. Su, Z. Liu, W. Yu, H. Zhu, O. Lo, B. Manor, T. Feng, J. Zhou (Beijing, China)

1:45pm-3:15pm: Sniffing Parkinson’s in the masses: Volatilome analysis for Parkinson’s Disease diagnostics

M. Silverdale, D. Trivedi, E. Sinclair, Y. Xu, C. Liscio, P. Banks, T. Kunath, R. Goodacre, P. Barran (Manchester, United Kingdom)

1:45pm-3:15pm: Somatosensory temporal discrimination in Parkinson’s disease, dystonia and essential tremor: Pathophysiological and clinical implications

N. Manzo, A. Conte, D. Belvisi, G. Ferrazzano, G. Fabbrini, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy

J.H. Lee, M.J. Lee, T.H. Kim (Yangsan-si, Gyeongsangnam-do, Republic of Korea)

1:45pm-3:15pm: Spectrum of movement disorders in patients of autoimmune encephalitis of non-neoplastic aetiology

D. Dash, M. Tripathi, K. Ihtisham (Delhi, India)

1:45pm-3:15pm: Spectrum of movement disorders with anti-neuronal antibodies: Case series

A. Kumar, S. Mehta, V. Lal (Chandigarh, India)

1:45pm-3:15pm: Speech and Language Therapy (SLT) for Inpatients with Parkinson’s (IwP) in a Large District General Hospital

J. Martin, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Speech in Huntington’s Disease

J.C.S. Chan, A. Vogel, J. Stout (Victoria, Australia)

1:45pm-3:15pm: Spinocerebellar Ataxia Type 2 Presenting with Chorea: Korean Cases

D. Yoo, J.Y. Lee, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Staged bilateral Gamma Knife Thalamotomy for severe essential tremor

T. Witjas-Slucki, R. Carron, JP. Azulay, A. Eusebio, J. Regis (Marseille, France)

1:45pm-3:15pm: Start React Paradigm In Patients With Cervical Dystonia

R. Singh, S. Choudhury, A. Roy, K. Chatterjee, M. Mondal, M. Baker, S. Baker, H. Kumar (Kolkata, India)

1:45pm-3:15pm: STN-DBS responsive motor complication and pathological gambling in type IV SCA3

M. Kuo, C. Tai, R. Wu (New Taipei, Taiwan)

1:45pm-3:15pm: Stop Signal Reaction Time (SSRT) in Dystonia and its Correction after Botulinum Toxin Treatment

A. Roy, S. Choudhury, R. Singh, K. Chatterjee, B. Mondal, J. Ganguly, M. Baker, S. Baker, H. Kumar (Kolkata, India)

1:45pm-3:15pm: Striatal FP-CIT SPECT findings for progressive supranuclear palsy subtypes

M. Yogo, M. Morita, M. Suzuki (Tokyo, Japan)

1:45pm-3:15pm: Striatum of the ouabain-induced pharmacological DYT12 mouse model is affected by structural and metabolic abnormalities

L. Rauschenberger, Y. Al-Zuraiqi, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

1:45pm-3:15pm: Study of eye movements by video-oculography in essential tremors

M. De Verdal, A. Lozza, D. Renard, E. Thouvenot, G. Castelnovo (Nimes, France)

1:45pm-3:15pm: Subjective and objective complaints of (functional) tremor: An individual approach

G. Kramer, J. Rosmalen, N. Maurits, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: Submandibular gland is a suitable tissue for alpha synuclein pathology in Parkinson’s disease

JH. Shin, SH. Park, CW. Shin, JH. Kim, TJ. Yun, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Surface Modified Solid Lipid Nanoparticles for the targeted delivery to brain: Management of HIV-1 Associated Dementia

S. Bhargava, V. Bhargava (Kanpur, India)

1:45pm-3:15pm: Sydenham’s Chorea: Realities and Challenges in Sub-Saharan Africa

A. Nitcheu Woga, A. Balde, F. Sakadi, N. Tassiou, A. Bah, F. Cisse, E. Minko (Conakry, Guinea)

1:45pm-3:15pm: Symptomatic Isolated Tongue Tremor of Cortical Origin Due to Stroke

S. Thakolwiboon, D. Ruthirago, P. Laengvejkal, J. Kim, H. Wilms (Lubbock, TX, USA)

1:45pm-3:15pm: Systemic variables that exacerbated physiological tremor in a general hospital in Mexico

D. Rebolledo, O. Gonzalez, J. Rebolledo, Z. Rebolledo (Toluca de Lerdo, Mexico)

1:45pm-3:15pm: Task effects on lingual kinematics in dysarthric individuals with Parkinson’s disease: Insights from two cases

M. Wong (Hong Kong, Hong Kong)

1:45pm-3:15pm: Task-specific embouchure dystonia in a flutist

I. Bledsoe (San Francisco, CA, USA)

1:45pm-3:15pm: Telepsychiatry for Patients with Parkinson’s disease

M. Heiry, N. Galifianakis, J. Ostrem, A. Seritan (San Francisco, CA, USA)

1:45pm-3:15pm: Temporal discrimination threshold in musician’s dystonia – an endophenotype?

F. Borngräber, T. Paulus, J. Junker, S. Passmann, R. Reilly, M. Hutchinson, C. Klein, A. Kühn, E. Altenmüller, T. Bäumer, A. Schmidt (Berlin, Germany)

1:45pm-3:15pm: Temporal Discrimination Threshold is Associated with Multiple Regions of Resting-State Brain Activity in Musician’s Dystonia

F. Maguire, R. Reilly, K. Simonyan (Dublin, Ireland)

1:45pm-3:15pm: Temporal Gait Parameters in Parkinson’s Disease: A Study Using PDlogger, A Quantitative Gait Measuring Device

N. Chia, J. Derrick, V. Mikos, S. Ng, A. Tay, S-C. Yen, K. Koh, D. Tan, K. Prakash, L. Tan, W.L. Au (Singapore, Singapore)

1:45pm-3:15pm: Tendency towards being a “Morning person” increases risk of Parkinson’s disease: evidence from Mendelian randomisation

A. Noyce, D. Kia, K. Heilbron, J. Jepson, G. Hemani, D. Hinds, D. Lawlor, G. Davey Smith, J. Hardy, A. Singleton, M. Nalls, N. Wood (London, United Kingdom)

1:45pm-3:15pm: Thalamic Tremor Following Focused Ultrasound Thalamotomy for Essential Tremor

T. Osterholt, A. Fois, T. Popa, F. Vial Undurraga, S. Horovitz, M. Hallett, D. Haubenberger (Bethesda, MD, USA)

1:45pm-3:15pm: The “Second-Night” Effect: A Comparison of Sleep Behavior between the Sleep Laboratory and In-Home Settings

X. Cai, C. Dethridge, A. Chang, J. Bhangu, D. Karlin, T. Wager, F. Hameed, A. Steinman, D. Volfson, E. Pickering, K. Thomas (Cambridge, MA, USA)

1:45pm-3:15pm: The association of primary dystonia with tics – chance or new syndrome?

C. Del Gamba, A. Latorre, U. Bonuccelli, R. Ceravolo, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings

K. Erb, J. Daneault, S. Amato, P. Bergethon, C. Demanuele, T. Kangarloo, S. Patel, V. Ramos, D. Volfson, P. Wacnik, H. Zhang, D. Karlin, H. Huggins, L. Soll, G. Costante, G. Vergara-Diaz, F. Parisi, J. Banghu, C. Brooks, C. Dethridge, A. Abrami, E. Bilal, V. Caravagio, S. Heisig, R. Norel, E. Pissadaki, J. Rice, B. Ho, K. Thomas, P. Bonato (Cambridge, MA, USA)

1:45pm-3:15pm: The Catalonian Multiple System Atrophy Registry (CMSAR): The motor features and their impact on disability status in MSA patients

A. Perez-Soriano, DM. Giraldo, J. Rios-Guillermo, E. Muñoz, Y. Compta, MJ. Marti, On-behalf-of-Catalonian-MSA-Registry (Barcelona, Spain)

1:45pm-3:15pm: The change of SIRT1 and HIF-1 in MPTP treated mouse

X.X. Cui, S.Y. Dong, Y.J. Guo, W.J. Zhao, Y.C. Wu (Shanghai, China)

1:45pm-3:15pm: The characteristic of gait in progressive progressive supranuclear palsy

Y. Takamatsu, N. Matsuda, I. Aiba (Kyoto, Japan)

1:45pm-3:15pm: The Characteristics of Patients with Movement Disorders in a Diverse Inner-City Hospital

L. Nwabuobi, J. Agee, M. Ko, R. Gilbert (New York, NY, USA)

1:45pm-3:15pm: The clinical spectrum of motor stereotypies in progressive supranuclear palsy: An early, frequent and underestimated symptom

J. Pagonabarraga, A. Horta-Barba, I. Illan, I. Aracil, H. Bejr-Kasem, J. Pérez-Pérez, J. Marín-Lahoz, B. Pascual-Sedano, S. Martinez-Horta, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: The clinical value of SPECT in identifying dystonic muscles of patients with cervical dystonia

L. Jin, L. Feng, I. Djibo, S. Chen, F. Teng, B. Li, H. Ma (Shanghai, China)

1:45pm-3:15pm: The distinct cognitive syndromes of Huntington’s disease: A two-year follow-up study

S. Martinez-Horta, F. Sampedro, A. Horta-Barba, J. Perez-Perez, J. Pagonabarraga, J. Marin-Lahoz, H. Bejr-Kasem, I. Aracil, MA. Boti, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: The effect of thalamic and subthalamic deep brain stimulation on speech in patients with essential tremor: A prospective, randomized, double-blind crossover study

J. Becker, T. Dembek, P. Reker, J. Petry-Schmelzer, D. Mücke, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: The epiphenomenon of movement disorders post-stroke period

J. Shodmonov, B. Muinjanov (Tashkent, Uzbekistan)

1:45pm-3:15pm: The etiologies of chronic progressive cerebellar ataxia in a Korean population

J. Youn, M. Kim, JH. AHN, JW. Cho, JS. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: The FOG score detects relevant changes of gait freezing for patients and experts

U. Fietzek, S. Schulz, K. Ziegler, A. Ceballos-Baumann (Munich, Germany)

1:45pm-3:15pm: The impact of a wearable device on Parkinson’s disease motor symptom management in patients starting rotigotine transdermal patch

S. Isaacson, B. Boroojerdi, K. Klos, S. Carson, M. Markowitz, D. Heldman, M. Phillips, D. Terricabras, F. Woltering, D. Truong (Boca Raton, FL, USA)

1:45pm-3:15pm: The impact of APOε4 polymorphisms and mutations in the GBA gene on the clinical features of Dementia with Lewy Bodies among Ashkenazi Jews

T. Shiner, A. Mirelman, Y. Rozenblum, G. Kave', M. Gana Weisz, A. Bar-Shira, A. Thaler, T. Gurevich, A. Orr-Urtreger, N. Gilad, N. Bregman (Tel Aviv, Israel)

1:45pm-3:15pm: The impact of bilingualism in brain structure and function in early and mild Huntington’s disease

S. Martinez-Horta, A. Moreu, F. Sampedro, J. Perez-Perez, A. Horta-Barba, J. Pagonabarraga, J. Marin-Lahoz, H. Bejr-Kasem, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: The Impact of short in-patient rehabilitation courses for people with Parkinson´s disease

S. Kinos, K. Martikainen, T. Vahlberg, R. Marttila (Turku, Finland)

1:45pm-3:15pm: The independence in daily living activities is the best predictor for quality of life in people with Parkinson’s disease

C. Dionizio, E. Okamoto, C. Miranda, M. d'Alencar, M.E. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: The international MDSGene initiative: Systematically exploring genotype-phenotype correlations of hereditary movement disorders

S. Petkovic, S. Schaake, J. Huang, H. Madoev, A. Rasheed, C. Lill, K. Lohmann, C. Klein, C. Marras (Lübeck, Germany)

1:45pm-3:15pm: The Levodopa Response Trial and the Parkinson Disease Digital Biomarker Challenge: Monitoring symptoms of Parkinson’s disease in the lab and home using wearable sensors

J. Daneault, G. Vergara-Diaz, G. Costante, E. Fabara, G. Ferreira-Carvalho, F. Golabchi, F. Parisi, S. Sapienza, Y. Chae, P. Snyder, P. Aubin, P. Banda, D. Brunner, R. Dorsey, L. Mangravite, W. Marks, E. Neto, U. Rubin, E. Soderberg, D. Daeschler, S. Moore, S. Sieberts, L. Omberg, P. Bonato, The Parkinson's Disease Digital Biomarker DREAM Challenge Consortium (Newark, NJ, USA)

1:45pm-3:15pm: The phenotype of ATP1A3+ Rapid-Onset Dystonia-Parkinsonism (RDP) is broader than previously defined

I. Haq, B. Snively, C. Suerken, J. Cook, C. Miller, K. Sweadner, L. Ozelius, C. Whitlow, A. Brashear (Winston Salem, NC, USA)

1:45pm-3:15pm: The Predictor Factors on Quality of Life in Patients with Parkinson’s Disease

AD. Wijono, RT. Pinzon (Yogyakarta, Indonesia)

1:45pm-3:15pm: The prevalence and associated features of REM sleep without atonia

F. Dijkstra, M. Viaene, I. de Volder, D. Crosiers, P. Cras (Antwerp, Belgium)

1:45pm-3:15pm: The Prevalence of Dystonic Tremor and Tremor Associated with Dystonia (TAWD) in Patients with Cervical Dystonia

L. Hvizdosova, M. Nevrly, P. Otruba, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid conditions and secondary complications

S. Güler, A. Caylan, F. Turan (Edirne, Turkey)

1:45pm-3:15pm: The Quality of life in Parkinson’s disease. A follow-up study among 621 Finnish people with Parkinson

K. Martikainen, S. Kinos, T. Vahlberg, R. Marttila (Turku, Finland)

1:45pm-3:15pm: The Quality of Life of the participants in a group singing intervention for people with Parkinson’s: A comparison across China (Beijing), South Korea (Seoul) and Australia (Brisbane)

C. Chang, Y. Irons, E. Han, S. Kim, X. Jiang, D. Stewart (Beijing, China)

1:45pm-3:15pm: The role of deep brain stimulation targeting GPi in patients with multiple system atrophy

P. Hedera, D. Claassen, D. Isaacs (Nashville, TN, USA)

1:45pm-3:15pm: The role of immediate communication by text or phone calls by patients with fluctuation motor complaints in Parkinson’s disease and other movement disorders

A E. Constantino (Clinton, MD, USA)

1:45pm-3:15pm: The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy

P. Huang, H.Y. Zhou, Y.Y. Tan, S.D. Chen (Shanghai, China)

1:45pm-3:15pm: The scaling properties of chorea and levodopa-induced dyskinesia are similar to voluntary movements

J. Daneault, C. Duval, J. Miranda (Newark, NJ, USA)

1:45pm-3:15pm: The severity of motor symptoms and depression are the higher predictor for the decrease in daily living activities independence in people with Parkinson’s disease

C. Dionizio Dias, E. Okamoto, C. Miranda, M. d'Alencar, M.E. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: The spectrum of involuntary movements in patients with motor neuron disease – a cross-sectional study

K. Vogelnik, L. Dolenc Grošelj, B. Koritnik, L. Leonardis, J. Zidar, M. Kojović (Ljubljana, Slovenia)

1:45pm-3:15pm: The Timed Up & Go test (time) is inversely associated with fall frequency in progressive supranuclear palsy

N. Matsuda, Y. Takamatsu, I. Aiba (Nagoya, Japan)

1:45pm-3:15pm: The use of a clinical “exercise -immobility test” in a patient with paroxysmal hypnogenic dyskinesia

A. Shalash, A. Abushouk, H. Elrasas (Cairo, Egypt)

1:45pm-3:15pm: The Use of eConsult in a Movement Disorders Clinic

D. Grimes, A. Ohman, C. Liddy, E. Keely, A. Afkhim, T. Mestre (Ottawa, ON, Canada)

1:45pm-3:15pm: The use of smartphone task derived features to predict clinical scores in Parkinson’s Disease (PD)

C. Lo, S. Arora, F. Baig, T. Barber, M. Lawton, A. Zhan, M. Little, M. Hu (Oxford, United Kingdom)

1:45pm-3:15pm: The Use of Technology-Enabled Care (TEC) in Patients with Parkinson’s Disease: An Italian Survey

C. Di Nuzzo, R. Ferrucci, L. Bertolasi, L. Lo Piano, N. Modugno, M. Onofrj, C. Pacchetti, F. Stocchi, F. Tamma, S. Marceglia, F. Mancini, A. Priori (Milan, Italy)

1:45pm-3:15pm: The utility of electrophysiological tests in the differentiation of upper limb tremor in young-onset patients

P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: There’s “still life after Parkinson’s”: A qualitative analysis of the Australian Sing to Beat Parkinson’s® project

D. Stewart, J. Irons, G. Hancox (South Brisbane, Australia)

1:45pm-3:15pm: Toward an automated, video-based method to measure motor severity in cervical dystonia

D. Peterson, Z. Zhang, J. Perlmutter, G. Stebbins, C. Comella (La Jolla, CA, USA)

1:45pm-3:15pm: Toxin-induced Parkinsonism: A report of two patients

Z. Aldaajani (Dhahran, Saudi Arabia)

1:45pm-3:15pm: Tracking RBD and PD progression with longitudinal structural brain connectomes

J. Suescun, O. Peña Nogales, T. Ellmore, R. de Luis-Garcia, M. Schiess, L. Giancardo (Houston, TX, USA)

1:45pm-3:15pm: Trans-spinal direct current stimulation for managing primary orthostatic tremor

J.C. Lamy, P. Varriale, E. ApartiS, Z. Kosutzka, E. Roze, M. Vidailhet (Paris, France)

1:45pm-3:15pm: Transcriptional profiling of peripheral blood monocytes from child Friedreich’s ataxia patient: New molecules and patterns of gene expression

H. Singh, V. Swarup, R. Singh, I. Singh, M. Faruq, S. Vivekanandhan, A. Srivastava (Delhi, India)

1:45pm-3:15pm: Treadmill-based gait analysis for gait abnormality of Parkinson disease

C. Shin, T. Ahn (Seoul, Republic of Korea)

1:45pm-3:15pm: Treating Huntington’s Disease using a holistic approach

T. Sinha (Patna, India)

1:45pm-3:15pm: Treatment with docosahexaenoic acid in Spinocerebellar Ataxia 38

D. Perani, L. Orsi, C. Costanzi, M. Ferrero, A. Zoppo, F. Tempia, D. Caruso, M. Grassi, A. Padovani, A. Brusco, B. Borroni (Brescia, Italy)

1:45pm-3:15pm: Tremor in dystonia: Clinical and electrophysiological assessment in a large series

Z. Jabarkheel, W. Hu, A. Ramirez-Zamora, I. Malaty, W. Deeb, M. Okun, A. Wagle Shukla (Gainesville, FL, USA)

1:45pm-3:15pm: Tremor in motor neuron disease may be central rather than peripheral in origin

A. Latorre, L. Rocchi, M. Stamelou, A. Batla, M. Ciocca, B. Balint, K. Sidle, A. Berardelli, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Tremor suppression by phase-specific transcranial alternating current stimulation in dystonia and essential tremor

F. Nieuwhof, E. Klimars, I. Toni, B. vande Warrenburg, R. Helmich (Nijmegen, Netherlands)

1:45pm-3:15pm: Trust the Patient not the Doctor: Health-related Quality of Life in Cervical Dystonia

M. Al Hussona, J. Dover, I. Ndukwe, S. O'Riordan, R. Beck, R. Reilly, M. Hutchinson (Dublin, Ireland)

1:45pm-3:15pm: Turkish version of the Johns Hopkins Restless Legs Syndrome Quality of Life Questionnaire (RLS-QoL): Validity and reliability study

S. Güler, N. Turan (Edirne, Turkey)

1:45pm-3:15pm: Turkish version quality of life in essential tremor questionnaire (quest): Validity and reliability study

S. Güler, N. Turan (Edirne, Turkey)

1:45pm-3:15pm: Two cases of hemichorea-hemiballism in nonketotic hyperglycemia

S.H. Yi, H.Y. Park (Iksan, Republic of Korea)

1:45pm-3:15pm: Under three seconds: Objective speech markers of ataxia in Multiple Sclerosis

G. Noffs, F. Boonstra, S. Kolbe, A. Evans, H. Butzkeuven, T. Perera, A. Walt, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm: Underserved Patient Access to Movement Disorders Care: Experience from a Tertiary Academic Referral Center

A. Giacobbe, E. Dinh, O. Nguyen, A. Ramirez-Zamora, M. Okun, L. Almeida (Gainesville, FL, USA)

1:45pm-3:15pm: Unique task specific oromandibular dystonia associated with Quran recitation

S. Koya Kutty, W.N. Wan Yahya, R. Remli, H.J. Tan, W.A. Wan Zaidi, C.S. Khoo, C.F. Ng, N.A. Mohd Fauzi, N.. Mohamed Ibrahim (Bandar Tun Razak, Malaysia)

1:45pm-3:15pm: Unusual prolonged survival in multiple system atrophy: A case report

DM. Giraldo, A. Garrido, C. Simonet, J. Saavedra, Y. Compta, M. Marti, E. Tolosa, F. Valldeoriola (Barcelona, Spain)

1:45pm-3:15pm: Update on Convergence Spasm: Review of Psychogenic and Organic Case Reports

R. Fekete, S. Jankovic (Valhalla, NY, USA)

1:45pm-3:15pm: Uric acid and cholesterol in patients with newly diagnosed essential tremor: Multicenter study

S.Y. Kang, C. Lee, J.H. Yoon, J.H. Park, S.W. Choi, M.J. Son, J.Y. Hong, M.K. Sunwoo (Hwaseong, Republic of Korea)

1:45pm-3:15pm: Urinary symptoms and Urodynamic findings in patients with SCAs and DRPLA

M. Jang, A. Kim, B. Jeon, H. Kim (Jeollabuk-do, Republic of Korea)

1:45pm-3:15pm: Urodynamic findings in a cohort of patients with SCA7 reporting lower urinary tract symptoms

T. Uchiyama, J. Ribeiro, P. Giunti, P. Georgopoulos, M. Pakzad, R. Sakakibara, S. Kuwabara, K. Hirata, J. Panicker (Chiba, Japan)

1:45pm-3:15pm: Use of barium swallow using rasgulla to detect focal dystonia of pharyngeal muscles: An indigenous method

P. Samal, V. Goyal, M. Singh, M.V.P. Srivastava, E. A (New Delhi, India)

1:45pm-3:15pm: Use of the Non-Medication Complex in the Treatment of the Spasticity

O. Tondiy (Kharkiv, Ukraine)

1:45pm-3:15pm: Usefulness of combined examination using Frontal Assessment Battery (FAB) and Single Photon Emission Computer Tomography in the differentiation of 4 repeats (4R) tauopathic atypical parkinsonism

P. Alster, D. Koziorowski, L. Królicki, A. Friedman (Warsaw, Poland)

1:45pm-3:15pm: Usefulness of gait-aid system using smart glasses for freezing gait of atypical parkinsonian syndromes

H. Lee, B. Jung (Daegu, Republic of Korea)

1:45pm-3:15pm: Usefulness of Sway Area for Assessing Balance and Stability in People with Sporadic Adult Onset Cerebellar Ataxia

PW. Ko, YH. Lim, K. Kang, HW. Lee (Daegu, Republic of Korea)

1:45pm-3:15pm: Usefulness of ultrasound-guided botulinum toxin injections in a case of cervical dystonia

C. Figueiredo, L. Rebordão, M. Santos, P. Lobo, C. Costa (Amadora, Portugal)

1:45pm-3:15pm: Using APPs in a Movement Disorders clinic can quickly and efficiently increase the number of new patients seen without compromising patient satisfaction

J. Atem, L. Lanford (Dallas, TX, USA)

1:45pm-3:15pm: Using remotely collected data to identify Parkinson’s disease (PD) subtypes

T. Dominey, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Using saccades as an early test of levodopa treatment in Parkinson’s Disease

Z.J. Lu, S. Dillon, P. Zetegren, M. Brzezick, C. Kennard, J. FitzGerald, C. (Oxford, United Kingdom)

1:45pm-3:15pm: Utility of Acute Levodopa Challenge Test In Early Parkinsonism

M. Acharya, A. Biswas, G. Ganguly, S. Das (Kolkata, India)

1:45pm-3:15pm: Vascular parkinsonism: Clinical features and comparison with Parkinson’s disease

C. Simonet, A. Garrido, F. Valldeoriola, MJ. Martí, Y. Compta (Barcelona, Spain)

1:45pm-3:15pm: Vertical and horizontal eye movements in a large cohort of early manifest Huntington’s disease: Evidence from ENROLL-HD

W. Muller, M. MacAskill, L. Paermentier, T. Anderson (Christchurch, New Zealand)

1:45pm-3:15pm: Vestibulo-Ocular Reflex Assessment in Patients with Sporadic Ataxia

H. Teive, B. Zeigelboim, K. Kronbauer, A. Vom Scheidt, R. Santos, N. Mello (Curitiba, Brazil)

1:45pm-3:15pm: Visual cueing using laser-shoes reduces freezing of gait in Parkinson patients at home

C. Barthel, M. van Helvert, R. Haan, A. Janssen, A. Delval, N. de Vries, V. Weerdesteyn, B. Debu, R. van Wezel, B. Bloem, M. Ferraye (Nijmegen, Netherlands)

1:45pm-3:15pm: Visual impairment and falls in Parkinson’s disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Voluntary suppression of Parkinson’s tremor

R. Blakemore, M. MacAskill, D. Myall, T. Anderson (Christchurch, New Zealand)

1:45pm-3:15pm: West Sweden Parkinson Objective Measurement Registry Study (WestPORTS)

F. Bergquist, A. Ax, A. Sjostrom, S. Wallerstedt (Gothenburg, Sweden)

1:45pm-3:15pm: What activities increase the risk of falling in atypical parkinsonian syndromes? A comparative study with Parkinson’s disease

P. Panyakaew, N. Kantachadvanich, S. Chaiwong, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: What increases the risk of malnutrition in geriatric Parkinson’s disease population?

M. Gultekin, F. Fırat Ozer, S. Akın, A. Ozturk (Kayseri, Turkey)

1:45pm-3:15pm: What strategies do Parkinson’s disease patients use for getting out of bed? Preliminary results from multisite wearable sensors analysis

J. Sringean, C. Anan, C. Thanawattano, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Which is the best condition to evaluate the decline in gait automaticity in people with Parkinson’s disease? A ParkiMob study

M. d'Alencar, Y. Uscapi, J. Miranda, M. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: Which is the best manual test to predict the daily living activities’ independence in people with Parkinson’s disease?

C. Dionizio Dias, E. Okamoto, C. Miranda, M. d'Alencar, M.E. Piemonte (São Paulo, Brazil)

1:45pm-3:15pm: White matter microstructural alterations in Huntington Disease: When neurodegeneration starts?

P. Azevedo, L. Piovesana, M. Nogueira, R. Guimarães, A. Amato Filho, F. Cendes, Í. Lopes-Cendes, C. Yasuda (Campinas, Brazil)

1:45pm-3:15pm: Who uses guidance techniques for abobotulinumtoxinA injections in the routine management of cervical dystonia?

V. Misra, R. Trosch, P. Maisonobe, S. Om (London, United Kingdom)

1:45pm-3:15pm: Wrist-worn accelerometer measures of activity by people with Parkinson’s during and following dance

R. Hadley, P. Lovatt, L. Bottoms, L. Annett (Hatfield, United Kingdom)

1:45pm-3:15pm: Writing tremor: Should we look for a TOR1A mutation?

C. Aerts, F. Cassim, I. Strubi-Vuillaume, A. Destee, B. Sablonnière, G. Collod-Béroud, L. Defebvre, A. Kreisler (Nimes, France)

1:45pm-3:15pm: Zolpidem effect in task specific dystonia – clinical and neurophysiological study

K. Vogelnik, M. Grmek, R. Perellon Alfonso, P. Tomše, M. Trošt, M. Kojović (Ljubljana, Slovenia)

1:15pm-2:45pm: “Frequency of autonomic and cardiovascular abnormalities in Mexican patients with early Parkinson’s disease”

J. Balderas, A. Gonzalez (Mexico City, Mexico)

1:15pm-2:45pm: A bayesian network approach for prediction of future dementia in Parkinson’s disease

P. Surathi, M. Mirian, K. Sundvick, S. Appel-Cresswell, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm: A comprehensive digital biomarker active testing and passive monitoring suite for the remote and frequent assessment of motor symptom progression in Parkinson’s disease

K. Taylor, R. Postuma, F. Boess, F. Lipsmeier, T. Kilchenmann, L. Verselis, J. Soto, M. Koller, C. Gossens, A. Post, J. Sevigny, M. Lindemann (Basel, Switzerland)

1:15pm-2:45pm: A cortical neural signature of motor interruption in patients with Parkinson’s disease and freezing of gait

J. Baarbé, M. Brown, U. Saha, K. Lizarraga, A. Weissbach, N. Drummond, C. Rinchon, P. Kapoor, J. Saravanamuttu, R. Chen (Toronto, ON, Canada)

1:15pm-2:45pm: A detailed clinical study of pain in 1957 participants with Parkinson’s disease

M. Silverdale, C. Kobylecki, L. Kass-Iliyya, P. Martinez-Martin, D. Grosset, M. Hu, M. Lawton, S. Cotterill, R. Chaudhuri, H. Morris, F. Baig, N. Williams, L. Hubbard (Manchester, United Kingdom)

1:15pm-2:45pm: A Florbetapir [F18] amyloid PET Imaging study in Parkinson’s disease Dementia (PDD): The influence of amyloid deposition on cognitive status and course of disease progression

G. Palermo, G. Aghakhanyan, L. Tommasini, D. Frosini, D. Volterrani, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

1:15pm-2:45pm: A founder French-Canadian GBA mutation, p.W378G, as a cause for synucleinopathies and Gaucher disease

Z. Gan-Or, J. Ruskey, S. Zhou, L. Roncière, A. Alam, D. Spiegelman, J. Trempe, R. Postuma, N. Dupre, D. Amato (Montreal, QC, Canada)

1:15pm-2:45pm: A longitudinal PET study to assess progression of laterality in Parkinson’s disease

AA. Roussakis, N. Lao-Kaim, A. Martin-Bastida, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: A metabolomic signature of treated and drug-naïve patients with Parkinson disease: A pilot study

J. Troisi, A. Landolfi, C. Vitale, K. Longo, A. Cozzolino, M. Squillante, M.C. Savanelli, P. Barone, M. AmbonI (Salerno, Italy)

1:15pm-2:45pm: A patient with myotonic dystrophy type 1 and parkinsonism

J. Choi, J. Lee, H. Kim, B. Jeon (Seoul, Republic of Korea)

1:15pm-2:45pm: A pilot study of plasma ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) as a potential blood-based biomarker in Parkinson’s disease

A. Ng, YJ. Tan, ZH. Lu, S. Ng, E. Ng, F. Setiawan, N. Keong, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: A post-mortem and in vivo study of neuroinflammation and Toll like-receptors in Parkinson’s disease

A. Kouli, W.L. Kuan, K. Scott, X. He, R. Barker, C. Williams-Gray (Cambridge, United Kingdom)

1:15pm-2:45pm: A promising model for cognitive dysfunction in Parkinson’s Disease by AAV-mediated alpha-synuclein overexpression in hippocampus

E. Cinar, G. Yalcin-Cakmakli, E. Saka, A. Ulusoy, B. Tel, B. Elibol (Ankara, Turkey)

1:15pm-2:45pm: A Psychometric Analysis of the MDS UPDRS-II and III in Early Parkinson’s disease: Do the Numbers Add Up?

A. Regnault, B. Boroodjerdi, J. Meunier, M. Bani, S. Cano (Lyon, France)

1:15pm-2:45pm: A review of modifiers of Parkinsonism in the Leucine-rich repeat kinase 2 (LRRK2) population

J. Staisch (Portland, OR, USA)

1:15pm-2:45pm: A Study of Pain in Parkinson’s Disease

S. Meenakshisundaram, B. Samivel, T. Sundaram, LN. Ranganathan (Chennai, India)

1:15pm-2:45pm: A Theranostic Approach to Intervene the Link Between Parkinson’s Disease (PD) and LRRK – 2 Mutation

P. Basavaraju, P. Moorthi (Coimbatore, India)

1:15pm-2:45pm: A unique case of DAT positive Parkinson’s disease along with a mutable Huntington’s gene

P. Prakash, S. Baser, M. Flaherty, T. Leichliter (Pittsburgh, PA, USA)

1:15pm-2:45pm: Abnormal Functional Connectivity in Cerebellar Locomotor Region is associated with the severity of freezing of gait in patients with Parkinson’s disease

K. Bearti, A. Suppa, S. Pietracupa, N. Upadhyay, C. Giannì, G. Leodori, F. Di Biasio, N. Modugno, N. Petsas, G. Grillea, A. Zampogna, A. Berardelli, P. Pantano (Rome, Italy)

1:15pm-2:45pm: Abnormal NMDA-related Electrophysiology in Parkinson Disease Dementia

J.C. Chen, H.M. Heng, C.H. Tsai (Taichung, Taiwan)

1:15pm-2:45pm: Absence of the nigrosome-1 area in 3 tesla resonance and its relation with hyperechogenicity of the substantia nigra in patients with Parkinson’s disease

J.S. Bestoso, M. Pérez Akly, L. Ciancaglini, C. Stefani C, J. Norscini, J. Funes, C. Besada, D. Bauso (Buenos Aires, Argentina)

1:15pm-2:45pm: Acid sphingomyelinase deficiency rescues mitochondrial dysfunction in gba-/- zebrafish (Danio rerio)

M. Keatinge, L. Trollope, H. Mortiboys, O. Bandmann (Sheffield, United Kingdom)

1:15pm-2:45pm: Acoustic analysis and subjective vocal perception of Parkinson’s disease patients and healthy control and the relation to depression and quality of life

Y. Manor, S. Naor, D. Shpunt, N. Diamant, N. Zivion, L. Hayat, A. Yaron, A. Hillel, A. Ezra, I. Opher, Y. Hauptman, R. Aloni-Lavi, A. Faust-Socher, T. Gurevich (Tel Aviv, Israel)

1:15pm-2:45pm: Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

1:15pm-2:45pm: Adult neurogenesis is impaired in pink1-/- zebrafish (Danio rerio)

S. Bandmann, M. Keatinge, M. Placzek, O. Bandmann (Sheffield, United Kingdom)

1:15pm-2:45pm: Affective Theory of Mind Impaired in Parkinson’s Disease: Negative- and Neutral- specific impairments of Emotion State Decoding

C.H. Tan, S.C. Tu, R.L. Yu (Kaohsiung, Taiwan)

1:15pm-2:45pm: Agreement Between Patients and Informants on the Penn Parkinson’s Daily Activity Questionnaire

B. Deck, S. Xie, J. Rick, A. Chen-Plotkin, J. Duda, J. Morley, N. Dahodwala, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

1:15pm-2:45pm: Alpha-synuclein oligomer and rotenone treatments injury the dopaminergic neuron via inhibiting the expression of gene SEMA6D

X. Yingyu (Guangzhou, China)

1:15pm-2:45pm: Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease

Y. Xiaodong, Q. Yiwei, X. Shaoqing, C. Shengdi, X. Qin (Shanghai, China)

1:15pm-2:45pm: Alteration to Basal Ganglia Morphology in Freezing of Gait in Parkinson’s Disease

N. D'Cruz, G. Vervoort, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

1:15pm-2:45pm: Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson’s disease

JY. Lee, YK. Kim, SA. Shin, SH. Seo, JS. Lee, YS. Lee, JM. Jeong, B. Jeon (Seoul, Republic of Korea)

1:15pm-2:45pm: Altered amplitude of low-frequency fluctuations and functional connectivity in excessive daytime sleepiness in Parkinson disease

X. Wang, K. Zhang (Nanjing, China)

1:15pm-2:45pm: Altered connectivity in ventral and dorsal attentional networks in patients with Parkinson’s disease: Association with freezing of gait

I. Maidan, Y. Jacob, N. Giladi, J. Hausdorff, A. Mirelman (Tel Aviv, Israel)

1:15pm-2:45pm: Altered putamen and cerebellum connectivity between different subtypes of Parkinson’s disease

B. Shen, L. Zhang (Nanjing, China)

1:15pm-2:45pm: Alzheimer’s Disease Genetic Risk Variants Predict Cognitive Decline in Parkinson’s Disease

T. Tropea, K. Maddy, J. Rick, J. Trojanowkski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)

1:15pm-2:45pm: Amyloid deposition affects cognitive manifestations in Parkinson’s disease: The PPMI dataset

E. Fiorenzato, R. Biundo, D. Cecchin, AC. Frigo, L. Weis, J. Kim, A. Strafella, A. Antonini (Venice, Italy)

1:15pm-2:45pm: Amyloid PET and cognition in Parkinson’s disease

T. Melzer, M. Stark, D. Myall, R. Keenan, L. Livingston, M. Almuqbel, M. MacAskill, T. Pitcher, K. Horne, S. Grenfell, M. Pascoe, B. Young, J. Wang, S. Marsh, D. Miller, J. Dalrymple-Alford, T. Anderson (Christchurch, New Zealand)

1:15pm-2:45pm: An analysis of cortical thickness in early Parkinson’s disease patients with cognitive impairment

M. Mei, K. Nie, Y. Gao, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm: An investigation of the relationship between computational neuropsychological testing outcomes and symptoms of Parkinson’s disease

L. Jiang, Y. Zhu, Z. Ye, Z. Pei, L. Chen (Guangzhou, China)

1:15pm-2:45pm: Analysis of gene polymorphisms of Parkinson’s disease in Han Chinese population

H. Jin, J. Zhang, K. Li, C. G, C. Liu (Suzhou, China)

1:15pm-2:45pm: Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study

A. Guerra, A. Suppa, V. D'Onofrio, F. Di Stasio, F. Asci, G. Fabbrini, A. Berardelli (Rome, Italy)

1:15pm-2:45pm: Antibodies to alpha-Synuclein in Parkinson disease

D. Labunskiy (Santa Rosa, CA, USA)

1:15pm-2:45pm: Apathy in Parkinson’s disease is associated with abnormal alpha oscillatory behaviour during incentivized movement

M. Zhu, S. Garg, A. HajiHosseini, S. Appel-Cresswell, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm: Apathy in Parkinson’s disease is associated with REM sleep behavior disorder

F. Ricordeau, M. Figorilli, A. Marques, T. Vidal, B. Beudin, B. Debilly, P. Derost, M. Puligheddu, F. Durif, M.L. Fantini (Clermont Ferrand, France)

1:15pm-2:45pm: Apathy in rapid eye movement sleep behaviour disorder is associated with serotonin depletion in the raphe nuclei

T. Barber, L. Griffanti, K. Muhammed, D. Drew, K. Bradley, D. McGowan, M. Crabbe, C. Lo, C. Mackay, M. Husain, M. Hu, J. Klein (Oxford, United Kingdom)

1:15pm-2:45pm: Application of the Movement Disorder Society Prodromal Criteria in healthy G2019S-LRRK2 carriers

A. Mirelman, R. Saunders-Pullman, R. Alcalay, S. Shustak, A. Thaler, B. Cohen, A. Hillel, T. Gurevich, D. Raymond, H. Mejia-Santana, L. Ozelius, L. Clark, M. Gana-Weisz, A. Bar-Shira, A. Orr-Urtreger, S. Bressman, K. Marder, N. Giladi (Tel Aviv, Israel)

1:15pm-2:45pm: Applying Intervention Mapping methodologies to enhance Data Completeness in Movement Disorders-related Scales

C. Goetz, S. Luo, G. Stebbins (Chicago, IL, USA)

1:15pm-2:45pm: Are the MDS-UPDRS-based composite scores clinically applicable?

N. Kovács, A. Juhász, Z. Aschermann (Pécs, Hungary)

1:15pm-2:45pm: Assessing hemifacial spasm: The HFSG scale

S. Simoni, N. Tambasco, E. Sacchini, E. Marsili, P. Nigro, E. Brahimi, M. Romoli, F. Paolini Paoletti, M. Filidei, P. Calabresi (Perugia, Italy)

1:15pm-2:45pm: Assessing the Quality of Economic Evaluation of Treatment Options for Parkinson’s disease Using the Quality of Health Economic Studies (QHES) Scale

M. Azharuddin, M. Adil, P. Ghosh, M. Sharma (New Delhi, India)

1:15pm-2:45pm: Assessing working memory dysfunction with letter n-back functional MRI task in early-stage Parkinson’s disease

A. Martin-Bastida, N. Lao-Kaim, S. Pietracupa, M. Wall, A. Roussakis, Y. Xing, S. Schwarz, D. Auer, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Assessment of clinical peculiarities of violations of vertical vision in patients with Parkinson’s disease

M. Salokhiddinov, D. Akramova (Tashkent city, Uzbekistan)

1:15pm-2:45pm: Assessment of pain and its correlation with quality of life in Parkinson’s disease

K. Anand, A. Agrawal, P. Kumar (New Delhi, India)

1:15pm-2:45pm: Association analysis of miRNA-linked variants with Parkinson’s disease and multiple system atrophy in a large Chinese population

X.J. Gu, Y.P. Chen, B. Cao, R.W. Ou, Q.Q. Wei, B. Zhao, Y. Wu, W. Song, H.F. Shang (Chengdu, People’s Republic of China)

1:15pm-2:45pm: Association between MAPT haplotype and hippocampal repetition suppression in Parkinson’s disease

E. Yoon, T. Alrazi, M. Ramezani, I. Kathol, J. Sarna, T. Hammer, L. Derwent, J. Cheetham, Z. Gan-Or, G. Rouleau, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Association between peripheral inflammation and DATSCAN data of the striatal nuclei in different motor subtypes of Parkinson Disease

H. Sanjari Moghaddam, F. Ghazi Sherbaf, M H. Aarabi, M. Mojtahed Zadeh (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Association between serum Vitamin D levels and Parkinson’s disease: A systematic review and meta-analysis

XY. Luo, R. Ou, HF. Shang (Chengdu, China)

1:15pm-2:45pm: Association between sleep duration and subsequent risk of Parkinson´s disease and survival: Data from NEDICES study

R. López-Blanco, A. Sánchez-Ferro, J. Benito-León, F. Bermejo-Pareja, E. de Pablo-Fernández (Alcalá de Henares, Spain)

1:15pm-2:45pm: Association of GALC, ZNF184 and rs2280104 with PD in southern Chinese

G. Li, J. Liu, S.S. Cui, J.J. Du, P.C. Zhang, J.F. Ma, S.D. Chen (Shanghai, China)

1:15pm-2:45pm: Association of GBA polymorphisms and mutations with dementia in Parkinson disease: A 7-year study of three population-based incident cohorts

K. Lunde, J. Chung, I. Dalen, K. Pedersen, J. Linder, M. Domellöf, E. Elgh, A. Macleod, C. Tzoulis, J. Larsen, O. Tysnes, L. Forsgren, C. Counsell, G. Alves, J. Maple-Grødem (Stavanger, Norway)

1:15pm-2:45pm: Association of Olfaction dysfunction with Brain Microstructure in Prodromal Parkinson disease

H. Sanjari Moghaddam, M.H. Aarabi, Z. Valitabar (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Asymmetric olfactory deficit in H&Y stage-1 early onset Parkinson’s disease

J. Wang, R. Stanford, L. Spreen, T. Subramanian, Q. Yang (Hershey, PA, USA)

1:15pm-2:45pm: Automated Differential Diagnosis of Parkinsonian Syndromes Using FDG-PET Metabolic Brain Network Analysis

T. Rus, P. Tomše, L. Jensterle, M. Grmek, Z. Pirtošek, D. Eidelberg, C. Tang, M. Trošt (Ljubljana, Slovenia)

1:15pm-2:45pm: Automated immunohistochemical detection of pathological alpha-synuclein in human tissue biopsy

TS. Tsao, A. Racolta, H. Zhang, M. Robida, J. Pugh, T. Beach, T. Kremer, C. Czech, K. Taylor, W. Zago, L. Pestic-Dragovich, L. Tang, S. Dziadek (Tucson, AZ, USA)

1:15pm-2:45pm: Autonomic Dysfunction in Parkinson’s Disease: Role of New Surrogate Markers

S. Menon R, A. Lutterotti (Ernakulam, India)

1:15pm-2:45pm: B lymphocytes may be protective in early Parkinson’s disease and in an animal model of dopaminergic cell death

K. Scott, C. Williams-Gray, R. Wijeyekoon, S. Hayat, K. Hall, P. Tyers, R. Mathews, R. Barker, M. Clatworthy (Cambridge, United Kingdom)

1:15pm-2:45pm: Balance and gait analysis of GBA mutation carriers with Parkinson’s disease (PD)

A. Gera, J. Okeefe, N. Purcell, C. Huml, S. Ruehl, B. Ouyang, G. Pal (Chicago, IL, USA)

1:15pm-2:45pm: BDNF(V66M), EIF4G1(R1205H), VPS35(D620N) gene polymorphisms in South Indian PD Patients

T. Syed, T. S.D, S. Meka, S. Kumar, S. Thandra, V. Kutala, R. Kandadai, R. Borgihain (Hyderabad, India)

1:15pm-2:45pm: Behavior and PET Imaging Study in Parkinsonian Rat Models Induced by Injection of 6-OHDA in Medial Forebrain Bundle

W. Xian, Q. Guo, L. Jiang, Z. Pei, L. Chen (Guangzhou, China)

1:15pm-2:45pm: Beta burst coupling across the motor circuit in patients with Parkinson’s disease

G. Tinkhauser, F. Torrecillos, Y. Duclos, H. Tan, A. Pogosyan, P. Fischer, R. Carron, M. Welter, C. Karachi, W. Vandenberghe, B. Nuttin, T. Witjas, J. Régis, J. Azulay, A. Eusebio, P. Brown (Oxford, United Kingdom)

1:15pm-2:45pm: Bidirectional gut-to-brain and brain-to-gut propagation of α-synuclein pathology in non-human primates

ML. Arotçarena, S. Dovero, A. Prigent, M. Bourdenx, P. Aubert, I. Trigo, G. Porras, ML. Thiolat, M. Tasselli, C. Estrada, A. Recasens, J. Blesa, M. Herrero, N. Carillo, M. Vila, J. Obeso, P. Derkinderen, B. Dehay, E. Bezard (Bordeaux, France)

1:15pm-2:45pm: Biomarkers of rapid progression of cognitive decline in Parkinson’s disease

S. Martinez-Horta, F. Sampedro, J. Pagonabarraga, J. Marin-Lahoz, A. Horta-Barba, H. Bejr-Kasem, I. Aracil, J. Perez-Perez, MA. Boti, J. Kulisevsky. (Barcelona, Spain)

1:15pm-2:45pm: Blink Recovery Pattern and Somatosensory Evoked Blink Reflex in patients with Parkinsonism syndromes

S. Tandra, R.M. Mridula, R. Borgohain (Hyderabad, India)

1:15pm-2:45pm: Blockade D1-like and D2-like dopamine receptors within nucleus accumbens attenuate hyperalgesia responses in a 6-OHDA induced parkinson’s disease rat model

L. Li, CJ. Mao, XQ. Zhang, F. Wang, CF. Liu (Su Zhou, China)

1:15pm-2:45pm: Bmal1 deficiency aggravates MPTP-induced dopaminergic cell death through promoting neuroinflammation

C. Gu, W. Liu, X. Gu, F. Wang, Y. Yang, C. Liu (Su Zhou, China)

1:15pm-2:45pm: Bone health and laboratorial correlations of Vitamin D in Parkinson’s disease

L. Leandro, C. Moreira, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Brain Mechanisms of Associative Memory Deficits in Parkinson’s Disease without Dementia

T. Alrazi, J. Cheetham, L. Derwent, A. Hanganu, T. Hammer, I. Kathol, M. Kibreab, S. Lang, N. Ouellet, J. Provost, M. Ramezani, J. Sarna, E. Yoon, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Brain network activation (BNA): A new biomarker for Parkinson’s disease?

S. Hassin-Baer, Z. Pereman, R. Yahav, S. Israeli-Korn, G. Yahalom, S. Benizri, R. Shani-Hershkovich, G. Issachar, A. Geva, O. Cohen (Ramat Gan, Israel)

1:15pm-2:45pm: Brain Network Connectivity Measured by Diffusion Tensor Imaging Predicts Prognosis in Parkinson’s Disease

S.M. Fereshtehnejad, N. Abbasi, Y. Zeighami, K. Larcher, R. Postuma, A. Dagher (Montreal, QC, Canada)

1:15pm-2:45pm: Brain Perfusion pattern linked to depressive state in Parkinson’s: An arterial spin labelling MRI study

Y. Xing, S. Naidu, S. Schwarz, N. Bajaj, D. Auer (Nottingham, United Kingdom)

1:15pm-2:45pm: Brain responses evoked by thalamic and subthalamic deep brain stimulation

J. Hirschmann, C. Hartmann, J. Vesper, L. Wojtecki, M. Butz, A. Schnitzler (Düsseldorf, Germany)

1:15pm-2:45pm: Bupropion causing misdiagnosis in brain dopamine transporter imaging for parkinsonism

E. Honkanen, N. Kemppainen, T. Noponen, M. Seppänen, J. Joutsa, V. Kaasinen (Turku, Finland)

1:15pm-2:45pm: Burden of Eye disease in Parkinson’s disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:15pm-2:45pm: Can Preoperative Dopamine Transporter Imaging Predict the Long-Term Outcome of Deep Brain Stimulation in Patients with Parkinson’s Disease?

B. Thomsen, S. Jensen, A. Clausen, M. Karlsborg, E. Brødsgaard, L. Friberg, M. Lonsdale, A. Løkkegaard (Copenhagen, Denmark)

1:15pm-2:45pm: Cardiac sympathetic denervation can predict the wearing-off phenomenon in patients with Parkinson’s disease

S. Yoo, JS. Kim, JE. Lee, KS. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism

M. Bhargava, S. Bhargava (Kanpur, India)

1:15pm-2:45pm: Catecholamines interrelation in plasma of early diagnosed treatment-naive patients with Parkinson disease

D. Khasanova, Z. Zalyalova, M. Ugrumov (Kazan, Russian Federation)

1:15pm-2:45pm: Categorising visual hallucinations in early Parkinson’s disease

B. Clegg, G. Duncan, T. Khoo, R. Barker, D. Burn, A. Yarnall, R. Lawson (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Cell and animal models lacking RAB39B show biochemical and behavioural phenotypes that model aspects of Parkinson’s disease

Y. Gao, G. Wilson, S. Stephenson, K. Bozaoglu, M. Dottori, P. Thomas, P. Lockhart (Melbourne, Australia)

1:15pm-2:45pm: Cerebellar atrophy in different motor and non-motor subtypes of Parkinson’s disease

XX. Ma, CM. Li, W. Su, HB. Chen (Beijing, China)

1:15pm-2:45pm: Cerebellar tDCS modulates negative emotions recognition in Parkinson’s disease

F. Ruggiero, F. Cortese, M. Nigro, T. Bocci, L. Borellini, M. Vergari, F. Mameli, A. Priori, R. Ferrucci (Milano, Italy)

1:15pm-2:45pm: Cerebrospinal fluid protein biomarkers in PD patients after DBS-STN surgery: A retrospective analysis of patients that underwent surgery between 1993 and 2001

R. Constantinescu, K. Blennow, L. Rosengren, B. Eriksson, T. Gudmundsdottir, Y. Jansson, A. Renck, F. Bergquist (Gothenburg, Sweden)

1:15pm-2:45pm: Change of Cognition Functions after Subthalamic Nucleus-Deep Brain Stimulationin in Parkinson’s Disease

L. Wu, L. Chen (Guangzhou, China)

1:15pm-2:45pm: Changes in cortical thickness in patients with early Parkinson’s disease at different Hoehn and Yahr stages

Y. Gao, K. Nie, M. Mei, M. Guo, Z. Huang, L. Wang, J. Zhao, B. Huang, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm: Characteristics in relation to demographic, disease related and clinical variables of a cohort of Parkinson’s disease patients from Northern Sri Lanka

A. Keshavaraj, S. Kunathilagam (Jaffna, Sri Lanka)

1:15pm-2:45pm: Characteristics of brain mri in patient with Parkinson’s disease

K. Merryn, A. Shahab, R. Faisal, S. Marisdina, E. Bahar (Palembang, Indonesia)

1:15pm-2:45pm: Characterization of the gastrointestinal dysfunction in mice overexpressing the human mutation (A53T) of alpha-synuclein

S. Diwakarla, R. Constable, O. Artaiz, D. Finklestein, J. Berger, J. Furness (Melbourne, Australia)

1:15pm-2:45pm: Characterization of the preclinical model parkinQ311X

A. Ciammola, M. Regoni, D. Mercatelli, L. Croci, G. Serratto, S. Fasano, L. Murru, S. Novello, M. Pingue, V. Silani, G. Consalez, F. Valtorta, M. Passafaro, M. Morari, J. Sassone (Milan, Italy)

1:15pm-2:45pm: Cholinergic basal forebrain and hippocampal structure influence visuospatial function in Parkinson’s disease

R. Berlot, S. Brezovar, B. Koritnik, Z. Pirtošek, N. Ray (Ljubljana, Slovenia)

1:15pm-2:45pm: Circadian modifications in Parkinson disease

S. Guo (Wuhan, China)

1:15pm-2:45pm: Classification of Dopaminergic-State and Motor Activity by Theta, Beta and Gamma Activity in Parkinson’s Disease

I. Weber, C. Oehrn, N. Apetz, T. Dembek, F. Jung, E. Florin, L. Timmermann (Marburg, Germany)

1:15pm-2:45pm: Classifying carriers of the G2019S mutation in the LRRK2 gene using MRI radiomics analysis

M. Artzi, A. Thaler, A. Orr Urterger, T. Hendler, M. Sela, A. Mirelman, D. Ben Bashat (Tel Aviv, Israel)

1:15pm-2:45pm: Clinical and functional network features of visuoperceptual disturbances in Parkinson’s disease

K. Kawabata, H. Watanabe, R. Ohdake, K. Hara, E. Bagarinao, T. Kato, A. Ogura, M. Masuda, T. Yokoi, T. Tsuboi, M. Katsuno, G. Sobue (Nagoya, Japan)

1:15pm-2:45pm: Clinical and imaging progression in the PARS cohort: Results from 6 years of observation

D. Jennings, A. Siderowf, S. Eberly, D. Oakes, M. Stern, K. Marek (New Haven, CT, USA)

1:15pm-2:45pm: Clinical characteristics of frailty in Parkinson’s disease

M. Peball, P. Mahlknecht, M. Werkmann, K. Marini, F. Murr, H. Herzmann, H. Stockner, R. de Marzi, B. Heim, A. Djamshidian, P. Willeit, J. Willeit, S. Kiechl, M. Nocker, K. Mair, W. Poewe, K. Seppi (Innsbruck, Austria)

1:15pm-2:45pm: Clinical correlates of stuttering in advanced Parkinson’s disease

T. Tsuboi, H. Watanabe, Y. Tanaka, R. Ohdake, M. Hattori, K. Kawabata, K. Hara, D. Nakatsubo, S. Maesawa, Y. Kajita, T. Wakabayashi, M. Katsuno, G. Sobue (Nagoya, Japan)

1:15pm-2:45pm: Clinical differences between Parkinson’s disease motor phenotypes. Results from the COPPADIS Study Cohort

I. Legarda Ramirez, B. Vives Pastor, M. Menéndez González, M. Blázquez Estrada, M. Seijo, M. Lage Castro, R. Vázquez Gómez, J. Ruíz Martínez, A. Bergareche Yarza, C. Valero, MM. Kurtis, JR. Pérez Sánchez, O. de Fábregues-Boixar, J. González Ardura, C. Prieto, C. Ordás Bandera, P. Mir, P. Martínez Martín, D. Santos García (Palma de Mallorca, Spain)

1:15pm-2:45pm: Clinical evaluation of genetic changes of polymerase chain reaction in patients with PD at early stage

M. Salokhiddinov (Tashkent, Uzbekistan)

1:15pm-2:45pm: Clinical evaluation of insomnia in Parkinson’s disease and its effect on the quality of life of patients

M. Salokhiddinov. (Tashkent, Uzbekistan)

1:15pm-2:45pm: Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder

Y. Liu, XY. Zhu, XJ. Zhang, Y. Feng, SH. Kuo, W. Ondo, YC. Wu (Shanghai, China)

1:15pm-2:45pm: Clinical heterogeneity of excessive daytime sleepiness in Parkinson’s disease

O. Levin, O. Iakovleva, M. Poluektov (Moscow, Russian Federation)

1:15pm-2:45pm: Clinical phenotype analysis of Parkinson’s disease associated with LRRK2 variants in Chinese Han population

C. Gu, K. Li, J. Zhang, H. Jin, Y. Ge, C. Liu (Suzhou, China)

1:15pm-2:45pm: Clinical predictors of screen-defined dementia in early Parkinson’s

F. Baig, M. Lawton, M. Rolinski, C. Ruffmann, T. Barber, J. Klein, C. Lo, Y. Ben-Shlomo, M. Hu (Oxford, United Kingdom)

1:15pm-2:45pm: Clinical subtypes of Parkinson’s disease based on nonmotor symptoms: A cluster analysis

X. Xu, P. Chan (Beijing, China)

1:15pm-2:45pm: Closed loop spinal cord stimulation restores locomotion and desynchronizes corticostriatal beta oscillations

A. Yadav, E. Borda, M. Nicolelis (Durham, NC, USA)

1:15pm-2:45pm: Cognitive function is associated with Balance in Parkinson Disease: Cross-sectional study in Cali-Colombia

B. Munoz, J. Orozco, J. Valderrama, A. Navarro, Y. Castaño, J. Arango (Cali, Colombia)

1:15pm-2:45pm: Cognitive Impairment and Depression in Patients with Parkinson’s Disease

XD. Qu, SS. Li (Lanzhou, China)

1:15pm-2:45pm: Cognitive networks in Parkinson’s Disease Mild Cognitive Impairment: Salience Network disruption without gray matter loss

I. Aracil, F. Sampedro, J. Marin, J. Perez, H. Bejr-Kasem, S. Martinez-Horta, A. Horta, M. Boti, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Combined Neurite Orientation Dispersion and Density Imaging and Myelin Imaging Provide New Insights to White Matter Changes of the Neurocognitive-psychiatric Disorder in Parkinson’s Disease

C. Andica, K. Kamagata, T. Hatano, A. Saito, Y. Takenaka, T. Ogawa, G. Oyama, Y. Shimo, M. Hori, N. Hattori, S. Aoki (Tokyo, Japan)

1:15pm-2:45pm: Combining PET imaging and blood metabolomics data to improve machine learning models for Parkinson’s disease diagnosis

E. Glaab, A. Greuel, J.P. Trezzi, C. Jäger, Z. Hodak, L. Timmermann, M. Tittgemeyer, N. Diederich (Esch-sur-Alzette, Luxembourg)

1:15pm-2:45pm: Commonalities of prodromal non-motor symptoms between movement disorders

M. Moscovich, S. Heinzel, R. Postuma, R. Reilmann, T. Klockgether, H. Jacobi, G. Höglinger, D. Berg (Kiel, Germany)

1:15pm-2:45pm: Communication and Swallowing Disorders in People with Parkinson’s disease: A National Survey on Everyday Impacts and Service Access

M. Swales, D. Theodoros, A. Hill, T. Russell (St. Lucia, Australia)

1:15pm-2:45pm: Comorbid REM sleep behavior disorder and impulse control disorder symptoms in early parkinson’s disease: The PPMI cohort

M.L. Fantini, F. Durif, JC. Corvol, D. Weintraub, C. Caspell-Garcia (Clermont Ferrand, France)

1:15pm-2:45pm: Comparison of thermal sensation and pain thresholds in LRRK2 carriers and non carriers with Parkinson’s disease

A. Khlebtovsky, Y. Roditi, R. Djaldetti (Petach Tikva, Israel)

1:15pm-2:45pm: Comparison of Treatment Effectiveness of Conventional Functional Training (CFT) to Occupational Therapy (OT) Multi-modal CASH Program (CASH) in Improving Non-motor Symptoms and Carer Stress of Parkinson’s (PD) Patient at Intermediate and Advanced State

T. Tang, R. Wong, C. Lau, A. Chan, D. Chan, X.L. Zhu, W.S. Poon, V. Mok (Hong Kong)

1:15pm-2:45pm: Comparisons of cerebral glucose metabolism and striatal DAT binding in PD patients with and without RBD

P. Wu, Q. Xu, J. Wang, C. Zuo (Shanghai, China)

1:15pm-2:45pm: Compensatory functional activations in early-stage Parkinson’s disease: a cross-sectional motor planning fMRI study

A. Martin-Bastida, N. Lao-Kaim, S. Pietracupa, A. Roussakis, Y. Xing, S. Schwarz, D. Auer, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: Complementary value of MRI-based differential diagnosis in parkinsonism

S. Kim, E. Oh, Y. Lim, J. Ham, J. Lee, E. Sohn, A. Lee (Daejeon, Republic of Korea)

1:15pm-2:45pm: Computational and Biochemical analysis of lipid raft proteins: A new perspective approach to understand the progression of late onset Parkinson’s disease

L. Thangamani, S. Piramanayagam (Coimbatore, India)

1:15pm-2:45pm: Contribution of individual motor signs to striatal dopamine deficiency in parkinsonism

E. Mäkinen, J. Joutsa, E. Jaakkola, T. Noponen, J. Johansson, M. Pitkonen, R. Levo, T. Mertsalmi, F. Scheperjans, V. Kaasinen (Turku, Finland)

1:15pm-2:45pm: Correlation between mood and behavioral disorders and quality of life in patients with Parkinson’s disease

O. Galceava, A. Mita, L. Giurgiulescu, R. Latea, V. Tudorica, D. Gheonea, D. Stanca (Craiova, Romania)

1:15pm-2:45pm: Cortical correlates of dual-task turning with and without freezing of gait

M. Mancini, S. Stuart (Portland, OR, USA)

1:15pm-2:45pm: Curcumin improves cognitive function in rotenone-induced rat model of Parkinson’s disease (PD)

S. Madiha, S. Haider (Karachi, Pakistan)

1:15pm-2:45pm: DAT-imaging and clinical phenotypes of Parkinson’s disease

S. Varanese, S. Ruggieri, N. Modugno (Pozzilli, Italy)

1:15pm-2:45pm: Daughter’s ataxia reveals father’s genetic Parkinsonism. The first reported case of Spinocerebellar ataxia -15 presenting with levodopa responsive hemi Parkinsonism

M. Ghaly, C. Wools, A. Evans, E. Storey (St Albans, Australia)

1:15pm-2:45pm: Decreased amyloid-beta in patients with Idiopathic Parkinson’s Disease and white matter hyperintensities

I. Markaki, S. Klironomos, P. Svenningsson (Stockholm, Sweden)

1:15pm-2:45pm: Decreased interhemispheric homotopic connectivity in Parkinson’s disease patients with freezing of gait: A resting state fMRI study

L. Li, Y. Yuan, K. Zhang (Nanjing, China)

1:15pm-2:45pm: Degeneration of vagus nerve but not of accessory and phrenic nerve in Parkinson’s disease revealed by high-resolution ultrasound

U. Walter, P. Tsiberidou, M. Kersten, A. Storch, M. Löhle (Rostock, Germany)

1:15pm-2:45pm: Deletion of GBA2 in neuronopathic Gaucher’s disease medaka can’t rescue the phenotype

E. Nakanishi, N. Uemura, H. Akiyama, M. Kinoshita, H. Yamakado, S. Takeda, Y. Hirabayashi, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm: Depression (BDI-II) in Parkinson’s disease: Prevalence, types, and variables associated to major, minor and subclinical depression in COPPADIS cohort

M. Aguilar, P. Pastor, M. Almeria, I. Alvarez, S. Arribas, I. Gonzalez, M. Sierra, J. Infante, A. Avila, M. Catalan, F. Alonso, C. Villanueva, L. Lopez, V. Nogueira, V. Puente, A. Crespo, J. Garcia, F. Damas, E. Pacheco, P. Martínez-Martin, D. Santos, G. Coppadis (Terrassa, Spain)

1:15pm-2:45pm: Depression and associated factors in nondemented Chinese patients with Parkinson’s disease

J. Zhu, L. Zhang (Nanjing, China)

1:15pm-2:45pm: Depression, apathy, fatigue in Parkinson with or without STN DBS

L. Al-Nakeeb, M. Panisset (Montreal, QC, Canada)

1:15pm-2:45pm: Depressive symptoms effect subjective sleep quality in Parkinson’s Disease with and or without cognitive disturbance

J. Zhu, L. Zhang (Nanjing, China)

1:15pm-2:45pm: Depressive symptoms may predict the future development of freezing of gait in patients with Parkinson’s disease: Findings from a 5-year prospective study

T. Herman, S. Shema Shiratzky, L. Arie, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:15pm-2:45pm: Derivation and characterization of Parkinson’s disease related pattern using functional magnetic resonance imaging

W. Sako, T. Abe, S. Haji, N. Murakami, Y. Izumi, M. Harada, R. Kaji (Tokushima, Japan)

1:15pm-2:45pm: Determination of falling direction in Parkinson’s disease patients using a wearable sensor

Y. Okuma, H. Mitoma (Izunokuni, Japan)

1:15pm-2:45pm: Determining the effect of the HNMT, STK39 and NMD3 polymorphisms on the incidence of Parkinson’s disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese populations

Y.P. Chen, B. Cao, R.W. Ou, Q.Q. Wei, X.P. Chen, B. Zhao, Y. Wu, W. Song, H.F. Shang (Chengdu, People’s Republic of China)

1:15pm-2:45pm: Diabetes Mellitus Alters Resting State Functional Networks in Early-Stage Parkinson’s Disease without Dementia

R. Ye, T. Shen, L. Xu, X. Guan, M. Zhang, B. Zhang (Hangzhou, China)

1:15pm-2:45pm: Diagnostic accuracy and imaging correlates of the Free and Cued Selective Reminding Test for screening mild cognitive impairment in Parkinson’s disease

J. Pagonabarraga, A. Horta-Barba, J. Marín-Lahoz, S. Martinez-Horta, H. Bejr-Kasem, I. Aracil, J. Pérez-Pérez, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Diagnostic utility of a targeted resequencing technique of next generation sequencing in detecting copy number changes in PARK2

NY. Kim, SK. Hong, YE. Kim, HI. Ma, YJ. Kim (Anyang, Republic of Korea)

1:15pm-2:45pm: Dietary habits, motor and cognitive impairment in Parkinson’s Disease

A. Pilotto, MC. Rizzetti, m. Oppini, C. passeri, A. Alberici, R. Turrone, M. Cosseddu, D. Placidi, M. Turla, b. Borroni, R. Lucchini, A. Padovani (Brescia, Italy)

1:15pm-2:45pm: Differences in the Unified Dyskinesia Rating Scale based on age, Parkinson´s Disease and Dyskinesias duration

E. Cubo, S. Luo, S. Calvo, P. Martinez-Martín (Burgos, Spain)

1:15pm-2:45pm: Diffusion tensor imaging of olfactory tract in Parkinson’s disease

P. Nigro, N. Tambasco, A. Chiappiniello, S. Simoni, E. Brahimi, M. Romoli, F. Paolini Paoletti, M. Filidei, P. Calabresi (Perugia, Italy)

1:15pm-2:45pm: Diminished fMRI global signal differences between eyes closed and eyes open resting state in RBD and PD

J. Suescun, M. Schiess, L. Giancardo, R. Castriotta, T. Ellmore (Houston, TX, USA)

1:15pm-2:45pm: Direction of Turning in Parkinson’s Disease: More Affected Side or Less Affected Side?

S.M. Cheon, J.W. Kim (Busan, Republic of Korea)

1:15pm-2:45pm: Discriminating Idiopathic PD Patients and Controls in PPMI Using Integrative Multi-Modal Neuroimaging Analysis with Graph Convolutions

F. Wang, X. Zhang, L. He, C. Henchcliffe (New York, NY, USA)

1:15pm-2:45pm: Disrupted Amplitude of Low-frequency Fluctuations and Causal Connectivity in Parkinson’s Disease with Apathy

Y. Shen, J. Li, Y. Yuan, X. Wang, M. Wang, J. Wang, H. Zhang, L. Zhu, K. Zhang (Nanjing, China)

1:15pm-2:45pm: Dissociate effect of dopaminergic therapy in reward expectation and prediction error in PD patients with comorbid impulse control disorder

JF. Martin-Rodriguez, A. Rodriguez-Baena, L. Garrote Espina, P. Alvarez Toledo, S. Jesus, C. Mendez Barrio, A. Adarmes Gomez, F. Carrillo Garcia, M. Carballo Cordero, P. Mir (Seville, Spain)

1:15pm-2:45pm: Distinct Blood Leukocytes Expression Profiles of Long Non-coding RNAs and mRNAs in Parkinson’s disease patients

Y. Fan, Z. Xue (Wuhan, China)

1:15pm-2:45pm: Distinct effects of apathy and dopamine on effort-based decision making in Parkinson’s disease

C. Le Heron, O. Plant, S. Manohar, Y. Ang, M. Jackson, G. Lennox, M. Hu, M. Husain (Oxford, United Kingdom)

1:15pm-2:45pm: Distinct networks contribute to the dysexecutive and posterior cortical cognitive syndromes of cognitive impairment in Parkinson’s Disease

S. Lang, S. Jobert, B. Mejia-Constain, C. Degroot, A. Lafontaine, A. Hanganu, P. Bellec, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Distinguishing ON from OFF Motor State by Phone Attribute Codes in Patients with Parkinson’s Disease

K. Abedinpour, A. Asaei, M. Cernak, D. Milana, T. Advani, F. Pfister, U. Fietzek (Munich, Germany)

1:15pm-2:45pm: Does dopaminergic denervation of specific anatomical regions of the basal ganglia correlate with clinical features of Parkinsonism: A quantitative DaTscan study

M. Salgado, S. Aggarwal, J. Muller, S. Singh, D. Ney (Brooklyn, NY, USA)

1:15pm-2:45pm: Does the Basal Ganglia Dysfunction Affect Pisa Syndrome in Parkinson’s Disease?

Y.E. Huh, W-H. Chung, J. Youn, J.H. Ahn, J.W. Cho (Seongnam, Republic of Korea)

1:15pm-2:45pm: Dopaminergic and Metabolic Imaging in Parkinson’s Disease motor subtypes and their relations to parkinsonian tremor

J. Zhao, L. Li, P. Wu, J. Wang, C.T. Zuo (Shanghai, China)

1:15pm-2:45pm: Dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder

P. Wu, H. Yu, Z. Huang, C. Zuo (Shanghai, China)

1:15pm-2:45pm: Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease

YL. Tang, J. Wang (Shanghai, China)

1:15pm-2:45pm: Dual task walking differentially affects toe clearance in Lewy body disease: A contributor to dynamic falls risk?

L. Alcock, R. McArdle, L. Aubrook, B. Galna, A. Thomas, L. Rochester (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Dyspnea in Parkinson’s disease: A biomarker of disease’s severity?

G. Baille, T. Perez, F. Machuron, L. Defebvre, C. Chenivesse, C. Moreau (Lille, France)

1:15pm-2:45pm: Early cortical signature of development of visual hallucinations in ‘de novo’ Parkinson’s disease

H. Bejr-kasem, J. Pagonabarraga, S. Martínez-Horta, F. Sampedro, J. Marin-Lahoz, A. Horta-Barba, I. Aracil-Bolaños, J. Perez-Perez, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Early gastrointestinal dysfunction is predictive of faster progression in Parkinson’s disease

M. Camacho, J. Evans,, D. Breen, G. Cummins, R. Wijeyekoon, K. Scott, T. Stoker, R. Barker, C. Williams-Gray (Cambridge, United Kingdom)

1:15pm-2:45pm: Early stage Parkinson’s disease phenotypes

J. Toledo, MC. Rodriguez-Oroz, W. Ondo (Houston, TX, USA)

1:15pm-2:45pm: Early synaptic loss and synaptic instability in a mouse model of prodromal Parkinson’s disease

Y. Hatanaka, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm: Early-onset Parkinson’s disease in seven patients with heterozygosity for parkin mutation

C. Lima, A. Novo, M. Sousa, M. Almeida, A. Morgadinho, C. Januário (Coimbra, Portugal)

1:15pm-2:45pm: Early-onset parkinsonism and epilepsy: A Tunisian family carrying a novel SYNJ1 mutation

S. Ben Romdhan, R. Zouari, S. Sakka, N. Farhat, O. Hdiji, H. Haj Kacem, M. Dammak, C. Mhiri (Sfax, Tunisia)

1:15pm-2:45pm: eEF1A2 and Prdx1 as possible new targets for Parkinson’s disease therapeutics

W. Wirakiat, P. Dharmasaroja (Bangkok, Thailand)

1:15pm-2:45pm: EEG microstates changes in response to increase in dopaminergic stimulation in treated typical Parkinson’s disease patients without clinical fluctuations

V. Cortés, I. Serrano, N. Mendes, M. Del Castillo, A. Arroyo, J. Andreo, M. Del Valle, J. Herreros, JP. Romero, (Madrid, Spain)

1:15pm-2:45pm: Effect of bedtime levodopa/carpidopa/entacapone (Stalevo®) on sleep disturbance in patients with Parkinson’s disease with motor fluctuation

KW. Park, HS. Ryu, MS. Kim, NR. Choi, SJ. Chung (Seoul, Republic of Korea)

1:15pm-2:45pm: Effect of CDNF on non-motor symptoms like motivation, fear, stress and depression-like behavior

P. Stepanova, M. Voutilainen, E. Laakkonen, M. Airavaara, V. Voikar, P. Piepponen, R. Tuominen, M. Saarma (Helsinki, Finland)

1:15pm-2:45pm: Effect of deep brain stimulation on clinical outcome in Parkinson’s disease patients with different genetic status

M. Kestenbaum, R. Schvartz, Y. Balash, A. Hilel, A. Mirelman, N. Giladi, T. Gurevich (Tel Aviv, Israel)

1:15pm-2:45pm: Effect of different normative samples and cut-off values on determination of cognitive impairment in the Parkinson’s Progression Marker Initiative

K. Wyman-Chick, D. Weintraub, P. Martin, L. Erickson, M. (Saint Paul, MN, USA)

1:15pm-2:45pm: Effect of Glucocerebrosidase enzymatic activity on neural activation during a cognitive task in Parkinson’s disease patients

M. Ramezani, J.S. Provost, N. Auclair-Ouellet, I. Kathol, A. Hanganu, M. Kibreab, J. Cheetham, T. Hammer, L. Derwent, A. Robichaud, R. Chiang, J. Sarna, SP. Sardi, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Effect of levodopa on fronto-parietal network connectivity in freezing of gait in Parkinson’s disease

B. Bluett, E. Bayram, S. Banks, X. Zhuang, V. Mishra, Z. Yang, C. Bird, D. Cordes, Z. Mari, I. Litvan, K. Sreenivasan (Las Vegas, NV, USA)

1:15pm-2:45pm: Effect of medication on lexical tone production in Cantonese patients with Parkinson’s Disease

A. Chan, S. Chen, J. Shao, C.C. Zhang, I. Lam, S. Pang, V. Ngan, J. Tam, W.C. Yang, J. Ngan, S. Pinto (Hong Kong)

1:15pm-2:45pm: Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease

H. Jeong, S. Chung, J. Oh, J. Kim, P. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Effect of Urinary Dysfunction on Fatigue Syndrome in Parkinson’s disease

V. Datieva, O. Levin (Moscow, Russian Federation)

1:15pm-2:45pm: Effective Tools for Mild Cognitive Impairment Level I Criteria of Movement Disorder Society: Utility of Screening Tests and Their Interconversion

RL. Yu, WJ. Lee, JY. Li, YY. Chang, CC. Chen, JJ. Lin, YF. Sung, TK. Lin, RS. Chen, YH. Yang, YW. Yang, SJ. Wang, JL. Hsu, HC. Wang, JL. Fuh (Tainan, Taiwan)

1:15pm-2:45pm: Effects of age, motor severity and disease duration on finger tapping movement under dual-task in Parkinson’s disease patients

A. Miyake, T. Yamamoto, H. Kawasaki, N. Tamura, N. Araki (Saitama prefecture, Japan)

1:15pm-2:45pm: Effects of computerized cognitive training, with and without concurrent exercise, on executive functions in Parkinson’s disease

M. Fernandez-del-Olmo, JA. Sánchez-Molina, H. Fernandez-Lago, L. Morenilla-Burlo, J. Gómez-Varela, N. Fogelson (A Coruña, Spain)

1:15pm-2:45pm: Effects of Glial Heme Oxygenase-1 on Neuronal Alpha-Synuclein in the GFAP.HMOX1 Mouse Model of Parkinson’s Disease

M. Cressatti, W. Song, A. Turk, C. Galindez, H. Schipper (Montreal, QC, Canada)

1:15pm-2:45pm: Effects of N-methyl-D-aspartate receptor antagonist in Parkinson’s disease with dementia

Y. Chung, I. Song, L. Lee (Incheon, Republic of Korea)

1:15pm-2:45pm: Effects of neural stem cell transplantation on the differentiation of dopaminergic neurons in the substantia nigra and changes to rotational behavior of Parkinson’s disease rats

J.J. Xiao, X.P. Wang (Shanghai, China)

1:15pm-2:45pm: Effects of orthostatic hypotension and supine hypertension on cognition in Parkinson’s disease

H. Jeong (Changwon, Republic of Korea)

1:15pm-2:45pm: Effects of subthalamic nucleus deep brain stimulation in Parkinson’s disease are mediated by a prefronto-cerebellar-striatal loop

H. Hanssen, J. Steinhardt, A. Al-Zubaidi, A. Muenchau, M. Heldmann, P. Schramm, A. Neumann, D. Rasche, A. Saryyeva, J. Voges, I. Galazky, L. Buentjen, H. Heine, J. Krauss, V. Tronnier, T. Muente, N. Brueggemann (Luebeck, Germany)

1:15pm-2:45pm: Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study

W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, F. Pagan, B. Flatau-Baqué, J. Csikós, A. Blitzer (Wolfach, Germany)

1:15pm-2:45pm: Efficacy of liquid sinemet on non-motor symptoms in Parkinson’s disease

M. Danoudis, R. Iansek, C. Boon (Cheltenham, Australia)

1:15pm-2:45pm: Enhanced cingulate activity while anticipating pain – evidence for altered ‘top down’ processing of pain in PD

S. Martin, A. Jones, C. Brown, C. Kobylecki, M. Silverdale (Manchester, United Kingdom)

1:15pm-2:45pm: Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity

G. Ho, T. Imberdis, S. Nuber, U. Dettmer, D. Selkoe (Boston, MA, USA)

1:15pm-2:45pm: Epidemiological risk factors on cognition with PD patients in male: A cross-sectional study from southwest of China

Y. Wu, RW. Ou, H. Liu, QQ. Wei, XJ. Gu, Q. Han, LY. Zhang, W. Song, B. Cao, YP. Chen, B. Zhao, HF. Shang (Chengdu, China)

1:15pm-2:45pm: Erotophonophilia and severe impulse control disorder in a patient with Parkinson’s disease

C. vander Linden, H. Colle, D. Colle, J. Jankovic (Ghent, Belgium)

1:15pm-2:45pm: Evaluation of affective temperament and bipolarity among patients with Parkinson’ s disease

Y. Degirmenci, K. Altinbas, H. Kececi (Duzce, Turkey)

1:15pm-2:45pm: Evaluation of bradykinesia in Parkinson’s disease using a computerised evolutionary algorithm

R. Newby, S. Muhamed, P. Kempster, J. Alty, S. Jamieson, J. Cosgrove, S. Smith (Leeds, United Kingdom)

1:15pm-2:45pm: Evaluation of impulsivity in Parkinson’ s disease

Y. Degirmenci, K. Altinbas, H. Kececi (Duzce, Turkey)

1:15pm-2:45pm: Evaluation of non motor fluctuations in Parkinson disease by a visual analogue scale in Surgical Candidates

JPh. Azulay, C. Brefel-Courbon, C. Tranchant, F. Fluchere, A. Eusebio, M. Vaugoyeau, C. Magnaudet, T. Witjas (Marseille, France)

1:15pm-2:45pm: Evaluation of Non-motor Symptoms of Parkinson’s Disease Patients in a Hong Kong Chinese population using the HK-NMSQuest

V. Luk, N. Cheung, WC. Fong, G. Chan, A. Chan, KW. Fong, J. Lo, M. Ismail, J. Li, F. Chan, S. Chan, C. Chau, C. Ho, K.F. Leung, J. Lui, C. Wong, D. Chau, B. Chee, CW. Woo (Kowloon, Hong Kong)

1:15pm-2:45pm: Evaluation of pain in Parkinson’s disease

B. Durmus, O. Yilmaz Kusbeci, I. Inci (Izmir, Turkey)

1:15pm-2:45pm: Evaluation of Parkinson’s Disease Psychosis Requires Structured Questioning of Patients and Caregivers

P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, C. Andersson, S. Andes, D. Fredericks, A. Shim (Miami, FL, USA)

1:15pm-2:45pm: Evaluation of the Effect of STN-DBS on the Gastrointestinal Symptoms in Patients with Parkinson’s Disease via GIQLI

A. Yilmaz, E. Okuyucu, M. Ugur (Hatay, Turkey)

1:15pm-2:45pm: Evaluation of the Loneliness among the Caregivers of Parkinson Disease Dementia

M. Gultekin, A. Ekinci (Kayseri, Turkey)

1:15pm-2:45pm: Evaluation of the relationship between Leucine-rich repeat kinase 2 (LRRK2) S1647T variants and smoking with risk of Parkinson’s Disease in the Singapore population

ZH. Lu, S. Ng, X.X. Huang, E. Ng, M. Parimelalagan, F. Setiawan, L. Tan, W.L. Au, K.Y. Tay, ZY. Xu, K. Prakash, E.K. Tan (Singapore)

1:15pm-2:45pm: Evidence for dysregulation of inflammatory mechanisms involving the NF-κB complex in the living parkinsonian brain

S. Benoit, H. Xu, R. Alexandrova, G. Kaur, B. Thiruvahindrapuram, M. Hebb (London, ON, Canada)

1:15pm-2:45pm: Examination of paravertebral muscular force in camptocormia

R. Wolke, N. Margraf, J. Kuhtz-Buschbeck, G. Deuschl (Kiel, Germany)

1:15pm-2:45pm: Examining Parkinson’s disease psychosis treatment outcomes in the real world: The insyte observational study

J. Goldman, D. Fredericks, C. Heywood, A. Ryan, A. Shim (Chicago, IL, USA)

1:15pm-2:45pm: Executive dysfunctions and behavioral changes in early drug-naïve patients with Parkinson’s disease

S. Li, R. Ou, X. Yuan, H. Liu, Y. Bing, Q. Wei, W. Song, B. Cao, Y. Chen, H. Shang (Chengdu, China)

1:15pm-2:45pm: Executive Function and Frontoparietal Network Association in Freezing of Gait

E. Bayram, K. Sreenivasan, S. Banks, X. Zhuang, V. Mishra, D. Cordes, B. Bluett (Las Vegas, NV, USA)

1:15pm-2:45pm: Expanding the canvas of PARKIN mutations and clinical phenotypes in familial and early onset Parkinson’s disease patients

S. Pandey, L. Tomar, S. Kumar, B. Thelma (New Delhi, India)

1:15pm-2:45pm: Experimental rotenone model

X. Djakhangir, A. Ziyoda (Tashkent, Uzbekistan)

1:15pm-2:45pm: Exploring novel diffusion-derived biomarkers in Parkinson’s disease Freezing of Gait

B. Bluett, E. Bayram, S. Banks, Z. Mari, K. Sreenivasan, X. Zhuang, Z. Yang, C. Bird, D. Cordes, I. Litvan, V. Mishra (Las Vegas, NV, USA)

1:15pm-2:45pm: Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson’s disease

T. Stojkovic, E. Stefanova, I. Soldatovic, V. Markovic, I. Stankovic, F. Agosta, I. Petrovic, S. Galantucci, M. Filippi, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm: Eye Movements during Reading in Parkinson’s Disease: A Pilot Study

J. Waldthaler, P. Tsitsi, G. Öqvist Seimyr, M. Nilsson Benfatto, P. Svenningsson (Marburg, Germany)

1:15pm-2:45pm: Factors Associated with Non-adherence to Pharmacotherapy in Patients with Parkinson´s Disease Who Take Three and More Daily Doses of Dopaminergic Drugs

I. Straka, M. Škorvánek, M. Grofik, K. Danterová, M. Minár, J. Benetin, P. Valkovič (Bratislava, Slovakia)

1:15pm-2:45pm: Fatigue and depression are predictors of the tremor form of Parkinson’s disease

E. Kolupaeva, I. Zhukova, M. Nikitina, N. Zhukova, A. Latypova, O. Izhboldina, I. Mironova, M. Zhestikova, M. Titova, J. Kislukhina (Tomsk, Russian Federation)

1:15pm-2:45pm: FDG-PET and metabolomics in PD-associated GBA variants

A. Greuel, JP. Trezzi, E. Glaab, C. Jäger, Z. Hodak, K. Lohmann, C. Klein, L. Timmermann, A. Drzezga, M. Tittgemeyer, Y. Ma, N. Diederich, C. Eggers (Marburg, Germany)

1:15pm-2:45pm: Feasibility aspects of evaluating neuroplastic changes after balance training in Parkinson´s disease: A pilot randomised controlled trial

H. Johansson, M. Hagströmer, U. Ekman, B. Leavy, M. Freidle, E. Schalling, P. Svenningsson, E. Franzén (Huddinge, Sweden)

1:15pm-2:45pm: Feasibility of a health game on cognition in Parkinson’s disease: Interim analyses of the Parkin’Play Study

S. vd Weijer, M. Kuijf, A. Duits, R. Kessels, N. de Vries, S. Köhler, G. Tissingh, B. Bloem (Maastricht, Netherlands)

1:15pm-2:45pm: Flexed posture: Relationships with non-motor impairments and upper body activities in people with Parkinson’s disease

A. Forsyth, R. Joshi, N. Allen, C. Canning, S. Paul (Sydney, Australia)

1:15pm-2:45pm: Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed parkinsonian rats: Implications for learning and memory

E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

1:15pm-2:45pm: Freezing of Gait in Parkinson’s Disease: Clinico-biochemical Observations

B. Mondal, R. Banerjee, K. Chatterjee, A. Roy, S. Shubham, P. Basu, S. Choudhury, H. Kumar (Kolkata, India)

1:15pm-2:45pm: Freezing of gait recognition in Parkinson’s disease: A subject independent objective method

V. Rama Raju (Hyderabad, India)

1:15pm-2:45pm: Frequency of the LRRK2 and GBA mutations in Russian population with Parkinson’s disease

K. Senkevich, A. Emelyanov, M. Nikolaev, T. Usenko, A. Bezrukova, I. Miliukhina, A. Kopytova, A. Timofeeva, A. Yakimovsky, S. Pchelina (Saint-Petersburg, Russian Federation)

1:15pm-2:45pm: Frontal midline theta activity is reduced during cognitive control in Parkinson’s disease

A. Singh, S. Richardson, N. Narayanan, J. Cavanagh (Iowa City, IA, USA)

1:15pm-2:45pm: Frontal-subcortical cognitive impairments in Parkinson’s patients with freezing of gait

J. Garcia-Caldentey, MA. Prats-Sedano, E. Estelrich-Peyret, PJ. Garcia-Ruiz (Palma de Mallorca, Spain)

1:15pm-2:45pm: Full sequencing and haplotype analysis reveals LRRK2 protective haplotype in REM sleep behavior disorder

B. Ouled Amar-Bencheikh, J. Ruskey, I. Arnulf, Y. Dauvilliers, C. Charley Monaca, V. Cochen De-Cock, JF. Gagnon, D. Spiegelman, M. Hu, B. Högl, A. Stefani, L. Ferini-Strambi, G. Plazzi, E. Antelmi, P. Young, A. Heidbreder, B. Mollenhauer, F. Sixel-Döring, C. Trenkwalder, W. Oertel, J. Montplaisir, R. Postuma, G. Rouleau, Z. Gan-Or (Montreal, QC, Canada)

1:15pm-2:45pm: Functional Balance and Neuromuscular Strength Difficulties Like Fracture Predictors in a Parkinsonian Population

L. Leandro, C. Moreira, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Functional connectivity changes in relation to dopaminergic decline in Parkinson’s over time: A resting-state fMRI and 11C-PE2I PET imaging study

W. Li, N. Lao-Kaim, A. Roussakis, A. Martín-Bastida, N. Valle-Guzman, G. Paul, E. Soreq, R. Daws, T. Foltynie, R. Barker, A. Hampshire, P. Piccini (London, United Kingdom)

1:15pm-2:45pm: FuRST2.0: Development of a modified functional rating scale for use in premanifest and early-manifest Huntington’s disease

R. Fuller, P. Feigenbaum, C. Fitzer-Attas, N. La Pelle, S. Luo, C. Sampaio, G. Stebbins (Princeton, NJ, USA)

1:15pm-2:45pm: Further insights into excitatory-inhibitory balance of the primary motor cortex in Parkinson’s disease: A triple-pulse stimulation study

Y. Shirota, Y. Terao, Y. Ugawa, R. Hanajima (Tokyo, Japan)

1:15pm-2:45pm: Gastrointestinal Symptoms and Enteric Nerve Dysfunction in A53T Mice

R. McQuade, P. Rajasekhar, S. Diwakarla, R. Constable, D. Poole, J. Berger, D. Finkelstein, J. Furness (Melbourne, Australia)

1:15pm-2:45pm: Gaucher’s disease (GD) and Parkinsonism: An analysis from patients to relatives

I. Trezzi, E. Monfrini, E. Cassinerio, I. Motta, F. Nascimbeni, F. Carubbi, N. Bresolin, G. Comi, M. Cappelllini, A. Di Fonzo (Milan, Italy)

1:15pm-2:45pm: GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease

H. Yamakado, M. Ikuno, H. Akiyama, L. Parajuli, K. Taguchi, J. Hara, N. Uemura, Y. Hatanaka, K. Higaki, M. Tanaka, M. Koike, Y. Hirabayashi, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm: Gender differences in olfactory dysfunctions in Sardinian patients affected by Parkinson’s disease

P. Solla, C. Masala, A. Cannas, G. Defazio (Cagliari, Italy)

1:15pm-2:45pm: Gender Differences in Parkinson’s disease: Transcranial Magnetics Stimulation Study of Newly Diagnosed Drug-Naïve PD Patients

K. Kolmancic, R. Alfonso, Z. Pirtosek, K. Bhatia, M. Kojovic (Ljubljana, Slovenia)

1:15pm-2:45pm: Gender effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson’s disease

S. Cui, S. Chen (Shanghai, People’s Republic of China)

1:15pm-2:45pm: Gender-specific pattern of sensori-motor network connectivity in early untreated Parkinson’s disease patients

R. De Micco, F. Esposito, F. Di Nardo, A. De Mase, G. Caiazzo, A. Giordano, M. Siciliano, G. Tedeschi, A. Tessitore (Naples, Italy)

1:15pm-2:45pm: Genetic variations of SNCA and striatal dopaminergic dysfunction in patients with Parkinson’s disease

MJ. Lee, K. Pak (Busan, Korea)

1:15pm-2:45pm: Genome-wide association studies of motor and cognitive progression in Parkinson’s disease

M. Tan, L. Hubbard, M. Lawton, S. Kanavou, N. Wood, J. Hardy, Y. Ben-Shlomo, N. Williams, D. Grosset, H. Morris (London, United Kingdom)

1:15pm-2:45pm: Gut microbiota geography in Parkinson’s disease in the world

M. Hirayama, T. Maeda, T. Minato, M. Itoh, J. Takeda, T. Hamaguchi, M. Katsuno, K. Ohno (Nagoya, Japan)

1:15pm-2:45pm: Heart rate variability and Sympathetic skin response in Parkinson’s disease

M. Ben Djebara, A. Nasri, S. Mrabet, A. Gargouri, I. Kacem, R. Gouider (La Manouba, Tunisia)

1:15pm-2:45pm: Higher Levels of Serum Uric Acid Associated with Motor & Non-Motor Symptoms in Early Parkinson’s Disease

N. Chia, W.L. Au, Z. Lu, X. Huang, S. Ng, S. Acharyya, F. Setiawan, E. Ng, K.Y. Tay, E.K. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Higher motor cortex connectivity with subthalamic stimulation than with levodopa: A resting state fMRI study in Parkinson’s disease

R. Jech, K. Mueller, F. Růžička, Š. Holiga, T. Ballarini, O. Bezdicek, H. Möller, J. Vymazal, E. Růžička, L. Schroeter, D. Urgošík (Prague, Czech Republic)

1:15pm-2:45pm: Hypertriglyceridemia is associated with Parkinson disease mild cognitive impairment (PD-MCI)

S. Ng, KY. Tay, X. Huang, NSY. Chia, S. Archaryya, F. Setiawan, ZH. Lu, J. Tan, YL. Ng, MC. Wen, A. Ng, W. Au, EK. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Hypometabolism of the posterior parietal cortex in Parkinson’s disease with mild cognitive impairment predicts the conversion to dementia: 5-year longitudinal observations

KW. Park, NR. Choi, JH. Ko, SJ. Kim, SJ. Chung, CS. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Hypometabolism of the posterior parietal cortex in PD with dementia: [18F]FDG PET study

N.R. Choi, K.W. Park, M.S. Kim, J.H. Ko, S.J. Kim, S.J. Chung, C.S. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Identification and analysis of differential miRNA in exosomes of dopaminergic neurons overexpressing α-synuclein

Y. Liang, D. Lin, T. Zhou, D. Zheng (Guangzhou, China)

1:15pm-2:45pm: Identification of gut microbial genes in Parkinson’s disease by shotgun metagenomic analysis

Y. Qian, X. Yang, S. Xu, S. Chen, Q. Xiao (Shanghai, China)

1:15pm-2:45pm: Identification of putative serum biomarkers for parkin-related Parkinson’s disease by metabolome analysis

T. Ogawa, T. Hatano, A. Okuzumi, S. Ueno, A. Mori, Y. Oji, M. Fujimaki, T. Koinuma, S. Saiki, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm: Identifying delirium and it prevalence in idiopathic Parkinson’s disease

R. Lawson, C. McDonald, D. Burn (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Identifying the neural correlates of doorway freezing in Parkinson’s disease

E. Matar, J. Shine, P. Ward, M. Gilat, K. Ehgoetz-Martens, M. Frank, A. Moustafa, S. Naismith, S. Lewis (Sydney, Australia)

1:15pm-2:45pm: Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea

F. Pagan, W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, B. Flatau-Baqué, J. Csikós, A. Blitzer (Washington, DC, USA)

1:15pm-2:45pm: Impact of Late-onset REM Sleep Behavior Disorder on the Symptoms of Parkinson’s Disease

Y. Saitoh, M. Murata, Y. Takahashi (Tokyo, Japan)

1:15pm-2:45pm: Impact of postural stability estimation in HY scale. (Pull test Vs. limits of stability assessment)

P. Serrano, A. Arroyo, J. Andreo, V. Cortés, JP. Romero (Madrid, Spain)

1:15pm-2:45pm: Impaired performance on measures of goal-directed behavior are associated with greater caregiver burden in Parkinson’s disease

N. Dahodwala, C. McMillan, C. Nwadiogbu, J. Liu, A. Miller, M. Pavon, D. Weintraub, L. Massimo (Philadelphia, PA, USA)

1:15pm-2:45pm: Impaired stopping reversed through dopamine replacement in Parkinson’s disease

S. Choudhury, A. Roy, R. Singh, K. Chatterjee, B. Mondal, M. Baker, S. Baker, H. (Kolkata, India)

1:15pm-2:45pm: Impaired topographic organization in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson’s disease

Y.B. Hou, Q.Q. Wei, R.W. Ou, J. Yang, W. Song, Q.Y. Gong, H.F. Shang (Chengdu, People’s Republic of China)

1:15pm-2:45pm: Improvement of antisaccade amplitude by the STN DBS and target eccentricity

A. Yugeta, Y. Terao, Y. Ugawa (Tokyo, Japan)

1:15pm-2:45pm: Improvement of Levodopa-Responsive Chronic Pain after STN-DBS in Parkinson’s disease

A. Gera, G. Pal (Chicago, IL, USA)

1:15pm-2:45pm: Impulse control disorders and compulsive behaviours in Parkinson’s disease. Results from the COPPADIS Study Cohort

S. Jesus Maestre, M. Labrador Espinosa, A. Adarmes Gómez, C. Mendez Barrio, JC. Martinez Castrillo, A. Alonso Cánovas, P. Sanchez Alonso, S. Novo Ponte, MG. Alonso Losada, N. Lopez Ariztegui, J. Segundo Rodriguez, MI. Morales Casado, I. Gaston, F. Lacruz Bescos, P. Clavero Ibarra, J. Kulisevsky, J. Pagonabarraga Mora, B. Pascual Sedano, P. Martinez Martín, D. Santos Garcia, P. Mir Rivera, G. Coppadis Study (Seville, Spain)

1:15pm-2:45pm: Impulsive-Compulsive Behaviour disorders: A longitudinal study in de-novo in Parkinson’s disease patients

L. Ricciardi, C. Lambert, M. Edwards, F. Morgante (London, United Kingdom)

1:15pm-2:45pm: In vivo MRI signatures of hippocampal subfield pathology in patients with Parkinson’s disease and psychosis

A. Lenka, M. Ingalhalikar, A. Shah, J. Saini, S. Hegde, A. Shyam Sundar, R. Yadav, P. Pal (Bangalore, India)

1:15pm-2:45pm: In vivo staging of pathology in REM sleep behaviour disorder

K. Knudsen, T. Fedorova, A. Hansen, M. Sommerauer, M. Otto, K. Svendsen, A. Nahimi, M. Stokholm, N. Pavese, C. Beier, D. Brooks, P. Borghammer (Aarhus, Denmark)

1:15pm-2:45pm: Increased Parkin expression in a PARK20 (SYNJ1 mutation) iPSCs-based model

W. Mandemakers, R. Masius, E. Berger, M. Grochowska, M. Quadri, M. Minneboo, M. Picillo, P. Barone, J. Schwamborn, V. Bonifati (Rotterdam, Netherlands)

1:15pm-2:45pm: Influence of dopamine deficiency on interhemispheric crosstalk in Parkinson’s disease

P. Loehrer, F. Nettersheim, I. Weber, F. Jung, L. Timmermann (Marburg, Germany)

1:15pm-2:45pm: Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?

I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

1:15pm-2:45pm: Integrated whole exome sequencing and chromosomal microarray in familial Parkinson’s disease

L. Robak, R. Du, B. Yuan, S. Gu, Z. Akdemir, J. Jankovic, J. Lupski, J. Shulman (Houston, TX, USA)

1:15pm-2:45pm: Interaction between MAPT H1 and APOE4 in early Parkinson’s Disease

C. Lambert, Z. Ahmed, P. Ostergaard, L. Ricciardi, F. Morgante, T. Barrick, M. Edwards (London, United Kingdom)

1:15pm-2:45pm: Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synuclenopathies

I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, M.M. Carmona-Abellan, I. Marcilla-Garcia, L. Alonso-Herrero, G. Marti-Andres, T. Tuñon-Alvarez, M.R. Luquin-Piudo (Pamplona, Spain)

1:15pm-2:45pm: Interaction of TDP-43 with IAPP in pancreatic beta cells of patients with sinucleinopathies

R. Valenti-Azcarate, I. Martinez-Valbuena, C. Arean-Cuns, I. Marcilla-García, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

1:15pm-2:45pm: Intercultural differences in the frequency of impulsive control disorders in Parkinson’s disease

J. Martinez Castrillo, C. Lastras Fernandez-Escandon, I. Domingez Zabaleta, C. Estevez Fraga, G. Sanchez Diez, A. Alonso Canovas (Madrid, Spain)

1:15pm-2:45pm: Interest in Genetic Testing in PD Patients with DBS

A. Fraint, G. Pal, L. Verhagen, D. Hall, K. Marder (Chicago, IL, USA)

1:15pm-2:45pm: Intrinsic functional connectivity correlates of anxiety in cognitively unimpaired drug-naïve patients with Parkinson’s disease

R. De Micco, M. Siciliano, F. Di Nardo, A. De Mase, A. Giordano, G. Caiazzo, F. Esposito, G. Tedeschi, A. Tessitore (Naples, Italy)

1:15pm-2:45pm: Investigating the influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

YJ. Tan, Y. Zhao, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan, A. Ng (Singapore, Singapore)

1:15pm-2:45pm: Investigating the role of microRNA biogenesis pathway in neuroprotection in primary neuronal culture model of Parkinson’s disease

J. Konovalova, S. Er, S. Soleimanbeigi, P. Chmielarz, A. Domanskyi (Helsinki, Finland)

1:15pm-2:45pm: Investigation of the incidences of non-motor symptoms in first-degree relatives and the spouses of patients with Parkinson’s disease

J.B. Liu, X.J. Zhang, C.F. Liu (Yangzhou, China)

1:15pm-2:45pm: Is Heart Rate variability a differential biomarker in REM sleep behavior disorder, Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy?

F. Bernhard, G. Mayer, K. Kesper, A. Bauer, A. Janzen, E. Sittig, W. Cassel, D. Vadasz, N. Mix, V. Ries, W. Oertel (Marburg, Germany)

1:15pm-2:45pm: Is REM sleep behavior disorder associated with excessive daytime sleepiness in military veterans with Parkinson’s disease?

A. Sarwar, S. Moore (Houston, TX, USA)

1:15pm-2:45pm: Is repetitive transcranial magnetic stimulation an effective tool to treat pain in Parkinson’s Disease?

M. Bonello, T. Nurmikko, M. Steiger (Liverpool, United Kingdom)

1:15pm-2:45pm: Item Response Theory Analysis of the Unified Dyskinesia Rating Scale Items

C. Goetz, S. Luo, G. Stebbins (Chicago, IL, USA)

1:15pm-2:45pm: Knockdown of eEF1A2 reduced neuronal survival in a SH-SY5Y cellular model of Parkinson’s disease through the PI3K/Akt/mTOR pathway

K. Khwanraj, P. Dharmasaroja (Bangkok, Thailand)

1:15pm-2:45pm: Kufor-Rakeb syndrome and a rare ATP13A2 missense mutation in a Portuguese patient

H. Salhi, S. Montaut, D. Devos, J. Chelly, F. Galacteros, P. Brugières, P. Remy, G. Fenelon (Créteil, France)

1:15pm-2:45pm: Kufor-Rakeb Syndrome with prominent dystonia and new mutations in ATP13A2 gene in two siblings

T. Yamasaki, J. Thakkar, L. Noll, J. Slevin (Lexington, KY, USA)

1:15pm-2:45pm: L-Dopa Responsiveness is Correlated to Fluorodeoxyglucose Metabolism and Dopamine Transporter Availability in Parkinson’s Disease

D. Su, W. Hu, X. Zhao, Z. Liu, H. Ma, J. Zhou, T. Feng (Beijing, China)

1:15pm-2:45pm: Lack of TMEM230 mutations in patients with familial and sporadic Parkinson’s disease in a Taiwanese population

T. Fan, C. Lin, H. Lin, M. Chen, R. Wu (Taoyuan, Taiwan)

1:15pm-2:45pm: Levels of plasma alpha-synuclein as measured using Single Molecule Array technology is higher in Parkinson’s disease compared to controls and is not influenced by LRRK2 genotype

YJ. Tan, A. Ng, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Levodopa and subthalamic stimulation do not have the same effect on subjective cost for distal and axial efforts in Parkinson’s disease

C. Atkinson-Clement, E. Cavazzini, C. Baunez, A. Zénon, S. Pinto, F. Fluchère, E. Robin, T. Witjas, JP. Azulay, A. Eusebio (Aix-en-Provence, France)

1:15pm-2:45pm: Levodopa-induced dyskinesia in Parkinson’s disease: Sleep matters

N. Amato, M. Manconi, J.C. Möller, S. Sarasso, P. Stanzione, C. Städler, A. Kaelin-Lang, S. Galati (Lugano, Switzerland)

1:15pm-2:45pm: Listen to the heart: Do loud vagal rhythms disharmonize the autonomic symphony in Parkinson’s disease patients with the LRRK2 mutation?

C. Carricarte Naranjo, C. Marras, N. Visanji, D. Cornforth, L. Sanchez-Rodriguez, B. Schuele, S. Goldman, M. Estévez Báez, P. Stein, A. Lang, H. Jelinek, A. Machado García (Havana, Cuba)

1:15pm-2:45pm: Long-term and dopamine dependent dynamics of subthalamic nucleus local field potentials in Parkinson’s disease

N. Drummond, K. Udupa, U. Saha, T. Hoque, J. Saravanamuttu, A. Fasano, A. Lozano, M. Hodaie, S. Kalia, R. Chen (Toronto, ON, Canada)

1:15pm-2:45pm: Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions

F. Pagan, W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, B. Flatau-Baqué, J. Csikós, A. Blitzer (Washington, DC, USA)

1:15pm-2:45pm: Longitudinal changes in Neuromelanin MRI Signal in Parkinson’s Disease

R. Gaurav, N. Pyatigorskaya, C. Ewenczyk, R. Valabregue, K. Evans, I. Arnulf, M. Vidailhet, S. Lehéricy (Paris, France)

1:15pm-2:45pm: Longitudinal decline in white matter integrity in Parkinson’s disease: An analysis of Parkinson Progression Markers Initiative diffusion tensor imaging data

K. Taylor, F. Sambataro, A. Bertolino, J. Dukart (Basel, Switzerland)

1:15pm-2:45pm: Longitudinal development of nigral iron load in Parkinson’s Disease

S. Franthal, L. Pirpamer, C. Rodler, N. Homayoon, M. Koegl, P. Katschnig-Winter, K. Wenzel, C. Langkammer, S. Ropele, R. Schmidt, P. Schwingenschuh (Graz, Austria)

1:15pm-2:45pm: Longitudinal MRI to predict cognitive impairment in Parkinson’s disease

T. Melzer, D. Myall, L. Livingston, M. Almuqbel, M. MacAskill, T. Pitcher, K. Horne, S. Grenfell, M. Pascoe, D. Miller, R. Keenan, J. Dalrymple-Alford, T. Anderson (Christchurch, New Zealand)

1:15pm-2:45pm: Loss of VPS29 disrupts retromer function and synaptic transmission, leading to neurodegeneration in Drosophila

H. Ye, D. Li-Kroeger, Y. Li, H. Bellen, J. Shulman (Houston, TX, USA)

1:15pm-2:45pm: Lottery choice task as a detect tool for PD patients with pathological gambling

W. Liu, R. Wu, J. Goh (Hualien, Taiwan)

1:15pm-2:45pm: Low body weight is associated with poor functional status in Parkinson’s disease (PD)

HF. Chan, N. Cheung, D. Chau, CW. Woo, B. Chee, A. Leung, S. Or, WC. Fong (Hong Kong)

1:15pm-2:45pm: LRRK2 and GBA genetic mutations are not uncommon in an unselected Ashkenazi elderly cohort with PD

S. Isaacson, J. Isaacson (Boca Raton, FL, USA)

1:15pm-2:45pm: LRRK2 p.Leu119Pro and p.Leu488Pro in a family with neuropathologycally confirmed Parkinson´s disease without Lewy bodies

L. Vela-DeSojo, J. Hoenicka, P. Pire-Garcia, C. Guerrero, M. Osuna-Lopez, S. Ocaña-Lopez (Alcorcón, (Madrid), Spain)

1:15pm-2:45pm: Lysosphingolipids accumulation in macrophage model of Gaucher disease

M. Nikolaev, A. Kopytova, K. Senkevich, A. Emelyanov, G. Baydakova, E. Zakharova, G. Salogub, S. Pchelina (Gatchina, Russian Federation)

1:15pm-2:45pm: MANF improves the MPP+/MPTP-induced Parkinson’s disease via improvement of mitochondrial function and inhibition of oxidative stress

Y. Liu, J. zhang, Q. Cai, H. Sun, L. Jin (Shanghai, China)

1:15pm-2:45pm: Measuring salivary cortisol levels in persons with Parkinson’s disease (PD)

A. Hiller, B. Lobb, J. Proulx, J. Quinn (Portland, OR, USA)

1:15pm-2:45pm: Meta-Analysis of Short-afferent inhibition and Cognitive Impairment in Parkinson’s Disease

J.F. Martin-Rodriguez, P. Mir (Seville, Spain)

1:15pm-2:45pm: Microarray analysis upon an synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease

E. Tao (Guangzhou, China)

1:15pm-2:45pm: Microbiota DNA in the blood of patients with Parkinson’s disease

S.Q. Xu, Y.W. Qian, X.D. Yang, S.D. Chen, Q. Xiao (Shanghai, China)

1:15pm-2:45pm: Microglial activation, white matter and hippocampal damage correlate with cognitive impairment in chronic cerebral hypoperfused and MPTP-lesioned mice

Y. Gao, H. Tang, K. Nie, R. Zhu, L. Gao, S. Feng, L. Wang, J. Zhao, Z. Huang, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm: MicroRNA expression misregulation in iPSC-derived dopaminergic neurons from sporadic and LRRK2-associated Parkinson disease patients

R. Fernández-Santiago, T. Botta-Orfila, X. Morató, C. Calatayud, R. Raquel, MJ. Martí, C. Gaig, A. Raya, A. Consiglio, E. Tolosa, M. Ezquerra (Barcelona, Spain)

1:15pm-2:45pm: MicroRNAs as Biomarkers for Parkinson’s Disease

S. Bissonnette, C. Thomas, A. Labadorf, R. James, M. Saint-Hilaire, R. Myers (Boston, MA, USA)

1:15pm-2:45pm: Microstructural Abnormalities in Drug-naïve Parkinson’s Disease with Mild Cognitive Impairment: A Diffusion Tensor Imaging Study

N. Li, L. Wang, X. Suo, Z. Lu, J. Li, J. Peng, Q. Gong, R. Peng (Chengdu, Sichuan Province, China)

1:15pm-2:45pm: Microstructural Changes in Normal Appearing White Matter in Parkinson’s Disease (PD) Correlate with Motor, Tremor, and Neuropsychiatric Scores

J. Kim, T. Baumeister, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm: Microstructural changes in white and grey matter related to apathy, depression and anxiety in de novo Parkinson’s disease patients

S. Prange, E. Metereau, A. Maillet, E. Lhommée, H. Klinger, P. Pelissier, D. Ibarrola, RA. Heckemann, E. Broussolle, A. Castrioto, L. Tremblay, V. Sgambato, P. Krack, S. Thobois (Bron, France)

1:15pm-2:45pm: Mind and Movement in Parkinson’s disease: An experience with yoga

S. Varanese, N. Modugno (Pozzilli, Italy)

1:15pm-2:45pm: Mineralization pattern of the deep gray matter by susceptibility-weighted magnetic resonance imaging to differentiate Parkinsonian disorders

M. Modi, P. Singh (Chandigarh, India)

1:15pm-2:45pm: Missing Data in the Unified Dyskinesia Rating Scale (UDysRS)

S. Luo, X. Ren, W. Han, C. Goetz, G. Stebbins (Durham, NC, USA)

1:15pm-2:45pm: Mitochondrial phenotype related to the A30P alpha-synuclein mutation as a patient-derived cellular model of Parkinson’s disease

B. Santos, P. Barbuti, P. Antony, J. Arias, A. Hummel, J. Schwamborn, R. Krüger (Belval, Luxembourg)

1:15pm-2:45pm: Modulation of CaMKIIa-NR2B interaction in levodopa-induced dyskinesia in 6-OHDA- lesioned Parkinson’s rats

XS. Wang, WW. Wang, CL. Xie (Wenzhou, China)

1:15pm-2:45pm: Molecular Genetics and Functional Studies of LRRK2 Gene Variations in Parkinson’s Disease

M-L. Chen, R-M. Wu (Taipei, Taiwan)

1:15pm-2:45pm: Molecular mechanisms of GCH1-associated Parkinson’s disease

J. Terbeek, W. Vandenberghe (Leuven, Belgium)

1:15pm-2:45pm: Molecular-genetic nature of Parkinson’s disease in the East European cohort

A. Ivashynka, S. Likhachev (Minsk, Belarus)

1:15pm-2:45pm: Motivational effects on action selection and memory

S. Hirschbichler, J. Ibáñez, L. Rocchi, R. Greenwood, J. Rothwell, S. Manohar (London, United Kingdom)

1:15pm-2:45pm: Motor and non-motor symptoms of a 7.5-year prospective study of patients with Parkinson’s disease

A. Yoritaka, Y. Shimo, T. Hatano, N. Hattori (Saitama, Japan)

1:15pm-2:45pm: Motor cortical inhibitory and facilitatory circuit interactions in Parkinson’s disease

J. Saravanamuttu, N. Radhu, K. Udupa, C. Gunraj, J. Baarbé, R. Chen (Toronto, ON, Canada)

1:15pm-2:45pm: Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Cerebrospinal Fluid C-Reactive Protein

H. Sanjari Moghaddam, M.H. Aarabi (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Multi-echo GRE and DTI MR imaging of the Substantia Nigra in early Parkinson’s disease: A pilot 1-year prospective controlled study

T. Mestre, G. Melkus, G. Santos, D. Grimes, S. Chakraborty (Ottawa, ON, Canada)

1:15pm-2:45pm: Multi-limb dual-task cost in Parkinson disease: Evaluating effects of implicit and explicit cues

T. McIsaac, R. Cohen, R. Bay, J. Gupta, C. Adler (Mesa, AZ, USA)

1:15pm-2:45pm: Multimorbidity predicts quality of life but not motor severity in early Parkinson’s disease

R. Gravell, G. Duncan, T. Khoo, D. Burn, A. Sayer, R. Barker, R. Lawson, A. Yarnall (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

L. Chahine, T. Beach, C. Coffey, C. Caspell-Garcia, C. Alder, G. Serrano, S. Mosovsky, T. Foroud, C. Linder, H. Riss, D. Ecklund, J. Seibyl, A. Mallya, V. Arnedo, L. Riley, K. Dave, D. Jennings, B. Mollenhauer (Pittsburgh, PA, USA)

1:15pm-2:45pm: Nanoscale imaging reveals disorganization of the brain extracellular space in Lewy body-injected mice

F. Soria, N. Danne, C. Paviolo, E. Doudnikoff, B. Dehay, L. Groc, L. Cognet, E. Bezard (Bordeaux, France)

1:15pm-2:45pm: Natural history of RBD in Parkinson´s disease and response to dopaminergic and non-dopaminergic antiparkinsonian treatment

M. Ruiz-Lopez, V. Bruno, ME. Freitas, R. Rajalingam, A. Chang, S. Fox, A. Lang (Toronto, ON, Canada)

1:15pm-2:45pm: Natural occurring antibodies reduce aggregation of α-synuclein

A. Braczynski, E. Agerschou, Y. Kronimus, W. Hoyer, R. Dodel, B. Falkenburger, J. Schulz, J. Bach (Aachen, Germany)

1:15pm-2:45pm: Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD

M. Matarazzo, P. Martínez Martín, J.C. Martínez-Ávila, A. Gómez de-la-Cámara, L. Giancardo, T. Arroyo Gallego, P. Montero Escribano, V. Puertas-Martín, I. Obeso, I. Butterworth, C.S. Mendoza, M.J. Catalán, J.A. Molina-Arjona, F. Bermejo-Pareja, J.C. Martínez-Castrillo, L. López-Manzanares, A. Alonso-Canovas, J. Herreros-Rodríguez, M. Gray, Á. Sánchez-Ferro (Vancouver, BC, Canada)

1:15pm-2:45pm: Neurocognitive outcomes of STN-DBS in patients with Parkinson’s disease: A 10-year review of local experiences in Hong Kong

V. Tang, X.L. Zhu, D. Chan, C. Lau, A. Chan, V. Mok, J. Yeung, W.S. Poon (Hong Kong)

1:15pm-2:45pm: Neuroinflammation Predicts Dompaminergic Deficit in Early Parkinson Disease: DAT SPECT Imaging Study

F. Rahmani, M. Rahmani (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Neuromodulation by rTMS in Parkinsons Disease: A fMRI Study

P. Bhat, V. Goyal, S. Kumaran, C. Goyal, A. Srivastava, M. Behari, S. Dwivedi (New Delhi, India)

1:15pm-2:45pm: Neuronal KIF5b deletion induces striatum-dependent locomotor impairments and defects in membrane presentation of dopamine D2 receptors

T. Falzone, L. Cromberg, M. Alloatti, I. Fernandez Bessone, T. Saez (Buenos Aires, Argentina)

1:15pm-2:45pm: Neuropathological correlates of psychiatric disorders in PD

J. Hinkle, N. Fischer, K. Perepezko, C. Bakker, M. Broen, A. Butala, T. Dawson, A. Leentjens, Z. Mari, C. Marvel, K. Mills, E. Moukheiber, A. Pantelyat, O. Pletniková, L. Rosenthal, M. Shepard, J. Troncoso, J. Wang, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm: Neurophysiological correlates of bradykinesia in Parkinson’s disease

M. Bologna, A. Guerra, G. Paparella, L. Giordo, D. Alunni Fegatelli, AR. Vestri, J. Rothwell, A. Berardelli (Rome, Italy)

1:15pm-2:45pm: Neuroprotection effects of probiotics strains on a chronic MPTP-induced mouse model of Parkinson’s disease

Y. Qian, X. Yang, S. Xu, Q. Xiao (Shanghai, China)

1:15pm-2:45pm: Neuroprotective effect of exogenous melatonin on apoptosis of neuroadernergic neurons in a rat model of Parkinson’s disease

F. Yadolahi, M. Mehrpour (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Neuroprotective potential of curcumin in combination with piperine against 6-hydroxy dopamine induced motor deficit and neurochemical alterations in rats

S. Singh (Moga, India)

1:15pm-2:45pm: Neuropsychiatric disorders in observed patients with Parkinson’s disease

S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)

1:15pm-2:45pm: Neuropsychological and clinical assessment for the differential diagnosis of patients with PDD vs. DLB

E. Fiorenzato, L. Weis, V. Camparini, F. Pistonesi, R. Schifano, E. Gasparoli, A. Antonini, R. Biundo (Venice, Italy)

1:15pm-2:45pm: Neuropsychological Assessment of Cognitive Dysfunction in Parkinson’s Disease: A Comparison of Four Screening Instruments

S. Schnitzler, L. Flitsch, S. Kaesberg, J. Kessler, E. Kalbe, M. Barbe (Cologne, Germany)

1:15pm-2:45pm: Neuropsychological Evaluation of a Vietnamese-speaking Man with Parkinson’s Disease and Consideration for Deep Brain Stimulation Surgery: A Case Report

B. Tran, K. Lawler (Philadelphia, PA, USA)

1:15pm-2:45pm: Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report

B. Lisewska, P. Lisewski, P. Szarwas, N. Piekuś-Słomka, D. Rość (Bydgoszcz, Poland)

1:15pm-2:45pm: New approach to assess changes in brain activation during real walking using EEG

I. Maidan, S. Shustak, T. Shiner, N. Giladi, J. Hausdorff, A. Mirelman (Tel Aviv, Israel)

1:15pm-2:45pm: New evidence for thalamic dysfunction in Parkinsonian rats

L. Grandi, G. Di Giovanni, E. Fedele, G. Orban, A. Salvadè, W. Song, A. Stefani, A. Kaelin-Lang, S. Galati (Taverne, Switzerland)

1:15pm-2:45pm: No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

F. Hopfner, S. Müller, D. Steppat, J. Miller, N. Schmidt, K.P. Wandinger, F. Leypoldt, D. Berg, A. Franke, W. Lieb, L. Tittmann, M. Balzer-Geldsetzer, S. Baudrexel, R. Dodel, R. Hilker-Roggendorf, E. Kalbe, J. Kassubek, T. Klockgether, I. Liepelt-Scarfone, B. Mollenhauer, P. Neuser, K. Reetz, O. Riedel, C. Schulte, J. Schulz, A. Spottke, A. Storch, C. Trenkwalder, G. Deuschl, G. Kuhlenbäumer (Kiel, Germany)

1:15pm-2:45pm: No differences in the total burden of non-motor symptoms between Parkinson’s disease and non-degenerative parkinsonism

E. Jaakkola, J. Joutsa, E. Mäkinen, T. Noponen, M. Pitkonen, R. Levo, T. Mertsalmi, F. Scheperjans, V. Kaasinen (Turku, Finland)

1:15pm-2:45pm: No MPTP-induced behavioral deficits or Striatal field potential alterations in crossbreds of MPTP-susceptible and MPTP-resistant mice strains

P. Alladi, D. Vidyadhara, S. Arun, B. Kutty (Bengaluru, India)

1:15pm-2:45pm: Non motor symptoms in parkinsonism: A cross sectional study

V. Kataria, V. Goyal (New Delhi, India)

1:15pm-2:45pm: Non-invasive, automated corneal nerve quantification reveals neurodegeneration in Parkinson’s disease: A potential novel imaging biomarker

S. Lim, M. Ferdousi, A. Kalteniece, C. Kobylecki, R. Malik, M. Silverdale (Salford, United Kingdom)

1:15pm-2:45pm: Non-motor outcomes of subthalamic DBS in PD depend on the location of volume of activated tissue

JN. Petry-Schmelzer, H. Dafsari, M. Krause, T. Dembek, A. Keyoumars, A. Rizos, M. Silverdale, J. Evans, M. Barbe, G. Fink, P. Martinez-Martin, V. Visser-Vandewalle, A. Antonini, L. Timmermann, K. Ray-Chaudhuri (Cologne, Germany)

1:15pm-2:45pm: Non-Motor Symptom In Young Onset Parkinson Disease as a Cause of Pharmacoresistence In Epilepsy

M. Awadh (Birmingham, United Kingdom)

1:15pm-2:45pm: Non-motor symptoms in Parkinson’s Disease: Frequency, types and correlated factors compared to a group of healthy controls. Results from the COPPADIS Study Cohort

L. Planellas, M. Martí, P. Santacruz, A. Cámara, S. Jesus Maestre, F. Carrillo García, P. Mir, M. Aguilar, P. Pastor, J. García Caldentey, E. Estelrich Peyret, N. Caballol Pons, I. Legarda, B. Vives Pastor, J. Hernández Vara, G. Martí Andrés, I. Cabo, L. López Manzanares, M. Gallego-de-la-Sacristana, P. Martínez Martín, D. Santos García, G. COPPADIS STUDY (Barcelona, Spain)

1:15pm-2:45pm: Non-motor symptoms in patients with idiopathic and converted REM Sleep Behavior Disorder

P. Chan, W. Mao, XN. Liu, SQ. Zhan, H. Zhang, Y. Li (Beijing, China)

1:15pm-2:45pm: Non-motor symptoms of Parkinson’s disease: Evaluation of urinary disorders

K. Karbozova. (Bishkek, Kyrgyzstan)

1:15pm-2:45pm: Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease

P. Prange, T. Danaila, C. Laurencin, C. Caire, E. Metereau, H. Merle, E. Broussolle, D. Maucort-Boulch, S. Thobois (Bron, France)

1:15pm-2:45pm: Novel GBA risk factor gene mutation p.W378R in a kindred with Gaucher’s disease and Parkinson’s disease

M. Lubomski, M. Hayes, M. Kennerson, M. Ellis, S. Chu, J. Blackie, J. O’Sullivan, G. Nicholson (Sydney, Australia)

1:15pm-2:45pm: Novel population-specific mutationsin PINK1 and Parkin genes from India

A. Kishore, M. Sturm, A. Asok, C. Schulte, D. KP, S. Krishnan, O. Riess, M. Sharma (Trivandrum, India)

1:15pm-2:45pm: Nucleotide repeats as genetic risk factors in a Swedish Parkinson’s disease cohort

J. Laffita Mesa, L. Brodin, P. Svenningsson (Stockholm, Sweden)

1:15pm-2:45pm: Nurr1 gene: A new research target for Parkinson’s disease

W. Le (Dalian, China)

1:15pm-2:45pm: Nursing diagnoses, outcomes and ICNP® interventions related to urinary dysfunction in Parkinson’s disease

M. Tosin, B. Oliveira (Santos-SP, Brazil)

1:15pm-2:45pm: Objective and quantifiable assessment of sleep in patients with Parkinson’s disease using a wearable sensor

A. Mirelman, I. Hilell, N. Omer, A. Thaler, M. Kestenbaum, O. Assais, A. Orr-Urtreger, M. Brys, J. Cedarbaum, J. Hausdorff, N. Giladi (Tel Aviv, Israel)

1:15pm-2:45pm: Objective intestinal dysfunction in REM sleep behaviour disorder

K. Knudsen, T. Fedorova, A. Hansen, M. Sommerauer, AM. Haase, M. Otto, K. Svendsen, K. Ostergaard, K. Krogh, P. Borghammer (Aarhus, Denmark)

1:15pm-2:45pm: Odor identification in PD patients and controls in Estonian cohort

I. Kalju, T. Toomsoo, K. Vender (Tallinn, Estonia)

1:15pm-2:45pm: Off-painfull state in Parkinson’s disease patients: A redflag of complulsive behavior. Data from a PET-FDG study

G. Albani, A. Cistaro, P. Fania, S. Margotti, V. Arena, A. Mauro (Verbania, Italy)

1:15pm-2:45pm: Olfactory dysfunction, sleep disturbances, neuronal loss, and regional brain atrophy in an inducible mouse model of Alpha-Synucleinopathy

E. Brison, S. Zehntner, A. Zijdenbos, K. Luk, B. Bedell (Montreal, QC, Canada)

1:15pm-2:45pm: Olfactory Hallucinations as a Non-motor sign of Parkinson’s disease – A cross-sectional study amongst patients in a tertiary movement center

S. Chandra, M. Schiess, R. Mehanna (Houston, TX, USA)

1:15pm-2:45pm: Olfactory impairment correlates strongly with limbic blood flow in patients with Parkinson’s disease

K. Ohta, T. Nakajima (Niigata, Japan)

1:15pm-2:45pm: Opposite effects of dopamine on specific NoGo perfomance in young and late onset Parkinson’s disease and the relationship to nigrostriatal degeneration

D. Kübler, H. Schroll, U. Scheller, R. Buchert, A. Kühn (Berlin, Germany)

1:15pm-2:45pm: Optimization of deep brain stimulation in STN among patients with Parkinson’s disease using a novel EEG-based tool

D. Sand, Z. Peremen, D. Haor, S. Israeli-Korn, D. Arkadir, M. Abu Snineh, Z. Israel, S. Hassin-Baer, R. Eitan, H. Bergman, A. Geva (Jerusalem and Herzlia, Israel)

1:15pm-2:45pm: Pain is correlated with other motor and non-motor symptom in Parkinson’s disease

Y. Liu, X.Y. Zhu, X.J. Zhang, S.L. Yang, T.Y. Feng, Y.C. Wu (Shanghai, China)

1:15pm-2:45pm: Pallidal beta bursts in Parkinson’s disease and Dystonia

R. Lofredi, WJ. Neumann, C. Brücke, J. Huebl, GH. Schneider, A. Kühn (Berlin, Germany)

1:15pm-2:45pm: Paraneoplastic and neuronal surface antibodies in Parkinson’s disease and atypical parkinsonian disorders

R. Constantinescu, C. Malmeström, D. Krýsl, D. Jons, M. Axelsson (Gothenburg, Sweden)

1:15pm-2:45pm: Parkinson-related CHCHD2 is necessary for oligomerization of ALS/FTD-related CHCHD10

D. Narendra, X. Huang, B. Wu, Y. Liu, D. Nguyen, M. Marani (Bethesda, MD, USA)

1:15pm-2:45pm: Parkinson’s disease anxiety is associated with Lewy bodies in the Anterior Cingulate

N. Fischer, J. Hinkle, K. Perepezko, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm: Parkinson’s disease motor symptoms are linked to red nucleus volume and cerebellar metabolism

A. Bonnet, R. Sanford, A. Riou, S. Drapier, F. Le Jeune, M. Vérin, D.L. Collins (Rennes, France)

1:15pm-2:45pm: Partial depletion of peripheral M1 macrophages ameliorates the neuroinflammation and dopaminergic neuronal death in the brain of a MPTP-induced mouse model of PD

A. Yan, Y. Zhang, J. Lin, L. Song, X. Wang, Z. Liu (Shanghai, China)

1:15pm-2:45pm: Patient Experience of Parkinson’s Disease Psychosis Management

P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, A. Shim, D. Fredericks (Miami, FL, USA)

1:15pm-2:45pm: Patients with Parkinson’s disease and psychosis have altered structural connectivity of the executive and visual networks

P. Pal, A. Lenka, M. Ingalhalikar, A. Shah, J. Saini, S. Arumugham, S. Hegde, L. George, R. Yadav (Bangalore, India)

1:15pm-2:45pm: Patterns of Long-Term Custodial Care in Parkinson Disease Psychosis

J. Wetmore, H. Yan, M. Irfan, A. Shim, Y. Peng, D. Gilbertson, S. Li (Minneapolis, MN, USA)

1:15pm-2:45pm: Patterns of rhythmic single unit activity of the subthalamic nucleus in patients with Parkinson’s disease

E. Belova, A. Nezvinskiy, R. Medvednik, A. Tomskiy, A. Sedov (Moscow, Russian Federation)

1:15pm-2:45pm: PD associated with GBA and LRRK2 mutations: Genotype-phenotype correlation

V. Livneh, G. Yahalom, L. Greenbaum, S. Israeli-Korn, T. Fay-Karmon, S. Hassin, Z. Gan Or (Ramat Gan, Israel)

1:15pm-2:45pm: Performance of Parkinson´s disease cognitive scale rating scale (PD-CRS) after subthalamic nucleus deep brain stimulation. Comparison with Mattis Dementia Rating Scale (MDRS) and Mini-Mental State Examination (MMSE)

C. García-Sánchez, B. Pascual-Sedano, A. Gironell, R. Rodriguez, J. Pagonabarraga-Mora, J. Marin-Lahoz, J. Pérez-Perez, A. Campolongo, C. izquierdo, H. Bejr-Kasen, I. Aracil, S. Martínez -Horta, A. Horta, M. Botí, E. Marin, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Peripheral Inflammatory Mediators in Parkinson’s Disease – A Potential Biomarker

K. Chatterjee, A. Roy, R. Banerjee, S. Halder, S. Choudhury, P. Basu, S. Shubham, H. Kumar (Kolkata, India)

1:15pm-2:45pm: Personality Traits and Sleep Quality in Parkinson’s disease patients

JY. Yun, HJ. Kim, HN. Kim, HL. Kim (Seoul, Republic of Korea)

1:15pm-2:45pm: Pharmacological modulation of lysosomal glucocerebrosidase activity in the Thy1-aSYN mouse model of Parkinson’s disease

K. Belarbi, E. Cuvelier, H. Carrie, M.A. Bonte, W. Sibran, C. Leghay, J. Von Gerichten, V. Nordström, R. Sandhoff, T. Comptdaer, N. Jouy, E. Mutez, A. Destee, C. Pincon, B. Gressier, M.C. Chartier-Harlin (Lille, France)

1:15pm-2:45pm: Pilot study of a new tool to optimize dopaminergic treatment in Parkinson’s disease: The OPTIPARK Scale Project

J. Máñez Miró, F. Vivancos-Matellano, P. Martínez-Martín (Mostoles, Spain)

1:15pm-2:45pm: Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis

A. Espay, M. Guskey, N. Larsen, B. Coate, J. Vizcarra, S. Factor, J. Friedman, D. Weintraub, A. Lang (Cincinnati, OH, USA)

1:15pm-2:45pm: Pisa syndrome in Parkinson’s disease: Evidence for bilateral vestibulospinal dysfunction

G. Di Lazzaro, T. Schirinzi, S. Di Girolamo, R. Di Mauro, A. Pisani (Rome, Italy)

1:15pm-2:45pm: PLA2G6-related juvenile-onset Parkinsonism: clinical features and cognitive profile in a cohort of Chinese patients

C. Chen, Y.M. Sun, F.T. Liu, S.S. Luo, Z.T. Ding, J.J. Wu, J. Wang (Shanghai, China)

1:15pm-2:45pm: Plasma levels of vitamin D in patients with Parkinson’s disease: Correlation with Mini Mental State Examination and disease duration

M. Barichella, L. Lorio, C. Bolliri, A. Giana, V. Ferri, G. Pinelli, E. Cassani, S. Caronni, C. Esposito, G. Riboldazzi, A. Maras, A. Perretti, F. Del Sorbo, P. Amadeo, R. Cilia, E. Cereda, G. Pezzoli (Milan, Italy)

1:15pm-2:45pm: Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease

I. Mironova, A. Latypova, I. Zhukova, O. Izhboldina, E. Kolupaeva, N. Zhukova, S. Ivanova (Tomsk, Russian Federation)

1:15pm-2:45pm: Potential indicator of antiparkinsonian drug efficacy: an attempt to explore imaging findings

S. Taguchi, N. Tanabe, H. Oiwa, M. Hayashi, C. Nagatomi, S. Saeki, K. Nakashima, T. Yuasa, A. Yasumoto, H. Ando, T. Higa, A. Fujikake, T. Fukuoka, K. TokuI, Y. Okada, J. Niwa, M. Izumi, N. Nakao, M. Doyu (Nagakute, Japan)

1:15pm-2:45pm: Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure

S. Hegde, M. Pulido-Rios, A. McNamara, J. Smith, W. Smith, J. Kanodia, D. Bourdet (South San Francisco, CA, USA)

1:15pm-2:45pm: Predictive factors of fast cognitive decline in Parkinson’s disease after subthalamic stimulation: Myth or reality?

F. Fluchere, F. Ory-Magne, M. Anheim, V. Rousseau, A. Eusebio, O. Lagha Boukbiza, B. Lemesle, T. Witjas, N. Longato, C. Tranchant, C. Brefel-Courbon, JP. Azulay (Marseille, France)

1:15pm-2:45pm: Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up

S. Perez-Lloret, A. Sauerbier, C. Falup-Percurariu, M. Tinazzi, K.R. Chaudhuri (Buenos Aires, Argentina)

1:15pm-2:45pm: Predictors of freezing of gait in newly diagnosed Parkinson’s disease: Clinical, dopamine transporter imaging and CSF markers in the PPMI cohort

R. Kim, J. Lee, H.J. Kim, A. Kim, B. Jeon, U.J. Kang, S. Fahn (Seoul, Republic of Korea)

1:15pm-2:45pm: Prefrontal cortical stimulation to treat anxiety and depression in Parkinson’s disease

C. de Hemptinne, W. Chen, C. Racine, A. Seritan, A. Miller, J. Mergenthaler, S. Rajagopalan, J. Ostrem, M. San Luciano, P. Starr (San Francisco, CA, USA)

1:15pm-2:45pm: Preliminary Results of Psychometric Properties of the Freezing of Gait Questionnaire in Turkish Patients with Parkinson’s Disease

E A. Ozturk, F. Nazli, B. Gonenli Kocer, S B. Tonuk, A. Can, N. Tezel, C. Uz, O. Ecerkale, F A. Cakci (Ankara, Turkey)

1:15pm-2:45pm: Preliminary Results of Psychometric Properties of the Turkish version of Falls Efficacy Scale – International in Patients with Parkinson’s Disease

F. Nazli, E A. Ozturk, B. Gonenli Kocer, S B. Tonuk, N. Tezel, A. Can, C. Uz, O. Ecerkale, F A. Cakci (Ankara, Turkey)

1:15pm-2:45pm: Preliminary Study of Depression in Parkinson’s Disease with Diffusion Tensor Imaging

C. Dejie, S. QuanXi, C. Shihuo (Yunfu, Guangdong, China)

1:15pm-2:45pm: Presence of Lewy dots in the brain of patients with Creutzfeldt-Jakob disease

R. Valenti-Azcarate, I. Martinez-Valbuena, M. Tuñon-Alvarez, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, E. Erro-Aguirre, M. Luquin-Piudo (Pamplona, Spain)

1:15pm-2:45pm: Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

HS. Yoo, SJ. Chung, BS. Ye, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Prevalence and associations for depression in patients with Parkinson’s disease: A Sri Lankan experience

T. Herath, C. Rodrigo, M. Withana (Colombo, Sri Lanka)

1:15pm-2:45pm: Prevalence and relationship of non-motor symptoms of Parkinson’s disease with plasma uric levels

Y. Zubair, S. Oyakhire, S. Abdulrahaman, O. Medu, S. Bwala (Abuja, Nigeria)

1:15pm-2:45pm: Prevalence and risk factor of peak-dose dyskinesia in Thai patients with Parkinson’s disease

S. Klanbut, C. Luangsinsiri, N. Piyaparneekul, C. Khongbut, K. Methawasin (Nakhon Nayok, Thailand)

1:15pm-2:45pm: Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson’s disease

J. Zhu, L. Zhang (Nanjing, China)

1:15pm-2:45pm: Prevalence of Autonomic dysfunction and its correlation with Clinico-imageological features in Parkinson’s Disease

R. Borgohain, S. Turaga, R. Kandadai, S. Tandra, M. Katragadda, S. Meka, T. Syed (Hyderabad, India)

1:15pm-2:45pm: Prevalence of non-motor symptoms in Parkinson’s disease and its impact on quality of life in a tertiary care center in India

M. Karri, B. Ramasamy, R. Kalidoss (Coimbatore, India)

1:15pm-2:45pm: Prevalence of Patient-Reported Symptoms of Dysphonia and Dysphagia in Movement Disorder Patients at an Academic Medical Center

M. Finger, M. Siddiqui, J. Tate, I. Haq, L. Madden (Winston-Salem, NC, USA)

1:15pm-2:45pm: Profiles of microRNA in cerebrospinal fluid could be potential biomarkers for identifying motor subtype of Parkinson’s disease

W. Jang (Gangneung, Republic of Korea)

1:15pm-2:45pm: Progression of sleep disorders spectrum in Parkinson’s Disease: A 5 year clinical longitudinal study

1:15pm-2:45pm: Properties of oscillatory neuronal activity in the basal ganglia and thalamus in patients with Parkinson’s disease

P. Zhuang, M. Hallett, G. Du, Y. Zhang, Y. Li (Beijing, China)

1:15pm-2:45pm: Propranolol Induced Visual Hallucinations: A Case Report Charles Bonnets Syndrome in Parkinson Disease

M. Şenol, M. Kendirli (Istanbul, Turkey)

1:15pm-2:45pm: Protective effects of Mucuna pruriens seed on rat brain: A therapeutic potential drug for Parkinson’s disease

S. Rajput, S. Sinha (New Delhi, India)

1:15pm-2:45pm: Proteomic analysis of tear-fluid reveals disease-specific patterns in patients with Parkinson’s Disease

M. Börger, S. Funke, F. Maass, A. Leha, AE. Roser, AK. Wüstemann, M. Bähr, F. Grus, P. Lingor (Göttingen, Germany)

1:15pm-2:45pm: PrP as a receptor of alpha-synuclein in the pancreas of patients with synucleinopathies

I. Martinez-Valbuena (Pamplona, Spain)

1:15pm-2:45pm: PTRHD1 loss-of-function mutation in an African family with parkinsonism and intellectual disability

IJcken, M. van Slegtenhorst, V. Bonifati (Rotterdam, Netherlands)

1:15pm-2:45pm: Pupil evaluation as the test for the clinical manifestations of Parkinson’s disease

T. Araga, M. Shiraishi, K. Shinohara, Y. Hasegawa (Kawasaki, Japan)

1:15pm-2:45pm: Putaminal dopamine depletion in de novo Parkinson’s disease predicts future development of wearing-off

S.J. Chung, Y. Lee, J.S. Oh, J.S. Kim, P.H. Lee, Y.H. Sohn (Goyang, Republic of Korea)

1:15pm-2:45pm: Quality of Life in Parkinson’s Disease: Impact of Depression and Apathy

H. Nagayama (Tokyo, Japan)

1:15pm-2:45pm: Quantification of the PD Motor Syndrome Using an Inclusive Score (PD9) Derived from Sensor Data with Deep Learning

F. Pfister, J. Goschenhofer, T. Um, D. Pichler, K. Abedinpour, D. Kulic, B. Bischl, A. Ceballos-Baumann, U. Fietzek (Munich, Germany)

1:15pm-2:45pm: Quantitative analysis of DaT uptake and neuromelanin MR contrast in patients with Parkinson’s disease and healthy controls

D. Ben Bashat, M. Artzi, A. Mirelman, T. Thaler, A. Orr Urterger, M. Weisz, E. Even-Sapir, K. Evans, R. Hutchison, J. Cedarbaum, H. Lerman Shacham (Tel Aviv, Israel)

1:15pm-2:45pm: Quantitative Keyboard Tapping Measurement Correlates with Electrophysiological Changes in STN LFPs of PD Patients Treated with L-dopa Better Than UPDRS Subscores

M. Ozturk, A. Abosch, D. Francis, J. Wu, N. Ince (Houston, TX, USA)

1:15pm-2:45pm: Rasagiline as Adjunctive Therapy Induced Impulse Control Disorders in Parkinson’s Disease

M. Şenol, M. Kendirli (Istanbul, Turkey)

1:15pm-2:45pm: Rasch analysis of the Hospital Anxiety and Depression Scale among patients with early-stage Parkinson’s disease

H.J. Yang, B.S. Park, J.Y. Park, E.M. Lee, S.Y. Kim, W.J. Kim, J.H. Kwon (Ulsan, Republic of Korea)

1:15pm-2:45pm: Red cell distribution with levels in Parkinson’s disease patients

G. Ozgen Kenangil, B.C. Ari, F. Altuntas Kaya, M. Demir, F. Mayda Domac (Istanbul, Turkey)

1:15pm-2:45pm: Reduced vesicular storage of catacholamines enhance MPTP-induced death of dopaminergic neurons in locus coeruleus and olfactory bulb

K. Ma, J. Huang, L. Liu, X. Fang, Y. Xia, F. Wan, S. Yin, L. Kou, N. Xiong, T. Wang (Wuhan, China)

1:15pm-2:45pm: Relation of asymmetry of dopamine depletion with motor or non-motor symptoms in patients with Parkinson’s disease: A pilot study

K.Y. Kwon, J.Y. Lee, K. Im (Seoul, Republic of Korea)

1:15pm-2:45pm: Relationship between cyclooxygenase-2 gene polymorphisms and Parkinson’s disease susceptibility in Chinese Han population

M. Ye, Y. Yao, H. Gao (Nanjing, China)

1:15pm-2:45pm: Relationship between dopaminergic asymmetric degeneration and attentional resources in Parkinson’s disease

P. Ortelli, D. Ferrazzoli, V. Cian, L. Caremani, G. Madeo, G. Palamara, R. Maestri, G. Frazzitta (Gravedona ed Uniti, Italy)

1:15pm-2:45pm: Relationship between dysphagia severity and gait disturbance in Parkinson’s disease

C. Kobylecki, I. Shiderova, E. Michou (Salford, United Kingdom)

1:15pm-2:45pm: Relationship of Vitamin D deficiency with Parkinson’s disease risk

M. Sanoeva, N. Mansurova (Bukhara, Uzbekistan)

1:15pm-2:45pm: Relationships between specific subtypes of mild cognitive impairment and grey matter atrophy in Parkinson’s disease

K. Nie, M. Mei, Y. Gao, M. Guo, B. Huang, Z. Huang, L. Wang, J. Zhao, Y. Zhang, D. Xiong, L. Wang (Guangzhou, China)

1:15pm-2:45pm: Remote patient monitoring with a digital biomarker approach generates clinically distinctive and meaningful sensor feature data in Parkinson’s disease: Differential relationships with MDS-UPDRS-III, PDQ-39 and DaT-SPECT

F. Lipsmeier, K. Taylor, R. Postuma, D. Wolf, T. Kilchenmann, A. Scotland, J. Schjodt-Erkisen, W. Cheng, J. Siebourg-Polster, L. Jin, J. Soto, L. Verselis, F. Boess, M. Koller, M. Grundman, T. Kremer, C. Czech, C. Gossens, M. Lindemann (Basel, Switzerland)

1:15pm-2:45pm: Reproductive factors influence on cognitive function of Parkinson’s disease in female patients-from a cross-sectional study

Y. Wu, H. Liu, R.W. Ou, Q.Q. Wei, H.F. Shang (Chengdu, People’s Republic of China)

1:15pm-2:45pm: Research on nearinfrared brain function imaging for Freezing of Gait in Parkinson’s Disease

Y. Jingjing, L. Zhanhua, C. Ming (Dalian, China)

1:15pm-2:45pm: Resistance to Parkinson’s disease among LRRK2 mutation carriers is associated with higher plasma levels of urate but not its purine precursors

M. Schwarzschild, R. Bakshi, R. Logan, M. Zorlu, X. Chen, A. Ascherio, E. Macklin (Boston, MA, USA)

1:15pm-2:45pm: Resting state fMRI points to disparate brain network activations in early Parkinson’s disease

L. Salamanca, E. Glaab, R. Balling, G. Dooms, N. Diederich (Esch-sur-Alzette, Luxembourg)

1:15pm-2:45pm: Resting state networks abnormalities among healthy LRRK2 mutation carriers

A. Thaler, Y. Jacob, T. Gurevich, R. Helmich, B. Bloem, A. Orr-Urtreger, N. Giladi, L. Yahimovich, A. Mirelman, T. Hendler (Tel-Aviv, Israel)

1:15pm-2:45pm: Resting-state connectivity and cognitive changes in Parkinson’s disease: A four-year follow-up study

HC. Baggio, B. Segura, A. Abos, A. Campabadal, C. Uribe, A.I. Garcia-Diaz, M.J. Marti, Y. Compta, F. Valldeoriola, C. Junque (Barcelona, Spain)

1:15pm-2:45pm: Resting-state fMRI in Parkinson’s disease patients with cognitive impairment: A meta-analysis

A. Wolters, S. vd Weijer, A. Leentjens, A. Duits, H. Jacobs, M. Kuijf (Maastricht, Netherlands)

1:15pm-2:45pm: Restless legs syndrome in Parkinson’s disease patients: a comparative study on prevalence, clinical features, motor and non-motor symptoms

S.Y. You, J.S. Lee, S.M. Jeon, Y.W. Cho (Daegu, Republic of Korea)

1:15pm-2:45pm: Retinal and choroidal changes in autosomal recessive PD are similar to idiopathic PD

A. Colpak, A. Agin, G. Yalcin-Cakmakli, S. Kadayifcilar, A. Bilgic, B. Eldem, B. Elibol (Ankara, Turkey)

1:15pm-2:45pm: Return to automaticity: cortical activity during gait in Parkinson’s disease

S. Stuart, R. Morris, G. Booth, M. Mancini (Portland, OR, USA)

1:15pm-2:45pm: Risk estimation in the years preceding diagnosis of Parkinson’s disease in the PREDICT-PD cohort

S. Auger, D. Rack, J. Bestwick, G. Giovannoni, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)

1:15pm-2:45pm: Rivastigmine solution in the one-year treatment of Parkinson’s disease dementia and dementia with Lewy bodies

P.Y. Chiu (Changhua, Taiwan)

1:15pm-2:45pm: Role of microglia in the transmission of α-syn-containing exosomes

Y. Xia, G. Zhang, J. Huang, N. Xiong, K. Ma, X. Guo, F. Wan, L. Kou, S. Yin, T. Wang (Wuhan, China)

1:15pm-2:45pm: Role of Sex on Cholinergic Activity and Attention in Parkinson’s disease

D. Martini, R. Morris, T. Madhyastha, T. Grabowski, J. Quinn, F. Horak (Portland, OR, USA)

1:15pm-2:45pm: Saccades in Parkinson’s disease: Hypometric, slow, or maladaptive?

L. Neilson, F. Ghasia, A. Shaikh (Cleveland, OH, USA)

1:15pm-2:45pm: Safinamide and Rasagiline effect on motor fluctuation, sleep quality and daytime sleepiness in Parkinson’s Disease: A validated questionnaires study

C. Liguori, A. Stefani, N. Mercuri, M. Pierantozzi (Rome, Italy)

1:15pm-2:45pm: Salivary Alpha-Synuclein a new tool for the diagnosis of Parkinson’s disease?

C. Aerts, C. Hirtz, V. Gonzalez, L. Collombier, M. De Verdal, C. Geny, M. Charif, E. Moulis, P. Fabbro-Peray, D. Deville Periere, P. Lapeyrie, G. Castelnovo, S. Lehmann (Nimes, France)

1:15pm-2:45pm: Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy

G. Vivacqua, A. Fabbrini, R. Mancinelli, D. Belvisi, G. Fabbrini, A. Suppa, A. Berardelli (Cambridge, United Kingdom)

1:15pm-2:45pm: Screening performance of abbreviated versions of the UPSIT smell test

T. Joseph, S. Auger, L. Peress, D. Rack, A. Schrag, A. Noyce (London, United Kingdom)

1:15pm-2:45pm: Selection of antiparkinson drug and cognition in Japanese Parkinson Disease patients

K. Konaka, Y. Kajiyama, R. Gajanan, M. Mihara, N. Hattori, H. Mochizuki (Suita, Japan)

1:15pm-2:45pm: Selection of odorants for diagnosis of Parkinson’s disease

O. Izhboldina, N. Zhukova, V. Alifirova, A. Latypova, I. Zhukova, .Uu. Mironova, M. Nikitina, E. Kolupaeva (Tomsk, Russia)

1:15pm-2:45pm: Semi-automated segmentation and quantification of the substantia nigra depigmentation in Parkinson’s disease – a multicentre case control MRI study in 284 participants

Y. Xing, S. Schwarz, A. Martin-Bastida, L. Parkes, H. Abdul-Sapuan, S. Naidu, M. Silverdale, D. Grosset, P. Piccini, D. Burn, N. Bajaj, N. Pavese, D. Auer (Nottingham, United Kingdom)

1:15pm-2:45pm: Sensory signs and neuropathic pain in advanced Parkinson’s disease under levodopa treatment

A.E. Elia, G. Devigili, M. Damasco, L.M. Romito, P. Soliveri, S. Rinaldo, M. Falsitta, R. Eleopra (Milan, Italy)

1:15pm-2:45pm: Serum glutamate is associated with the motor subtype of Parkinson’s disease

A. Latypova, I. Mironova, O. Izhboldina, I. Zhukova, N. Zhukova, E. Kolupaeva (Tomsk, Russian Federation)

1:15pm-2:45pm: Serum Leptin levels in Iranian patients with Parkinson’s disease

M. Salari, M. Etemadifar, M. Barzegar (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Serum Uric Acid Level and Its Relationship to Non-Motor Symptomatology in Parkinson’s disease

O. Odeniyi, N. Okubadejo, O. Ojo, M. Danesi (Lagos, Nigeria)

1:15pm-2:45pm: Sex Differences in Cognitive Performance in De-Novo Parkinson’s Disease

S. Banks, E. Bayram, J. Kaylegian, B. Bluett (Las Vegas, NV, USA)

1:15pm-2:45pm: Sexual Dysfunction in Women with Parkinson’s Disease

A. Hannoun, A. Deb, K. Smith (Worcester, MA, USA)

1:15pm-2:45pm: Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease

A. Batla, U. Uchiyama, S. Simeoni, C. Melbourne, M. Baldwin, L. DeMin, G. Gonzales, C. Haslam, M. Pakzad, S. Islam, S. Eriksson, K. Bhatia, J. Panicker (London, United Kingdom)

1:15pm-2:45pm: SIRT1/AMPK pathway is involved in neuroprotective effects of resveratrol on MPTP-induced neuron loss

Y.J. Guo, S.Y. Dong, W.J. Zhao, Y.C. Wu (Shanghai, China)

1:15pm-2:45pm: Skin Deposition of Pathological Alpha-Synuclein in Idiopathic REM-sleep Behavior Disorder and Parkinsonism

A. Al-Qassabi, TS. Tsao, S. Dziadek, A. Racolta, T. Kremer, C. Czech, K. Taylor, W. Zago, R. Postuma (Montreal, QC, Canada)

1:15pm-2:45pm: Sleep Disturbances and Quality of Life in People with Parkinson’s disease

U. Chotphoksap, D. Tan, S.B. Tan, EK. Tan, S. Wang, J. Chew, E. Poh, X. Chen, T.Y. Kam, K. Prakash (Singapore, Singapore)

1:15pm-2:45pm: Sleep, Fatigue and Health-related quality of life in a cohort of Parkinson disease patients

O. Ojo, N. Okubadejo, O. Odeniyi, N. Osemwegie, O. Oguntunde (Idi-araba, Nigeria)

1:15pm-2:45pm: Smooth muscle dysfunction in the gastrointestinal system in the 6-OHDA model of Parkinson´s Disease

P. Murillo, P. Aronsson, M. Winder, T. Carlsson (Gothenburg, Sweden)

1:15pm-2:45pm: Social interaction and Cognition in patients with Parkinson’s disease

A. Kumon, M. Sagawa, M. Saruwatari, N. Kawashima, K. Hasegawa (Sagamihara, Japan)

1:15pm-2:45pm: Soluble TREM2 and Central and Peripheral Inflammatory Biomarkers in Parkinson’s Disease

L. Bekris, M. Khrestian, Y. Shao, H. Fernandez, J. Leverenz (Cleveland, OH, USA)

1:15pm-2:45pm: Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia

C. Alcacer, M. Mendonca, A. Klaus, MA. Cenci, R. Costa (Lisbon, Portugal)

1:15pm-2:45pm: Speech intelligibility and comprehensibility in Slovak patients with Parkinson’s disease

A. Kušnírová, Ľ. Mičianová, Z. Košutzká, I. Straka, M. Egryová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

1:15pm-2:45pm: Status of riding bicycle and reasons for cessation of cycling in patients with Parkinson disease: A Japanese single center cross-sectional survey

K. Takahashi, K. Ota, K. Seo, H. Kawasaki, K. Ikeda, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Tamura, N. Araki, T. Yamamoto (Saitama-ken, Japan)

1:15pm-2:45pm: Stigma and communication in people with Parkinson’s disease (PPD)

M. Bacigalupe (La Plata, Argentina)

1:15pm-2:45pm: STN DBS – A study of frequency of gait (fog) in Parkinson’s disease

V. Rama Raju, R. Borgohain (Hyderabad, India)

1:15pm-2:45pm: STN DBS modulates cortical auditory processing in advanced Parkinson’s Disease; a MEG-study

K. Valkonen, J. Mäkelä, K. Airaksinen, J. Nurminen, R. Kivisaari, E. Pekkonen (Helsinki, Finland)

1:15pm-2:45pm: Striatal dopamine transporter availability changes reflect gastrointestinal dysautonomia severity in early Parkinson’s disease

J. Hinkle, K. Perepezko, K. Mills, Z. Mari, A. Butala, T. Dawson, A. Pantelyat, L. Rosenthal, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm: Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease

YS. Oh, DW. Ryu, JS. Kim, CH. Lyoo (Seoul, Republic of Korea)

1:15pm-2:45pm: Structural Abnormalities in the Cerebellar Peduncles of patients with Freezing of Gait: A Diffusion Tensor Imaging Study

K. Bharti, A. Suppa, S. Pietracupa, N. Upadhyay, C. Giannì, G. Leodori, F. Di Biaso, N. Modugno, N. Petasas, G. Grilla, A. Zampogna, A. Berardelli, P. Pantano (Rome, Italy)

1:15pm-2:45pm: Structural neural correlates of independent gait domains in Parkinson’s disease

J. Wilson, B. Galna, S. Lord, A. Yarnall, R. Lawson, G. Duncan, T. Khoo, D. Burn, L. Rochester, J.P. Taylor (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Study of prevalence of non-motor symptoms in typical and atypical parkinsonism as compared to age and sex matched healthy controls

N. Barad, C. Sankhla (Mumbai, India)

1:15pm-2:45pm: Study on Correlation between Serum Vitamin D Level and Cognition of Parkinson’s Disease

XY. Xu, J. Qian, XS. Huang, SY. Tian, D. Tong (Dalian, China)

1:15pm-2:45pm: Study on feasibility to develop a central nervous system (CNS) Leucine-rich repeat kinase 2 (LRRK2) PET tracer

Z. Zeng, P. Miller, T. Graham, L. Tong, D. Hesk, W. Li, E. Hostetler (West Point, PA, USA)

1:15pm-2:45pm: Subcortical and Cortical 123I-FP-CIT binding deficits and mild cognitive impairment in Parkinson’s disease

A. Pilotto, F. Schiano DiCola, E. Premi, V. Garibotto, A. Scalvini, R. Turrone, R. Grasso, B. Bigni, S. Gipponi, B. Paghera, MC. Rizzetti, b. Borroni, A. Padovani (Brescia, Italy)

1:15pm-2:45pm: Subjective and objective urinary dysfunction in parkinson’s disease and atypical parkinsonisms

Y. Lee, J. Kim (Seoul, Republic of Korea)

1:15pm-2:45pm: Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson’s Disease

P. Huang, H.Y. Zhou, S.D. Chen (Shanghai, China)

1:15pm-2:45pm: Substantia nigra hyperechogenicity is similarly enlarged in Gaucher and in GBA mutation carriers

D. Arkadir, A. Zimran (Jerusalem, Israel)

1:15pm-2:45pm: Substantia nigra T1 maps for the diagnosis of Parkinson’s disease

C. Juri, L. Tapia, J. Cruz, S. Uribe, M. Andia (Santiago, Chile)

1:15pm-2:45pm: Subthalamic Nucleus Local Field Potential Beta Activity in Chinese Advanced PD Patients

J. Wu, J. Li, C. Xu, S. Mei, Y. Zhang (Minneapolis, MN, USA)

1:15pm-2:45pm: Subthalamic nucleus stimulation normalises effort-based decision-making in Parkinson’s disease

C. Atkinson-Clement, E. Cavazzini, A. Zénon, T. Witjas, F. Fluchère, C. Baunez, JP. Azulay, A. Eusebio (Aix-en-Provence, France)

1:15pm-2:45pm: Subthalamic theta oscillations in Parkinson’s disease

C. Oehrn, I. Weber, N. Apetz, T. Dembek, F. Jung, E. Florin, L. Timmermann (Marburg, Germany)

1:15pm-2:45pm: Suicide attempts, suicidal and death ideation in Parkinson’s disease

MM. Dumitru, A. Papari (Iasi, Romania)

1:15pm-2:45pm: Survival of patients with Parkinson’s disease is influenced by the mutations in the LRRK2 but not GBA gene

A. Thaler, T. Kozlovski, T. Gurevich, A. Bar Shira, M. Gana-Weisz, A. Orr-Urtreger, L. Goldstein, N. Giladi, A. Mirelman (Tel-Aviv, Israel)

1:15pm-2:45pm: T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review

J. Baird, J. Quinn (Portland, OR, USA)

1:15pm-2:45pm: Tau and α-synuclein autoantibodies as potential biomarkers for Parkinson’s and Alzheimer’s diseases

A. Shalash, M. Salama, M. Makar, T. Roushdy, M. El-Balkimy (Cairo, Egypt)

1:15pm-2:45pm: Tef polymorphism predicts the decline of sleep disturbances in Parkinson’s disease

P. Hua, W. Liu (Nanjing, China)

1:15pm-2:45pm: Temporal evolution of biomarkers from healthy ageing, isolated REM sleep behavior to early Parkinson’s disease

B. Mollenhauer, M-L. Muntean, J. Zimmermann, K. Focke, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, WH. Oertel, F. Sixel-Döring, C. Trenkwalder (Kassel, Germany)

1:15pm-2:45pm: Tetrahydroisoquinoline Molecule Identified in Traditional Ayurveda Medicine Modulates Inflammation in MPTP Mice

R. Banerjee, R. Paidi, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

1:15pm-2:45pm: The analysis of cognitive impairment associated with Parkinson’s disease

Z. Mao, X. Xue (Hubei, China)

1:15pm-2:45pm: The Association between Infections and Parkinson Disease: A Systematic Review and Meta-analysis

M. Morra, S. Ghozy, E. Sakr, M. Elfaituri, M. Khattab, M. Mahmoud, S. Mehyar, M. Alhattab, A. Ahmed Ismail, M. Abdelmongy, M. Fahmy, E. Gharib, A. Hallab, N. Huy (Cairo, Egypt)

1:15pm-2:45pm: The Association Between Inhibitory Control and Freezing of Gait Severity in Parkinson’s Disease

E. Bayram, S. Banks, J. Longhurst, B. Bluett (Las Vegas, NV, USA)

1:15pm-2:45pm: The association between pain and physical activity in people with Parkinson’s Disease (PD)

H. Khalil, A. Al-Sharman, N. Alissa, K. El-Salem, D. Al-Shorafat (Irbid, Jordan)

1:15pm-2:45pm: The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson’s disease and analysis of relevant factors

K. Nie, Y. Gao, M. Mei, M. Guo, Z. Huang, L. Wang, J. Zhao, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm: The Clinical Research of Parkinson’s Disease with Rapid Eye Movement Sleep Behavior Disorder

Y. Wang, Z. Liang (Dalian, China)

1:15pm-2:45pm: The comparative clinical analysis of sleep patterns in patients with Amyotrophic Lateral Sclerosis and Parkinson’s disease

S. Shuang, Z. Liang (Dalian, China)

1:15pm-2:45pm: The comparison of three brief cognitive tests for diagnosing mild cognitive impairment in newly diagnosed Parkinson’s disease

S. Kim, J. Jung, D. Seog (Busan, Republic of Korea)

1:15pm-2:45pm: The development of an instrument for measuring Parkinson’s patient empowerment

P. Viwattanakulvanid (Bangkok, Thailand)

1:15pm-2:45pm: The difference in cerebellar blood flow reduction in multiple system atrophy and Parkinson’s disease

N. Murakami, W. Sako, S. Haji, Y. Izumi, R. Kaji (Tokushima, Japan)

1:15pm-2:45pm: The difference in posture reaction against backward perturbation between patients with Parkinson’s disease and healthy controls

K. Kannari, S. Koseki, C. Narita, S. Sugo. (Aomori, Japan)

1:15pm-2:45pm: The difference of the change of finger surface temperature after short time cold stress test between Parkinson disease and Multiple system atrophy

M. Takahashi, A. Hagiwara, K. Abe, A. Inaba, S. Orimo (Tokyo, Japan)

1:15pm-2:45pm: The effect of age on Substantia Nigra Hyperechogenicity in PD patients and healthy controls

T. Toomsoo, A-H. Pool, I. Liepelt–Scarfone, L. Kadastik-Eerme, I. Rubanovits, T. Asser, D. Berg, P. Taba (Tallinn, Estonia)

1:15pm-2:45pm: The Effect of Sleep Deprivation on Short-Term Memory and Emotion of Rotenone Treated Zebrafish Model of Parkinson Disease

Y. Xiong, D. Lv, S. Wei, F. Wang, C. Liu (Suzhou, China)

1:15pm-2:45pm: The effects of sensory reward cues on risky decision making in Parkinson’s disease

M. Cherkasova, P. Surathi, S. Yeung, AJ. Stoessl, M. McKeown, S. Appel-Cresswell, C. Winstanley, J. Barton (Vancouver, BC, Canada)

1:15pm-2:45pm: The Gut Microbiota in a Canadian Parkinson’s Disease Cohort

M. Cirstea, E. Golz, B. MacVicar, B. Finlay, S. Cresswell (Vancouver, BC, Canada)

1:15pm-2:45pm: The hardest symptoms that bother patients with Parkinson’s disease before and 3 months after Deep brain stimulation and Continuous infusion of levodopa-carbidopa intestinal therapy

V. Vuletic (Rijeka, Croatia)

1:15pm-2:45pm: The increased α-syn expression inhibits exosomal secretion

Y. Ishiguro, T. Tsunemi, A. Yoroizaka, W. Akamatsu, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm: The Inter-rater Reliability of Parkinson’s Disease Sleep Scale 2 Indonesian Version

R. Buana, R. Pinzon (Yogyakarta, Indonesia)

1:15pm-2:45pm: The International Parkinson and Movement Disorder Society Non-Motor Scale (MDS-NMS) for Parkinson’s Disease: Preliminary results from an international validation

K. Ray Chaudhuri, D. Weintraub, A. Rizos, A. Schrag, P. Martinez-Martin (London, United Kingdom)

1:15pm-2:45pm: The neural effects of a randomized controlled cognitive training program for treating freezing of gait in Parkinson’s disease

M. Gilat, C. Walton, L. Mowszowski, J. Shine, J. Hall, M. Georgiades, A. Muller, C. O'Callaghan, K. Ehgoetz Martens, J. Szeto, S. Naismith, S. Lewis (Sydney, Australia)

1:15pm-2:45pm: The Parkinson’s Families Project: A family-based study of early onset and familial Parkinson’s disease

M. Tan, A. Costantini, S. Lubbe, E. Brown, J. Bras, N. Wood, A. Schapira, J. Hardy, H. Morris (London, United Kingdom)

1:15pm-2:45pm: The phenomenology of visual hallucinations in Parkinson’s disease: A descriptive analysis of Myanmar and Thai patients

Z. Shwe, J. Sringean, E. The, W. Thit, R. Bhidayasiri (Yangon, Myanmar)

1:15pm-2:45pm: The Polymorphism of SREBF1 Gene rs11868035 G/A Is Associated with susceptibility to Parkinson’s disease in a Chinese Population

F. Lou, M. Li, XG. Luo, Y. Ren (Shenyang, China)

1:15pm-2:45pm: The Portuguese Version of Montreal Cognitive Assessment as a screening test comparing Vascular Parkinsonism and Parkinson´s Disease in a hospital cross-section study

A. Velon, M. Mendes, R. Almendra, A. Almeida, M. Correia, C. (Vila Real, Portugal)

1:15pm-2:45pm: The Prevalence of Gastrointestinal Symptoms in Parkinson’s Disease Patients in Bethesda Hospital, Yogyakarta, Indonesia

A. Al Jody, R. Pinzon (Yogyakarta, Indonesia)

1:15pm-2:45pm: The Prevalence of Tandem Gait Abnormality in Parkinson’s Disease

J. Margolesky, S. Bette, D. Shpiner, T. Rundek, C. Luca, H. Moore, C. Singer (Miami, FL, USA)

1:15pm-2:45pm: The pulmonary function and respiratory muscle strength tests of elderly people with Parkinson’s disease: A two-year observational study

R. Gonçalves, J. Neto, P. Cortêz, C. Silva, N. De Souza, E. Souza, T. Freitas, C. Barros, E. Leon, F. Sanchez, E. Andrade (Manaus, Brazil)

1:15pm-2:45pm: The relationship between asymmetric dopamine loss and cognition in early Parkinson’s disease patients from PPMI study

R. Biundo, E. Fiorenzato, L. Weis, A. Antonini (Venice, Italy)

1:15pm-2:45pm: The Reliability Study of King’s Parkinson’s Disease Pain Scale in Indonesian Version

V. Wijaya, R. Pinzon (Yogyakarta, Indonesia)

1:15pm-2:45pm: The role of DUODOPA Treatment on Non-Motor Symptoms, Specificly Autonomic Dysfunctions

H. Ekmekci, M. Gültekin, A. Mammadli, Ş. Öztürk (Konya, Turkey)

1:15pm-2:45pm: The role of exposure to pesticides in the etiology of Parkinson’s disease: F-DOPA positron emission tomography study

R. Djaldetti, A. Steinmetz, A. Rigbi, Y. Roditi, L. Greenbaum, M. Lorberboym (Petah Tiqva, Israel)

1:15pm-2:45pm: The study of 18F-FDG PET / CT imaging in the value on Parkinson’s disease

Z. Mao, Z. Xue (Hubei, China)

1:15pm-2:45pm: The subthalamic stimulation inhibit bladder contraction by modulating local field potential and monoamine in the medial prefrontal cortex

T. Yamamoto, R. Sakakibara, T. Uchiyama, S. Kuwabara (Chiba, Japan)

1:15pm-2:45pm: The use of DaT scan for diagnosis of Idiopathic Parkinson’s disease and Parkinson’s Plus syndromes in clinical practice (HEFT experience)

M. Awadh, G. Ferris, K. Alam (Birmingham, United Kingdom)

1:15pm-2:45pm: The use of DaT-SPECT scanning in the differential diagnosis of Parkinsonism: Are guidelines being followed?

J. Carling, A. Coldstream, W. Gray, R. Walker (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: The usefulness of 18 F-DOPA PET scan in diagnostically challenging patients at a movement disorder clinic

M. Khider, A. Dorutyer, J. Warwick, J. Carr (Cape Town, South Africa)

1:15pm-2:45pm: The validity of the Arabic King’s PD Pain Scale in people with Parkinson’s disease

H. Khalil, A. Al-Sharman, N. Alissa, K. El-Salem, D. Al-Shorofat (Irbid, Jordan)

1:15pm-2:45pm: Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson’s Therapy

N. Verma (Baddi, India)

1:15pm-2:45pm: Three Tesla susceptibility-weighted MR imaging of parkinsonism and idiopathic REM sleep behavior disorder: Comparison with 123I-FP-CIT SPECT

J.M. Kim, Y.J. Bae, Y.S. Song, K.J. Kim, S.E. Kim, B. Jeon (Seongnam-si, Republic of Korea)

1:15pm-2:45pm: Total CSF alpha-synuclein is inversely associated with non-motor symptoms in a population of patients with Parkinson’s Disease

T. Schirinzi, G. Sancesario, G. Di Lazzaro, B. Biticchi, N. Mercuri, S. Bernardini, A. Pisani (Rome, Italy)

1:15pm-2:45pm: Tractographically defined subthalamic connectivity is associated with apathy in Parkinson’s disease and healthy subjects

N. Vanegas-Arroyave, Y. Gazes, D. Tomishon, A. Boehme (New York, NY, USA)

1:15pm-2:45pm: Traditional Chinese Medicine in treating for salivation and nocturia for patient with Parkinson’s disease

W. Pan, T. Liu, M. Wang, B. Qin (Shanghai, China)

1:15pm-2:45pm: Transcranial imaging of substantia nigra hyperechogenicity in a Chinese cohort of Parkinson’s disease

G. Hongling, Y. Qingmei (Wuhan, China)

1:15pm-2:45pm: Transcranial magnetic stimulation increases cognition globally and longitudinally in Parkinson’s disease

J. Trung, A. Hanganu, S. Jobert, C. Degroot, B. Mejia-Constain, M.A. Bruneau, A.L. Lafontaine, Q.P.N. Clinicians, A. Strafella, O. Monchi (Montréal, QC, Canada)

1:15pm-2:45pm: Turning during gait is associated with gray matter density of the nucleus basalis of Meynert in Parkinson’s disease

R. Morris, T. Madhyastha, D. Martini, K. Smulders, J. Quinn, V. Kelly, K. Edwards, C. Zabetian, T. Grabowski, F. Horak (Portland, OR, USA)

1:15pm-2:45pm: Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) -mediated ubiquitination attributed to localization of Mortalin to mitochondria

L. Wu, W. Yang, Y. Tan, J. Ding, S. Chen (Shanghai, China)

1:15pm-2:45pm: Ultrasonographic signatures associated with movement disorders (USA-MD study): A population-based longitudinal study

A. Crespo Cuevas, L. Ispierto, E. Lopez-Cancio, A. Planas, T. Canento, M. Hernandez-Pérez, R. Alvarez, D. Vilas (Badalona, Spain)

1:15pm-2:45pm: Unilateral abnormal dopamine transporter (DaT) scans: Early indicator of Parkinson’s disease and degenerative Parkinsonism

N. Heng, M.Y. Chin, C. Monaghan, J. Dadvidson, T. Gilbertson, M. Muqit (Dundee, United Kingdom)

1:15pm-2:45pm: Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism

R. Cilia, M. Barichella, M. Severgnini, E. Cassani, C. Bolliri, S. Caronni, V. Ferri, R. Cancello, S. Faierman, G. Pinelli, C. Ceccarani, G. De Bellis, L. Zecca, E. Cereda, C. Consolandi, G. Pezzoli (Milan, Italy)

1:15pm-2:45pm: Unveiling the function of altered gut microbiota composition in Parkinson’s disease

A.H. Tan, C.W. Chong, C.S.J. Teh, I.K.S. Yap, M.F. Loke, J. Bowman, S.L. Song, J.Y. Tan, B.H. Ang, Y.Q. Tan, H.S. Yong, A.E. Lang, S. Mahadeva, S.Y. Lim (Kuala Lumpur, Malaysia)

1:15pm-2:45pm: Usefulness of a simple symptom assessment scale for multiple system atrophy: data from HoRC-MSA Project

M. Matsushima, K. Sakushima, I. Yabe, Y. Kanatani, Y. Ito, T. Matsuoka, T. Katayama, H. Uesugi, K. Sako, A. Takei, S. Shimohama, N. Sato, S. Kikuchi, H. Sasaki (Sapporo, Japan)

1:15pm-2:45pm: Using Vision to Predict Dementia in Parkinson’s Disease

L-A. Leyland, R. Mahmood, S. Hewitt, M. Durteste, F. Bremner, M. Lai, L. Miller, A. Saygin, C. Song, P. Keane, A. Schrag, R. Weil (London, United Kingdom)

1:15pm-2:45pm: Utilizing latent class analysis to explore the sleep disturbance subtypes in Parkinson’s disease patients

H.J. Yang, H.J. Kim, S.J. Kim (Ulsan, Republic of Korea)

1:15pm-2:45pm: Validation of a One-Page Impulse Control Disorder Questionnaire in a Parkinson’s Disease Clinic

L. Williams, B. Magennis, N. Feerick, T. Lynch (Dublin, Ireland)

1:15pm-2:45pm: Validation of a patient/caregiver questionnaire to evaluate nocturnal hypokinesia in Parkinson’s disease

R. Bhidayasiri, O. Jitkritsadakul, J. Sringean, P. Martinez-Martin, C. Anan, N. Kantachadvanich, R. Chaudhuri, N. Hattori (Bangkok, Thailand)

1:15pm-2:45pm: Validation of protein phosphatases that regulate the LRRK2 phosphorylation cycle

M. Drouyer, M. Emanuele, R. Lefebvre, K. Cailliau-Maggio, A. martoriati, T. Comptdaer, P. Semaille, E. Mutez, W. Sibran, N. Wolkoff, E. Lobbestael, M. Bolliger, V. Baekelandt, J. Nichols, MC. Chartier-Harlin, JM. Taymans (Lille, France)

1:15pm-2:45pm: Validation of the French version of the Munich Dysphagia Test-Parkinson’s disease (MDT-PD) in a multilingual population of the Luxembourg Parkinson’s Study (HELP-PD)

G. Hipp, M. Vaillant, P. Kolber, C. Pauly, L. Pavelka, D. Reiter, R. Krüger, J. Simons (Belvaux, Luxembourg)

1:15pm-2:45pm: Validation of the Hong Kong Chinese version of NMSQuest (HK-NMSQ)

V. Luk, N. Cheung, G. Chan, KF. Leung, NFJ. Lui, WW. Wong, I. Chan, C. Li (Kowloon, Hong Kong)

1:15pm-2:45pm: Validation of the new diagnostic criteria for fatigue in Parkinson’s disease

A. Mosejova, T. Merovova, I. Straka, V. Han, Z. Gdovinova, P. Valkovic, M. Skorvanek (Kosice, Slovakia)

1:15pm-2:45pm: Validation of the Parkinson’s Disease Pain Symptoms Scale (PD-PSS): An interim report

D. Ciampi-de-Andrade, S. Perez-Lloret, N. Hollenstein, R. Curry, V. Rossetto Barbosa, G. Kägi, S. Hägele-Link, J. Walch, R. Gonzenbach, J-P. Lefaucheur, S. Beer, C. Möller, V. Mylius (Sao Paulo, Brazil)

1:15pm-2:45pm: Validity And Reliability Of Nineteen-Item Wearing-Off Questionnaire In Turkish Patients

H. Çotur Levent, AY. Yılmaz, MC. Akbostancı (Ankara, Turkey)

1:15pm-2:45pm: Variable selection using machine-learning to identify new signatures of patient-derived aggregated α-synuclein-induced neurodegeneration in non-human primates

M. Bourdenx, A. Nioche, S. Dovero, M.L. Arotçarena, S. Camus, G. Porras, M.L. Thiolat, N. Rougier, A. Prigent, P. Aubert, S. Bohic, N. Kruse, B. Mollenhauer, S. Novello, M. Morari, I. Trigo, M. Goillandeau, M. Tasselli, C. Perier, N. Garcia Carrillo, C. Estrada, A. Recasens, J. Blesa, M. Herrero, P. Derkinderen, M. Vila, J. Obeso, B. Dehay, E. Bezard (Bordeaux, France)

1:15pm-2:45pm: Variants in MCCC1/LAMP3 and DGKQ Identified Through GWAS are Not Associated with PD in a Malaysian Malay Cohort

JL. Lim, AH. Tan, SY. Lim, AA. Azlina (Kuala Lumpur, Malaysia)

1:15pm-2:45pm: Vascular risk factors prevalence differences between Vascular Parkinsonism (VaP) and Parkinson Disease (PD) in a hospital cross-section study

A. Velon, M. Mendes, R. Raimundo, R. Jesus, R. Almendra (Vila Real, Portugal)

1:15pm-2:45pm: Visual deficits of self-motion perception in Parkinson’s disease

S. Yakubovich, O. Halperin, S. Hassin, S. Israeli-Korn, A. Zaidel (Ramat Gan, Israel)

1:15pm-2:45pm: Visual hallucinations and autonomic burden are inversely associated with physical activity in PD

J. Hinkle, K. Perepezko, N. Fischer, Z. Mari, L. Marsh, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm: Vowel characteristics associated with Parkinson’s disease in Cantonese

N. Leung, E. Tong, M. Ng (Pokfulam, Hong Kong)

1:15pm-2:45pm: Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson’s disease

KJ. Pak, HK. Shin, EJ. Kim, JH. Lee, CH. Lyoo, JS. Son, MJ. Lee, HJ. Son (Busan, Republic of Korea)

1:15pm-2:45pm: What can we learn from fMRI capture of visual hallucinations in Parkinson’s disease?

K. Dujardin, D. Roman, G. Baille, D. Pins, S. Lefebvre, C. Delmaire, L. Defebvre, R. Jardri (Lille, France)

1:15pm-2:45pm: What happens when I watch a ballet? Preliminary fMRI findings on somatosensory empathy in Parkinson Disease

S. Palermo, R. Morese, M. Zibetti, M. Stanziano, A. Pontremoli, A. Romagnolo, G. Carlotti, A. Zardi, M. Valentini, L. Lopiano (Turin, Italy)

1:15pm-2:45pm: White Matter Hyperintensities and Mortality among Patients with Parkinsonism in Olmsted County, MN (1995-2010)

J. Yu, R. Brown, J. Huston, M. Mielke, C. stang, P. Turcano, R. Savica (Rochester, MN, USA)

1:15pm-2:45pm: Working memory maintenance and manipulation in Parkinson’s disease: An fMRI study

K. Giehl, A. Ophey, J. Hammes, S. Rehberg, C. Eggers, T. Lichtenstein, D. Maintz, E. Kalbe, T. van Eimeren (Cologne, Germany)

1:15pm-2:45pm: α-synuclein aggregation and propagation in marmoset brains deteriorates its motor function

T. Yabumoto, K. Baba, H. Hayakawa, K. Ikenaka, F. Yoshida, T. Uehara, R. Nakatani, H. Tsuda, S. Nagano, H. Hamanaka, Y. Nagai, M. Hirata, H. Mochizuki. (Osaka, Japan)

1:15pm-2:45pm: α-synuclein antibody 5G4 identifies manifest and prodromal Parkinson’s disease in colonic mucosa

M. Skorvanek, E. Gelpi, E. Mechirova, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, J. Ribeiro Ventosa, F. Kudela, K. Kulcsarova, S. Babinska, S. Toth, L. Gombosova, F. Trebuna, M. Lutz, Z. Gdovinova, G. Kovacs (Kosice, Slovakia)

1:15pm-2:45pm: α-Synuclein induced dopaminergic neurons mitochondrial dysfunction via cytochrome c oxidase subunit 2

D. Lin (Guangzhou, China)

1:15pm-2:45pm: α-synuclein propagation via olfactory pathway in non-human primate model

M. Sawamura, H. Onoe, N. Uemura, T. Isa, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm: α4β2-nicotinic receptor availability in Parkinson’s disease MCI and healthy controls: A pilot imaging study using [18F]-XTRA PET

K. Mills, Y. Du, J. Coughlin, A. Horti, M. Pomper, G. Smith (Baltimore, MD, USA)

« View all sessions from the .